frontiers | Research Topics

Epigenetic and metabolic regulation of immunotherapy mediated anti-tumor responses

Edited by
Sangeeta Goswami, Dipyaman Ganguly and Irina Apostolou

Published in
Frontiers in Immunology



ISSN 1664-8714
ISBN 978-2-83251-956-1
DOI 10.3389/978-2-83251-956-1

About Frontiers

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals.

Frontiers journal series

The Frontiers journal series is a multi-tier and interdisciplinary set of open-access, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the *Frontiers journal series* operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too.

Dedication to quality

Each Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public - and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation.

What are Frontiers Research Topics?

Frontiers Research Topics are very popular trademarks of the *Frontiers journals series*: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers editorial office: frontiersin.org/about/contact

Epigenetic and metabolic regulation of immunotherapy mediated anti-tumor responses

Topic editors

Sangeeta Goswami — University of Texas MD Anderson Cancer Center, United States

Dipyaman Ganguly — Indian Institute of Chemical Biology (CSIR), India

Irina Apostolou — Sumitomo Dainippon Pharma Oncology, United States

Citation

Goswami, S., Ganguly, D., Apostolou, I., eds. (2023). *Epigenetic and metabolic regulation of immunotherapy mediated anti-tumor responses*. Lausanne: Frontiers Media SA. doi: 10.3389/978-2-83251-956-1

Table of contents

frontiers in Immunology

REVIEW
published: 24 January 2022
doi: 10.3389/fimmu.2022.809761

A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy

Zaoqu Liu[1,2,3†], *Yuqing Ren*[4†], *Siyuan Weng*[1,2,3], *Hui Xu*[1,2,3], *Lifeng Li*[5,6*] *and Xinwei Han*[1,2,3*]

[1] Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, [2] Interventional Institute of Zhengzhou University, Zhengzhou, China, [3] Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China, [4] Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, [5] Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China, [6] Medical School, Huanghe Science and Technology University, Zhengzhou, China

OPEN ACCESS

Edited by:
Dipyaman Ganguly,
Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Anastasia Mpakali,
National Centre of Scientific Research Demokritos, Greece
Nahum Puebla-Osorio,
University of Texas MD Anderson Cancer Center, United States

***Correspondence:**
Xinwei Han
fcchanxw@zzu.edu.cn
Lifeng Li
lilifeng0317@163.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: 05 November 2021
Accepted: 03 January 2022
Published: 24 January 2022

Citation:
Liu Z, Ren Y, Weng S, Xu H, Li L and Han X (2022) A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. Front. Immunol. 13:809761. doi: 10.3389/fimmu.2022.809761

In recent years, immunotherapy has become a hot spot in the treatment of tumors. As an emerging treatment, it solves many problems in traditional cancer treatment and has now become the main method for cancer treatment. Although immunotherapy is promising, most patients do not respond to treatment or develop resistance. Therefore, in order to achieve a better therapeutic effect, combination therapy has emerged. The combination of immune checkpoint inhibition and epigenetic therapy is one such strategy. In this review, we summarize the current understanding of the key mechanisms of how epigenetic mechanisms affect cancer immune responses and reveal the key role of epigenetic processes in regulating immune cell function and mediating anti-tumor immunity. In addition, we highlight the outlook of combined epigenetic and immune regimens, particularly the combination of immune checkpoint blockade with epigenetic agents, to address the limitations of immunotherapy alone.

Keywords: epigenetics, immunotherapy, epigenetic regulation, T cells, immune checkpoint therapy, cancer therapy

CANCER IMMUNOTHERAPY

With technological advances in cell manufacturing and genetic engineering, as well as advances in immunology, molecular biology, and virology, immune cell therapy has been rapidly developed. Since the cellular division of immunological properties was defined, the function of adaptive immunity of B and T cells has attracted much attention (1). T cells have subsequently been demonstrated to have the ability to kill malignant cells, and the human immune system can eliminate cancer cells through acquired immune responses executed by T cells, which suggests that T cells can be rationally designed to control tumor growth. An increasing number of treatment modalities revolve around T cells to carry out research. Immunotherapy based on T cells is now regarded as an integral part of cancer treatment. However, clearing tumor cells by the immune system is not a simple process, which requires a series of conditions (2). First, cell death tumor-associated antigens are released from tumor cells into the tumor microenvironment to be captured by antigen-presenting cell (APC). Antigen-loaded APCs then process and present antigens along with major histocompatibility complex (MHC) complexes to the cell surface and transport them to

lymphoid organs. Primitive T cells in lymphoid organs recognize selected peptide-MHC complexes through the T cell receptor (TCR), which triggers the priming and activation of effector T cells. Subsequently, differentiated effector T cells leave lymphoid organs to infiltrate into tumors through the circulatory system. T cells recognize cancer cells carrying matching antigens through TCR interaction with peptide-MHC complexes and kill cancer cells by direct or indirect immune attack. Immune attack leads to the release of additional antigens from dead tumor cells, which triggers a new round of anti-tumor immune response. However, tumor generation often develops by immune escape through various mechanisms due to failure of immune surveillance. For example, if there is a lack of APCs, APCs are inhibited or immune checkpoints are activated, these result in impaired capture of antigens released into the tumor microenvironment, which cannot mediate T cell priming and activation (3, 4). When T cells migrate or infiltrate into tumor tissue, they may not be performed due to the lack of appropriate chemokines and immunosuppressive tumor microenvironment (TME) (5, 6). The tumoricidal activity of T cells can also be blocked by regulatory cells in the TME (such as, regulatory T cells, macrophages, myelosuppressive cells, etc.), or by activating immune checkpoints on tumor cells or macrophages (7). In conclusion, the occurrence of any of the above conditions can lead to immune escape and thus bring about the generation of tumors. Therefore, immunotherapy has emerged to relieve immunosuppression and restore anti-tumor immune responses, which include immune checkpoint blockade therapy, adoptive cellular immunotherapy (8, 9), cytokine-based therapy (10, 11), and vaccines (12). The most remarkable of these is immune checkpoint blocking therapy (ICBT) against immune checkpoints. In March 2011, immune checkpoint inhibition was introduced as a new cancer therapeutic paradigm with FDA approval of the anti-cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibody ipilimumab for the treatment of advanced melanoma. Since then, inhibitors against the CTLA-4 and PD-1 immune checkpoints have revolutionized the treatment of not only melanoma, but also malignant tumors such as non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin's lymphoma. Arguably, the success of ICBT is the most significant advance in the field of cancer treatment in the past decade.

Immune checkpoint activation, which is the interaction of receptors between T cells and on tumor cells (13–15) and APCs (16–18). Currently the most extensively studied are PD-1 and CTLA-4, as well as their respective ligands PD-L1 and CD80 or CD86. Therefore, the basic principle of immune checkpoint inhibition is to use antibodies against PD-1, PD-L1, or CTLA-4 for treatment to reverse the inhibitory effect of immune checkpoints and promote anti-tumor effects by preventing the interaction of these receptors. However, the clinical response of immune checkpoints depends on the immune status of the tumor. The presence of antigen-specific $CD8^+$ lymphocytes within the TME is a primary condition (19–21). Second, the composition of nearby immune cell populations must differentiate into an immune-permissive state (22–25). Third, tumors must have MHC class I-mediated antigen presentation functions (26). Only tumors with these characteristics can receive immune attack, otherwise it will be a state of immune evasion (27, 28), which allows cancer to evade immune detection and grow freely. These conditions make ICBT clinically limited, and most patients do not respond to treatment or develop resistance. Therefore, it is necessary to find a new mode of immunotherapy to overcome the dilemma, and the combination of immune checkpoint inhibition and epigenetic therapy is one such strategy. It has been shown that epigenetics can improve immune recognition and immunogenicity and thus play an important role in immune evasion (29–31). Although the concept of cooperation between epigenetic therapy and strategies such as immune checkpoint therapy has only recently emerged, many studies have highlighted the potential of this combination approach in many different cancer types (31–34). In addition, some ongoing clinical trials are currently exploring the effectiveness of this combination approach. In this review, we address the current understanding of the key mechanisms of how epigenetic mechanism influences cancer immune responses and reveal the key role of epigenetic processes in regulating immune cell function and mediating anti-tumor immunity. In addition, we highlight the outlook of combined epigenetic and immune regimens, particularly the combination of immune checkpoint blockade with epigenetic drugs, to address the limitations of immunotherapy alone.

ROLE OF EPIGENETICS IN CANCER THERAPY

Epigenetic dysregulation is a major mechanism in cancer development and progression (35, 36). Epigenetic regulation is a DNA-heritable modification that alters chromatin structure and gene expression without altering the underlying nucleotide sequence (37, 38). The modification process is mainly through changing the three-dimensional distribution of nucleosomes throughout the genome so that the way DNA is packaged is changed. This packaging process is fine-tuned by covalent labeling of amino acids on histones in the context of nucleosomes and methylation-mediated interactions of genomic DNA at CpG sites (38–40). In addition to DNA methylation, histone post-translational modifications, such as acetylation, methylation, and generalization, are also key regulators of chromatin structure that affect gene expression. There are also a variety of mechanisms that regulate the transcriptional state of genes: chromatin remodeling; histone variant exchange; and the role of non-coding RNAs. Epigenetic modifications of DNA and histones dynamically and reversibly regulate transcription, allowing chromatin to interconvert in both closed (heterochromatin) and open (euchromatin) states. The chromatin structure in the open state can allow access of transcriptional activators such as RNA polymerase and DNA-binding transcription factors to target genes and promote active transcription. In contrast, closed state chromatin is usually

associated with transcriptional silencing (41). Over the past few decades, attention has been paid to the development of epigenetic therapies as anticancer agents based on their direct effects on cancer cells. While recent studies have elucidated how epigenetic mechanisms acts on immune evasion, they have revealed the role of epigenetic drugs in modulating immune pathways to improve immune recognition and immunogenicity (29–31). A full understanding of the role of epigenetic regulatory mechanisms in cancer immunity is essential to exploit the potential of epigenetic drugs.

Epigenetic Alterations in Tumor Cells

Aberrant DNA methylation may be an important event leading to tumor development. In the 1980s, hypomethylation of genome-wide DNA was first observed in cancer cells (42), which may cause genomic instability, chromatin structure changes, as well as some gene expression rises. The specific methylation level of the gene promoter showed an elevated state. Aberrant methylation patterns are often associated with frequent mutations in genes that regulate DNA methylation (such as DNMT3a and TET2) in human cancers, leading to abnormal gene expression in human cancers. For example, local hypermethylation of tumor suppressor gene promoters silences their expression, which is directly associated with tumorigenesis (43). Abnormal patterns of histone modifications are also common in tumor cells. The number of modifications and modifications at different sites of histones is of great interest for transcriptional regulation of genes in tumor cells. For example, H3K4me3, which is widely studied, mediates the activation of transcription. On the other hand, H4K20me3 is closely related to the silencing of repetitive DNA and transposons (44) and mediates transcriptional repression (45). Loss of H4K20me3 is considered an important feature of cancer (46). Histone H4K16 acetylation and loss of H4K20 trimethylation have been reported as common hallmarks of human cancer (46). Post-translational modifications of histones together with DNA methylation determine the fate of gene expression which leads to the development of tumors. Moreover, epigenetics also affect anti-tumor immune responses, such as inducing neoantigen production, disrupting antigen presentation mechanisms, promoting inflammatory factor production and inducing immunosuppressive effects, thereby exacerbating tumor development.

Epigenetic alterations may lead to the reactivation of genes, which brings about the formation of new antigens in most cancers (47). The most typical example is the generation of Cancer/testis antigens (CTAs). CTA is an ideal target for cancer immunotherapy, especially for cancer vaccines and adoptive cell therapy, which is encoded by a set of genes that are mainly expressed in male germ cells under healthy conditions (48). However, CpG demethylation associated with these genes, as well as other epigenetic dysregulations, can re-express the gene encoding CTA in tumors. When CTAs, protein products of these genes, are reactivated in tumor tissues without immune privilege, they can induce adaptive immune responses, whose strong immunogenicity and tumor specificity make it a priority target for cancer immunotherapy (49).

Epigenetics can also cause dysregulation of antigen presentation mechanisms in tumor cells, making T cells unable to effectively recognize tumor cells. The presentation of tumor antigens requires the expression of MHC class I on the cell surface, which can be inhibited by DNA methyltransferase enzymes (DNMT) and histone deacetylase (HDAC). It has been demonstrated by the re-expression of MHC class I after DNMTi and HDACi treatment of cells (50, 51). Treatment of tumor cells and patients with DNMTi results in increased expression of genes required for antigen presentation (52). Histone methylation is also an important epigenetic mechanism leading to silencing of immunogenic factor expression, and its most obvious role is to inhibit MHC class I antigen presentation. In SCLC and neuroblastoma, targeted inhibition of histone methyltransferases can upregulate the expression of MHC class I in tumor cell lines. Similar findings have been observed in lymphomas (53).

Inflammatory cytokines are essential for the immune system. The differentiation, activation, entry of immune cells and immune attack on tumor cells are inseparable from inflammatory cytokines. Epigenetic mechanisms can regulate specific genes to promote the production of proinflammatory cytokines in tumor cells. Endogenous retroviruses (ERVs) are transposon elements in the genome that are silenced by DNA methylation in the human genome. ERV promoter DNA demethylation restores ERV expression. Activation of ERV brings about a "viral mimicry" state (54), in which tumor cells behave like virus-infected cells and initiate an innate immune response, leading to the production of type I and type III interferons (54, 55) (**Figure 1**). Autocrine and paracrine type I interferon signaling in TME promotes the production of proinflammatory cytokines and chemokines, resulting in enhanced tumor cell immunogenicity, and these changes can improve the effectiveness of immune checkpoint inhibitors (54, 55).

Tumor-induced immunosuppressive effect is one of the main reasons for tumor immune escape, and tumor-produced immunosuppressive molecules, such as PD-L1, can directly inhibit the immune response as well as recruit regulatory T cells that secrete immunosuppressive cytokines by themselves. Epigenetic mechanisms contribute to the regulation of PD-L1 expression, such that it is upregulated in tumor cells. For example, in glioblastoma multiforme and prostate cancer, PD-L1 expression and prognosis are inversely correlated with methylation of the PD-L1 gene promoter (56, 57). Studies have shown that in patients with metastatic melanoma treated with anti-PD-1 therapy, circulating exosome PD-L1 levels are positively correlated with interferon-γ (IFN-γ) signaling, which can stimulate PD-L1 expression (58). Inhibition of BET protein, the reader of histone acetylation, inhibits IFN-γ-induced PD-L1 expression (59, 60) In addition, in mouse models of ovarian cancer, BET inhibitors can reduce PD-L1 expression in tumor cells, tumor-associated dendritic cells and macrophages, thereby limiting tumor progression (61).

Epigenetic Effects on Immune Cells

Over the past decade, some studies have shown that the fate of cell differentiation during lymphocyte development is largely



FIGURE 1 | DNA demethylation restores ERV expression to induce viral mimicry. DNA demethylating drugs reactivate ERV promoters by inhibiting their methylation, resulting in bidirectional transcription of ERVs to produce dsRNAs, which are exported to the cytoplasm and sensed by pattern recognition receptors, such as MDA5. MDA5 binding to dsRNA induces recruitment of TANK-binding kinase 1 (TBK1) and aggregation of mitochondrial antiviral signaling protein (MAVs), which activate interferon regulatory factor 7(IRF7) by phosphorylation. Then, activated IRF7 moves into the nucleus and induces transcription of interferon-responsive genes (IRG). Consequently, type I/III interferons are produced, transported, and secreted into the tumor microenvironment. Secreted type I/III interferons increase the expression of antigen processing and antigen presentation mechanisms, improving the ability of cancer cells to present antigens.

influenced by epigenetic mechanisms (62). To some extent, epigenetic mechanisms can determine the functional and phenotypic changes of cells during activation of the adaptive immune system. For example, the function of dendritic cell (DC) is regulated by chromatin structure and histones. It has been shown that the activation of bone marrow-derived DCs is inhibited by the histone-H3K4-specific demethylase KDM5B, resulting in T cell responses that cannot proceed normally (63). Epigenetic regulation of cell differentiation has been studied in several major immune cell populations, including $CD8^+$ T cells, $CD4^+$ T cells, and myeloid cells.

Naive CD8 T cell responses in lymph nodes require the initiation of an autonomous program of differentiation and proliferation, which is the result of stimulation after antigen presentation by specialized antigen-presenting cells. During these processes, the epigenetic landscape of T cells changes (64). Under acute stimulation, naive T cell proliferates and differentiates into effector T cells to remove antigens. After antigen removal, a small proportion of memory effector cells survive the immune response stage and develop into functional memory T cells. Consequently, functional memory T cells can rapidly differentiate into effector T cells to perform immune effector function when they meet antigens again. However, under continuous antigen stimulation, the sensitivity of T cells to antigen response is reduced, and finally effector response cannot be produced to achieve a state of nonfunctional differentiation, which is called T cell depletion. Epigenetic programs influence each of these stages of differentiation. Gains and losses in genome-wide DNA methylation and histone modifications were observed during the differentiation of primitive $CD8^+$ T cells into $CD8^+$ effector T cells (65–67) The production of key effector genes by antigen-stimulated naive $CD8^+$ T cells, as well as the transcription start site (TSS) of transcription factors expressed in activated lymphocytes are demethylated, while genes associated with naive T cells, such as CCR7 and Tcf7, evolve T cell differentiation by increased methylation of the TSS to promote gene silencing (68, 69). Similarly, epigenetic mechanisms also regulate $CD8^+$ effector T cell dedifferentiation into memory T cells (70, 71). Memory-precursor CD8 T cells complete the reversal of epigenetic suppression of naive T cell-associated genes by demethylating key genes expressed in $CD8^+$ effector T cells (66, 70). It has been demonstrated that the DNA methylase DNMT3a is involved in inhibiting memory CD8 T cell production (70). Epigenetic

mechanisms are responsible for T cell exhaustion as well (66, 72). HDAC inhibitors can reverse the functional status of T cell exhaustion (73).

Regulatory T cells (Treg) associated with cancer progression that come from the transformation of traditional $CD4^+$ T cells have the ability to suppress immune responses and accumulate in both animal models and cancer patients (74). The growth and development of Treg cells are tightly regulated by epigenetics. EZH2 histone methylases deposit H3K27me3 marks in the regulatory elements of genes down-regulated in Treg cells in order to regulate the development of Treg cells (75, 76). EZH2 inhibition may prevent the accumulation of Treg cells in cancer thereby relieving their suppression of immune responses. Epigenetics also controls the expression and activity of Treg cell-specific genes, including Foxp3, a key transcription factor used to identify Treg cells (77). The gene encoding Foxp3, which controls development and function of Treg cells, is usually methylated (78–80), and silenced in naïve T cells or activated $CD4^+$ T cells, but methylated and expressed in Tregs (81). Foxp3 protein promotes Treg development through acetylation of HDAC9. Thus, effector differentiation of CD4 T helper cell lines is plastic and can be reversed in response to appropriate environmental stimuli with the participation of dynamic changes in epigenetics and transcription (82). The transcriptionally active mark H3K4me3 can be found at the locus of cytokine genes unique to each TH, while the repressed H3K27me3 mark turns other genes off (83).

Myeloid-derived suppressor cells (MDSCs) are a cell population known to induce peripheral blood T cell tolerance and inhibit T cell activation and proliferation (84–86), whose fate is also modulated by epigenetic modifications. Differentiation and activation of MDSCs mainly involves various histone modifications that regulate the binding of specific transcription factors to their target genes mainly by keeping the chromatin structure in an open state (87, 88). Sahakian et al. found that knockdown of histone deacetylase 11 (HDAC11) gene showed more inhibition of MDSC number in a mouse tumor model, suggesting that MDSC expansion and function is negatively regulated by HDAC11 (89). Zhang et al. also demonstrated that in addition to DNA methylation and histone acetylation, miRNAs and siRNAs can also eliminate cancer cells by altering the properties of MDSCs (90).

METABOLIC DYSREGULATIONS ARE LINKED TO EPIGENETIC CHANGES IN CANCER AND IMMUNE CELLS

Previously, there were limitations in our understanding of cancer, and it was believed that from tumor initiation, growth to metastasis, they were dominated by genetic mutations. In recent years, cellular metabolic remodeling and epigenetics, as one of the characteristics of cancer, are gradually well-known for the importance of tumor development. Tumor cells will show tightly regulated metabolic plasticity during tumorigenesis and metastasis. Like tumor cells, cellular metabolism is also a key factor in the maintenance of viability and function of immune cells. The advent of immunotherapy has made it increasingly important to understand more about the metabolic relationship between infiltrating tumor cells and immune cells. It has been shown that certain metabolic changes occur at the epigenetic level, and that many metabolites can act as substrates or cofactors for chromatin-modifying enzymes, which closely link epigenetics and metabolism and regulate each other. In some cases, various metabolic alterations and epigenetic modifications can prompt impeding immune surveillance or immune escape, thus playing an important role in tumor progression.

The most important cellular mechanism affecting the epigenetic landscape of tumor cells is the reprogramming of metabolic pathways, during which the characteristics of metabolites are changed (91, 92), producing the main players and regulators of epigenetic modifications. Accumulating evidence suggests that cellular intermediate metabolites drive the expression of epigenetic mechanisms through chemical post-translational modifications that alter chromatin structure and function (93, 94). The intertwined relationship between epigenetic modifications and metabolomes plays a very important role in the development and progression of tumor cells. First, metabolites in tumor cells affect the epigenetic modification landscape as cofactors of modification enzymes., modification donors, or antagonistic molecules. Almost all epigenetic modification processes require the participation of metabolites. acetyl-CoA produced from glycolysis, NAD+ produced from the combination of glycolysis and oxidative phosphorylation, and S-adenosyl methionine (SAM) generated from a carbon cycle as a substrate or cofactor involved in DNA methylation and posttranslational modification processes of histone (95). Moreover, metabolic enzymes also have a great impact on the regulation of epigenetics. For example, DNMT mediates DNA methylation using SAM as a methyl donor, and histone methylation catalyzed by histone methyltransferase (HMT) also requires the participation of SAM (96). The metabolic enzyme nicotinamide N-methyltransferase (NNMT) can catalyze the transfer of the methyl moiety from SAM to nicotinamide, thereby decomposing SAM into 1-Methyl Nicotinamide (1MNA). Cancer cells overexpressing NNMT have shown alterations in their SAM and histone methylation levels while acquiring a more aggressive phenotype (97). The reaction catalyzed by NNMT hinders the SAM mediated DNA and histone methylation process. Therefore, metabolites and metabolic enzymes play a very wide and important role in epigenetic modification of tumors. Second, epigenetic modifications can directly alter the expression of metabolic enzymes and transporters or regulate cellular metabolism by affecting the expression of signal transducers and transcription factors. For example, the hypomethylation state of genomic DNA allows the expression of PKM2, the rate-limiting enzyme of glycolysis, to be up-regulated in a variety of tumors (98).

Metabolic reprogramming of cancer cells has emerged as a key immunosuppressive mechanism to modulate anti-tumor immune responses. Metabolic status plays multiple roles in determining

innate immune cell function and fate (99). Infiltrating $CD8^+$ T cell metabolism in the tumor microenvironment is often characterized by functional disorders and unique epigenetic manifestations in tumors or other tissues (100), which are all major factors affecting anti-tumor immunotherapy. It has been reported that tumor cells can affect epigenetic modification of T cells by regulating metabolites in their microenvironment. Tumor cells disrupt methionine metabolism in $CD8^+$ T cells, thereby reducing intracellular levels of methionine and the methyl donor SAM and leading to loss of dimethylation at lysine 79 of histone H3 (H3K79me2), which leads to low expression of STAT5 and impaired T cell immunity (101). Since T cell function requires activation of many metabolic pathways to provide energy and raw materials, metabolic reprogramming is essential for T cell activation and differentiation. Among them, polyamine synthesis is a marker of T cell activation and proliferation. Puleston et al. reported that polyamine-hypusine deficiency leads to extensive epigenetic remodeling driven by altered histone acetylation and a re-wired tricarboxylic acid (TCA) cycle, which has an impact on the ability of $CD4^+$ helper T cells to differentiate into different functional fates (102). Accumulating evidence suggests that metabolism affects cell signaling and epigenetics, thereby controlling the lifespan of T cells and converting T cells to an exhaustion state, which inhibits effector function and leads to adverse effects on immune checkpoint molecules (ICM) targeted therapies. How metabolic stress affects T cell exhaustion remains an active area of research (103).

EPIGENETIC DRUGS ENHANCE ANTI-TUMOR IMMUNE RESPONSES

The ability of epigenetic drugs to upregulate the expression of immune signaling components in cancer cells has been established (29, 34, 104), such as histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitor (DNMTi). DNMTi, commonly known as demethylating agents, is the most widely used epigenetic therapy for the treatment of cancer. They are analogues of nucleoside cytidine that irreversibly sequester DNMT proteins from DNA, leading to global DNA hypomethylation. HDACis interfere with the function of histone deacetylases and act by controlling the degree of tightness of DNA wrapped around histones. Treatment of affected tumor animals with DNMTi and/or HDACi can alter immunosuppressive TME and enhance tumor-infiltrating lymphocytes (50, 105–107). These effects are the result of enhanced tumor antigen expression and/or presentation, "viral mimicry" effects, inhibition of T-cell exhaustion, induction of chemokine expression, or a combination thereof.

The methylation effect of DNMTis can lead to CTA re-expression in cancer cells of many different solid tumors (108–110). And 5-Azacytidine can increases the anti-tumor T cell profile in patients with Hodgkin's lymphoma, suggesting that inhibition of DNMT improves new antigen presentation capacity and immunogenicity in tumor cells. In addition to CTA, other TAAs are also regulated by epigenetic drugs, such as high molecular melanoma-associated antigens (HMW-MAAs). 5-AZA-CdR demethylates the HMW-MAAs gene promoter in melanoma cells, resulting in the re-expression of HMW-MAAs at the mRNA and protein levels (111). Although the induction of CTA up-regulation by HDACi is much lower than that by DNMTis (112), it can induce the expression of MHC class I to increase antigen presentation. In the mouse melanoma model, inhibition of HDAC-I with romidepsin enhanced MHC- I expression and enhanced killing activity of $CD8^+$ T cells. Moreover, HDAC inhibition also induces the expression of MHC class I antigen processing and presentation genes, including TAP1, TAP2, LMP2, LMP7 and B2M (113–115).

A key pathway by which DNMTi upregulates immune signaling in cancer is through the viral mimicry pathway. In ovarian cancer cell lines, DNMTis promotes transcription of dsRNA by repressing the silent expression of hypermethylated endogenous retroviruses (ERVs), upregulates dsRNA activates cytoplasmic dsRNA sensors and activates downstream signaling pathways, and induces IFN-β signaling (55). The production of type I and type III interferons induced by the viral mimicry pathway would increase antigen presentation and processing of cancer cells in the tumor microenvironment. Roulois et al. had similar findings in colon cancer cells treated with 5-AZA-CdR (54). The ERVs represent a large fraction of repetitive elements in the human genome that are silenced by DNA methylation. Treatment with DNMT inhibitors allows cancer cells to enter a "viral mimicry" state in which they behave like virus-infected cells, leading to activation of the interferon pathway. These changes were shown to enhance the effectiveness of immune checkpoint inhibitors (54, 55). Further studies revealed that histone deacetylases (HDACs) and KDM1A, the "eraser" of H3K4me1/2 also have similar effects in inhibiting ERV and ERV-induced interferon pathway activation (105, 116).

T cell exhaustion is one of the major causes of immune evasion. A state of T cell differentiation induced by continuous antigen stimulation, resulting in impaired cell function. It is characterized by reduced production of effector molecules and expression of multiple inhibitory receptors including PD-1 (117, 118). T cell exhaustion may be responsible for rendering patients treated with checkpoint inhibitors unresponsive or relapsing. Blockade of PD-1 can only partially and temporarily reverse the phenotype of these T cells that have undergone chronic stimulation with antigen, and epigenetic interventions may help revitalize exhausted T cells. Indeed, treatment of exhausted T cells with HDAC inhibitors restores their functional status (119). In a mouse model of melanoma, the combined use of anti-PD-1 and HDACi therapy was shown to improve survival in mice (120). In the context of chronic antigen exposure, DNMT3a performs methylation of a program associated with exhaustion in $CD8^+$ T cells. Inhibition of DNMT3a reverses the phenomenon and prevents T cell exhaustion (66).

Epigenetically suppressed chemokines have recently been found to have an important role in tumor immune escape. These chemokines would protect tumor cells from immune responses, affecting immune cell infiltration of TME mainly by inhibiting the trafficking of T cells. In ovarian cancer, H3K27me3 and DNMT1 epigenetically regulate the Thelper1 (Th1) type

chemokines CXCL9 and CXCL10, which determine their production (121). Epigenetic regulation using DNMTi is able to induce expression of chemokines and infiltration of Th1 tumors. In lung cancer, HDACis have also been shown to have similar effects that can enhance the expression of T cell chemokines and the infiltration of TME (65). In addition, epigenetic drugs can also increase immune-mediated cytolysis and tumor cell recognition through the action of the innate immune system. For example, HDACi treatment can increase the expression of NK cell surface activating receptor NKG2D by increasing the binding of H3 acetylation on gene promoters, thereby enhancing NK-mediated tumor cell targeting (122). Several different HDACIs have also been shown to increase NK cell killing of tumor cells by upregulating the stress-inducing ligands, such as MICA, MICB, and ULBP1-3, in tumor cells from many different solid malignancies (123–125).

COMBINATION THERAPY OF EPIGENETIC DRUGS AND IMMUNE CHECKPOINT INHIBITORS

As mentioned above, epigenetic mechanisms have an important impact on both host immune cells and tumor cells, and epigenetic drugs have been demonstrated to improve cancer immunotherapy efficacy in many aspects. The combination of immunotherapy and epigenetic drugs is an upsurge in the study of cancer treatment in recent years, the most remarkable of which is the combination of immune checkpoint blockade therapy and epigenetics (**Figure 2**). The classical epigenetic drugs HDACi and DNMTi have been approved by the FDA for cancer therapy. In the animal model of ovarian cancer, the addition of the demethylating drug azacitidine to anti-CTLA-4 antibody therapy significantly elevated the expression of



FIGURE 2 | Combining epigenetic drugs with immune checkpoint inhibitors. Persistent antigen stimulation and inflammatory factors in chronic inflammation can cause dysfunction of tumor-infiltrating T cells, up-regulation of immune checkpoints, and production of immune evasion, which are associated with epigenetic modifications. Anti-PD-1 relieves the inhibitory effect of the epidemic checkpoint on tumor cells and antigen presenting cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2 in the tumor microenvironment. Epigenetic modifiers can enhance antigen presentation by tumor cells, thereby enhancing the immune effects of T cells. Moreover, epigenetic modifiers inhibitors, such as BET, can also inhibit the expression of PD-L1 on the surface of tumor cells and tumor-infiltrating immune cells. Moreover, EZH2 inhibitors prevent the conversion of CD4 T cells into Treg cells to up-regulate the immune response of other cells. Therefore, the combination therapy of epigenetic modifiers with immune checkpoint inhibitors embodies great advantages.

chemokines by NK cells and $CD8^+$ T cells, inhibited tumor growth and prolonged survival in ovarian cancer models compared with immune checkpoint inhibition alone (126). Other studies have provided evidence that the use of DNMT inhibitors can also enhance the effectiveness of anti-PD-1 antibodies. Yu et al. described the mechanism by which decitabine enhanced the expression of immune-related genes such as major histocompatibility complex genes and cytokine-related genes in a syngeneic mouse CT26 colon cancer model and found an increased accumulation of cytolytic $CD8^+$ T cells in the tumor, demonstrating the sensitizing effect of decitabine against PD-1 antibody therapy (127). In addition, azacytidine was able to up-regulate the expression of PD-L1 gene at the transcriptional level and also directly on the cell surface in an *in vitro* cell lung cancer cell line model. Identifying the use of epigenetic therapies in checkpoint inhibitor therapy may elicit more potent immune responses (128).

The regulation of HDAC is multifaceted, which involves NK cell ligand activation and increased cytotoxicity, regulation of MHC class I and class II molecules, elevation of proinflammatory cytokines, and regulation of Treg and Treg Foxp3 gene expression (129). It has been shown that panobinostat is able to modulate different serum cytokines associated with T cell activation in patients with Hodgkin's lymphoma while entinostat can induce immune-related genes associated with antigen presentation in breast cancer (130). PD-L1 expression of tumor antigen presenting cells and T cells was upregulated after treatment of various solid tumor arterial models with HDAC and CTLA-4 inhibitors. Inhibition of HDAC, PD-1, and CTLA-4 can lead to complete tumor rejection. In addition, the HDAC inhibitor entinostat induces depletion of MDSCs and enhances the efficacy of anti-PD-1 therapy (131, 132). Studies have shown that the up-regulation of immune checkpoints is epigenetically regulated through the action of HDACi that regulate PD-L1 expression in melanoma. In the mouse melanoma cell model, mice treated with a combination of panobinostat and anti-PD-1 showed slower tumor progression and higher survival (120).

In recent years, epigenetic drugs with new targets have also gradually entered the horizon of researchers and are approved for cancer treatment. In 2020, the EZH2 inhibitor, Tazverik, was approved for the treatment of epithelioid sarcoma, making it the first approved histone "writer" inhibitor and the first to be used to treat solid tumors (133). Goswami et al. found that peripheral blood T cells from patients treated with anti-CTLA-4 antibody increased EZH2 expression (121, 134). Subsequently, they demonstrated that EZH2 inhibitor alone enhanced the cytotoxic activity of human $CD8^+$ effector T cells, altered the phenotype and function of human Treg cells, and had an immunotherapy-sensitizing effect against CTLA-4 in mouse bladder cancer and melanoma models (121, 134). In addition, the combination of EZH2 inhibitors and azacytidine increases immune cell infiltration in TME, slows tumor progression, and improves the efficacy of anti-PD-L1 therapy (121). Other drugs, such as inhibitors against LSD1, PRMT5, and BET proteins, can also enhance the efficacy of immunotherapy. Together, these findings provide evidence to support the effectiveness of combining epigenetic agents and immune checkpoint inhibition.

CONCLUSION

The rapid development of cancer immunology has attracted a lot of research efforts and achieved outstanding results. Immune checkpoint blockade represents a new milestone in cancer therapy with promising prospects in terms of clinical benefit and enhanced durability of tumor response. Recent studies have shown that epigenetic regulation affects all aspects of the interaction between tumor cells and the immune system. Thus, epigenetic regulation can induce robust antitumor immune responses. The combination of epigenetic regulation and immunotherapy has been proved can relieve some of the limitations of single immunotherapy, which makes it a promising combination therapy partner for cancer immunotherapy. In this review, we have elucidated the mechanism of the immunological effects of epigenetic regulation on tumor cells and immune cells, and discussed the combination therapy of epigenetic drugs and immune blocking point inhibition therapy. There is an increasing number of epigenetically targeted drugs approved for cancer therapy, and their combination with immunotherapy will certainly have more possibilities. The future will also see the development of new methods that represent the combination of genetic drugs with emerging immunotherapies, including tumor vaccine and adoptive T cell therapies, which will face great challenges, but also provide new opportunities for improving cancer therapeutic interventions.

AUTHOR CONTRIBUTIONS

ZL designed this work. YR collected materials. YR wrote this manuscript. ZL, XH, SW, HX, and LL edited and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

FUNDING

This study was supported by the National Natural Science Foundation of China (Grant No. 82002433).

REFERENCES

1. Cooper MD, Miller J. Discovery of 2 Distinctive Lineages of Lymphocytes, T Cells and B Cells, as the Basis of the Adaptive Immune System and Immunologic Function: 2019 Albert Lasker Basic Medical Research Award. *JAMA* (2019) 322:1247–8. doi: 10.1001/jama.2019.13815
2. Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity* (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012
3. Fu C, Jiang A. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. *Front Immunol* (2018) 9:3059. doi: 10.3389/fimmu.2018.03059

4. Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, et al. Hijacking Antibody-Induced CTLA-4 Lysosomal Degradation for Safer and More Effective Cancer Immunotherapy. *Cell Res* (2019) 29:609–27. doi: 10.1038/s41422-019-0184-1
5. Krummel MF, Bartumeus F, Gerard A. T Cell Migration, Search Strategies and Mechanisms. *Nat Rev Immunol* (2016) 16:193–201. doi: 10.1038/nri.2015.16
6. Joyce JA, Fearon DT. T Cell Exclusion, Immune Privilege, and the Tumor Microenvironment. *Science* (2015) 348:74–80. doi: 10.1126/science.aaa6204
7. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive Strategies That Are Mediated by Tumor Cells. *Annu Rev Immunol* (2007) 25:267–96. doi: 10.1146/annurev.immunol.25.022106.141609
8. Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, et al. Epigenetic Modification Augments the Immunogenicity of Human Leukocyte Antigen G Serving as a Tumor Antigen for T Cell-Based Immunotherapy. *Oncoimmunology* (2016) 5:e1169356. doi: 10.1080/2162402X.2016.1169356
9. Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, et al. DNA Methyltransferase Inhibition Increases Efficacy of Adoptive Cellular Immunotherapy of Murine Breast Cancer. *Cancer Immunol Immunother* (2016) 65:1061–73. doi: 10.1007/s00262-016-1868-8
10. Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, et al. Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response Against Melanoma. *J Invest Dermatol* (2017) 137:159–69. doi: 10.1016/j.jid.2016.08.024
11. Gollob JA, Sciambi CJ. Decitabine Up-Regulates S100A2 Expression and Synergizes With IFN-Gamma to Kill Uveal Melanoma Cells. *Clin Cancer Res* (2007) 13:5219–25. doi: 10.1158/1078-0432.CCR-07-0816
12. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, et al. A Phase I Trial Combining Decitabine/Dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children With Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma. *Cancer Immunol Immunother* (2015) 64:1251–60. doi: 10.1007/s00262-015-1731-3
13. Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade. *Science* (1996) 271:1734–6. doi: 10.1126/science.271.5256.1734
14. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. Crystal Structure of the B7-1/CTLA-4 Complex That Inhibits Human Immune Responses. *Nature* (2001) 410:608–11. doi: 10.1038/35069118
15. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on Tumor Cells in the Escape From Host Immune System and Tumor Immunotherapy by PD-L1 Blockade. *Proc Natl Acad Sci USA* (2002) 99:12293–7. doi: 10.1073/pnas.192461099
16. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of Programmed Death 1 Ligands by Murine T Cells and APC. *J Immunol* (2002) 169:5538–45. doi: 10.4049/jimmunol.169.10.5538
17. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated Monocytes in Peritumoral Stroma of Hepatocellular Carcinoma Foster Immune Privilege and Disease Progression Through PD-L1. *J Exp Med* (2009) 206:1327–37. doi: 10.1084/jem.20082173
18. Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, et al. Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. *Clin Cancer Res* (2011) 17:5668–73. doi: 10.1158/1078-0432.CCR-11-0239
19. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. *In Situ* Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. *J Clin Oncol* (2009) 27:5944–51. doi: 10.1200/JCO.2008.19.6147
20. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the Introduction of the 'Immunoscore' in the Classification of Malignant Tumours. *J Pathol* (2014) 232:199–209. doi: 10.1002/path.4287
21. Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms Regulating T-Cell Infiltration and Activity in Solid Tumors. *Ann Oncol* (2017) 28:xii18–32. doi: 10.1093/annonc/mdx238
22. Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages Impede CD8 T Cells From Reaching Tumor Cells and Limit the Efficacy of Anti-PD-1 Treatment. *Proc Natl Acad Sci USA* (2018) 115:E4041–50. doi: 10.1073/pnas.1720948115
23. Shin JI, Ha SJ. Regulatory T Cells-an Important Target for Cancer Immunotherapy. *Nat Rev Clin Oncol* (2014) 11:307. doi: 10.1038/nrclinonc.2013.208-c1
24. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T Cells in Tumors From Patients With Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer. *Cancer Res* (2001) 61:4766–72.
25. Togashi Y, Shitara K, Nishikawa H. Regulatory T Cells in Cancer Immunosuppression - Implications for Anticancer Therapy. *Nat Rev Clin Oncol* (2019) 16:356–71. doi: 10.1038/s41571-019-0175-7
26. de Charette M, Marabelle A, Houot R. Turning Tumour Cells Into Antigen Presenting Cells: The Next Step to Improve Cancer Immunotherapy? *Eur J Cancer* (2016) 68:134–47. doi: 10.1016/j.ejca.2016.09.010
27. Beatty GL, Gladney WL. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. *Clin Cancer Res* (2015) 21:687–92. doi: 10.1158/1078-0432.CCR-14-1860
28. Dustin ML. The Immunological Synapse. *Cancer Immunol Res* (2014) 2:1023–33. doi: 10.1158/2326-6066.CIR-14-0161
29. Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic Drugs as Immunomodulators for Combination Therapies in Solid Tumors. *Pharmacol Ther* (2014) 142:339–50. doi: 10.1016/j.pharmthera.2013.12.015
30. Heninger E, Krueger TE, Lang JM. Augmenting Antitumor Immune Responses With Epigenetic Modifying Agents. *Front Immunol* (2015) 6:29. doi: 10.3389/fimmu.2015.00029
31. Terranova-Barberio M, Thomas S, Munster PN. Epigenetic Modifiers in Immunotherapy: A Focus on Checkpoint Inhibitors. *Immunotherapy* (2016) 8:705–19. doi: 10.2217/imt-2016-0014
32. Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, et al. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. *Clin Cancer Res* (2015) 21:4040–7. doi: 10.1158/1078-0432.CCR-14-2914
33. Weintraub K. Take Two: Combining Immunotherapy With Epigenetic Drugs to Tackle Cancer. *Nat Med* (2016) 22:8–10. doi: 10.1038/nm0116-8
34. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining Epigenetic and Immunotherapy to Combat Cancer. *Cancer Res* (2016) 76:1683–9. doi: 10.1158/0008-5472.CAN-15-2125
35. Jones PA, Baylin SB. The Fundamental Role of Epigenetic Events in Cancer. *Nat Rev Genet* (2002) 3:415–28. doi: 10.1038/nrg816
36. Esteller M. Epigenetics in Cancer. *N Engl J Med* (2008) 358:1148–59. doi: 10.1056/NEJMra072067
37. Jones PA, Takai D. The Role of DNA Methylation in Mammalian Epigenetics. *Science* (2001) 293:1068–70. doi: 10.1126/science.1063852
38. Kouzarides T. Chromatin Modifications and Their Function. *Cell* (2007) 128:693–705. doi: 10.1016/j.cell.2007.02.005
39. Jones PA, Baylin SB. The Epigenomics of Cancer. *Cell* (2007) 128:683–92. doi: 10.1016/j.cell.2007.01.029
40. Shen H, Laird PW. Interplay Between the Cancer Genome and Epigenome. *Cell* (2013) 153:38–55. doi: 10.1016/j.cell.2013.03.008
41. Li B, Carey M, Workman JL. The Role of Chromatin During Transcription. *Cell* (2007) 128:707–19. doi: 10.1016/j.cell.2007.01.015
42. Fardi M, Solali S, Farshdousti Hagh M. Epigenetic Mechanisms as a New Approach in Cancer Treatment: An Updated Review. *Genes Dis* (2018) 5:304–11. doi: 10.1016/j.gendis.2018.06.003
43. Schubeler D. Function and Information Content of DNA Methylation. *Nature* (2015) 517:321–6. doi: 10.1038/nature14192
44. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, et al. A Silencing Pathway to Induce H3-K9 and H4-K20 Trimethylation at Constitutive Heterochromatin. *Genes Dev* (2004) 18:1251–62. doi: 10.1101/gad.300704
45. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial Patterns of Histone Acetylations and Methylations in the Human Genome. *Nat Genet* (2008) 40:897–903. doi: 10.1038/ng.154
46. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of Acetylation at Lys16 and Trimethylation at Lys20 of Histone H4 Is a Common Hallmark of Human Cancer. *Nat Genet* (2005) 37:391–400. doi: 10.1038/ng1531
47. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of Mutational Processes in Human Cancer. *Nature* (2013) 500:415–21. doi: 10.1038/nature12477

48. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis Antigens, Gametogenesis and Cancer. *Nat Rev Cancer* (2005) 5:615–25. doi: 10.1038/nrc1669
49. Whitehurst AW. Cause and Consequence of Cancer/Testis Antigen Activation in Cancer. *Annu Rev Pharmacol Toxicol* (2014) 54:251–72. doi: 10.1146/annurev-pharmtox-011112-140326
50. Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA Methyltransferase Inhibition Upregulates MHC-I to Potentiate Cytotoxic T Lymphocyte Responses in Breast Cancer. *Nat Commun* (2018) 9:248. doi: 10.1038/s41467-017-02630-w
51. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors. *J Immunol* (2000) 165:7017–24. doi: 10.4049/jimmunol.165.12.7017
52. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune Regulation by Low Doses of the DNA Methyltransferase Inhibitor 5-Azacitidine in Common Human Epithelial Cancers. *Oncotarget* (2014) 5:587–98. doi: 10.18632/oncotarget.1782
53. Ennishi D, Takata K, Beguelin W, Duns G, Mottok A, Farinha P, et al. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. *Cancer Discov* (2019) 9:546–63. doi: 10.1158/2159-8290.CD-18-1090
54. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. *Cell* (2015) 162:961–73. doi: 10.1016/j.cell.2015.07.056
55. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer *via* dsRNA Including Endogenous Retroviruses. *Cell* (2015) 162:974–86. doi: 10.1016/j.cell.2015.07.011
56. Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, et al. Comprehensive Analysis of PD-L1 Expression in Glioblastoma Multiforme. *Oncotarget* (2017) 8:42214–25. doi: 10.18632/oncotarget.15031
57. Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, et al. PD-L1 Promoter Methylation Is a Prognostic Biomarker for Biochemical Recurrence-Free Survival in Prostate Cancer Patients Following Radical Prostatectomy. *Oncotarget* (2016) 7:79943–55. doi: 10.18632/oncotarget.13161
58. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 Contributes to Immunosuppression and Is Associated With Anti-PD-1 Response. *Nature* (2018) 560:382–6. doi: 10.1038/s41586-018-0392-8
59. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. *Cell Rep* (2017) 18:2162–74. doi: 10.1016/j.celrep.2017.02.011
60. Ebine K, Kumar K, Pham TN, Shields MA, Collier KA, Shang M, et al. Interplay Between Interferon Regulatory Factor 1 and BRD4 in the Regulation of PD-L1 in Pancreatic Stellate Cells. *Sci Rep* (2018) 8:13225. doi: 10.1038/s41598-018-31658-1
61. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET Bromodomain Inhibition Promotes Anti-Tumor Immunity by Suppressing PD-L1 Expression. *Cell Rep* (2016) 16:2829–37. doi: 10.1016/j.celrep.2016.08.032
62. Kioussis D, Georgopoulos K. Epigenetic Flexibility Underlying Lineage Choices in the Adaptive Immune System. *Science* (2007) 317:620–2. doi: 10.1126/science.1143777
63. Ptaschinski C, Mukherjee S, Moore ML, Albert M, Helin K, Kunkel SL, et al. RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis *In Vivo*. *PLoS Pathog* (2015) 11:e1004978. doi: 10.1371/journal.ppat.1004978
64. Wilson CB, Makar KW, Perez-Melgosa M. Epigenetic Regulation of T Cell Fate and Function. *J Infect Dis* (2002) 185 Suppl 1:S37–45. doi: 10.1086/338001
65. Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, et al. And Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. *Clin Cancer Res* (2016) 22:4119–32. doi: 10.1158/1078-0432.CCR-15-2584
66. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. *De Novo* Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. *Cell* (2017) 170:142–57.e19. doi: 10.1016/j.cell.2017.06.007
67. Chang JT, Wherry EJ, Goldrath AW. Molecular Regulation of Effector and Memory T Cell Differentiation. *Nat Immunol* (2014) 15:1104–15. doi: 10.1038/ni.3031
68. Perez-Salvia M, Esteller M. Bromodomain Inhibitors and Cancer Therapy: From Structures to Applications. *Epigenetics* (2017) 12:323–39. doi: 10.1080/15592294.2016.1265710
69. Xu Y, Vakoc CR. Targeting Cancer Cells With BET Bromodomain Inhibitors. *Cold Spring Harb Perspect Med 7* (2017) 7:7–25. doi: 10.1101/cshperspect.a026674
70. Youngblood B, Hale JS, Kissick HT, Ahn E, Xu X, Wieland A, et al. Effector CD8 T Cells Dedifferentiate Into Long-Lived Memory Cells. *Nature* (2017) 552:404–9. doi: 10.1038/nature25144
71. Carty SA, Gohil M, Banks LB, Cotton RM, Johnson ME, Stelekati E, et al. The Loss of TET2 Promotes CD8(+) T Cell Memory Differentiation. *J Immunol* (2018) 200:82–91. doi: 10.4049/jimmunol.1700559
72. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, et al. Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells. *J Immunol* (2013) 191:540–4. doi: 10.4049/jimmunol.1203161
73. Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, et al. Origin and Differentiation of Human Memory CD8 T Cells After Vaccination. *Nature* (2017) 552:362–7. doi: 10.1038/nature24633
74. Nishikawa H, Sakaguchi S. Regulatory T Cells in Cancer Immunotherapy. *Curr Opin Immunol* (2014) 27:1–7. doi: 10.1016/j.coi.2013.12.005
75. Kitagawa Y, Wing JB, Sakaguchi S. Transcriptional and Epigenetic Control of Regulatory T Cell Development. *Prog Mol Biol Transl Sci* (2015) 136:1–33. doi: 10.1016/bs.pmbts.2015.07.011
76. DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, et al. The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity After Activation. *Immunity* (2015) 42:227–38. doi: 10.1016/j.immuni.2015.01.007
77. Lee W, Lee GR. Transcriptional Regulation and Development of Regulatory T Cells. *Exp Mol Med* (2018) 50:e456. doi: 10.1038/emm.2017.313
78. Morikawa H, Sakaguchi S. Genetic and Epigenetic Basis of Treg Cell Development and Function: From a FoxP3-Centered View to an Epigenome-Defined View of Natural Treg Cells. *Immunol Rev* (2014) 259:192–205. doi: 10.1111/imr.12174
79. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 Regulates FOXP3 Expression in Human CD4+CD25+ Regulatory T Cells Through a STAT-Dependent Mechanism and Induces the Expansion of These Cells *In Vivo*. *Blood* (2006) 108:1571–9. doi: 10.1182/blood-2006-02-004747
80. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic Control of the Foxp3 Locus in Regulatory T Cells. *PLoS Biol* (2007) 5:e38. doi: 10.1371/journal.pbio.0050038
81. Lal G, Bromberg JS. Epigenetic Mechanisms of Regulation of Foxp3 Expression. *Blood* (2009) 114:3727–35. doi: 10.1182/blood-2009-05-219584
82. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T Cell Lineage Differentiation. *Immunity* (2009) 30:646–55. doi: 10.1016/j.immuni.2009.05.001
83. Russ BE, Prier JE, Rao S, Turner SJ. T Cell Immunity as a Tool for Studying Epigenetic Regulation of Cellular Differentiation. *Front Genet* (2013) 4:218. doi: 10.3389/fgene.2013.00218
84. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. *Cancer Res* (2010) 70:68–77. doi: 10.1158/0008-5472.CAN-09-2587
85. Zhang H, Li ZL, Ye SB, Ouyang LY, Chen YS, He J, et al. Myeloid-Derived Suppressor Cells Inhibit T Cell Proliferation in Human Extranodal NK/T Cell Lymphoma: A Novel Prognostic Indicator. *Cancer Immunol Immunother* (2015) 64:1587–99. doi: 10.1007/s00262-015-1765-6
86. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells. *J Immunol* (2010) 184:3106–16. doi: 10.4049/jimmunol.0902661
87. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic Control of Myeloid Cell Differentiation, Identity and Function. *Nat Rev Immunol* (2015) 15:7–17. doi: 10.1038/nri3777
88. Ivashkiv LB, Park SH. Epigenetic Regulation of Myeloid Cells. *Microbiol Spectr* (2016) 4:571–90. doi: 10.1128/microbiolspec.MCHD-0010-2015

89. Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, et al. Histone Deacetylase 11: A Novel Epigenetic Regulator of Myeloid Derived Suppressor Cell Expansion and Function. *Mol Immunol* (2015) 63:579–85. doi: 10.1016/j.molimm.2014.08.002
90. Zhang C, Wang S, Liu Y, Yang C. Epigenetics in Myeloid Derived Suppressor Cells: A Sheathed Sword Towards Cancer. *Oncotarget* (2016) 7:57452–63. doi: 10.18632/oncotarget.10767
91. Dai Z, Ramesh V, Locasale JW. The Evolving Metabolic Landscape of Chromatin Biology and Epigenetics. *Nat Rev Genet* (2020) 21:737–53. doi: 10.1038/s41576-020-0270-8
92. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic Reprogramming and Cancer Progression. *Science* (2020) 368:eaaw5473. doi: 10.1126/science.aaw5473
93. Zheng Q, Maksimovic I, Upad A, David Y. Non-Enzymatic Covalent Modifications: A New Link Between Metabolism and Epigenetics. *Protein Cell* (2020) 11:401–16. doi: 10.1007/s13238-020-00722-w
94. Wang YP, Lei QY. Metabolic Recoding of Epigenetics in Cancer. *Cancer Commun (Lond)* (2018) 38:25. doi: 10.1186/s40880-018-0302-3
95. Thakur C, Chen F. Connections Between Metabolism and Epigenetics in Cancers. *Semin Cancer Biol* (2019) 57:52–8. doi: 10.1016/j.semcancer.2019.06.006
96. Varier RA, Timmers HT. Histone Lysine Methylation and Demethylation Pathways in Cancer. *Biochim Biophys Acta* (2011) 1815:75–89. doi: 10.1016/j.bbcan.2010.10.002
97. Klose RJ, Kallin EM, Zhang Y. JmjC-Domain-Containing Proteins and Histone Demethylation. *Nat Rev Genet* (2006) 7:715–27. doi: 10.1038/nrg1945
98. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, et al. Tissue-Specific Isoform Switch and DNA Hypomethylation of the Pyruvate Kinase PKM Gene in Human Cancers. *Oncotarget* (2014) 5:8202–10. doi: 10.18632/oncotarget.1159
99. Kelly B, O'Neill LA. Metabolic Reprogramming in Macrophages and Dendritic Cells in Innate Immunity. *Cell Res* (2015) 25:771–84. doi: 10.1038/cr.2015.68
100. Shyer JA, Flavell RA, Bailis W. Metabolic Signaling in T Cells. *Cell Res* (2020) 30:649–59. doi: 10.1038/s41422-020-0379-5
101. Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 Alters T Cell Methionine Metabolism and Histone Methylation. *Nature* (2020) 585:277–82. doi: 10.1038/s41586-020-2682-1
102. Puleston DJ, Baixauli F, Sanin DE, Edwards-Hicks J, Villa M, Kabat AM, et al. Polyamine Metabolism Is a Central Determinant of Helper T Cell Lineage Fidelity. *Cell* (2021) 184:4186–202.e20. doi: 10.1016/j.cell.2021.06.007
103. Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and Epigenetic Regulation of T-Cell Exhaustion. *Nat Metab* (2020) 2:1001–12. doi: 10.1038/s42255-020-00280-9
104. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* (2015) 373:23–34. doi: 10.1056/NEJMoa1504030
105. Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. *Cell* (2017) 171:1284–300.e21. doi: 10.1016/j.cell.2017.10.022
106. Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, et al. HDAC6 Inhibition Synergizes With Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. *Cancer Res* (2019) 79:5482–9. doi: 10.1158/0008-5472.CAN-19-1302
107. Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 Inhibitors Improve Anti-PD-1 Immune Checkpoint Blockade Therapy by Decreasing the Anti-Inflammatory Phenotype of Macrophages and Down-Regulation of Immunosuppressive Proteins in Tumor Cells. *Sci Rep* (2019) 9:6136. doi: 10.1038/s41598-019-42237-3
108. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, et al. The Biology of Cancer Testis Antigens: Putative Function, Regulation and Therapeutic Potential. *Mol Oncol* (2011) 5:164–82. doi: 10.1016/j.molonc.2011.02.001
109. James SR, Link PA, Karpf AR. Epigenetic Regulation of X-Linked Cancer/Germline Antigen Genes by DNMT1 and DNMT3b. *Oncogene* (2006) 25:6975–85. doi: 10.1038/sj.onc.1209678
110. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 Tumor Antigen Is Up-Regulated by the Demethylating Agent 5-Aza-2'-Deoxycytidine. *Cancer Res* (1994) 54:1766–71.
111. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Gene Expression by Promoter DNA Methylation in Human Melanoma Cells. *Oncogene* (2006) 25:2873–84. doi: 10.1038/sj.onc.1209319
112. Wischnewski F, Pantel K, Schwarzenbach H. Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells. *Mol Cancer Res* (2006) 4:339–49. doi: 10.1158/1541-7786.MCR-05-0229
113. Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, et al. Epigenetic Priming Restores the HLA Class-I Antigen Processing Machinery Expression in Merkel Cell Carcinoma. *Sci Rep* (2017) 7:2290. doi: 10.1038/s41598-017-02608-0
114. Khan AN, Gregorie CJ, Tomasi TB. Histone Deacetylase Inhibitors Induce TAP, LMP, Tapasin Genes and MHC Class I Antigen Presentation by Melanoma Cells. *Cancer Immunol Immunother* (2008) 57:647–54. doi: 10.1007/s00262-007-0402-4
115. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-Regulation of HLA Class I Antigens in Prostate Cancer Tissues and Up-Regulation by Histone Deacetylase Inhibition. *J Urol* (2007) 178:692–6. doi: 10.1016/j.juro.2007.03.109
116. Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 Ablation Stimulates Anti-Tumor Immunity and Enables Checkpoint Blockade. *Cell* (2018) 174:549–63.e19. doi: 10.1016/j.cell.2018.05.052
117. Wherry EJ, Kurachi M. Molecular and Cellular Insights Into T Cell Exhaustion. *Nat Rev Immunol* (2015) 15:486–99. doi: 10.1038/nri3862
118. Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic Stability of Exhausted T Cells Limits Durability of Reinvigoration by PD-1 Blockade. *Science* (2016) 354:1160–5. doi: 10.1126/science.aaf2807
119. Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y, Shen H. Epigenetic Manipulation Restores Functions of Defective CD8(+) T Cells From Chronic Viral Infection. *Mol Ther* (2014) 22:1698–706. doi: 10.1038/mt.2014.91
120. Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy With PD-1 Blockade. *Cancer Immunol Res* (2015) 3:1375–85. doi: 10.1158/2326-6066.CIR-15-0077-T
121. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic Silencing of TH1-Type Chemokines Shapes Tumour Immunity and Immunotherapy. *Nature* (2015) 527:249–53. doi: 10.1038/nature15520
122. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, et al. The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. *Pharm Res* (2015) 32:779–92. doi: 10.1007/s11095-013-1231-0
123. Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular Helper T-Cells: Expanding Roles in T-Cell Lymphoma and Targets for Treatment. *Br J Haematol* (2014) 166:326–35. doi: 10.1111/bjh.12941
124. Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 Represses the Expression of NKG2D Ligands ULBPs in Epithelial Tumour Cells: Potential Implications for the Immunosurveillance of Cancer. *Oncogene* (2009) 28:2370–82. doi: 10.1038/onc.2009.117
125. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, et al. Valproic Acid Cooperates With Hydralazine to Augment the Susceptibility of Human Osteosarcoma Cells to Fas- and NK Cell-Mediated Cell Death. *Int J Oncol* (2012) 41:83–91. doi: 10.3892/ijo.2012.1438
126. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes With CTLA-4 Blockade in a Murine Ovarian Cancer Model. *Cancer Immunol Res* (2015) 3:1030–41. doi: 10.1158/2326-6066.CIR-15-0073
127. Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, et al. Low-Dose Decitabine Enhances the Effect of PD-1 Blockade in Colorectal Cancer With Microsatellite Stability by Re-Modulating the Tumor Microenvironment. *Cell Mol Immunol* (2019) 16:401–9. doi: 10.1038/s41423-018-0026-y
128. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, et al. Alterations of Immune Response of Non-Small Cell Lung Cancer With Azacytidine. *Oncotarget* (2013) 4:2067–79. doi: 10.18632/oncotarget.1542

129. West AC, Smyth MJ, Johnstone RW. The Anticancer Effects of HDAC Inhibitors Require the Immune System. *Oncoimmunology* (2014) 3:e27414. doi: 10.4161/onci.27414
130. Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, et al. Immune Regulatory Effects of Panobinostat in Patients With Hodgkin Lymphoma Through Modulation of Serum Cytokine Levels and T-Cell PD1 Expression. *Blood Cancer J* (2014) 4:e236. doi: 10.1038/bcj.2014.58
131. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of Metastatic Mouse Cancers Resistant to Immune Checkpoint Blockade by Suppression of Myeloid-Derived Cells. *Proc Natl Acad Sci USA* (2014) 111:11774–9. doi: 10.1073/pnas.1410626111
132. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. *Clin Cancer Res* (2017) 23:5187–201. doi: 10.1158/1078-0432.CCR-17-0741
133. Leslie M. First EZH2 Inhibitor Approved-For Rare Sarcoma. *Cancer Discov* (2020) 10:333–4. doi: 10.1158/2159-8290.CD-NB2020-006
134. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 Expression in T Cells Improves Efficacy of Anti-CTLA-4 Therapy. *J Clin Invest* (2018) 128:3813–8. doi: 10.1172/JCI99760

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers in Immunology

REVIEW
published: 24 January 2022
doi: 10.3389/fimmu.2022.781660

Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy

Adeleye O. Adeshakin[1,2,3†], *Funmilayo O. Adeshakin*[1,2†], *Dehong Yan*[1,2*] *and Xiaochun Wan*[1,2*]

[1] *Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China,* [2] *University of Chinese Academy of Sciences, Beijing , China,* [3] *Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, United States*

OPEN ACCESS

Edited by:
Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Michal Kuczma, Georgia State University, United States
Varun Sasidharan Nair, Helmholtz Association of German Research Centers (HZ), Germany

***Correspondence:**
Dehong Yan
dh.yan@siat.ac.cn
Xiaochun Wan
xc.wan@siat.ac.cn

†*These authors have contributed equally to this work*

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *30 September 2021*
Accepted: *03 January 2022*
Published: *24 January 2022*

Citation:
Adeshakin AO, Adeshakin FO, Yan D and Wan X (2022) Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. Front. Immunol. 13:781660. doi: 10.3389/fimmu.2022.781660

Immunotherapy has emerged as a promising approach to combat immunosuppressive tumor microenvironment (TME) for improved cancer treatment. FDA approval for the clinical use of programmed death receptor 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors revolutionized T cell-based immunotherapy. Although only a few cancer patients respond to this treatment due to several factors including the accumulation of immunosuppressive cells in the TME. Several immunosuppressive cells within the TME such as regulatory T cells, myeloid cells, and cancer-associated fibroblast inhibit the activation and function of T cells to promote tumor progression. The roles of epigenetic modifiers such as histone deacetylase (HDAC) in cancer have long been investigated but little is known about their impact on immune cells. Recent studies showed inhibiting HDAC expression on myeloid-derived suppressor cells (MDSCs) promoted their differentiation to less suppressive cells and reduced their immunosuppressive effect in the TME. HDAC inhibitors upregulated PD-1 or PD-L1 expression level on tumor or immune cells sensitizing tumor-bearing mice to anti-PD-1/PD-L1 antibodies. Herein we discuss how inhibiting HDAC expression on MDSCs could circumvent drawbacks to immune checkpoint inhibitors and improve cancer immunotherapy. Furthermore, we highlighted current challenges and future perspectives of HDAC inhibitors in regulating MDSCs function for effective cancer immunotherapy.

Keywords: MDSCs, HDAC, epigenetic signaling pathways, anti-PD-1/PD-L1, T cell-based immunotherapy

INTRODUCTION

The tumor microenvironment is extremely immunosuppressive in the advanced cancer stage and targeting immunosuppressive phenotypes is a promising approach in cancer immunotherapy (1–4). The FDA approved two classes of immunotherapy for clinical use which include inhibitors of cytotoxic T-cell lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1/programmed death-ligand 1 (PD-1/PD-L1) (5–7). Studies have shown that immunotherapy is effective in the treatment of

certain cancers such as melanoma, lung, and renal carcinoma (6, 8–10). Nevertheless, only a few cancer patients respond to these treatments due to numerous factors such as tumor immunogenicity, inhibition of signal transduction, antigen presentation, upregulation of certain inhibitory molecules on T cells, poor persistence, and low effector function of T cells to demonstrate a cytotoxic effect on some tumor (11–15). Besides, tumor-infiltrating immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), cancer-associated fibroblast (CAF) to mention a few contribute tremendously to the failure of immune checkpoint blockades (16–19). These immunosuppressive cells inhibit T cells effector functionality and their anti-tumor responses (16, 20).

In the tumor milieu, conventional-type 1 dendritic cells (DCs) possess the ability to cross-present tumor antigens and produce IL-12 to activate cytotoxic T cells for immune responses against cancer (21, 22). DCs are required to promote the anti-tumor effect of immune checkpoint blockades (22). More recently, NK and DCs subset (stimulatory DCs) axis were reported to define tumor response to checkpoint therapy, cytotoxic T cells response, and overall survival in melanoma tumor immune microenvironment (23, 24). Barry et al. demonstrated that a formative cytokine, Fms-related tyrosine kinase 3 ligand (FLT3LG) for conventional DCs was mainly produced by NK cells and played a critical role in regulating the level of stimulatory DCs for anti-tumor responses (23). Specifically, the authors showed that non-T cells have a significant impact on protective immunity since the frequencies of T cells exhaustion did not determine response to PD-1 therapy contrary to previous understanding (25). Thus, this observation requires further studies to delineate which immune cells predict responses to therapy.

Beyond the protective role of immune cells against tumor regression or elimination of pathogens, immune cells have been identified to play a critical role in normal tissue function such as tissue development and maintenance. Several immune cell types are heterogeneous which are distinct from the dual conception of tolerance versus destructive immunity. For instance, innate myeloid cells (DCs and macrophages) and T cells undergo multiple metabolic and epigenetic reprogramming impacting their roles in healthy or pathological conditions. This reprogramming can induce pro-inflammatory or anti-inflammatory cytokines production that drives contrasting activities of these immune cells. During chronic viral infection, epigenetic reprogramming leads to cytotoxic T cells exhaustion limiting T cells' ability to recognize and kill non-self and infected cells (26). This exhaustion undermines the destructive potential of T cells responses and restricts the immunopathological effects for extensive eradication of infected host cells. Presently, other cell types that function with exhausted T cells to limit viral-specific T cell immunity are not fully characterized but are likely to be specific myeloid cells subsets (27). Tissue repair and wound healing is a good example of an immune response that is neither involved in tolerance nor destruction, but instead focuses on attaining tissue homeostasis. To achieve this, myeloid cell populations such as monocytes and macrophages have been identified (28). These emerging attributes of the immune system by engaging in non-destructive responses that promote cellular homeostasis besides pathogen protection were considered as a continuum between stringent approaches of tolerance and destruction regarded as immune accommodation archetypes (29). It is therefore evident that mobilizing the required immune response archetype is crucial for physiological and pathological conditions.

This necessitates the need to consider the immune system as a continuum of accommodation archetypes as these may influence our understanding of diseases especially cancer. As previously mentioned above, the tumor immune microenvironment accommodates several immune cell phenotypes that imitate these archetypes and contributes to tumor progression. Although, in some cancer types, data from patients' cohorts exhibit wound healing gene signatures highlighting archetype remodeling (30). Another study showed variable components of late tissue-repair archetypes in cancers such as TAMs and Tregs (31). Krummel et al. highlighted that robust patient responsiveness to immunotherapies may require improved therapeutic or inhibition of subsets of certain immune archetypes in each tumor microenvironment (29). Thus, there is a need to explore how identifying archetype patterns will impact prognosis and immunotherapy for improved clinical responses in cancer patients.

MDSCs are pathologically activated immature myeloid cells that inhibit or induce several immune cells such as T, NK, Tregs, macrophages, neutrophils, and CAF during cancer, infection, graft versus host disease, and other conditions (32–35). MDSCs have been reported to demonstrate different roles in various pathological conditions (36). Most studies have studied MDSCs in the context of promoting immunosuppression in cancer, but recent studies have identified their therapeutic potential in reducing the severity of infection and autoimmune diseases which is yet to be fully understood (32, 37). Sarkar et al. showed that early recruitment of MDSCs subset in ocular herpes simplex virus type 1 (HSV1) infection suppressed effector $CD4^+$ T cells proliferation and cytokine production in a contact-dependent manner (32). HSV1 infection initiates the manifestation of a severe inflammation called herpetic stromal keratitis (HSK) – a foremost cause of infectious blindness globally (38, 39). However, injection of *in vitro*-generated MDSCs from bone marrow precursor cells into HSV1-infected mice decreased the severity of HSK lesion at the onset of clinical HSK (32). Likewise, the transferred MDSCs in mice did not only induce anti-inflammatory responses but promoted endogenous Treg which could be clinically relevant (32).

In tumor-bearing mice, MDSCs can be characterized as $CD11b^+Gr1^+$ cells; these cells can be further subdivided into monocytic MDSCs ($CD11b^+Ly6G^-Ly6C^{hi}$) and polymorphonuclear (PMN) MDSCs ($CD11b^+Ly6G^+Ly6C^{low}$). MDSCs differentiate to other suppressive immune cells such as TAMs which accumulate in the TME and support tumor proliferation. Since MDSCs are phenotypically similar to monocytes and neutrophils, this led to the complexity in their identification and clearly defined functional assay. PMN-MDSCs account for about 70-80% of MDSCs in tumor models; secrete arginase 1 (ARG1) and

upregulate NADPH which contributes to ROS production that inhibits immune cells function and activate of STAT3 signaling pathway (36, 40). On the other hand, M-MDSCs secrete ARG1, inducible nitric oxide (iNOS), and activate the STAT1 signaling pathway (36). Like murine MDSCs, there are two major subsets of human MDSCs which are M-MDSCs and PMN-MDSCs. In human peripheral blood mononuclear cell (PBMC), M-MDSCs consists of $CD11b^{+}CD14^{+}HLA\text{-}DR^{-/lo}CD15^{-}$ while PMN-MDSCs subset includes $CD11b^{+}CD14^{-}CD15^{+}$ or $CD11b^{+}CD14^{-}CD66b^{+}$. Recently, another subset of MDSCs in humans referred to as early-stage MDSCs (eMDSCs) was proposed to demonstrate colony-forming activity based on the immature nature of the cell population. eMDSCs is a mixed group of MDSCs with several immature progenitors that include – Lin^{-} (CD3, CD14, CD15, CD19, CD56) $HLA\text{-}DR^{-}CD33^{+}$ (41–43). However, these eMDSCs are yet to be identified or defined in mice.

MDSCs accumulate in patients' tissues from several types of cancer (42–55). Reports have it that a higher frequency of tumor-infiltrating MDSCs is associated with advanced stage and high-grade tumors (52, 53). Importantly, several studies showed that the proportion of MDSCs in different cancer patients determines their responses to chemo- or immuno- therapy, and overall survival (51–54, 56–58). Presently, most immunotherapeutic strategies target lymphoid cells by adoptive transfer of tumor-specific T cells or reactivation of pre-existing anti-tumoral T-cells. Despite these approaches, certain drawbacks encountered with current therapies are associated with MDSCs accumulation. Therefore, researchers are investigating potential therapeutic strategies both at the pre-clinical and clinical levels aimed at targeting MDSCs for enhanced cancer immunotherapy.

Epigenetic modification in cancer cells had been identified over the years but its impact on immune cells regulation has only begun to emerge. A recent study proposed the combination of different epigenetic drugs as a promising anti-tumor therapy by blocking the expression of several members of the histone deacetylase (HDAC) family to alter the function of both PMN-MDSCs and M-MDSCs (59). In this way, targeting epigenetic pathways in cancer inhibited MDSCs' role which may prime host immune responses for immunotherapy. More so, immune cell responses using epigenetic modifiers were reported in combination with other immunotherapies such as immune checkpoint inhibitors (60–62), adoptive cellular immunotherapy (63, 64), cytokine-based therapy (65), and vaccines (66). Therefore, future studies need to investigate the underlying mechanism(s) of how epigenetic agents can block MDSCs function for a potential anti-tumor effect that may guide translational research. Herein we summarize how manipulating HDAC expression in MDSCs could augment immune checkpoints blockade and highlight current challenges with HDAC inhibitors for effective cancer immunotherapy.

OVERVIEW OF EPIGENETIC REGULATION OF MDSCs

Epigenetic remodeling is a hallmark of cancer development and proliferation (67, 68). Epigenetic regulation is an inherent change to DNA that affects chromatin structure and gene expression without distorting the nucleotide sequence (69). Certain epigenetic therapies for cancer include HDAC, histone methyltransferase (HMT), and DNA methyltransferase (DNMT) inhibitors capable of stimulating tumor cells and enhancing host immune cells anti-tumor response. Treatment with epigenetic modifiers sensitizes response to immune checkpoint inhibitors in cancer patients (70). HMT inhibitors had been reported to be effective in the treatment of multiple myeloma (71) while DNMT inhibitors revealed promising outcomes in both pre-clinical and clinical studies available (72). Nevertheless, only a few HMT and DNMT inhibitors demonstrated anti-tumor potential in the clinic. On the contrary, HDAC inhibitors are a unique class of small molecule drugs with a wide range of effects on tumor cells and multiple cellular processes such as cellular differentiation, cellular compartmentalization, autophagy, and anti-angiogenesis (73, 74). Considering HDACs' impact on chromatin structure, modulation of transcriptional factors, and their participation in multiple cellular processes, they are regarded as a promising molecular target to regulate gene expression and functions of specific proteins (75). The roles of HDAC inhibitors are not limited to tumor cells but have been identified to regulate immune cells' function. Interestingly, recent studies reported that HDAC inhibitors reduced MDSCs function – a major immunosuppressive cell in the tumor microenvironment and promoted anti-tumor immune responses (59, 60, 76). However, it is yet to be fully deciphered the underlying mechanism of action on how HDAC inhibitors control MDSCs accumulation for improved cancer immunotherapy.

HDACs REGULATE MDSCs FUNCTION

Histone deacetylases (HDACs) are category of enzymes removing acetyl groups from N-acetyl lysine, an amino acid on histone tails to regulate chromatin structure and functions (77–79). They also modulate myriads of non-histone proteins (80). HDACs family has about 18 members which are classified into four (4) main classes: Class I, II, III, and IV (81). Class I, II, and IV are named classical HDACs and comprise 11 members while class III are homologs of yeast silent information regulator 2 proteins and referred to as sirtuins (81). Class I HDACs include HDAC - 1, 2, 3, and 8; class II HDACs include HDAC - 4, 5, 7, and 9 (class IIa) and HDAC - 6 and 10 (class IIb) whereas class IV only member is HDAC 11. Class I HDAC members are more abundantly distributed and well expressed in most cells without restriction to the nucleus alone (81). However, class II HDACs demonstrate certain restrictions with tissue-specific expression and alternates between the cytoplasm and nucleus (82).

Emerging evidence had shown that HDAC inhibitors possess an anti-tumor effect and demonstrated a synergistic effect with cancer immunotherapy (83). Nevertheless, the cytotoxic impact of HDAC inhibitors on tumor cells requires more understanding while little is known on how HDAC inhibition modulates immune cells function especially MDSCs. Several HDAC

inhibitors affect MDSCs accumulation and function in contrasting ways as summarized in **Table 1**.

TRICHOSTATIN A

Trichostatin A (TSA), panHDAC inhibitor enhanced anti-tumor effect for Epstein-Barr virus (EBV)-associated tumor by inducing cell cycle arrest, apoptosis, and triggering EBV lytic cycle in lymphoblastoid cell lines (98). EBV-associated tumors are known to bypass immune surveillance while treatment with TSA-induced lytic genes that caused strong cytotoxic T lymphocyte responses (98, 99). Similarly, TSA suppressed proliferation and promoted apoptosis of esophageal squamous cell carcinoma *via* epigenetic regulation of apoptosis-related proteins (100). Besides, GM-CSF-induced bone-marrow-derived MDSCs in the presence or absence of TSA showed remarkable differences in myeloid cell differentiation *in vitro* (84). TSA promoted the accumulation of various undifferentiated myeloid cells exhibiting immunosuppressive functions like MDSCs in an iNOS1 and heme oxygenase-1 (HO-1) dependent manner. Likewise, an *ex vivo* experiment showed an increased proportion of $CD11b^{+}Gr1^{+}$ cells with suppressive activity in the spleen of naive mice treated with GM-CSF and TSA (84).

VALPROIC ACID

On the contrary, a class I HDAC inhibitor, valproic acid (VPA) promoted the differentiation of *in vitro* GM-CSF induced bone marrow-derived-MDSCs into dendritic cells (DCs) and macrophages with less suppressive effect (85). Zhiqi et al., demonstrated that VPA reduced PMN-MDSCs accumulation from GM-CSF stimulated bone marrow cultured cells (86). They showed that VPA treatment in a dose-dependent manner attenuated the suppressive function of MDSCs on T-cells. It was reported that VPA attenuated the immunosuppressive function of MDSCs *via* downregulating the expression of retinoblastoma 1 (Rb1), toll-like receptor 4 (TLR4), programmed cell death 1 ligand (PD-L1), interleukin-4 receptor-alpha (IL-4Rα)/arginase axis signaling pathways. Similarly, VPA-conditioned *in vitro* derived MDSCs injected into EL4 tumor-bearing mice significantly inhibited tumor progression compared to the control mice (86). Furthermore, our group reported VPA treatment promoted the accumulation of less suppressive MDSCs mainly M-MDSCs in the spleen and bone

TABLE 1 | Summary of the effects of HDAC inhibitors on MDSCs in several cancers.

HDAC Inhibitors	Class	Cancer type	Mechanism of action on MDSCs	References
Trichostatin A (TSA)	I, II	*In vitro*	Accumulation of CD11b+Gr1+ myeloid cell *via* iNOS1 and HO-1upregulation	(84)
Valproic acid	I	*In vitro*	Induced macrophage and DC generation	(85)
		Lymphoma	Reduced PMN-MDSCs accumulation *in-vitro* and decrease tumor growth *in-vivo* Repressed PD-L1, TLR4, Rb1, IL-4Rα/ARG1 signaling axis in MDSCs	(86)
			Decreased tumor-infiltrating MDSCs *via* repression of CCR2	(76)
		Melanoma	Induced M-MDSCs accumulation Downregulated MDSCs ARG1, IL-6 and IL-10 *via* IRF1/IRF8 activation	(60)
Entinostat	I	Lung Renal	Blocked MDSCs immunosuppressive function through reduced expression of ARG1, iNOS, and COX2	(87)
		Breast Pancreatic	Induced less suppressive PMN-MDSCs that promoted T cell proliferation	(88)
		Breast	Downregulation of CD40 expression in PMN-MDSCs and M-MDSCs	(89)
		Lung Breast Oesophageal	Reduced trafficking of PMN-MDSCs and MDSCs from bone marrow to pre-metastatic microenvironment *via* downregulating CXCR2 and CCR2.	(90)
		Lymphoma	Reduced PMN-MDSCs immunosuppressive function	(59)
Ricolinostat	II	Lung	Reduced M-MDSCs accumulation	
Mocetinostat	I, IV	Colorectal	Reduced intratumoral MDSCs accumulation Induced expression of genes involved in immune evasion and antigen presentation	(91)
Sodium butyrate Vorinostat	I, II	*In-vitro* Breast	Promoted MDSCs apoptosis *via* increased production of ROS *in vitro* Decreased MDSCs accumulation in blood, spleen, and tumor while activating CD8+T	(92)
Vorinostat		Melanoma	Reduced MDSCs recruitment into the tumor site *via* downregulation of CCL2	(93)
		Neuroblastoma	Decreased M-MDSCs accumulation Reduced transcript for ARG1, S100A8, S100A9 and PD-L1	(94)
ACY241	IIb	Myeloma	Reduced MDSCs proportion	(95)
CG-745	I, IIb	Renal cell carcinoma Hepatocellular Carcinoma Colorectal	reduced Treg production *via* increased expression of IL-2 and IFN-γ Induced immune microenvironmental changes *via* Inhibiting tumor-infiltrating MDSCs	(96) (97)

marrow of B16F10-bearing mice with reduced IL-6, IL-10, and ARG1 expression *via* activation of IRF1/IRF8 transcriptional axis (60). Importantly, VPA treatment in bone marrow-derived MDSC co-culture with T cells reactivated T cells ability for TNFα production thus conferred anti-tumor effect (60). More recently, Zhiqi et al., revealed that VPA treatment of EL4-bearing mice reduced tumor-infiltrating M-MDSCs through downregulating CCR2 expression while there was no effect on PMN-MDSCs proportion (76). Although VPA did not affect both M-MDSCs and PMN-MDSCs accumulation in the spleen of EL4-bearing mice; T-cells proliferation was more when splenic PMN-MDSCs from mice administered VPA were co-cultured with T cells but no changes were observed on T cells proliferation in M-MDSCs isolated from VPA-treated mice compared to the control (76). Altogether these suggest the potential of VPA in reducing the immunosuppressive attribute of PMN-MDSCs with a slight effect on M-MDSCs to promote $CD8^+$ T and NK cell proliferation and activation.

ENTINOSTAT, RICOLINOSTAT AND 5-AZACYTIDINE

Likewise, entinostat, another class 1 HDAC inhibitor promoted the accumulation of PMN-MDSCs and M-MDSCs in lung and renal murine tumor models (87). However, entinostat inhibited the immunosuppressive function of MDSCs *via* the reduced level of ARG1, iNOS, and COX2 as well as enhanced T cells proliferation in a co-culture system of MDSCs and T cells (87). In HER2/neu breast cancer and Panc02 metastatic pancreatic cancer murine model, entinostat reduced tumor burden and improved survival of the mice (88). It was reported that the anti-tumor effect of entinostat was through the accumulation of less immunosuppressive PMN-MDSCs in the TME that demonstrated impaired ability to inhibit T cells proliferation (88). Yusuke et al. reported that entinostat reduced PMN-MDSC and M-MDSCs proportion with downregulation of MDSC CD40 expression in metastatic estrogen receptor-positive breast cancer patients (89). Recently, Gabrilovich and colleagues demonstrated that treatment with entinostat in EL4 and LLC tumor models did not affect tumor growth (59). Although entinostat reduced PMN-MDSCs immunosuppressive function while M-MDSCs function was unaltered. It was observed that M-MDSCs had high expression of class II HDAC, specifically HDAC6 while further treatment with entinostat increased HDAC6 expression. Ricolinostat, a specific inhibitor of HDAC 6 reduced M-MDSCs accumulation without affecting tumor growth in mice while the combination of entinostat and ricolinostat significantly slowed tumor progression and reduce both MDSCs subsets in mice (59). These studies suggest that the anti-tumor effect of entinostat is cancer type-dependent and may need to be evaluated in other cancer types for an informed treatment option. Therefore, the combination of specific inhibitors of class I and II HDACs are required to block both MDSCs subsets accumulation and function for reduced tumor growth.

Recent reports demonstrated that MDSCs contributed to the development of pre-metastatic tumor microenvironment and residual tumor cells after surgical removal of the primary tumor (90, 101). While a low dose of entinostat (50nM) and 5-azacytidine (100nM) disrupted the pre-metastatic niche and inhibited metastasis. Mechanistically, it was deduced that this therapy restricted M-MDSCs and PMN-MDSCs trafficking from the bone marrow to the pre-metastatic microenvironment *via* downregulating CCR2 and CXCR2 expression respectively (90). Importantly, combined therapy of epigenetic modifiers and CCR2 antagonist increased disease-free survival as well as overall survival of mice. Entinostat and 5-azacytidine promoted the differentiation of splenic M-MDSCs into more – interstitial macrophage-like phenotypes, thus blocking MDSCs accumulation in the lung pre-metastatic niche (90).

MOCETINOSTAT

Mocetinostat is a selective inhibitor of class I and IV HDAC that regulates the epigenetic signaling of tumor and immune cells (102). In the CT26 colorectal mice model, it decreased intratumoral MDSCs and Treg accumulation while it increased $CD8^+$T cells infiltration (91). Mocetinostat regulated histone modification and induced the expression of genes involved in immune evasion and antigen presentation in tumor cells (91). However, how mocetinostat controls MDSCs function remains unreported thus mechanistic studies on how mocetinostat impairs tumor-infiltrating MDSCs accumulation will be necessary.

VORINOSTAT AND SODIUM BUTYRATE

Suberoylanilide hydroxamic acid, SAHA (also known as vorinostat), and Sodium butyrate (NaB) which are Class I and II non-specific HDAC inhibitors depleted accumulation of GM-CSF induced bone marrow-derived MDSCs and those isolated from the bone-marrow of 4T1 mammary-bearing mice (92). Treatment with SAHA and NaB promoted MDSCs apoptosis *via* increased production of ROS while *in vitro* generated bone marrow-derived MDSCs treated with SAHA and NaB failed to suppress T cells proliferation compared to control. Also, SAHA demonstrated its anti-tumor potential on the 4T1 mammary mice model by decreasing MDSCs accumulation in the spleen, blood, and tumor while promoting the activation and function of $CD8^+$ T cells (92). Laura et al. showed SAHA reduced gene expression of pro-inflammatory cytokines (IL-1α, TNFα) and immunosuppressive growth factor (TGFβ) in tumor lysate from spontaneous ret transgenic mouse melanoma model. Also, chemokine (C-C motif) ligand 2 (CCL2) was downregulated which led to reduced MDSCs recruitment into the tumor site and contributed to reduced melanoma growth (93). In the neuroblastoma mice model, SAHA decreased M-MDSCs accumulation but increased the number of macrophage effector cells in TME (94). Importantly, the transcripts levels of arginase1, S100A8, S100A9, and PD-L1 which are critical for promoting immunosuppressive activities were significantly

reduced in myeloid cells isolated from SAHA-treated tumors (94). Collectively, these studies suggest that SAHA creates an immune permissive tumor microenvironment and promises as a potential targeted therapy for various tumors.

ACY241

HDAC6 specific inhibitor, ACY241 in combination with proteasome inhibitors and immunomodulatory drugs demonstrated anti-myeloma potential (95). It was reported that ACY241 reduces the proportion of MDSCs, Tregs, and the expression of PD-1/PD-L1 on $CD8^+$ T cells in the bone marrow cells from myeloma patients. ACY241 induced antigen-specific memory T cells *via* the upregulation of transcription regulators such as Bcl-6, Eomes, HIF-1, and T-bet associated with the activation of downstream AKT/mTOR/p65 pathway (95). More recently, ACY241 induced accumulation of lung tumor-infiltrating T and NK cells while it reduced Tregs in non-small cell lung cancer (NSCLC)-bearing treated mice (103). Also, tumor-associated macrophages showed increased expression in MHC and co-stimulatory molecules such as CD80, CD86, and CD40 while it reduced inhibitory ligands like PD-L1 and PD-L2. ACY241 in combination with Oxaliplatin – a chemotherapy drug-induced T cells effector function, significant anti-tumor response, and increased survival of NSCLC bearing mice (103). This highlights the mechanisms by which ACY241 confers anti-tumor activity through regulating immune responses in patients and suggests a rationale for its clinical use in combination with other therapies in several cancers.

CG-745

CG-745 is a class I and IIb HDAC inhibitor that has shown anti-cancer effects against prostate, colorectal, pancreatic, cholangiocarcinoma, and non-small cell lung cancer while its exact role in mediating immune responses remains unknown (104–107). In a murine model of renal cell carcinoma, CG745 reduced Treg production *via* increased expression of IL-2 and IFN-γ (96). A recent study demonstrated that CG-745 inhibited tumor-infiltrating M2 macrophage polarization and MDSCs while promoting NK and T cells proliferation in human PBMC (97). It was observed that CG-745 induced immune microenvironment changes and promoted PBMC cytotoxic activity.

HDAC 11, the newest and only class IV HDAC member was reported to be involved in the differentiation of bone marrow generated immature myeloid cells (iMC) to neutrophils, macrophages, and DCs (108). Bone marrow and spleen isolated from HDAC11 promoter-driven eGFP reporter transgenic mice (TgHDAC11-eGFP) showed high expression of eGFP denoting HDAC11 transcriptional activation in these cells at steady-state. When these mice were challenged with pancreatic cancer (PANCO2), MDSCs expansion was observed in their lymphoid tissues similar to tumor-bearing wild-type mice (108). Importantly, flow cytometry analysis revealed a reduction in eGFP expression of myeloid cells compartment from TgHDAC11-eGFP mice, indicating that the transition of iMC to MDSCs may require the downregulation of HDAC11. These authors further demonstrated that functional analysis using both TgHDAC11-eGFP and HDAC11KO mice strongly suggests that HDAC11 might be a negative regulator of MDSC expansion/function *in vivo* through control of suppressive IL-10 production. Despite the above observation myeloid-specific HDAC11 KO in tumor-bearing mice will be critical for understanding the role of HDAC11 in MDSCs accumulation and function.

EFFECTS OF HDAC INHIBITORS ON IMMUNE CHECKPOINT PROTEINS

Immune checkpoint proteins have continued to receive considerable attention to evaluate the potential of several treatment options for cancer immunotherapy. Anti-CTLA-4 therapy showed a better response in metastatic melanoma patients with a lower proportion of M-MDSCs in their peripheral blood compared to non-responders (109). This observation corroborates another study that reported higher M-MDSCs percentage on treatment with anti-CTLA-4 resulted in poor clinical response due to impaired T-cells activation and function (110). Other studies also reported the reduced proportion of circulating MDSCs level at onset as a prognostic marker for response to anti-CTLA-4 therapy in patients with malignant melanoma (53, 58, 111). CT26 colorectal carcinoma and 4T1 spontaneous mammary tumors shown to be modestly immunogenic and highly metastatic respectively are among the most common syngeneic tumors models used for evaluating novel therapeutic approaches. In CT26 and 4T1 resistant to ICB, treatment with epigenetic modulator decreased MDSCs accumulation and function, thereby improving tumor responses to anti-CTLA4 and anti-PD-1 therapy (112). Thus, combination therapy targeting MDSCs together with ICB improved tumor responses unlike monotherapy thus benefit cancer immunotherapy.

Surprisingly, it was observed that while entinostat significantly reduced MDSCs cell viability, 5-azacytidine had no effect (112). Another study showed that treatment of immune-resistance breast and pancreatic cancer cells with entinostat decreased PMN-MDSCs accumulation and their function that led to a less immunosuppressive tumor microenvironment (88). Interestingly, entinostat effect on MDSCs function and immune-related gene expression augmented response to anti-PD-1 and anti-CTLA4 therapy in both mice models (88). More recently, VPA plus anti-PD-1 antibody compared to their single therapy repressed the growth of B16F10 and EL4 tumor models *via* VPA impaired tumor-infiltrating M-MDSCs accumulation in the tumor microenvironment (76). These suggest that treatment with epigenetic modifiers inhibits MDSCs accumulation and function thereby augments immune checkpoint inhibitors for successful cancer treatment. Hence, the underlying mechanism of epigenetic regulators in immunobiology and how it affects the response to ICB needs to be fully investigated.

In the tumor microenvironment, tumor and myeloid cells such as MDSCs, macrophages, and DCs can upregulate PD-L1 expression in response to inflammation (113, 114). This increased PD-L1 expression inhibits the effectiveness of cancer immunotherapy. Histone deacetylase (HDAC) inhibitors combat ICB resistance by attenuating the immunosuppressive function of MDSCs and sensitizing tumor cells to ICB. VPA and RGFP966 (HDAC 3 selective inhibitor) induced histone acetylation to facilitate PD-L1 transcription through the recruitment of bromodomain-containing protein 4 (BRD4) (115). Surprisingly, BRD4 inhibitor, JQ1 reduced PD-L1 upregulation triggered by HDAC inhibition. Inhibition of HDAC3 augmented the therapeutic effect of PD-L1 blockade by increasing PD-L1 expression on tumor and DCs in B-cells lymphoma (115). Furthermore, HDAC3 inhibition-induced PD-L1 expression could partly be one of the underlying mechanisms responsible for VPA resistance *via* evasion of immune surveillance checkpoints. This deduction is based on our previous study in which VPA alone failed to retard tumor growth in melanoma-bearing wild-type mice but slightly did in LLC-bearing mice (60). On the contrary, the combination of anti-PD-L1 antibody and VPA dramatically impaired tumor progression compared to PD-L1 blockade therapy alone. Mechanistically, MDSCs co-treated with VPA and anti-PD-L1 demonstrated impaired suppressive function and enhanced production of TNFα by T cells for anti-tumor effect. These findings corroborate the work of other researchers that host PD-L1 expression is crucial for PD-L1 blockade-mediated inhibition of tumor growth (114, 116). Thus, VPA could augment the therapeutic potential of the PD-L1 pathway blockade by increasing PD-L1 expression in tumor cells (**Figure 1**).

Recently, it was observed that bone marrow-infiltrating $CD8^+$ T cells from acute myeloid leukemia (AML) patients demonstrated downregulated expression of immune checkpoint (IC) receptors including PD-1 which could contribute to upregulation of immune checkpoint ligands such as PD-L1 due to poor PD-1/PD-L1 interaction (117). However, treatment with VPA increased the expression of IC receptors. Likewise, genetic ablation of dual-specificity phosphatase 2 (DUSP2) (a newly identified T cell suppressor and key epigenetic immune modulator acting *via* HDAC complex) in $CD8^+$ T cells upregulated genes involved in IC receptors. Interestingly, both VPA and DUSP 2 knockdown improved the effector functionality of $CD8^+$ T cells; suggesting that downregulation in IC receptors is associated with pathological HDAC expression and resistance to IC inhibitors (117). Collectively, these studies depict HDAC inhibitors demonstrate the potential to increase immune checkpoint proteins expression and promote sensitivity to ICB as a combination therapy for ICB resistance in cancer patients.

FUTURE PERSPECTIVES AND CURRENT CHALLENGES WITH HDAC INHIBITORS IN CANCER IMMUNOTHERAPY

The majority of the FDA-approved HDAC inhibitors in the clinic are for the treatment of hematological cancers. Despite its clinical success for lymphoma and myeloma, it has failed to demonstrate



FIGURE 1 | HDAC inhibition suppresses MDSCs function in the TME and promotes anti-PD-1/PD-L1 tumor immunotherapy. HDAC inhibition blocks tumor-infiltrating MDSCs accumulation in various cancer by downregulating the expression of genes involved in promoting the suppressive role of MDSCs which led to reduced tumor growth. Anti-PD-1/PD-L1 antibody inhibits immune checkpoint proteins expression on tumor and T-cell to confer anti-tumor effect. The combination of HDAC inhibitors and anti-PD-1/PD-L1 promotes T cells activation to inhibit tumor growth. Likewise, HDAC inhibitors augment anti-PD-1/PD-L1 tumor immunotherapy *via* reduced MDSCs function. Hence, the interaction of several immune cells within the TME determines the success of cancer immunotherapy strategies. HDAC, Histone deacetylase; MDSCs, Myeloid-derived suppressor cells; anti-PD-1/PD-L1, antibody against programmed death receptor 1/programmed death-ligand 1; ARG1, arginase 1; iNOS, inducible nitric oxide; IL-6, interleukin 6; IL-10, interleukin 10; IL-4Rα, interleukin 4 receptor alpha; COX2, cyclooxygenase 2; CCR, C-C Motif Chemokine Receptor 2; CXCR - CXC chemokine receptor 2; TLR4, toll-like receptor 4; Rb1, retinoblastoma 1.

significant effects as monotherapy in solid tumors. Although certain HDAC inhibitors such as entinostat (118), panobinostat (119), belinostat (120), and romidepsin (121) used as a single agent demonstrated significant anti-cancer effects in solid tumors from a phase I study but had negligible effects in phase II study. Besides, these inhibitors induced several side effects in the patients (122–126). Similarly, extensive pretreatment of the combination of HDAC inhibitors (azacytidine and entinostat) had an appreciable response in phase I/II study with recurrence and metastasis in non-small cell lung cancer (127).

To date, the reason HDAC inhibitors are efficacious in hematological malignancies unlike solid tumors is yet to be understood. However, several factors could be responsible such as lack of persistence and penetration into the solid masses as well as accumulation of immunosuppressive cells resident in solid tumors. Another critical and complex factor to consider in the administration of HDAC inhibitors is the metabolic state of the host; since epigenetic and metabolic changes in cancer cells are interrelated (128). Epigenetic modifiers such as HDACs regulate the expression of genes involved in metabolism and have become targets for cancer therapy (129). Although little is known on how regulating epigenetic or metabolic alteration could affect cancer immunotherapy and could be another future direction to explore.

Nevertheless, the future of HDAC inhibitors in solid tumors will depend tremendously on three major signs of progress in the field. One will be to improve the potency and specificity of next-generation HDAC inhibitors. Second, because HDAC inhibitors have reports of cellular toxicity profiles, it will be beneficial to understand the enigmatic HDAC biochemistry in cancer. This could reveal information on biomarkers that can be used to identify cancer patients that will respond to HDAC inhibitors therapy. Third, we believe that a comprehensive understanding of HDAC mechanisms of action will help identify other chemotherapies or ICIs that can be combined with HDAC inhibitors to circumvent current drawbacks. This will be a crucial landmark for HDAC therapies and will probably improve the clinical efficacy of future HDAC inhibitors.

Recently, it was discovered that female mounts a greater immune response compared to their male counterparts based on variation in sex hormones and sex-chromosome-related genes (130, 131). Conforti et al., reported that ICB was more effective in male patients compared to female patients while anti-PD-1/PD-L1 antibody combined with chemotherapy demonstrated enhanced therapeutic benefit for female patients compared to male patients (132). These suggested that therapies targeted at boosting immune responses will be less effective in female patients. On the other hand, phase III randomized clinical trials reported that sex-related factors may not affect the efficacy of ICB in melanoma patients (133). These contrasting results may be based on sample size or an inherent disparity in cancer etiology. Thus, gender-variation to immune response cannot be overemphasized in immunotherapy design and analysis. Since HDAC is well known to regulate mammalian gene expression, therefore, it is pertinent for other studies to investigate if HDAC inhibitors will augment anti-PD-L1 tumor immunotherapy or other ICB in both genders uniformly for effective translational research.

CONCLUSION

Despite evidence from the literature that HDAC inhibitors are promising therapy to block MDSCs function in several cancers, it remains unknown the key molecular mechanisms by which HDACs specifically regulate MDSCs function – a major drawback to current cancer immunotherapies. While the data from *in vitro*-generated MDCSs are indispensable for *in vivo* studies, MDSCs obtained from tumor-bearing animals could differ in their suppressive properties and should be considered in future experimental designs. Therefore, it is pertinent for future studies to focus on elaborating how these emerging HDAC inhibitors in the clinic could completely block MDSCs accumulation or other immunosuppressive cells such as tumor-associated macrophages, regulatory T cells, or stromal cells resident in the tumor milieu.

AUTHOR CONTRIBUTIONS

AA and DY conceived the idea. AA and FA wrote the manuscript. DY and XW revised and supervised the writing. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Key R&D Program of China (Grants 2019YFA0906100 and 2021YFC3300100), National Natural Science Foundation of China (Grants 82071772, 81501356, and 81373112), Key-Area Research and Development Program of Guangdong Province (2019B020201014), the Shenzhen Basic Science Research Project (Grants JCYJ201908 07161419228, JCYJ20170818155135838, JCYJ20170818164619194, and JCYJ20170413153158716), China Postdoctoral Science Foundation (2019M660220), Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515110359), Nanshan pilot team project (LHTD20160004), Start-up funding (CYZZ20180307154657923), and the SIAT-GHMSCB Biomedical Laboratory for Major Diseases and Dongguan Introduction Program of Leading Innovative and Entrepreneurial Talents.

REFERENCES

1. Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. *Front Immunol* (2020) 11:940. doi: 10.3389/fimmu.2020.00940
2. Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of Targeting the Tumor Immune Microenvironment Over Blocking Immune

Checkpoint in Cancer Immunotherapy. *Signal Transduct Target Ther* (2021) 6(1):72. doi: 10.1038/s41392-020-00449-4
3. Scott EN, Gocher AM, Workman CJ, Vignali D. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment. *Front Immunol* (2021) 12:702726. doi: 10.3389/fimmu.2021.702726
4. Hangai S, Kawamura T, Kimura Y, Chang CY, Hibino S, Yamamoto D. Orchestration of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Ubiquitous Cellular Protein TCTP Released by Tumor Cells. *Nat Immunol* (2021) 22(8):947–57. doi: 10.1038/s41590-021-00967-5
5. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-Related Adverse Events With Immune Checkpoint Blockade: A Comprehensive Review. *Eur J Cancer (Oxf Eng: 1990)* (2016) 54:139–48. doi: 10.1016/j.ejca.2015.11.016
6. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell* (2018) 175(2):313–26. doi: 10.1016/j.cell.2018.09.035
7. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. *Annu Rev Pathol: Mech Dis* (2021) 16:223–49. doi: 10.1146/annurev-pathol-042020-042741
8. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* (2017) 67(1):7–30. doi: 10.3322/caac.21387
9. Yu X, Huang X, Chen X, Liu J, Wu C, Pu Q, et al. Characterization of a Novel Anti-Human Lymphocyte Activation Gene 3 (LAG-3) Antibody for Cancer Immunotherapy. *MAbs* (2019) 11(6):1139–48. doi: 10.1080/19420862.2019.1629239
10. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. *Cancer Cell* (2020) 38(4):500–15.e3. doi: 10.1016/j.ccell.2020.08.005
11. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. *Lancet* (2017) 389(10088):2492–502. doi: 10.1016/S0140-6736(17)31046-2
12. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. *Lancet Oncol* (2018) 19(7):940–52. doi: 10.1016/S1470-2045(18)30351-6
13. Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial. *Lancet Oncol* (2020) 21(4):571–80. doi: 10.1016/S1470-2045(20)30011-5
14. Murciano-Goroff YR, Warner AB, Wolchok JD. The Future of Cancer Immunotherapy: Microenvironment-Targeting Combinations. *Cell Res* (2020) 30(6):507–19. doi: 10.1038/s41422-020-0337-2
15. Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. *Cell* (2020) 182(3):655–71.e22. doi: 10.1016/j.cell.2020.06.001
16. Adeshakin AO, Liu W, Adeshakin FO, Afolabi LO, Zhang M, Zhang G, et al. Regulation of ROS in Myeloid-Derived Suppressor Cells Through Targeting Fatty Acid Transport Protein 2 Enhanced Anti-PD-L1 Tumor Immunotherapy. *Cell Immunol* (2021) 362:104286. doi: 10.1016/j.cellimm.2021.104286
17. Xiang X, Wang J, Lu D, Xu X. Targeting Tumor-Associated Macrophages to Synergize Tumor Immunotherapy. *Signal Transduct Target Ther* (2021) 6(1):75. doi: 10.1038/s41392-021-00484-9
18. Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, et al. Hedgehog-Induced PD-L1 on Tumor-Associated Macrophages Is Critical for Suppression of Tumor-Infiltrating CD8+ T Cell Function. *JCI Insight* (2021) 6(6):e146707. doi: 10.1172/jci.insight.146707
19. Son J, Cho JW, Park HJ, Moon J, Park S, Lee H, et al. Tumor-Infiltrating Regulatory T-Cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling. *Cancer Immunol Res* (2020) 8(11):1393–406. doi: 10.1158/2326-6066.CIR-19-0828
20. Yan DH, Adeshakin AO, Xu M, Afolabi LO, Zhang G, Chen YH, et al. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor. *Front Immunol* (2019) 10:1399. doi: 10.3389/fimmu.2019.01399
21. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. *Cancer Cell* (2014) 26(5):638–52. doi: 10.1016/j.ccell.2014.09.007
22. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. *Immunity* (2016) 44(4):924–38. doi: 10.1016/j.immuni.2016.03.012
23. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A Natural Killer-Dendritic Cell Axis Defines Checkpoint Therapy-Responsive Tumor Microenvironments. *Nat Med* (2018) 24(8):1178–91. doi: 10.1038/s41591-018-0085-8
24. Afolabi LO, Bi J, Li X, Adeshakin AO, Adeshakin FO, Wu H, et al. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat. *Front Immunol* (2021) 12:701671. doi: 10.3389/fimmu.2021.701671
25. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, et al. Partially Exhausted Tumor-Infiltrating Lymphocytes Predict Response to Combination Immunotherapy. *JCI Insight* (2017) 2(14):e93433. doi: 10.1172/jci.insight.93433
26. Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, et al. Chromatin States Define Tumour-Specific T Cell Dysfunction and Reprogramming. *Nature* (2017) 545(7655):452–6. doi: 10.1038/nature22367
27. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B. Chronic But Not Acute Virus Infection Induces Sustained Expansion of Myeloid Suppressor Cell Numbers That Inhibit Viral-Specific T Cell Immunity. *Immunity* (2013) 38(2):309–21. doi: 10.1016/j.immuni.2012.10.022
28. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. *Immunity* (2016) 44(3):450–62. doi: 10.1016/j.immuni.2016.02.015
29. Mujal AM, Krummel MF. Immunity as a Continuum of Archetypes. *Science* (2019) 364(6435):28–9. doi: 10.1126/science.aau8694
30. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou YT, et al. The Immune Landscape of Cancer. *Immunity* (2018) 48(4):812–30.e14. doi: 10.1016/j.immuni.2018.03.023
31. Engblom C, Pfirschke C, Pittet MJ. The Role of Myeloid Cells in Cancer Therapies. *Nat Rev Cancer* (2016) 16(7):447–62. doi: 10.1038/nrc.2016.54
32. Sarkar R, Mathew A, Sehrawat S. Myeloid-Derived Suppressor Cells Confer Infectious Tolerance to Dampen Virus-Induced Tissue Immunoinflammation. *J Immunol* (2019) 203(5):1325–37. doi: 10.4049/jimmunol.1900142
33. Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 Specifies the Functional Polarization of Myeloid-Derived Suppressor Cells During Tumorigenesis. *J Exp Med* (2020) 217(2):e20182005. doi: 10.1084/jem.20182005
34. Xiang H, Ramil CP, Hai J, Zhang C, Wang H, Watkins AA, et al. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma. *Cancer Immunol Res* (2020) 8(4):436–50. doi: 10.1158/2326-6066.CIR-19-0507
35. Tumino N, Di Pace AL, Besi F, Quatrini L, Vacca P, Moretta L. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT. *Front Immunol* (2021) 12:638841. doi: 10.3389/fimmu.2021.638841
36. Gabrilovich DI, Nagaraj S. Myeloid-Derived Suppressor Cells as Regulators of the Immune System. *Nat Rev Immunol* (2009) 9(3):162. doi: 10.1038/nri2506
37. Hegde S, Leader AM, Merad M. MDSC: Markers, Development, States, and Unaddressed Complexity. *Immunity* (2021) 54(5):875–84. doi: 10.1016/j.immuni.2021.04.004
38. Streilein JW, Dana MR, Ksander BR. Immunity Causing Blindness: Five Different Paths to Herpes Stromal Keratitis. *Immunol Today* (1997) 18(9):443–9. doi: 10.1016/S0167-5699(97)01114-6

39. Wang L, Wang R, Xu C, Zhou H. Pathogenesis of Herpes Stromal Keratitis: Immune Inflammatory Response Mediated by Inflammatory Regulators. *Front Immunol* (2020) 11:766. doi: 10.3389/fimmu.2020.00766
40. Yan D, Yang Q, Shi M, Zhong L, Wu C, Meng T, et al. Polyunsaturated Fatty Acids Promote the Expansion of Myeloid-Derived Suppressor Cells by Activating the JAK/STAT3 Pathway. *Eur J Immunol* (2013) 43(11):2943–55. doi: 10.1002/eji.201343472
41. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for Myeloid-Derived Suppressor Cell Nomenclature and Characterization Standards. *Nat Commun* (2016) 7:12150–0. doi: 10.1038/ncomms12150
42. Greten TF, Manns MP, Korangy F. Myeloid Derived Suppressor Cells in Human Diseases. *Int Immunopharmacol* (2011) 11(7):802–7. doi: 10.1016/j.intimp.2011.01.003
43. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, et al. Complexity and Challenges in Defining Myeloid-Derived Suppressor Cells. *Cytometry B Clin Cytom* (2015) 88(2):77–91. doi: 10.1002/cytob.21206
44. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated Myeloid-Derived Suppressor Cells in Pancreatic, Esophageal and Gastric Cancer Are an Independent Prognostic Factor and Are Associated With Significant Elevation of the Th2 Cytokine Interleukin-13. *Cancer Immunol Immunother: CII* (2011) 60(10):1419–30. doi: 10.1007/s00262-011-1028-0
45. De Sanctis F, Bronte V, Ugel S. Tumor-Induced Myeloid-Derived Suppressor Cells. *Microbiol Spectr* (2016) 4(3):MCHD-0016-2015. doi: 10.1128/microbiolspec.MCHD-0016-2015
46. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients With Colorectal Carcinoma. *PloS One* (2013) 8(2):e57114–4. doi: 10.1371/journal.pone.0057114
47. Lu L-C, Chang C-J, Hsu C-H. Targeting Myeloid-Derived Suppressor Cells in the Treatment of Hepatocellular Carcinoma: Current State and Future Perspectives. *J Hepatocell Carcinoma* (2019) 6:71–84. doi: 10.2147/JHC.S159693
48. Najjar YG, Finke JH. Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer. *Front Oncol* (2013) 3:49–9. doi: 10.3389/fonc.2013.00049
49. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. *Trends Immunol* (2016) 37(3):208–20. doi: 10.1016/j.it.2016.01.004
50. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor SP. Correlation Between Frequencies of Blood Monocytic Myeloid-Derived Suppressor Cells, Regulatory T Cells and Negative Prognostic Markers in Patients With Castration-Resistant Metastatic Prostate Cancer. *Cancer Immunol Immunother: CII* (2014) 63(11):1177–87. doi: 10.1007/s00262-014-1591-2
51. Bergenfelz C, Roxa A, Mehmeti M, Leandersson K, Larsson AM. Clinical Relevance of Systemic Monocytic-MDSCs in Patients With Metastatic Breast Cancer. *Cancer Immunol Immunother: CII* (2020) 69(3):435–48. doi: 10.1007/s00262-019-02472-z
52. Okła K, Czerwonka A, Wawruszak A, Bobinski M, Bilska M, Tarkowski R, et al. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. *Front Immunol* (2019) 10:691–1. doi: 10.3389/fimmu.2019.00691
53. Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients With Stage IV Melanoma Treated With Ipilimumab. *Clin Cancer Res: an Off J Am Assoc Cancer Res* (2016) 22(23):5661–72. doi: 10.1158/1078-0432.CCR-15-3104
54. Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, et al. CD14(+) S100A9(+) Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer. *Am J Respir Crit Care Med* (2012) 186(10):1025–36. doi: 10.1164/rccm.201204-0636OC
55. Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, et al. Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer. *Curr Cancer Drug Targets* (2011) 11(6):734–51. doi: 10.2174/156800911796191024
56. Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting Myeloid-Derived Suppressor Cells Using All-Trans Retinoic Acid in Melanoma Patients Treated With Ipilimumab. *Int Immunopharmacol* (2018) 63:282–91. doi: 10.1016/j.intimp.2018.08.007
57. Iwata T, Kondo Y, Kimura O, Morosawa T, Fujisaka Y, Umetsu T, et al. PD-L1(+)MDSCs Are Increased in HCC Patients and Induced by Soluble Factor in the Tumor Microenvironment. *Sci Rep* (2016) 6:39296. doi: 10.1038/srep39296
58. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment With Ipilimumab. *Clin Cancer Res: an Off J Am Assoc Cancer Res* (2015) 21(24):5453–9. doi: 10.1158/1078-0432.CCR-15-0676
59. Hashimoto A, Fukumoto T, Zhang R, Gabrilovich D. Selective Targeting of Different Populations of Myeloid-Derived Suppressor Cells by Histone Deacetylase Inhibitors. *Cancer Immunol Immunother* (2020) 69(9):1929–36. doi: 10.1007/s00262-020-02588-7
60. Adeshakin AO, Yan D, Zhang M, Wang L, Adeshakin FO, Liu W, et al. Blockade of Myeloid-Derived Suppressor Cell Function by Valproic Acid Enhanced Anti-PD-L1 Tumor Immunotherapy. *Biochem Biophys Res Commun* (2020) 522(3):604–11. doi: 10.1016/j.bbrc.2019.11.155
61. Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Aberrant Apoptotic Machinery Confers Melanoma Dual Resistance to BRAF (V600E) Inhibitor and Immune Effector Cells: Immunosensitization by a Histone Deacetylase Inhibitor. *Am J Clin Exp Immunol* (2014) 3(1):43–56.
62. Yeon M, Kim Y, Jung HS, Jeoung D. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma. *Front Cell Dev Biol* (2020) 8:486. doi: 10.3389/fcell.2020.00486
63. Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, et al. Epigenetic Modification Augments the Immunogenicity of Human Leukocyte Antigen G Serving as a Tumor Antigen for T Cell-Based Immunotherapy. *Oncoimmunology* (2016) 5(6):e1169356. doi: 10.1080/2162402X.2016.1169356
64. Luker AJ, Graham LJ, Smith TJ, Camarena C, Zellner MP, Gilmer JS, et al. The DNA Methyltransferase Inhibitor, Guadecitabine, Targets Tumor-Induced Myelopoiesis and Recovers T Cell Activity to Slow Tumor Growth in Combination With Adoptive Immunotherapy in a Mouse Model of Breast Cancer. *BMC Immunol* (2020) 21(1):8. doi: 10.1186/s12865-020-0337-5
65. Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, et al. Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response Against Melanoma. *J Invest Dermatol* (2017) 137(1):159–69. doi: 10.1016/j.jid.2016.08.024
66. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, et al. A Phase I Trial Combining Decitabine/Dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children With Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma. *Cancer Immunol Immunother* (2015) 64(10):1251–60. doi: 10.1007/s00262-015-1731-3
67. Jones PA, Baylin SB. The Fundamental Role of Epigenetic Events in Cancer. *Nat Rev Genet* (2002) 3(6):415–28. doi: 10.1038/nrg816
68. Sun L, Zhang H, Gao P. Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer. *Protein Cell* (2021). doi: 10.1007/s13238-021-00846-7
69. Esteller M. Epigenetics in Cancer. *N Engl J Med* (2008) 358(11):1148–59. doi: 10.1056/NEJMra072067
70. Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, et al. Epigenetic Therapy Activates Type I Interferon Signaling in Murine Ovarian Cancer to Reduce Immunosuppression and Tumor Burden. *Proc Natl Acad Sci USA* (2017) 114p(51):E10981–90. doi: 10.1073/pnas.1712514114
71. Rabal O, San JE, Agirre X, Sanchez-Arias JA, de Miguel I, Ordonez R, et al. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a With In Vivo Efficacy in Multiple Myeloma. *J Med Chem* (2021) 64(6):3392–426. doi: 10.1021/acs.jmedchem.0c02255
72. Mikkelsen SU, Gillberg L, Lykkesfeldt J, Gronbaek K. The Role of Vitamin C in Epigenetic Cancer Therapy. *Free Radic Biol Med* (2021) 170:179–93. doi: 10.1016/j.freeradbiomed.2021.03.017
73. Villagra A, Sotomayor EM, Seto E. Histone Deacetylases and the Immunological Network: Implications in Cancer and Inflammation. *Oncogene* (2010) 29(2):157–73. doi: 10.1038/onc.2009.334

74. Khan O, La Thangue NB. HDAC Inhibitors in Cancer Biology: Emerging Mechanisms and Clinical Applications. *Immunol Cell Biol* (2012) 90(1):85–94. doi: 10.1038/icb.2011.100
75. Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 Inhibitors Improve Anti-PD-1 Immune Checkpoint Blockade Therapy by Decreasing the Anti-Inflammatory Phenotype of Macrophages and Down-Regulation of Immunosuppressive Proteins in Tumor Cells. *Sci Rep* (2019) 9(1):6136. doi: 10.1038/s41598-019-42237-3
76. Xie Z, Ikegami T, Ago Y, Okada N, Tachibana M. Valproic Acid Attenuates CCR2-Dependent Tumor Infiltration of Monocytic Myeloid-Derived Suppressor Cells, Limiting Tumor Progression. *Oncoimmunology* (2020) 9 (1):1734268. doi: 10.1080/2162402X.2020.1734268
77. Narlikar GJ, Fan H-Y, Kingston RE. Cooperation Between Complexes That Regulate Chromatin Structure and Transcription. *Cell* (2002) 108(4):475–87. doi: 10.1016/S0092-8674(02)00654-2
78. Kouzarides T. Chromatin Modifications and Their Function. *Cell* (2007) 128 (4):693–705. doi: 10.1016/j.cell.2007.02.005
79. Yang X-J, Seto E. Lysine Acetylation: Codified Crosstalk With Other Posttranslational Modifications. *Mol Cell* (2008) 31(4):449–61. doi: 10.1016/j.molcel.2008.07.002
80. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, et al. Cutting Edge: Negative Regulation of Dendritic Cells Through Acetylation of the Nonhistone Protein STAT-3. *J Immunol (Baltimore Md: 1950)* (2009) 182 (10):5899–903. doi: 10.4049/jimmunol.0804388
81. Johnstone RW. Histone-Deacetylase Inhibitors: Novel Drugs for the Treatment of Cancer. *Nat Rev Drug Discov* (2002) 1(4):287–99. doi: 10.1038/nrd772
82. Haberland M, Montgomery RL, Olson EN. The Many Roles of Histone Deacetylases in Development and Physiology: Implications for Disease and Therapy. *Nat Rev Genet* (2009) 10(1):32–42. doi: 10.1038/nrg2485
83. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC Inhibitors and Immunotherapy; A Double Edged Sword? *Oncotarget* (2014) 5(16):6558–72. doi: 10.18632/oncotarget.2289
84. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone Deacetylase Inhibition Facilitates GM-CSF-Mediated Expansion of Myeloid-Derived Suppressor Cells In Vitro and In Vivo. *J Leukoc Biol* (2012) 91(5):701–9. doi: 10.1189/jlb.0311119
85. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic Silencing of Retinoblastoma Gene Regulates Pathologic Differentiation of Myeloid Cells in Cancer. *Nat Immunol* (2013) 14 (3):211–20. doi: 10.1038/ni.2526
86. Xie Z, Ago Y, Okada N, Tachibana M. Valproic Acid Attenuates Immunosuppressive Function of Myeloid-Derived Suppressor Cells. *J Pharmacol Sci* (2018) 137(4):359–65. doi: 10.1016/j.jphs.2018.06.014
87. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. *Clin Cancer Res* (2017) 23(17):5187–201. doi: 10.1158/1078-0432.CCR-17-0741
88. Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers Into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. *Cancer Immunol Res* (2018) 6(12):1561–77. doi: 10.1158/2326-6066.CIR-18-0070
89. Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, et al. The Interplay of Epigenetic Therapy and Immunity in Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer: Correlative Analysis of ENCORE 301, a Randomized, Placebo-Controlled Phase II Trial of Exemestane With or Without Entinostat. *Oncoimmunology* (2016) 5(11): e1219008. doi: 10.1080/2162402X.2016.1219008
90. Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, et al. Epigenetic Therapy Inhibits Metastases by Disrupting Premetastatic Niches. *Nature* (2020) 579 (7798):284–90. doi: 10.1038/s41586-020-2054-x
91. Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, et al. The Class I/IV HDAC Inhibitor Mocetinostat Increases Tumor Antigen Presentation, Decreases Immune Suppressive Cell Types and Augments Checkpoint Inhibitor Therapy. *Cancer Immunol Immunother* (2018) 67 (3):381–92. doi: 10.1007/s00262-017-2091-y
92. Wang HF, Ning F, Liu ZC, Wu L, Li ZQ, Qi YF, et al. Histone Deacetylase Inhibitors Deplete Myeloid-Derived Suppressor Cells Induced by 4T1 Mammary Tumors In Vivo and In Vitro. *Cancer Immunol Immunother* (2017) 66(3):355–66. doi: 10.1007/s00262-016-1935-1
93. Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, et al. Histone Deacetylase Inhibitor-Temozolomide Co-Treatment Inhibits Melanoma Growth Through Suppression of Chemokine (C-C Motif) Ligand 2-Driven Signals. *Oncotarget* (2014) 5(12):4516–28. doi: 10.18632/oncotarget.2065
94. Kroesen M, Bull C, Gielen PR, Brok IC, Armandari I, Wassink M, et al. Anti-GD2 mAb and Vorinostat Synergize in the Treatment of Neuroblastoma. *Oncoimmunology* (2016) 5(6):e1164919. doi: 10.1080/2162402X.2016.1164919
95. Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone Deacetylase (HDAC) Inhibitor ACY241 Enhances Anti-Tumor Activities of Antigen-Specific Central Memory Cytotoxic T Lymphocytes Against Multiple Myeloma and Solid Tumors. *Leukemia* (2018) 32(9):1932–47. doi: 10.1038/s41375-018-0062-8
96. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, et al. Synergistic In Vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination With Interleukin 2 in a Murine Model of Renal Cell Carcinoma. *Clin Cancer Res* (2007) 13(15 Pt 1):4538–46. doi: 10.1158/1078-0432.CCR-07-0014
97. Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. *J Cancer* (2020) 11(14):4059–72. doi: 10.7150/jca.44622
98. Seo JS, Cho NY, Kim HR, Tsurumi T, Jang YS, Lee WK, et al. Cell Cycle Arrest and Lytic Induction of EBV-Transformed B Lymphoblastoid Cells by a Histone Deacetylase Inhibitor, Trichostatin A. *Oncol Rep* (2008) 19(1):93–8. doi: 10.3892/or.19.1.93
99. Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, et al. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. *Front Oncol* (2020) 10:600. doi: 10.3389/fonc.2020.00600
100. Ma J, Guo X, Zhang S, Liu H, Lu J, Dong Z, et al. Trichostatin A, a Histone Deacetylase Inhibitor, Suppresses Proliferation and Promotes Apoptosis of Esophageal Squamous Cell Lines. *Mol Med Rep* (2015) 11(6):4525–31. doi: 10.3892/mmr.2015.3268
101. Tang F, Tie Y, Hong W, Wei Y, Tu C, Wei X. Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection. *Ann Surg Oncol* (2021) 28(7):4030–48. doi: 10.1245/s10434-020-09371-z
102. Baird A-M, Richard D O, Byrne KJ, Gray SG. Epigenetic Therapy in Lung Cancer and Mesothelioma. In: *Epigenetic Cancer Therapy*. Boston: Academic Press (2015). p. 189–213.
103. Bag A, Schultz A, Bhimani S, Dominguez W, Cen L, Adeegbe D. The Immunomodulatory Properties of the HDAC6 Inhibitor ACY241 Supports Robust Anti-Tumor Response in NSCLC When Coupled With the Chemotherapy Drug Oxaliplatin. *bioRxiv* (2021) 2010–21. doi: 10.1101/2021.10.01.462824
104. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, et al. A Novel Histone Deacetylase Inhibitor, CG200745, Potentiates Anticancer Effect of Docetaxel in Prostate Cancer via Decreasing Mcl-1 and Bcl-XL. *Invest New Drugs* (2012) 30(4):1434–42. doi: 10.1007/s10637-011-9718-1
105. Chun SM, Lee JY, Choi J, Lee JH, Hwang JJ, Kim CS, et al. Epigenetic Modulation With HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells. *PloS One* (2015) 10(3):e0119379. doi: 10.1371/journal.pone.0119379
106. Lee HS, Park SB, Kim SA, Kwon SK, Cha H, Lee DY, et al. A Novel HDAC Inhibitor, CG200745, Inhibits Pancreatic Cancer Cell Growth and Overcomes Gemcitabine Resistance. *Sci Rep* (2017) 7:41615. doi: 10.1038/srep41615
107. Jung DE, Park SB, Kim K, Kim C, Song SY. CG200745, an HDAC Inhibitor, Induces Anti-Tumour Effects in Cholangiocarcinoma Cell Lines via miRNAs Targeting the Hippo Pathway. *Sci Rep* (2017) 7(1):10921. doi: 10.1038/s41598-017-11094-3
108. Sahakian E, Powers J, Rock-Klotz J, Adriani M, Woan KV, Merino O, et al. A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-

Derived Suppressor Cell (MDSC) Expansion. *Am Soc Hematol* (2011) 118 (21):2439. doi: 10.1182/blood.V118.21.2439.2439
109. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of Circulating MDSC Correlate With Clinical Outcome of Melanoma Patients Treated With Ipilimumab. *Cancer Immunol Immunother: CII* (2014) 63(3):247–57. doi: 10.1007/s00262-013-1508-5
110. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-Derived Suppressor Cells Predict Survival of Patients With Advanced Melanoma: Comparison With Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells. *Clin Cancer Res: an Off J Am Assoc Cancer Res* (2014) 20(6):1601–9. doi: 10.1158/1078-0432.CCR-13-2508
111. Martens A, Wistuba-Hamprecht K, Geukes FM, Yuan J, Postow MA, Wong P, et al. Baseline Peripheral Blood Biomarkers Associated With Clinical Outcome of Advanced Melanoma Patients Treated With Ipilimumab. *Clin Cancer Res: an Off J Am Assoc Cancer Res* (2016) 22(12):2908–18. doi: 10.1158/1078-0432.CCR-15-2412
112. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of Metastatic Mouse Cancers Resistant to Immune Checkpoint Blockade by Suppression of Myeloid-Derived Cells. *Proc Natl Acad Sci USA* (2014) 111 (32):11774–9. doi: 10.1073/pnas.1410626111
113. Nguyen LT, Ohashi PS. Clinical Blockade of PD1 and LAG3–potential Mechanisms of Action. *Nat Rev Immunol* (2015) 15(1):45–56. doi: 10.1038/nri3790
114. Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on Host Cells Is Essential for PD-L1 Blockade-Mediated Tumor Regression. *J Clin Invest* (2018) 128(2):580–8. doi: 10.1172/JCI96061
115. Deng S, Hu Q, Zhang H, Yang F, Peng C, Huang C. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti–PD-L1 Therapy. *Mol Cancer Ther* (2019) 18(5):900–8. doi: 10.1158/1535-7163.MCT-18-1068
116. Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host Expression of PD-L1 Determines Efficacy of PD-L1 Pathway Blockade-Mediated Tumor Regression. *J Clin Invest* (2018) 128(4):1708. doi: 10.1172/JCI96113
117. Radpour R, Stucki M, Riether C, Ochsenbein AF. Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow-Infiltrating T Cells in Acute Myeloid Leukemia. *Front Oncol* (2021) 11:1145. doi: 10.3389/fonc.2021.663406
118. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, et al. Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma. *J Clin Oncol* (2005) 23(17):3912–22. doi: 10.1200/JCO.2005.02.188
119. Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA, et al. A Phase I Study of Panobinostat in Combination With Gemcitabine in the Treatment of Solid Tumors. *Clin Adv Hematol Oncol* (2011) 9(3):225–30.
120. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients With Advanced Solid Tumors. *Clin Cancer Res* (2008) 14(3):804–10. doi: 10.1158/1078-0432.CCR-07-1786
121. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients With Refractory Neoplasms. *Clin Cancer Res* (2002) 8(3):718–28.
122. Drappatz J, et al, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R. Phase I Study of Panobinostat in Combination With Bevacizumab for Recurrent High-Grade Glioma. *J Neurooncol* (2012) 107(1):133–8. doi: 10.1007/s11060-011-0717-z
123. Sherman EJ, Su YB, Lyall A, Schoder H, Fury MG, Ghossein RA, et al. Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine-Refractory Thyroid Carcinoma. *Thyroid* (2013) 23(5):593–9. doi: 10.1089/thy.2012.0393
124. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, et al. Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy. *J Clin Oncol* (2012) 30(18):2248–55. doi: 10.1200/JCO.2011.38.9411
125. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, et al. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. *J Clin Oncol* (2012) 30(27):3361–7. doi: 10.1200/JCO.2011.41.2395
126. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, et al. Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors. *Cancer Chemother Pharmacol* (2012) 70(2):251–8. doi: 10.1007/s00280-012-1911-1
127. Rodríguez-Paredes M, Esteller M. A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non-Small Cell Lung Cancer. *Cancer Discov* (2011) 1(7):557–9. doi: 10.1158/2159-8290.CD-11-0271
128. Wong CC, Qian Y, Yu J. Interplay Between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches. *Oncogene* (2017) 36 (24):3359–74. doi: 10.1038/onc.2016.485
129. Yu X, Ma R, Wu Y, Zhai Y, Li S. Reciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer. *Front Genet* (2018) 9:394. doi: 10.3389/fgene.2018.00394
130. Klein SL, Flanagan KL. Sex Differences in Immune Responses. *Nat Rev Immunol* (2016) 16(10):626–38. doi: 10.1038/nri.2016.90
131. Wang S, Cowley LA, Liu XS. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. *Molecules* (2019) 24 (18):3214. doi: 10.3390/molecules24183214
132. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-Analysis. *Lancet Oncol* (2018) 19(6):737–46. doi: 10.1016/S1470-2045(18)30261-4
133. Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, et al. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. *J Clin Med* (2018) 7(12):542. doi: 10.20944/preprints201808.0307.v2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers in Immunology

ORIGINAL RESEARCH
published: 26 January 2022
doi: 10.3389/fimmu.2021.783362

Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer

Zhiwei Wu[1†], Zhixing Lu[1†], Liang Li[1], Min Ma[1], Fei Long[1], Runliu Wu[1], Lihua Huang[2], Jing Chou[1], Kaiyan Yang[1], Yi Zhang[3], Xiaorong Li[1], Gui Hu[1], Yi Zhang[1] and Changwei Lin[1*]*

[1] Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central South University, Changsha, China, [2] School of Life Sciences, Central South University, Changsha, China, [3] Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

OPEN ACCESS

Edited by:
Irina Apostolou,
Sumitomo Dainippon Pharma Oncology, United States

Reviewed by:
Jian Huang,
Coriell Institute For Medical Research, United States
Abhinav Jain,
University of Texas MD Anderson Cancer Center, United States

***Correspondence:**
Changwei Lin
linchangwei@csu.edu.cn
Yi Zhang
yzhangxy3@csu.edu.cn

[†]These authors have contributed equally to this work

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: 26 September 2021
Accepted: 28 December 2021
Published: 26 January 2022

Citation:
Wu Z, Lu Z, Li L, Ma M, Long F, Wu R, Huang L, Chou J, Yang K, Zhang Y, Li X, Hu G, Zhang Y and Lin C (2022) Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer. Front. Immunol. 12:783362. doi: 10.3389/fimmu.2021.783362

Background: Ferroptosis is a newly defined form of programmed cell death that plays an important role in many cancers. However, ferroptosis-related lncRNAs (FRLs) involved in the regulation of colon cancer are not thoroughly understood. This study aimed to identify a prognostic FRL signature in colon cancer and explore its potential molecular function.

Methods: RNA-seq data and relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database, and a list of ferroptosis-related genes was extracted from the FerrDb website. Analysis of differentially expressed FRLs was performed using the 'limma' package in R software. By implementing coexpression analysis and univariate Cox analysis, we then identified prognostic FRLs. Using Cox regression analysis with the least absolute shrinkage and selection operator (LASSO) algorithm, we constructed a prognostic model based on 4 FRLs. We evaluated the prognostic power of this model using Kaplan–Meier (K-M) survival curve analysis and receiver operating characteristic (ROC) curve analysis. Moreover, the relationships between the signature and immune landscape, somatic mutation and drug sensitivity were explored. Finally, *in vitro* experiments were conducted to validate the functions of AP003555.1 and AC000584.1.

Results: A 4-FRL signature was constructed. Two risk groups were classified based on the risk score calculated by this signature. The signature-based risk score exhibited a more powerful capacity for survival prediction than traditional clinicopathological features in colon patients. Additionally, we observed a significant difference in immune cells, such as CD4+ and CD8+ T cells and macrophages, between the two groups. Moreover, the high-risk group exhibited lower IC50 values for certain chemotherapy drugs, such as cisplatin, docetaxel, bleomycin or axitinib. Finally, the *in vitro* experiments showed that ferroptosis processes were suppressed after AP003555.1 and AC000584.1 knockdown.

Conclusion: The proposed 4-FRL signature is a promising biomarker to predict clinical outcomes and therapeutic responses in colon cancer patients.

Keywords: lncRNAs, ferroptosis, colorectal cancer, prognostic signature, immune microenvironment

INTRODUCTION

Colon cancer is the third most-diagnosed cancer and the second leading cause of cancer-related deaths in the world. Colon cancer seriously endangers human health (1). According to the latest online epidemiological database, there were more than 1.9 million new colon cancer cases in 2020, and 0.9 million deaths were recorded in the same year (2). The incidence rate and mortality rate have continuously risen in recent years. Even with the rapid development of cancer screening methods, many patients are diagnosed at an advanced stage with multiple symptoms, such as haematochezia or colonic obstruction (2). However, there are only a few effective therapeutic targets for colon cancer patients (3). Therefore, along with improvements in surgical treatments and chemoradiotherapies, it is also crucial and important to explore additional diagnostic biomarkers and possible therapeutic targets.

Ferroptosis is a newly defined form of regulated cell death driven by loss of activity of the lipid repair enzyme glutathione peroxidase 4 (GPX4) and the subsequent accumulation of lipid-based reactive oxygen species (ROS), particularly lipid hydroperoxides (4). This type of programmed cell death has been associated with carcinogenesis, intracerebral haemorrhage, degenerative diseases, stroke, and kidney degeneration (5). Ferroptosis has unique morphological and bioenergetic features that can be easily distinguished from other types of programmed cell death, such as apoptosis or necrosis. Currently, inducing cancer ferroptosis is considered a promising therapeutic strategy, especially for drug-resistant cancers (6). However, only a few ferroptosis-related therapeutic targets have been identified in colon cancer (7–9). Thus, further clinical sample-based screenings for ferroptosis-related genes (FRGs) are necessary for colon cancer diagnoses and treatments.

Long noncoding RNA (lncRNA) refers to a type of noncoding RNA more than 200 nucleotides in length. LncRNAs constitute a major class of transcripts that are encoded by the genome but are mostly not translated into proteins (10). In the past few decades, mounting evidence has shown that lncRNAs play key roles in regulating proliferation, metastasis, the cell cycle and programmed death in cancers (11, 12). For example, we showed that lncRNA LUCAT1 could promote proliferation in colon cancer (13). Recently, many researchers also found that lncRNAs, namely, LINC00618, could play a role in the ferroptosis process in cancer; this lncRNA was found to accelerate ferroptosis in an apoptosis-dependent manner (14). Similarly, LINC00336 inhibits ferroptosis as a competing endogenous RNA in lung cancer (15). Moreover, recent studies have demonstrated that lncRNA GABPB1-AS1 regulates erastin-induced ferroptosis with GABPB1 in HepG2 hepatocellular carcinoma (16). However, current studies screening ferroptosis-related lncRNAs (FRLs) in colon cancer are limited. Accordingly, it is important to identify key FRLs with prognostic significance in colon cancer patients.

In this study, we obtained RNA sequencing (RNA-seq) data from a colon adenocarcinoma (COAD) dataset and ultimately identified four differentially expressed FRLs and developed a prognostic model. Then, the mechanism of action of FRLs in colon cancer was further analysed by gene set enrichment analysis (GSEA), immunoinfiltration analysis and chemotherapy drug sensitivity analysis. Finally, we also tentatively validated the role of two FRLs with high expression in regulating ferroptosis *in vitro*.

Our findings could help to predict the prognosis of colon cancer patients and provide references for clinical chemotherapy and immunotherapy.

MATERIALS AND METHODS

Data Acquisition

The RNA-Seq data of 437 COAD samples, including 39 normal samples and 398 tumour samples, and corresponding clinical characteristics were downloaded from The Cancer Genome Atlas (TCGA) website (https://portal.gdc.cancer.gov/projects/TCGA-COAD). Then, Ensembl IDs were converted to official gene symbols, and log2 processing of the data was performed. LncRNAs and protein-coding genes were screened by the Ensembl human genome browser GRCh38.

Identification of Ferroptosis-Related LncRNAs

The list of FRGs was downloaded from FerrDb (http://www.zhounan.org/ferrdb/index.html) and contained 121 validated human FRGs. Subsequently, Spearman correlation coefficients were calculated based on FRGs and lncRNA expression profiles to identify FRLs ($|R^2|>0.4$ and $p < 0.001$) (17).

Differential Expression Analysis

The limma package (18) was used to screen the lncRNA expression matrix between COAD samples and normal colon samples. The criteria for DElncRNAs were $|\log_2(\text{fold change})| > 1$ and a false discovery rate (FDR) <0.05 (19).

Construction of the Coexpression Network

To demonstrate the correlation of the FRLs and their corresponding mRNAs, the lncRNA-mRNA coexpression network was constructed by Cytoscape software (version 3.7.2, http://www.cytoscape.org/). Then, a Sankey diagram was plotted to show the degree of correlation between FRLs (risk/protect) and their corresponding mRNAs.

Construction of Ferroptosis-Related Prognostic Signature

The intersecting genes of FRLs and DElncRNAs were filtered by Cox univariate analysis based on the 'survival' R package, defining potential prognostic FRLs ($p < 0.001$). A total of 398 patients were randomly separated into training or validation cohorts at a 1:1 ratio. Then, least absolute shrinkage and selection operator (LASSO)–Cox regression analysis was applied to these prognostic candidates. Finally, by choosing the optimal penalty parameter λ correlated with the minimum 10-fold cross-validation, we established a four-gene optimal prognostic model. The formula for ferroptosis-related prognostic risk scores for each patient was

$$\text{Risk score} = \Sigma_1^n \, coef_i * x_i$$

where x_i and $coef_i$ represent the expression of each lncRNA and its corresponding coefficient, respectively. According to the median value of the risk score, the patients in the training cohort were divided into low-risk and high-risk groups. The Kaplan–Meier curve was generated by using the 'survminer' R package with the log-rank test to compare overall survival (OS) between the high/low-risk group. A receiver operating characteristic curve (ROC) (20) was generated to evaluate the predictive accuracy of the signature *via* the 'timeROC' R package. To assess the model feasibility, the risk score was calculated in the validation cohort based on the same formula in the training cohort, and then, the same validation method was performed as above.

Functional Enrichment Analysis

The genes differentially expressed between the high-risk and low-risk groups were identified ($|\log_2(\text{fold change})|>1$ and FDR<0.05) with the 'edgeR' (21) R package and functionally annotated based on the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) with the 'clusterProfiler' R package (22) (adjusted p value< 0.05).

Gene Set Enrichment Analysis

To explore the molecular and biological differences in these two groups, GSEA was implemented between high/low ferroptosis risk score groups based on the KEGG and HALLMARK gene sets from the molecular signature database (https://www.gsea-msigdb.org/gsea/msigdb) used as references *via* the 'clusterProfiler' R package ($p < 0.05$ and FDR<0.25) (23). Single-sample GSEA (ssGSEA) was performed on several representative gene sets with the 'GSVA' R package.

Assessment of Immune Cell Infiltration and Immune Microenvironment

The ESTIMATE algorithm was used to assess immune infiltration in COAD patients (24). The difference in immune cell infiltration in the two groups of patients was evaluated using the CIBERSORT algorithm (25). CIBERSORT is an analysis tool using expression data to represent the cell composition of complex tissues based on preprocessed gene expression profiles. LM22 of CIBERSORT defines 22 immune cell subsets obtained from the CIBERSORT web portal (http://CIBERSORT.stanford.edu/).

Finally, TIDE (http://tide.dfci.harvard.edu/) algorithms were used to predict immune checkpoint response inhibitors of PD-1 and CTLA4 in the low- and high-risk score groups (26). $p < 0.05$ was considered significant.

Drug Sensitivity Prediction

The 'pRRophetic' (27) R package was used to predict the IC50 of chemotherapy drugs; this value indicates the effectiveness of a substance in inhibiting specific biological or biochemical processes.

Tissue Sample Collection and Colon Cancer Cell Line Culture

All tissue samples were collected from the Gastrointestinal Surgery Department of Xiangya 3rd Hospital, which was approved by the Medical Ethics Committee of the hospital. We acquired informed consent from each involved patient before collection. Ten pairs of samples, including tumour tissues (T) and pericarcinous tissues (N), were obtained from colon cancer patients who underwent tumour resection surgery between October 2020 and August 2021. All samples were maintained at -80°C.

Human intestinal epithelial cells (FHCs) and human colon cancer cell lines (HCT116, HT29, SW480, SW620) were purchased from American Type Culture Collection (ATCC) and these cells were cultured in F-12, McCoy's 5A or Leibovitz's L-15 medium (Gibco BRL, United States).

With 10% foetal bovine serum (Gibco BRL, United States) at 37°C, 95% humidity, and a 5% CO2 cell incubator.

RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qRT–PCR)

Total cellular and tissue RNA was extracted from tissues or cell lines using Total RNA Extraction Reagent (10606ES60, Yeasen) based on standard protocols. Then, the obtained RNAs were used for cDNA synthesis with a cDNA synthesis kit (11139ES10, Yeasen). Gene expression was quantified by Roche LightCycler 480 using SYBR Green Master Mix (11201ES03, Yeasen), and the expression levels were calculated with the $2^{-\Delta\Delta Ct}$ method. GAPDH acted as the internal reference for normalization. All primers used for qRT–PCR were synthesized by Tsingke Biotech (Tsingke, China). The primer sequences used are listed in **Supplementary Table 1**.

Cell Counting Kit-8 (CCK-8) Assay

The cells were seeded in 96-well plates at 5×10^3 cells/well. Then, the cells were treated with different doses of erastin (10 μM) for 24 h. A CCK-8 assay kit (40203ES60, Yeasen) was used to detect cell proliferation at 450 nm. The average inhibition rate of cell activity at each concentration was calculated following the protocol (28).

Reactive Oxygen Species (ROS) Detection

To detect the ROS level in SW620 cells, 2′,7′-dichlorofluorescin diacetate (DCFH-DA; 5 μM, Sigma–Aldrich, USA) was added to

the L15 medium and incubated for 30 min. Fluorescence images were recorded using fluorescence microscopy.

Determination of Malondialdehyde (MDA) and Fe2+ Levels

MDA levels were detected by an MDA colorimetric assay kit (cell samples, E-BC-K028-M, Elabscience), and Fe2+ levels were measured using a FerroOrange probe (F374, Dojindo). The above assays were performed strictly following the official protocol.

Statistical Analysis

The Wilcox test was used to compare the proportion of tumour-infiltrating immune cells. Spearman correlation analysis was used to analyse the correlation between FRGs and FRLs. Differences in the proportions of clinical characteristics were analysed by the chi-squared test. Cox univariate regression analysis and multivariate Cox regression analysis were implemented to define the independent prognostic factor for OS. The predictive accuracy of the prognostic model for OS was evaluated by performing time-dependent ROC curve analysis. R software (version 4.10) was applied for all statistical analyses, and the 'ggplot2' (29) package was used for graph visualization. Statistical significance was defined as $p < 0.05$, and all p values were two-tailed.

RESULTS

Identification of Ferroptosis-Related Differentially Expressed LncRNAs in COAD

The research flow chart of our study is shown in **Figure 1**. The data for 437 COAD samples were downloaded from the TCGA database (https://portal.gdc.cancer.gov/repository). A total of 14086 lncRNAs and 19604 mRNAs were identified.

To identify the gene set involved in the process of ferroptosis first, the sequences of FRGs in *Homo sapiens* were downloaded from the FerrDb database (http://www.zhounan.org/ferrdb/) (30); these included 84 ferroptosis driver genes, 89 ferroptosis-related suppressors and 3 ferroptosis-related markers. After the multiannotated genes were screened, a total of 176 FRGs were identified. The details of these genes are documented in **Supplementary Table 2**. Then, Spearman correlation analysis was conducted between lncRNAs in the TCGA database. A PCA map and bar plots showing the distribution of those samples are shown in **Supplementary Figures 1A, B**. FRGs in the FerrDb database were used to determine FRLs. The inclusion parameters were selected as correlation coefficient ($|R^2|$) > 0.4 and p value (P)<0.001. In total, 2033 FRLs were defined. Then, we identified 2530 differentially expressed lncRNAs (DELs) in TCGA-COAD samples between normal and tumour tissue ($\log_2|$ FC| > 1, FDR < 0.05), including 1779 upregulated DELs and 751 downregulated DELs. A related volcano map is shown in **Supplementary Figure 1C**. Finally, we identified 705 ferroptosis-related DELs (FRDELs) (**Figure 2A**).

Identification of Prognostic Ferroptosis-Related Differentially Expressed lncRNAs

To verify the prognostic potential of the FRDELs, these FRDELs were evaluated for prognostic potential by Cox univariate regression analysis using the OS data of COAD patients in the TCGA database. Ultimately, 26 prognostic FRDELs (PFRDELs) in COAD were determined (**Figure 2B** and **Supplementary Figure 1D**). Twenty-five PFRDELs were "risk" genes, while only AC104819.3 could be treated as a "protective" gene. The correlation between 26 PFRDELs and 176 FRGs is shown in **Figure 2C** (the list of these lncRNAs is shown in **Supplementary Table 3**), which implied a reciprocal relationship (the correlation rate and the p value) between each PFRDEL and FRG.

To further evaluate the relationship between these 26 lncRNAs and the representative FRGs, a lncRNA-gene coexpression network was established (**Figure 2D**). Among these FRLs, lncRNA AC107308.1 had a tight linkage with FRGs. A total of 12 genes were coexpressed with lncRNA AC107308.1 (IREB2, NRAS, KRAS, ZEB1, PRKAA2, PRKAA1, TGFBR1, ATM, FBXW7, ANGPTL7, KLHL24, TUBE1). In addition, lncRNA LINC01138 was coexpressed with 10 genes (IREB2, NOX4, ALOX12, ZEB1, TGFBR1, ATM, FBXW7, ANGPTL7, ZNF419, KLHL24), and lncRNA LINC02381 also had a connection with 3 FRGs (ALOX15B, NOX4, CDO1). Among those FRGs, Acid 12-lipoxygenase (ALOX12), a well-known ferroptosis driver (31), had positive coexpression with 14 prognostic FRLs. HELLS is also connected with 7 FRLs, and the details of the coexpression network are shown in **Supplementary Table 4**. Subsequently, we further visualized the prognostic function and discovered the internal connection between PFRDELs and FRGs. We also established a Sankey diagram (32) that showed the relationship among FRLs, FRGs and their roles in COAD (**Figure 2E**).

Construction and Validation of a FRL Prognostic Model

To check the prognostic value of these FRDELs, the samples from TCGA-COAD database were classified randomly into two groups: a training group and a validation group. The clinical characteristics of the samples in the two groups are shown in **Table 1**.

A prognostic risk evaluation model based on only 4 FRLs was then constructed using the optimal penalty parameter (λ) for the LASSO model from the abovementioned 26 PFRDEL lesions in the training group. The cvfit and lambda curve are shown in **Figures 3A, B**. In this model, each COAD patient in the TCGA database was assigned a risk score using the following formula: Risk Score=AC104819.3*(-0.52383)+AP003555.1*0.12181+AC005841.1*0.25406+LINC02381*0.10087 (Note: the name of lncRNA indicates their expression level in TCGA database). Cox univariate and multivariate regression analyses were performed to evaluate the independent predictive potential of this signature. First, Cox univariate regression analysis demonstrated that the risk score of this signature was associated with the OS rates of COAD patients (p=0.011; **Figure 3C**). Furthermore, multivariate Cox regression analysis revealed that only this 4-FRL risk signature



FIGURE 1 | Study flowchart. A total of 14086 lncRNAs and 176 ferroptosis-related genes (FRGs) were obtained from TCGA and FerrDb databases, respectively. Then, 705 ferroptosis-related lncRNAs (FRLs) was identified according to Spearman correlation analysis. Next, univariate COX analysis was applied to screen for the prognostic FRLs. Based on this analysis, a 4-FRL signature was constructed. Subsequently, GSEA, KEGG, GO analyses, immune-related analyses, somatic mutation, and drug sensitivity assays were applied to identify the potential function of this signature. Finally, in vitro validations were conducted to explore the expression and function of these FRLs.

and age could act as an independent prognostic factor for predicting the OS rates of COAD patients in the TCGA database ($p < 0.001$; **Figure 3D**). The predictive nomogram calculated the likelihood of survival of those patients by adding up the scores identified on the points scale for the many related factors. The 1-, 3- and 5-year OS rates could be predicted accurately when compared with those of the ideal predictive model (**Figures 3E, F**).

Subsequently, we evaluated the prognostic value of this 4-FRL model. Then, the samples in the training group were classified into high-risk and low-risk groups according to the median value of the risk scores. The distribution of the risk scores and the distribution



FIGURE 2 | Prognostic analysis of differentially expressed ferroptosis-related lncRNAs and the construction of a coexpression network. **(A)** Venn diagram to identify the common lncRNAs of differentially expressed lncRNAs and ferroptosis-related lncRNAs. **(B)** Forest plots showing the results of the Cox univariate regression analysis approximately 26 prognostic differentially expressed ferroptosis-related lncRNAs. **(C)** The correlation between 26 prognostic ferroptosis-related lncRNAs and 176 ferroptosis-related genes in the TCGA-COAD cohort. The colour of each unit shows the degree of corelation. *p < 0.05, **p < 0.01, and ***p < 0.001. **(D)** Coexpression network of candidate lncRNAs and ferroptosis-related genes. **(E)** The Sankey diagram presents the detail connection between ferroptosis-related lncRNAs and ferroptosis-related genes.

TABLE 1 | The clinical characteristics of colon cancer patients in the training and validation group.

Characteristics	Training group No.	%	Validation group No.	%	P-value
Age	—		—		—
<=60	49		45		>0.05
>60	112		125		—
Gender	—		—		—
Male	83		94		>0.05
Female	78		76		—
AJCC Stage	—		—		—
I	30		28		>0.05
II	61		73		—
III	44		42		—
IV	26		27		—
T stage	—		—		—
T1	3		4		>0.05
T2	28		30		—
T3	115		115		—
T4	15		21		—
N stage	—		—		—
N0	94		105		>0.05
N1	37		38		—
N2	30		27		—
M stage	—		—		—
M0	135		143		>0.05
M1	26		27		—

of the OS status were visualized to show that those samples of the above two risk groups were reasonably distributed (**Figure 4A**). Kaplan–Meier survival analysis was then used to show that the OS rate of COAD patients in the high-risk group was worse than that in the low-risk group (**Figure 4D**). A time-dependent ROC curve was also generated in the training group. The areas under the curve (AUCs) were maintained at more than 0.75 at the 1-year, 3-year and 5-year points (**Figure 4G**). An ROC curve was also constructed to validate the outstanding prognostic accuracy of this signature compared to other clinicopathological characteristics (**Figure 4J**). To further evaluate the predictive efficacy of this 4-lncRNA signature, the distribution figures, heatmaps, Kaplan–Meier survival analysis and time-dependent ROC analysis were double validated in both the validation group and the overall group. The samples of the above two risk groups were also reasonably distributed in the validation group (**Figures 4B, E, H, K**) and the overall group (**Figures 4C, F, I, L**). It is obvious that individuals from the high-risk group may have higher mortality rates than low-risk individuals.

Relationship Between the 4-FRL Signature and the Clinicopathological Characteristics in COAD Patients

Three lncRNAs in our signature were considered risk lncRNAs, and they were upregulated in the high-risk group in the TCGA-COAD database. Only AC104819.3 was a protective lncRNA that was downregulated in the high-risk group (**Figure 5A**). We compared the differences in clinicopathological characteristics between the two risk subgroups. Interestingly, there were significant differences in tumour stage ($p<0.01$), T stage ($p<0.01$), N stage ($p<0.001$), M stage ($p<0.01$), microsatellite stability ($p<0.05$), venous invasion ($p<0.001$) and lymph invasion ($p<0.01$) (**Figure 5A**) between these two groups, and the above clinical characteristics were also compared separately in **Figures 5B–G**. The high-risk group exhibited advanced T and N stages compared with those of the low-risk group, and lymph and venous invasion were more frequent in the high-risk group. Interestingly, we also noticed that more patients from the high-risk group had a history of polyps. In sum, these results indicated that this 4-lncRNA signature has outstanding potential for predicting prognosis in COAD patients by evaluating their risk score by related gene expression level.

Discovery of Molecular Functions and Pathways by GSEA, GO and KEGG Analysis

To explore the underlying difference in biological functions and signalling pathways between the different risk groups classified by the 4-FRL signature. GSEA was performed. The results showed that many cancer proliferation pathways were enriched in the high-risk group, such as angiogenesis-related pathways and the KRAS pathway. Many immune-related pathways were also involved, such as the autoimmune thyroid disease, the IL2 pathway, and the intestinal immune network (**Figure 6A**). Moreover, many metabolic pathways were enriched in the low-risk group, such as bile acid metabolism, butanoate metabolism, propanoate metabolism and drug metabolism (**Figure 6B**). Interestingly, some pathways related to drug resistance, such as KESHELAVA multiple drug resistance, cisplatin resistance and the MAPK pathway, were also enriched. The details of the GSEA results are listed in **Supplementary Table 5**. We further investigated the differences in biological processes and



FIGURE 3 | Construction of a 4-ferroptosis-related-lncRNA signature and the analysis of independent prognostic potential. **(A, B)** cvfit and lambda curves showing the least absolute shrinkage and selection operator (LASSO) regression was performed with the minimum criteria. **(C, D)** Results of the univariate Cox regression analysis and multivariate Cox regression analysis regarding OS of the 4-ferroptosis-related-lncRNAs signature. **(E)** The nomogram to predict the 1-year, 3-year, and 5-year overall survival rate of colon cancer patients. **(F)** The calibration curve for evaluating the accuracy of the nomogram model. The dashed diagonal line in grey colour represents the ideal nomogram.

pathways in differentially expressed genes(DEGs) between the two risk groups. DEGs between the high-risk group and the low-risk group were determined by the cut-off of $\log_2|FC| > 1$ and FDR < 0.05, and annotation GO enrichment analysis and KEGG pathway analysis were then performed ($p<0.05$). The KEGG analysis showed that many immune-related pathways were significantly enriched, including systemic lupus erythematosus, Th1, Th2 and Th17 cell differentiation, antigen processing and presentation, which were similar to the results of GSEA (**Figure 6C**). GO analysis was conducted and indicated the enrichment of biological process (BP), molecular function (MF), and cell component (CC). The results of these three analyses are presented in **Figure 6D**. In summary, these results suggested that the risk score of the 4-lncRNA signature was mainly related to tumour metastasis, tumour immunity, biological metabolism and drug resistance in colon cancer.



FIGURE 4 | Construction and validation of the ferroptosis-related lncRNA signature model in the training cohort, validation and overall groups. **(A–C)** The distribution of the risk scores and the distributions of overall survival status and risk score in the training, validation and overall groups. **(D–F)** The Kaplan–Meier curves for survival status and survival time in the training, validation and overall groups. **(G–I)** The receiver operating characteristic (ROC) curve shows the potential of the prognostic ferroptosis-related lncRNAs signature in predicting 1-, 2-, and 3-year overall survival (OS) in the training, validation and overall groups. **(J–L)** AUC of ROC curves comparing the prognostic accuracy of the risk score and other prognostic factors in the training, validation and overall groups.

Immune-Related Analysis of COAD Patients Using the Prognostic Signature

To further explore the relationship between the ferroptosis-related signature and antitumour immunity in COAD patients, we identified the immune cell infiltration landscape of all patients with COAD from the TCGA database using the CIBERSORT algorithm. The proportion of each typical immune cell is shown in **Figure 7A**. To identify the differences in infiltrating immune cells between the high-risk and low-risk groups, the stromal score (substrate cells in the tumour tissue),



FIGURE 5 | Correlation analysis between the prognostic signature and different clinicopathological characteristics in the TCGA cohort. **(A)** The heatmap depicting the distribution of 12 different clinicopathological characteristics with the risk scores of each patient based on the signature. **(B–G)** The histogram depicting the significant difference of the risk scores in colon cancer patients stratified by T stage, N stage, M stage, lymph invasion, venous invasion and polyp history. *p < 0.05, **p < 0.01, and ***p < 0.001. ns, No significance.

immune score (immune cell infiltration in the tumour tissue) and estimate score (the summation of stromal and immune scores from individual cases) were compared, and these scores were all significantly higher in the high-risk group (p<0.001) (**Figure 7B**). Moreover, we also compared the proportion of each immune cell between the high-risk and low-risk groups and found that naive B cells, activated dendritic cells, M1 and M2 macrophages, neutrophils, monocytes, resting CD4 memory T cells, activated CD4 memory T cells, CD8 T cells, follicular helper T cells and regulatory T cells were significantly different between the two groups (**Figure 7C**).

We also compared the expression levels of immune checkpoint genes in the high-risk and low-risk groups. As shown in **Figure 7D**, 30 checkpoint genes were significantly different between the two groups. Among these, 28 genes presented with high expression in the high-risk group, including many validated effective immunotherapy targets, such as PDCD1 (PD-1), CD274 (PD-L1) and CTLA4. HHLA2



FIGURE 6 | Biological functional and pathway enrichment analysis of high-risk group and low-risk group based on the ferroptosis-related lncRNA prognostic signature. **(A)** GSEA showing significant enrichment of immune-related pathways and cancer proliferation pathways in the high-risk colon cancer patients. **(B)** GSEA showing significant enrichment of metabolism related pathways in the low-risk colon cancer patients. **(C)** GO analysis showing many immune-related biological processes were enriched. **(D)** KEGG analysis showing many immune-related pathways and cancer proliferation pathways were enriched.

and TNFSF15 expression was lower in the low-risk group than that in the high-risk group. Altogether, the relationships between the risk scores calculated by the 4-lncRNA signature and immune infiltration cells were evaluated, and the results indicated that the risk level of those COAD patients was associated with those immune infiltration cells.

Cancer-Related Gene Mutation and Drug Sensitivity in the 4-Ferroptosis-Related LncRNA Signature

To identify the difference in cancer-related gene mutations between the high-risk and low-risk groups, we first counted the gene mutation in each group. General information on representative gene mutations in both groups is shown in **Figures 8A–D**. Genes such as APC (75%), TP53 (65%), TNN (50%), KRAS (40%) and SYNE1 (26%) had the top five mutation frequencies in the high-risk group. APC (78%), TP53 (55%), TNN (45%), KRAS (44%) and PIK3CA (30%) were the top five genes with the highest mutation frequencies in the low-risk group. Generally, anti-oncogenes, such as TP53, had a relatively higher mutation rate in the high-risk group (65% vs. 55%), while oncogenes such as MUC16 presented a relatively lower mutation rate in the high-risk group (24% vs. 29%).

To further explore the difference in the two risk groups about the drug resistance potential. We compared the estimated IC50 levels of 138 chemotherapy drugs or inhibitors in the two groups. Among those, 11 representative drugs are shown in **Figures 8E–O**. We found that cisplatin, docetaxel, bleomycin, axitinib, gefitinib, pazopanib, rapamycin and tipifarnib may be candidate drugs for treating patients in the high-risk group. Lapatinib, mitomycin C, and AKT inhibitor VIII may not be ideal for patients in the high-risk group.

Validation of FRL Expression

To evaluate the protein-coding ability of these FRLs, we used PhyloCSF (33) to determine whether these FRLs are likely to represent conserved protein-coding regions. As shown in **Supplementary Figure 2**. AP003555.1, AC104819.3 and LINC02381 with negative scores were retained as potential noncoding RNAs (34), while AC005841.1 may have the



FIGURE 7 | Analysis of immune cell infiltration landscape in colon cancer patients. **(A)** Bar graphs exhibiting the distribution of tumour-infiltrating immune cells between the high-risk and low-risk groups based on the ferroptosis-related-lncRNAs signature. **(B)** Stroma, immune, and ESTIMATE scores in the high-risk and low-risk groups in colon cancer patients. **(C)** The boxplots for the comparison of the 22 immune cells between the high-risk and low-risk groups in the colon cancer patients. **(D)** The boxplots for the comparison of the immune checkpoints genes between the high-risk and low-risk groups in the colon cancer patients. *p < 0.05, **p < 0.01, and ***p < 0.001, ns, No significance.

potential to encode 4 kD short peptides because it obtained one exon with a positive score.

We further evaluated the expression levels of these 4 prognostic FRLs. We tested their expression level in the cell lines. As shown in **Figure 9A**, compared with those in the FHC line (established from normal fetal colonic mucosa), AP003555.1 and AC005841.1 were expressed at relatively higher levels in colon cancer cell lines (including HT29, HCT116, SW480, and SW620), but AC104819.3 and LINC02381 exhibited the opposite trend. We also validated the expression levels of these 4 lncRNAs in sample pairs retreated from colon cancer patients in our hospital. Similar expression trends were observed in clinical samples (**Figures 9B–E**). AP003555.1 and AC005841.1 showed higher expression levels in tumour tissues (T) than in pericarcinous tissues (N). These results further verified the correctness of the above bioinformatics research (**Supplementary Figure 1D**).



FIGURE 8 | Somatic mutation analysis and drug sensitive prediction in colon cancer patients. **(A–D)** MAF-summary plots and oncoplots of the somatic mutation showing the difference between the high-risk group and low-risk group in colon cancer patients. **(E–O)** Boxplot showing the mean differences in estimated IC50 values of 11 representative drugs (cisplatin, docetaxel, bleomycin, axitinib, gefitinib, pazopanib, rapamycin, tipifarnib, lapatinib, mitomycin C, AKT inhibitor VIII) between the two risk groups.

AP003555.1 and AC005841.1 Regulated Erastin-Induced Ferroptosis

As mentioned previously, compared with FHC, the expression of both AP003555.1 and AC005841.1 was significantly upregulated in the CRC cell lines, especially in HCT116 and SW480 cells. AC104819.3 and LINC02831 were slightly downregulated in CRC cells. Thus, AP003555.1 and AC005841.1 were chosen for further analysis. To further elucidate the potential function of these two FRLs, we implemented the stable knockdown of AP003555.1 and AC005841.1 using short hairpin RNAs in HCT116 and SW480 cells. The transfection efficiency was confirmed by qRT–PCR (**Figures 10A, B**). Then, a Cell Counting Kit-8 (CCK-8) assay was used to evaluate their roles in regulating the proliferation of colon cancer cells. The knockdown of AP003555.1 and AC005841.1 significantly inhibited cell proliferation in HCT116 and SW480 cells



FIGURE 9 | Validation of the expression level of the four ferroptosis-related lncRNAs in cell lines and tissues. **(A)** Expression analysis of four ferroptosis-related lncRNAs in four colon cancer cell lines (HT29,HCT116,SW480,SW620) with FHC lines (established from normal foetal colonic mucosa). **(B–D)** Expression analysis of AP003555.1, AC104819.3, AC005841.1 and LINC02381 in 10 pairs of colon cancer tissue samples. **p < 0.01, and ***p < 0.001.

compared to their control groups (**Figures 10C, D**). Ferroptosis is mainly characterized by the accumulation of ROS. ROS levels were clearly observed after HCT116 and SW480 cells were treated with 10 μM erastin (ferroptosis activator). As expected, erastin-induced ROS production was increased after the knockdown of both AP003555.1 and AC005841.1 (**Figures 10E, F**). Then, malondialdehyde (MDA) and Fe^{2+} levels were measured by MDA and FerroOrange assay kits, and MDA and Fe^{2+} levels were remarkably increased after AP003555.1 and AC005841.1 silencing after treatment with 10 μM erastin in CRC cells (**Figures 10G–J**).

DISCUSSION

Currently, many studies have focused on the roles of lncRNAs in the ferroptosis of cancer (35). The identification of FRLs is indispensable in searching for potential cancer targets. However, studies on FRLs in colon cancer remain limited.

In this study, we comprehensively analysed the expression profiles of 176 validated FRGs in humans provided by the latest online FerrDb database and screened out differentially expressed FRLs. Subsequently, the prognosis of each patient in the TCGA database and the expression profile of these FRLs were analysed. The results identified 26 prognostic FRLs. Then, a lncRNA-gene coexpression network was established, and we noticed that ALOX12 has high correlations with 12 prognostic FRLs. ALOX12 has been shown to play an important role in inflammation and oxidation (36). This enzyme can elevate the levels of mitogenic metabolites in cancer cells and thus increase the proliferation rate of cancers (37, 38). Recently, Bo Chu et al. found that ALOX12 inactivation diminishes p53-mediated ferroptosis induced by ROS stress and abrogates p53-dependent inhibition of tumour growth (17), which means that ALOX12 might function as a hub gene with a deep connection



FIGURE 10 | Ferroptosis regulation of AP003555.1 and AC005841.1. **(A, B)** Relative expression level of AP003555.1 and AC005841.1 after transfection with the corresponding shRNA. **(C)** The cell proliferation ability of HT116 and SW480 cells after the knockdown of AP003555.1. **(D)** The cell proliferation ability of HT116 and SW480 cells after the knockdown of AC005841.1. **(E, F)** The comparison of erastin-induced ROS in the treatment and control groups. **(G–J)** The ferroptosis process was evaluated by detecting MDA and Fe2+ levels in the non-erastin-induced and erastin-induced groups. *p < 0.05, **p < 0.01, and ***p < 0.001, ns, No significance.

with many essential FRLs. We also noticed that LINC02831 had high correlations with 3 mRNAs (NOX4, ALOX15B, and CDO1). LINC02381 is an oncogene that has been validated by many cancer researchers. For example, LINC02381 can promote cell proliferation and migration by targeting miR-133b in cervical cancer (39), and it inhibits gastric cancer by regulating the wnt pathway (40). However, how LINC02381 is involved in regulating ferroptosis still needs further exploration. Significantly, we noticed that LINC02381 expression was lower in tumour samples than in nontumour samples; however, it still functions as a "risk" lncRNA in colon cancer.

Furthermore, a novel prognostic 4-lncRNA model was created. Specifically, this signature is relatively easier to use in the clinic than many other identified signatures because it only included 4 lncRNAs, and it also exhibited a greater ability to predict the prognosis of colon cancer patients than the traditional TNM stage. Many adverse events, such as venous invasion or lymphatic metastasis, could also be foreseen by

evaluating the risk score of patients using this model. We divided colon cancer patients into a high-risk group and a low-risk group based on their risk scores calculated by the formula of this prognostic model. To further evaluate the mechanism of how this signature regulates the process of colon cancer. GSEA was then conducted. The results revealed that the pathway of angiogenesis ranks high in the high-risk group, and angiogenesis (the formation of new blood vessels) has been proven integral to cancer development (41). Cancer metastasis pathways such as cell adhesion or epithelial-mesenchymal transition (EMT) (42) were also enriched. The relationship between ferroptosis and the immunosuppressive microenvironment is a contentious issue (43). We noticed that many immune-related hallmarks were enriched, such as the intestinal immune network or IL2-STAT5 pathway, and we can reasonably assume that tumour immunity is closely related to ferroptosis in colon cancer. Lipid peroxidation has been considered a vital process in ferroptosis (44). Therefore, researchers also believe that aberrant metabolic and biochemical processes contribute to ferroptosis (45). Many metabolic pathways, including fatty acid metabolism, were also enriched. KEGG enrichment analysis and GO enrichment analysis, including BP, MF and CC, were also performed, and the enrichment pathway results were relatively similar to the GSEA results. In summary, we may infer from the results above that ferroptosis was inhibited in the high-risk group through some immune-related pathways. Therefore, colon cancer could initially develop in these patients.

Previous studies have also suggested that ferroptosis is closely related to tumour immunity. It is also considered immunogenic cell death (46). Wang et al. verified that CD8+ T cells could induce ferroptosis in tumour cells (47). Some studies also found that prostaglandin E2 (PGE2) facilitates tumour immune evasion (48, 49). However, no study has reported a direct relationship between ferroptosis and immune cell infiltration in colon cancer. After many immune-related pathways were enriched in our GSEA, we calculated the proportion of different types of tumour-infiltrating immune cells in colon cancer from TCGA database using CIBERSORT. As expected, we found that the high-risk group showed significantly higher immune, stromal and ESTIMATE scores than the low-risk group. Previous studies revealed that high immune and stromal scores as well as high infiltration of macrophages were associated with poor prognosis, which was in accordance with our results (50). Furthermore, patients in the high-risk group also presented relatively low expression levels of immune cells such as monocytes or dendrites, and immature immune cells such as naive B cells or immunosuppressive cells such as regulatory T cells were expressed at higher levels in the low-risk group. CD4 T cell responses are essential in the cancer immune cycle, and both significantly influence the clinical outcome (51). We witnessed a notable decrease in CD4 T cells in the high-risk group, and we assume that the CD4 function of colon cancer patients might be relatively inhibited or slowed in the high-risk group. The expression levels of many immune checkpoints, such as PD-1, PD-L1, and CTL4A, were higher in the high-risk group than in the low-risk group. Therefore, these patients might benefit from many immune checkpoint blockades (52), which might improve the prognosis of high-risk patients by enhancing their immunoreactivity or inducing ferroptosis.

Additionally, we evaluated the expression level of these 4 PFRDELs in our signature. The expression trend was basically consistent with the prediction of the previous bioinformatic analysis. Finally, many ferroptosis-related assays were conducted to elucidate the potential mechanisms of two lncRNAs in our signature, AP003555.1 and AC005841.1, which were proven to regulate ferroptosis in a ferroptosis-dependent manner. However, the role of LINC02381 in ferroptosis needs further exploration because no significant changes in MDA and Fe^{2+} levels were observed. Considering that the role of LINC02381 in cancer remains disputed (40, 41), we suggest that LINC02381 may work together with other genes in regulating ferroptosis. There are still some limitations that must be addressed. First, external validation was missing due to the lack of expression profiles of lncRNAs and OS data in other databases. Therefore, validation could only be performed *via* the TCGA database. Second, even though the expression levels of all 4 lncRNAs were checked by qRT–PCR in 10 pairs of clinical samples and 5 colon cancer cell lines, there were still not sufficient samples available, and more samples would be helpful to make the evidence more solid. Finally, the underlying mechanism of how these lncRNAs affect ferroptosis remains unknown. Further research on the relationship between these lncRNAs and FRGs is necessary.

CONCLUSION

Our study constructed a robust prognostic predictive model with only 4 FRLs, which, compared to other traditional clinicopathologic signatures, is relatively easy to test in patients. The relationship between our risk model and the immune landscape was preliminarily ascertained. The findings of our study offer many useful insights in predicting the prognosis of colon cancer patients and may even assist their treatment in clinical practice.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Medical Ethics Committee of the Thrid Xiangya hospital, Central South University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZW, ZL, and CL contributed to conception and design of the study. ZW and ZL organized the database. ZL performed the statistical analysis. ZW wrote the first draft of the manuscript. ZW and ZL wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version

FUNDING

This work was supported by the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (No. YX202107).

ACKNOWLEDGMENTS

We sincerely acknowledge The Cancer Genome Atlas (TCGA) for providing transcriptomic and clinicopathological data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.783362/full#supplementary-material

Supplementary Figure 1 | Identification of differentially expressed ferroptosis-related lncRNAs in COAD. **(A, B)** The PCA map and the bar plots showing the distribution of colon cancer samples. **(B)** The volcano map of lncRNAs differentially expressed in COAD. **(D)** The heatmap of these 26 lncRNAs showing the expression level of each lncRNA in each patient.

Supplementary Figure 2 | The results of 4 FRLs in PhyloCSF.

Supplementary Table 1 | The list of primer sequences used in our study.

Supplementary Table 2 | The details of all of the ferroptosis-related genes.

Supplementary Table 3 | The table of differentially expressed lncRNAs and ferroptosis-related lncRNAs.

Supplementary Table 4 | The list of genes involoved in the coexpression network.

Supplementary Table 5 | The list of pathways enriched in GSEA.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* (2021) 71(1):7–33. doi: 10.3322/caac.21654
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2021) 71(3):209–49. doi: 10.3322/caac.21660
3. Wang X, Ward PA. Opportunities and Challenges of Disease Biomarkers: A New Section in the Journal of Translational Medicine. *J Transl Med* (2012) 10:240. doi: 10.1186/1479-5876-10-240
4. Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol* (2016) 26(3):165–76. doi: 10.1016/j.tcb.2015.10.014
5. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* (2017) 171(2):273–85. doi: 10.1016/j.cell.2017.09.021
6. Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, et al. Molecular Mechanisms of Ferroptosis and Its Role in Cancer Therapy. *J Cell Mol Med* (2019) 23(8):4900–12. doi: 10.1111/jcmm.14511
7. Xia Y, Liu S, Li C, Ai Z, Shen W, Ren W, et al. Discovery of a Novel Ferroptosis Inducer-Talaroconvolutin A-Killing Colorectal Cancer Cells In Vitro and *In Vivo*. *Cell Death Dis* (2020) 11(11):988. doi: 10.1038/s41419-020-03194-2
8. Lu D, Yang Z, Xia Q, Gao S, Sun S, Luo X, et al. ACADSB Regulates Ferroptosis and Affects the Migration, Invasion, and Proliferation of Colorectal Cancer Cells. *Cell Biol Int* (2020) 44(11):2334–43. doi: 10.1002/cbin.11443
9. Li C, Tian Y, Liang Y, Li Q. Circ_0008035 Contributes to Cell Proliferation and Inhibits Apoptosis and Ferroptosis in Gastric Cancer *via* miR-599/EIF4A1 Axis. *Cancer Cell Int* (2020) 20(1):84. doi: 10.1186/s12935-020-01168-0
10. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. *Cancer Res* (2017) 77(15):3965–81. doi: 10.1158/0008-5472.CAN-16-2634
11. Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and Its Role in Cancer Metastasis. *Oncol Res* (2016) 23(5):205–17. doi: 10.3727/096504016X14549667334007
12. Peng WX, Koirala P, Mo YY. LncRNA-Mediated Regulation of Cell Signaling in Cancer. *Oncogene* (2017) 36(41):5661–7. doi: 10.1038/onc.2017.184
13. Wu R, Li L, Bai Y, Yu B, Xie C, Wu H, et al. The Long Noncoding RNA LUCAT1 Promotes Colorectal Cancer Cell Proliferation by Antagonizing Nucleolin to Regulate MYC Expression. *Cell Death Dis* (2020) 11(10):908. doi: 10.1038/s41419-020-03095-4
14. Wang Z, Chen X, Liu N, Shi Y, Liu Y, Ouyang L, et al. A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent Upon Apoptosis. *Mol Ther* (2021) 29(1):263–74. doi: 10.1016/j.ymthe.2020.09.024
15. Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Long Noncoding RNA LINC00336 Inhibits Ferroptosis in Lung Cancer by Functioning as a Competing Endogenous RNA. *Cell Death Differ* (2019) 26(11):2329–43. doi: 10.1038/s41418-019-0304-y
16. Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C, et al. LncRNA GABPB1-AS1 and GABPB1 Regulate Oxidative Stress During Erastin-Induced Ferroptosis in HepG2 Hepatocellular Carcinoma Cells. *Sci Rep* (2019) 9(1):16185. doi: 10.1038/s41598-019-52837-8
17. Kuemmerlen D, Echtermann T, Muentener C, Sidler X. Agreement of Benchmarking High Antimicrobial Usage Farms Based on Either Animal Treatment Index or Number of National Defined Daily Doses. *Front Vet Sci* (2020) 7:638. doi: 10.3389/fvets.2020.00638
18. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007
19. Tu Z, Wu L, Wang P, Hu Q, Tao C, Li K, et al. N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients. *Front Cell Dev Biol* (2020) 8:642. doi: 10.3389/fcell.2020.00642
20. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-Dependent ROC Curve Analysis in Medical Research: Current Methods and Applications. *BMC Med Res Methodol* (2017) 17(1):53. doi: 10.1186/s12874-017-0332-6
21. Robinson MD, McCarthy DJ, Smyth GK. Edger: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. *Bioinformatics* (2010) 26(1):139–40. doi: 10.1093/bioinformatics/btp616
22. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. Clusterprofiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data. *Innovation (NY)* (2021) 2(3):100141. doi: 10.1016/j.xinn.2021.100141
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. *Proc Natl Acad Sci USA* (2005) 102(43):15545–50. doi: 10.1073/pnas.0506580102

24. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Res* (2017) 77(21):e108–10. doi: 10.1158/0008-5472.CAN-17-0307
25. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells With CIBERSORT. *Methods Mol Biol* (2018) 1711:243–59. doi: 10.1007/978-1-4939-7493-1_12
26. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response. *Nat Med* (2018) 24(10):1550–8. doi: 10.1038/s41591-018-0136-1
27. Geeleher P, Cox N, Huang RS. Prrophetic: An R Package for Prediction of Clinical Chemotherapeutic Response From Tumor Gene Expression Levels. *PLoS One* (2014) 9(9):e107468. doi: 10.1371/journal.pone.0107468
28. Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G Facilitates Sorafenib Resistance Through Inhibition of Ferroptosis. *Hepatology* (2016) 64(2):488–500. doi: 10.1002/hep.28574
29. Villanueva RAM, Chen ZJ. ggplot2: Elegant Graphics for Data Analysis (2nd ed.). Measurement: Interdisciplinary Research and Perspectives. (2019) 17 (3):160–7. doi: 10.1080/15366367.2019.1565254
30. Zhou N, Bao J. FerrDb: A Manually Curated Resource for Regulators and Markers of Ferroptosis and Ferroptosis-Disease Associations. *Database (Oxford)* (2020) 2020:baaa021. doi: 10.1093/database/baaa021
31. Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 Is Required for P53-Mediated Tumour Suppression Through a Distinct Ferroptosis Pathway. *Nat Cell Biol* (2019) 21(5):579–91. doi: 10.1038/s41556-019-0305-6
32. Mica L, Niggli C, Bak P, Yaeli A, McClain M, Lawrie CM, et al. Development of a Visual Analytics Tool for Polytrauma Patients: Proof of Concept for a New Assessment Tool Using a Multiple Layer Sankey Diagram in a Single-Center Database. *World J Surg* (2020) 44(3):764–72. doi: 10.1007/s00268-019-05267-6
33. Lin MF, Jungreis I, Kellis M. PhyloCSF: A Comparative Genomics Method to Distinguish Protein Coding and Non-Coding Regions. *Bioinformatics* (2011) 27(13):i275–82. doi: 10.1093/bioinformatics/btr209
34. Wang J, Koganti PP, Yao J. Systematic Identification of Long Intergenic Non-Coding RNAs Expressed in Bovine Oocytes. *Reprod Biol Endocrinol* (2020) 18 (1):13. doi: 10.1186/s12958-020-00573-4
35. Zhi Y, Gao L, Wang B, Ren W, Liang KX, Zhi K. Ferroptosis Holds Novel Promise in Treatment of Cancer Mediated by Non-Coding RNAs. *Front Cell Dev Biol* (2021) 9:686906. doi: 10.3389/fcell.2021.686906
36. Zheng Z, Li Y, Jin G, Huang T, Zou M, Duan S. The Biological Role of Arachidonic Acid 12-Lipoxygenase (ALOX12) in Various Human Diseases. *BioMed Pharmacother* (2020) 129:110354. doi: 10.1016/j.biopha.2020.110354
37. Huang Z, Xia L, Zhou X, Wei C, Mo Q. ALOX12 Inhibition Sensitizes Breast Cancer to Chemotherapy *via* AMPK Activation and Inhibition of Lipid Synthesis. *Biochem Biophys Res Commun* (2019) 514(1):24–30. doi: 10.1016/j.bbrc.2019.04.101
38. Sarsour EH, Son JM, Kalen AL, Xiao W, Du J, Alexander MS, et al. Arachidonate 12-Lipoxygenase and 12-Hydroxyeicosatetraenoic Acid Contribute to Stromal Aging-Induced Progression of Pancreatic Cancer. *J Biol Chem* (2020) 295(20):6946–57. doi: 10.1074/jbc.RA120.012798
39. Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J. LINC02381 Promoted Cell Viability and Migration *via* Targeting miR-133b in Cervical Cancer Cells. *Cancer Manag Res* (2020) 12:3971–9. doi: 10.2147/CMAR.S237285
40. Jafarzadeh M, Soltani BM. Long Noncoding RNA LOC400043 (LINC02381) Inhibits Gastric Cancer Progression Through Regulating Wnt Signaling Pathway. *Front Oncol* (2020) 10:562253. doi: 10.3389/fonc.2020.562253
41. Viallard C, Larrivée B. Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets. *Angiogenesis* (2017) 20(4):409–26. doi: 10.1007/s10456-017-9562-9
42. Pastushenko I, Blanpain C. EMT Transition States During Tumor Progression and Metastasis. *Trends Cell Biol* (2019) 29(3):212–26. doi: 10.1016/j.tcb.2018.12.001
43. Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the Crossroads of Cancer-Acquired Drug Resistance and Immune Evasion. *Nat Rev Cancer* (2019) 19(7):405–14. doi: 10.1038/s41568-019-0149-1
44. Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, et al. Plasticity of Ether Lipids Promotes Ferroptosis Susceptibility and Evasion. *Nature* (2020) 585(7826):603–8. doi: 10.1038/s41586-020-2732-8
45. Zheng J, Conrad M. The Metabolic Underpinnings of Ferroptosis. *Cell Metab* (2020) 32(6):920–37. doi: 10.1016/j.cmet.2020.10.011
46. Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The Molecular Machinery of Regulated Cell Death. *Cell Res* (2019) 29(5):347–64. doi: 10.1038/s41422-019-0164-5
47. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. $CD8^+$ T Cells Regulate Tumour Ferroptosis During Cancer Immunotherapy. *Nature* (2019) 569(7755):270–4. doi: 10.1038/s41586-019-1170-y
48. Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, et al. Fatty Acid Transport Protein 2 Reprograms Neutrophils in Cancer. *Nature* (2019) 569(7754):73–8. doi: 10.1038/s41586-019-1118-2
49. Kalinski P. Regulation of Immune Responses by Prostaglandin E2. *J Immunol* (2012) 188(1):21–8. doi: 10.4049/jimmunol.1101029
50. Deng X, Lin D, Zhang X, Shen X, Yang Z, Yang L, et al. Profiles of Immune-Related Genes and Immune Cell Infiltration in the Tumor Microenvironment of Diffuse Lower-Grade Gliomas. *J Cell Physiol* (2020) 235(10):7321–31. doi: 10.1002/jcp.29633
51. Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T Lymphocyte Interplay in Controlling Tumor Growth. *Cell Mol Life Sci* (2018) 75(4):689–713. doi: 10.1007/s00018-017-2686-7
52. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade-Based Immunotherapy. *Science* (2018) 362(6411):eaar3593. doi: 10.1126/science.aar3593

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers in Immunology

ORIGINAL RESEARCH
published: 24 February 2022
doi: 10.3389/fimmu.2022.839362

Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy

Dechao Feng†, Xu Shi†, Facai Zhang, Qiao Xiong, Qiang Wei and Lu Yang**

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Background: We aimed to construct and validate an energy metabolism-related gene prognostic index (EMRGPI) to predict biochemical recurrence (BCR) in patients undergoing radical prostatectomy.

Methods: We used Lasso and COX regression analysis to orchestrate the EMRGPI in the TCGA database, and the prognostic value of EMRGPI was further validated externally using the GSE46602. All analyses were conducted with R version 3.6.3 and its suitable packages.

Results: SDC1 and ADH1B were finally used to construct the risk formula. We classified the 430 tumor patients in the TCGA database into two groups, and patients in the high-risk group had a higher risk of BCR than those in the low-risk group (HR: 1.98, 95%CI: 1.18-3.32, p=0.01). Moreover, in the GSE46602, we confirmed that the BCR risk in the high-risk group was 3.86 times higher than that in the low-risk group (95%CI: 1.61-9.24, p=0.001). We found that patients in the high-risk group had significantly higher proportions of residual tumor, older age, and T stage. SDC1 and ADH1B were significantly expressed low in the normal tissues when compared to the tumor tissues, which were opposite at the protein level. The spearman analysis showed that EMRGPI was significantly associated with B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, dendritic cells, stromal score, immune score, and estimate score. In addition, the EMRGPI was positively associated with the 54 immune checkpoints, among which CD80, ADORA2A, CD160, and TNFRSF25 were significantly related to the BCR-free survival of PCa patients undergoing RP.

Conclusions: The EMRGPI established in this study might serve as an independent risk factor for PCa patients undergoing radical prostatectomy.

Keywords: energy metabolism, prostate cancer, tumor immune microenvironment, biochemical recurrence, immune checkpoint

OPEN ACCESS

Edited by:
Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Isabel Quiros Gonzalez, Universidad de Oviedo, Spain
Yong Yang, China Pharmaceutical University, China

****Correspondence:***
Qiang Wei
weiqiang933@126.com
Lu Yang
wycleflue@163.com

†These authors have contributed equally to this work

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *19 December 2021*
Accepted: *07 February 2022*
Published: *24 February 2022*

Citation:
Feng D, Shi X, Zhang F, Xiong Q, Wei Q and Yang L (2022) Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy. Front. Immunol. 13:839362. doi: 10.3389/fimmu.2022.839362

INTRODUCTION

With the population aging, the overall health burden of prostate cancer (PCa) is increasing. Radical prostatectomy (RP) remains the first choice for the treatment of localized PCa. However, nearly 50% of patients encounter biochemical recurrence (BCR) after surgery (1). The current definition of BCR is heterogeneous, the most predictive threshold for metastasis after RP is PSA>0.4 ng/ml (2). After the radical radiotherapy, regardless of short-term hormone control, the definition of BCR is any PSA increase >2 ng/ml higher than the PSA nadir, regardless of the nadir value (3). It is believed that the impact of BCR on survival is only limited to a subgroup of patients with specific clinical risk factors (4). However, the prognosis of patients with BCR varies. Thus, indications for further treatment should not be based solely on meeting the threshold defined above for PSA, but rather a prediction method of individualized progression risk of PCa patients (5).

The occurrence of BCR is based on multiple systematic pathway alterations. In the process of tumor transformation, prostate cells undergo metabolic reprogramming to meet the needs of growth and proliferation. Metabolomics provides a down-stream measurement. Lucarelli et al. summarized that the PCa metabolome was characterized by accumulation of metabolic intermediates and increased expression of genes in the Krebs cycle, induction of *de novo* lipogenesis and cholesterol production (6, 7). Clendinen et al. proposed a nomogram to predict BCR through metabolomics, and found that many pathways altered, including amino acid metabolism, purine and pyrimidine synthesis, tricarboxylic acid (TCA) cycle, tryptophan catabolism, glucose, and lactate, and the lipid abundance was higher among BCR patients for a number of classes, including triglycerides, lysophosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, diglycerides, acyl carnitines, and ceramides (8). Studying the metabolic changes of the prostate is helpful to distinguish the indolent tumors from aggressive tumors, and to predict BCR.

Previous studies have reported several gene biomarker models to predict BCR for PCa patients undergoing RP (9–13), but the large number of genes in the model limits their clinical application. Adequate energy metabolism is essential for the survival of tumor cells. For the first time, we constructed and validated an energy metabolism-related gene prognostic index (EMRGPI) using only two genes to predict BCR in PCa patients undergoing RP. Our study has been registered in the ISRCTN registry (No. ISRCTN11560295).

Abbreviations: EMRGPI, energy metabolism-related gene prognostic index; RP, radical prostatectomy; PCa, prostate cancer; BCR, biochemical recurrence; TCA, tricarboxylic acid; PSA, prostate-specific antigen; OXPHOS, oxidative phosphorylation; CAF, cancer-associated fibroblast; EMT, epithelial-mesenchymal transition; TME, tumor immune microenvironment; TAM, tumor-associated macrophage; ECM, extracellular matrix; AR, androgen receptor; WGCNA, weighted gene co-expression network analysis; DEGs, differentially expressed genes; mRNA, message RNA; GSEA, gene set enrichment analysis.

METHODS

Data Preparation

We downloaded and integrated PCa data from the UCSC XENA and the previous study (14, 15). We extracted the matrix of message RNA (mRNA) and identified the tumor-related genes through weighted gene co-expression network analysis (WGCNA). The significantly relevance was defined as lcoefficientl > 0.3 and $p < 0.05$. Differentially expressed genes (DEGs) were analyzed, which were considered as llogFCl > 1 and padj < 0.01. Two energy metabolism-related gene sets (energy-requiring part of metabolism and reactome energy metabolism) were obtained from the molecular signature database (MsigDB, http://www.broad.mit.edu/gsea/msigdb/) (16). Subsequently, the candidate genes were identified through the intersection of tumor-related genes, DEGs and energy metabolism-related genes. We used the Lasso and COX regression analysis to figure out the independent risk genes associated with BCR-free survival, and then orchestrated the energy metabolism-related gene prognostic index (EMRGPI). The EMRGPI risk score= 0.348*SDC1+0.229*ADH1B. Patient data undergoing RP in the GSE46602 (17) were downloaded from the Gene Expression Omnibus (GEO) (18), and were further used to externally confirm the prognostic value of EMRGPI. In addition, we confirmed the differential expression of SDC1 and ADH1B at protein level through the human protein atlas (HPA) database (19, 20).

Function Analysis and Tumor Immune Environment (TME) Analysis

The genes interacted with SDC1 and ADH1B was analyzed through the GeneMANIA database (21). We divided the 430 tumor patients into high- and low-risk group according to the median of EMRGPI. Gene set enrichment analysis (GSEA) was conducted to explore the possible pathways (16, 22). Considering gene expression profile and risk groups, the minimum gene set was 5 and maximum was 5000. $P < 0.05$ and false discovery rate (FDR) < 0.10 were considered statistically significant.

We used the TIMER and ESTIMATE algorithms (23, 24) to analyze the TME of PCa patients. The spearman analysis was used to analyze the correlations between EMRGPI and TME parameters and 54 common immune checkpoints. We also explored the prognostic values of the checkpoints related to the EMRGPI in predicting BCR-free survival.

Statistical Analysis

We performed all analyses using software R 3.6.3 and its suitable packages. We utilized Wilcoxon test under the circumstance of non-normal data distribution. Variables could be entered into multivariate COX regression analysis if p value < 0.1 in the univariable Cox regression analysis. Survival analysis was conducted through log-rank test and presented as Kaplan-Meier curve. Besides, the Spearman analysis was used to assess the correlations among continuous variables if they did not meet Shapiro-Wilk normality test. Statistical significance was set as two-sided $p < 0.05$. Significant marks were as follows: no significance (ns), $p \geq 0.05$; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.

RESULTS

EMRGPI and Its Clinical Values

We obtained 498 tumor and 52 normal samples of PCa from the TCGA database, among which 430 PCa patients undergoing RP had complete data of BCR (**Supplementary Table 1**). Patients who experienced BCR were significantly associated with higher Gleason score and advanced T stages (**Supplementary Table 1**). We clustered the genetic mRNA expression of 498 tumor and 52 normal samples of PCa from the TCGA database using the WGCNA analysis (**Figure 1A**), and identified 2183 genes in the black, greenyellow, and pink modules which were highly related to tumor (**Figure 1B**). 66 candidate genes were found through the intersection of tumor-related genes, DEGs and energy metabolism-related genes (**Figure 1C**). 11 genes were found through the Lasso regression analysis using the methods of 10-fold cross-validation, where the lambda value was 0.0185 (**Figure 1D**). We also presented the trajectory diagram of the 11 genes in **Figure 1E**. A total of 7 of the 11 genes were significantly associated with BCR-free survival, and multivariate COX regression analysis was conducted using the 7 genes (**Figure 1F**). SDC1 and ADH1B were the independent risk factors of PCa patients, and we further constructed the risk formula using the two genes. We classified the 430 tumor patients in the TCGA database into two groups according to the median of the EMRGPI score, and patients in the high-risk group had a higher risk of BCR than those in the low-risk group (HR: 1.98, 95%CI: 1.18-3.32, p=0.01; **Figure 1G**). We further observed that the EMRGPI could serve as the independent risk factor of BCR for PCa patients through the multivariate COX regression analysis which enrolled the EMRGPI and clinical indicators in the TCGA database (**Supplementary Table 2**). Moreover, PCa patients in the GSE46602 (17) were divided into high- and low-risk groups based on the median of EMRGPI score, and we confirmed that the BCR risk in the high-risk group was 3.86 times higher than that in the low-risk group (95%CI: 1.61-9.24, p=0.001; **Figure 1H**). The diagnostic ability of EMRGPI distinguishing BCR patients from no BCR patients in the TCGA database was low (**Figures 1I, J**). Physical interactions and co-expression between ADH1B, and ADH1C, ADH1A and ALDH2 were observed, and CXCL2, MMP14, and TOPORS were predicted to interacted with SDC1 (**Figure 1K**). The age of high-risk group was significantly higher than that of low-risk group (61.58 ± 6.61 vs 60.29 ± 6.86, p=0.047; **Table 1**). Moreover, we found that patients in the high-risk group had significantly higher proportions of residual tumor (p=0.016), and T stage ($p < 0.001$) (**Table 1**).

Differential Expression of SDC1 and ADH1B and TME Analysis

The mRNA expression of SDC1 and ADH1B were significantly lower in the tumor tissues when compared to the normal tissues (**Figure 2A**), which were opposite at the protein levels through the HPA database (19, 20) (**Figures 2B, C**). The spearman analysis showed that EMRGPI was significantly associated with B cells (r: 0.27), CD4+ T cells (r: 0.42), CD8+ T cells (r: 0.29), neutrophils (r: 0.47), macrophages (r: 0.22), dendritic cells (r: 0.55), stromal score (r: 0.47), immune score (r: 0.41), and estimate score (r: 0.48) (**Figure 2D**). In addition, the EMRGPI was positively associated with the 54 immune checkpoints (**Figure 2E**), among which CD80 (HR: 1.76, 95%CI: 1.03-3.00, p=0.037; **Figure 2F**), ADORA2A (HR: 2.02, 95%CI: 1.09-3.44, p=0.01; **Figure 2G**), CD160 (HR: 2.29, 95%CI: 1.32-3.96, p=0.003; **Figure 2H**), and TNFRSF25 (HR: 1.92, 95%CI: 1.13-3.26, p=0.016; **Figure 2I**) were significantly related to the BCR-free survival of PCa patients undergoing RP.

Functional Enrichment Analysis

430 PCa patients in the TCGA database were classified into two groups according to the median of the EMRGPI score, and the results of GSEA analysis between low- and high-risk group were presented in **Table 2**. Several cancers, such as thyroid cancer, renal cell carcinoma, and small lung cancer, were enriched in high-risk group. In terms of signaling pathways, insulin, chemokine, WNT, T cell receptor, MAPK, and NOD like receptor signaling pathways were highly upregulated in high-risk group. In addition, several cellular and molecular processes, including regulation of actin cytoskeleton, snare interactions in vesicular transport, apoptosis, focal adhesion, extracellular matrix (ECM) receptor interaction, FC gamma R-mediated phagocytosis, endocytosis, and cell adhesion molecules, were enriched in the high-risk group.

DISCUSSION

Although surgery or radiotherapy can effectively improve the prognosis of PCa patients and prolong their survival, the rate of recurrence and metastasis remains high. Meanwhile, there may be a tendency of over-medical treatment for the large population of PCa patients (25). Magnetic resonance imaging variables, prostate-specific antigen (PSA), and Gleason score are currently common mainstream methods for predicting BCR (26, 27). It is currently recommended that PSA doubling time and pathological Gleason score are indicators used to grade the risk of BCR after RP (5). Actually, we observed that BCR patients had higher Gleason score and advanced T stages than no BCR patients in this study. Maxeiner et al. used magnetic-resonance-spectroscopy-based metabolomic profiles to establish a model for predicting BCR through changes in several metabolites including spermine/polyamines, glutamine, myo-inositol, phosphoryl choline, scylloinositol, and glutamate, with an accuracy of 78% (28). Stabler et al. used the combination of serum PSA with cystathionine, cysteine, and homocysteine as markers to predict BCR with an AUC of 0.86 (29). In this paper, from the perspective of energy metabolism, we firstly found individual approach of gene-level recurrence markers that are helpful to the clinical decision-making of PCa patients. Furthermore, compared to the previous gene signatures (9–13), we included two different genes in our study and provided a simpler prognostic gene formula from the perspective of energy metabolism.

Like other metabolic cancers, increased glycolysis can provide more metabolic intermediates and energy for the rapid



FIGURE 1 | Identification of EMRGPI and its clinical values. **(A)** gene cluster plot showing the process of WGCNA analysis; **(B)** modules and phenotype showing 2183 genes in the black, greenyellow, and pink modules which were highly related to tumor; **(C)** Venn plot showing the intersection of tumor-related genes, DEGs and energy metabolism-related genes; **(D)** variables screening through the Lasso regression analysis where the lambda value was 0.0185; **(E)** trajectory diagram of the 11 genes identified through the Lasso regression analysis; **(F)** forest plot showing the COX regress analysis of genes associated with BCR-free survival; **(G)** Kaplan-Meier curve showing survival difference of high- and low-risk group in the TCGA database; **(H)** Kaplan-Meier curve showing survival difference of high- and low-risk group in the GSE46602 (17); **(I)** ROC curve showing the diagnostic ability of EMRGPI in distinguishing BCR from no BCR; **(J)** Time-dependent ROC curve showing the diagnostic ability of EMRGPI in distinguishing BCR from no BCR; **(K)** Gene interacted with ADH1B and SDC1. BCR, biochemical recurrence; DEGs, differentially expressed genes; EMRGPI, energy metabolism-related gene prognostic index; WGCNA, weighted gene co-expression network analysis; mRNA, message RNA; ROC, receiver operating characteristic curve. prostate cancer patients were divided into high- and low-risk groups according to the median of the EMRGPI score.

TABLE 1 | The correlations between EMGPI and clinical parameters in the TCGA database.

Characteristic	Low-risk group	High-risk group	P value
Sample (n)	215	215	
Age, mean ± SD	60.29 ± 6.86	61.58 ± 6.61	0.047
BCR, n (%)			0.034
No	194 (45.1%)	178 (41.4%)	
Yes	21 (4.9%)	37 (8.6%)	
N stage, n (%)			0.310
N0	152 (40.5%)	154 (41.1%)	
N1	29 (7.7%)	40 (10.7%)	
Positive lymphnodes, n (%)			0.249
No	144 (40.2%)	144 (40.2%)	
Yes	29 (8.1%)	41 (11.5%)	
Residual tumor, n (%)			0.016
No	151 (36%)	122 (29.1%)	
Yes	62 (14.8%)	84 (20%)	
Gleason score, n (%)			0.066
GS=6	23 (5.3%)	16 (3.7%)	
GS=7	113 (26.3%)	93 (21.6%)	
GS=8	26 (6%)	33 (7.7%)	
GS=9	53 (12.3%)	73 (17%)	
T stage, n (%)			<0.001
T2	98 (23.1%)	57 (13.4%)	
T3-4	115 (27.1%)	154 (36.3%)	
Race, n (%)			0.088
ASIAN	9 (2.2%)	2 (0.5%)	
Black or African American	26 (6.2%)	24 (5.8%)	
White	172 (41.3%)	183 (44%)	

EMRGPI, energy metabolism-related gene prognostic index; BCR, biochemical recurrence; GS, Gleason score; SD, standard deviation.

proliferation of PCa cells (30). Shao et al. observed significant accumulation of metabolic intermediates in PCa and the enrichment of genes in the TCA cycle, indicating that the TCA cycle in PCa tissue is over-activated, and existence of potential replenishment pathways for the metabolism of pyruvate, glutamine and branched chain amino acids in PCa supplements the metabolites of the TCA cycle (31). Androgen receptor (AR) plays an important role in increasing glycolysis in PCa cells, which can induce flux through the classical TCA cycle and reductive carboxylation of glutamine (32–34). The AR constitutively actives splice variants, such as AR-V7, stimulates glycolysis to a similar degree to AR in changing metabolism, and at the same time improves the utilization of citrate, and possibly metabolize it into other compounds needed for cell growth, such as lipids, steroids and amino acids, which increases the tumor's ability to grow (34). It has been shown that androgens can stimulate AMPK-PGC1α cascade by increasing mitochondrial function and biogenesis, and activate glycolysis and oxidative phosphorylation (OXPHOS) (33). Clendinen et al. found that lactate and other end products of glucose catabolism increased in patients with BCR (1). The increased lactate may be related to the Warburg effect (35). Meanwhile, tumor cells induce the secretion of lactate and pyruvate by cancer-associated fibroblasts (CAFs) through aerobic glycolysis, and then they take up these energy-rich metabolites to promote efficient energy production through mitochondrial OXPHOS, thereby producing higher proliferation capacity, the reverse Warburg effect (36). This process of lactate exchange between CAFs and cancer cells is called lactate shuttle (37). In addition, different literatures also reported the relationship between elevated methionine metabolites such as cysteine and BCR (8, 29).

Alcohol dehydrogenase family (ADH1B and ADH1C) metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products (38). ADH1B (rs1229984) and aldehyde dehydrogenase 2 (ALDH2) (rs671) are the two main genes involved in ethanol metabolism (39, 40). Genetic polymorphisms of ADH1B, ADH1C and ALDH2 have been reported involving in the development and progression of many cancers, such as gastric cancer (41), head and neck cancers (42), esophageal cancer (43), and pancreatic cancer (44). In a mendelian randomization study, it was found that in ALDH1B1 (rs10973794) was associated with PCa mortality with low-grade prostate cancer (HR = 1.43; p = 0.002) (45). So far, epidemiologic evidence for association between alcohol intake and the risk of PCa still remain unclear. Many articles, meta-analyses and systematic reviews showed contradictory conclusions (46–49). The possible reason might be the gene polymorphism which was associated with the enzyme activity. SDC1 was found to be significantly associated with BCR for PCa patients undergoing RP (50, 51), which could mutually confirm with our results. Moreover, serum SDC-1 levels have also been confirmed to be related to PCa progression, overall survival, disease specific survival, and chemotherapy resistance (52, 53). The inflammation of tumor patients is not limited to the local tumor, but systemic inflammation, clinically manifested as increased myeloid cells, and neutrophil-to-lymphocyte ratio in the circulation is closely related to poor prognosis in cancers



FIGURE 2 | Differential expression of SDC1 and ADH1B and TME analysis. **(A)** volcano plot showing differentially expressed genes between tumor and normal tissues; **(B)** differential expression of SDC1 at protein level in the HPA database (19, 20); **(C)** differential expression of ADH1B at protein level in the HPA database (19, 20); **(D)** the correlations between EMRGPI and TME indicators; **(E)** the correlations between EMRGPI and immune checkpoints; **(F)** Kaplan-Meier curve showing survival difference of high- and low-expression of CD80 in the TCGA database; **(G)** Kaplan-Meier curve showing survival difference of high- and low-expression of ADORA2A in the TCGA database; **(H)** Kaplan-Meier curve showing survival difference of high- and low-expression of CD160 in the TCGA database; **(I)** Kaplan-Meier curve showing survival difference of high- and low-expression of TNFRSF25 in the TCGA database. BCR, biochemical recurrence; EMRGPI, energy metabolism-related gene prognostic index; TME, tumor immune microenvironment.

TABLE 2 | The results of gene set enrichment analysis between low- and high-risk group.

Gene set enrichment analysis (low vs high)	ES	NES	P value	FDR
Diseases				
Thyroid cancer	-0.5641	-1.7859	0.002	0.0993
Renal cell carcinoma	-0.4976	-1.7256	0.0061	0.0857
Chronic myeloid leukemia	-0.4632	-1.9046	0.004	0.0913
Small cell lung cancer	-0.5052	-1.6768	0.002	0.0902
Viral myocarditis	-0.6277	-1.6275	0.0179	0.0951
Prion diseases	-0.6151	-1.6357	0.0096	0.0948
Amyotrophic lateral sclerosis	-0.6664	-2.0416	0	0.0667
Signaling pathways				
Insulin signaling pathway	-0.422	-1.6726	0.0041	0.0859
Chemokine signaling pathway	-0.6329	-1.674	0.002	0.0887
WNT signaling pathway	-0.5035	-1.6844	0.002	0.0945
T cell receptor signaling pathway	-0.6221	-1.6316	0.0222	0.0954
MAPK signaling pathway	-0.4928	-1.6858	0	0.099
NOD like receptor signaling pathway	-0.6707	-1.6584	0.0118	0.0889
Epithelial cell signaling in helicobacter pylori infection	-0.4971	-1.7791	0.0095	0.0928
Cellular and molecular processes				
Aminoacyl tRNA biosynthesis	0.671	2.0732	0.002	0.0069
Protein export	0.6717	1.9508	0.004	0.0136
Terpenoid backbone biosynthesis	0.7399	1.9039	0.0043	0.0159
ECM receptor interaction	-0.67	-1.7404	0	0.084
Cell adhesion molecules	-0.6756	-1.6688	0	0.0845
Glycerophospholipid metabolism	-0.4809	-1.6577	0.0036	0.0861
Apoptosis	-0.5184	-1.7541	0	0.0862
FC gama R-mediated phagocytosis	-0.5799	-1.7315	0.006	0.0867
Focal adhesion	-0.5713	-1.7456	0.002	0.0875
Endocytosis	-0.4043	-1.7156	0.008	0.0891
Leukocyte transendothelial migration	-0.5816	-1.6832	0	0.0904
Snare interactions in vesicular transport	-0.4596	-1.7564	0.0094	0.0917
Regulation of actin cytoskeleton	-0.5287	-1.7681	0	0.0922
Vascular smooth muscle contraction	-0.5444	-1.6403	0.0039	0.0946

ECM, extracellular matrix; ES, enrichment score; NES, Normalized enrichment score; FDR, false discovery rate.

(54). Systemic mobilization of neutrophils promotes metastatic diffusion, while SDC1 shedding is a critical endogenous mechanism that facilitates the resolution of neutrophilic inflammation by aiding the clearance of proinflammatory chemokines (like CXCL12) in a heparan sulfate-dependent manner (54, 55). MMP14 is up-regulated in PCa cells, and may be involved in mediating the mutual crosstalk between PCa cells and periprostatic adipose tissue, promoting tumor invasion (56). SDC1 could inhibit early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14 (57). Besides, TOPORS is a ubiquitously expressed E3 ubiquitin ligase that can ubiquitinate the tumor suppressor gene p53 (58). Notably, we found that the transcriptional and protein levels of these two genes were completely opposite in this study, which indicated the role of epigenetic or post-transcriptional regulation.

The overexpression of focal adhesion kinase is associated with the formation and invasive activity of androgen-independent PCa cells (59). The activation of FAK/src/paxillin/Rac/JNK leads to an increase in the activity of matrix metalloproteinases and the reorganization of membrane molecules, changes in adhesion to collagen type I and invasion into collagen type I, and may be one of the mechanisms of PCa invasion (60). The remodeling of collagen ECM is thought to be related to aging and PCa growth and invasion, since the collagen matrix extracted from aged mice enhances the invasion and proliferation of PCa cells *in vitro* (61). Reactive stroma where metabolites and genes linked to immune functions and ECM remodeling are significantly upregulated is a common tissue feature in the TME of PCa and are also associated with BCR (62). The MAPK signaling pathway can be triggered by growth factors such as TGF-β, leading to the down-regulation of epithelial markers and the up-regulation of mesenchymal markers, resulting in epithelial-mesenchymal transition (EMT) (63–65). The activation of the non-canonical Wnt pathway induced by Wnt5a/Fzd2 is significantly related to EMT and metastasis, and has been proven to be an important predictor of BCR (66). This feature is also related to the decreased concentration of metabolites citrate and spermine, which are thought to be associated with aggressive PCa (66). A nomogram constructed based on the Wnt ligand gene family is used to predict BCR, and the C index is 0.719 (67). In addition, we also found that EMRGPI was related to chronic myelogenous leukemia, thyroid cancer, renal cell carcinoma, and small cell lung cancer through functional analysis, further proving its clinical relevance.

In this study, we observed that EMGPI was positively associated with the immune infiltrating cells and TME scores. We thought that the metabolic competition between

cancer cells and immune cells inhibited the function of immune cells and the metabolic reprogramming also played a significant role in suppressing the immune attack on the tumor cells and in resistance to therapies (68). Lactate is an immunosuppressive molecule, whose elevation in PCa cells and TME could promote the immune escape (69). Meanwhile, lactate inhibits the differentiation of monocytes and dendritic cells, and induces the inactivation of cytotoxic T lymphocytes (35). Moreover, the elevated lactate in TME can promote the polarization of tumor-related macrophages (TAMs) to M2 by activating the ERK/STAT3 signaling pathway (70), and tumor cells tend to survive and metastasize through its secretion of anti-inflammatory and promoting angiogenesis cytokines (71). Excessive production of pro-inflammatory cytokines and extracellular matrix-related molecules leads to the lipolysis of cancer cells to produce free fatty acids, which induce oxidative stress through the expression of pro-oxidant enzyme NADPH oxidase 5 (56). Then, increased reactive oxygen species production activates the HIF1/MMP14 pathway, which contributes to the invasion ability of PCa cells (56). At the same time, we observed that EMRGPI was correlated with stromal score. The interaction between tumor and stroma is also believed to play a role in the metabolic reprogramming of tumor cells. It is worth noting that this ability to induce metabolic reprogramming is bidirectional. CAF is induced to up-regulate the expression of the glucose transporter GLUT1, enhance the production and the output of lactate through the *de novo* expression of monocarboxylic acid transporter 4 (72). At the same time, after PCa cells are in contact with CAF, the expression of GLUT1 decreases, and the input of lactate through the lactate transporter MCT1 increases and then lactate enters the TCA cycle (72). The so-called reverse Warburg effect describes a metabolic symbiosis model in which CAF provides energy and metabolites for epithelial cancer cells (72). In tumor stroma, matrix components. including CAFs establish a metabolic symbiosis relationship with PCa cells through lactate shuttle and cellular bridges both *in vitro* and *in vivo*, which ultimately leads to a high exploitation of mitochondria, TCA cycle deregulation and enhanced PCa invasiveness (73). Other stromal components such as adipocytes are also believed to possess a similar metabolic symbiosis relationship and are believed to be related to PCa metastasis (74, 75). In TRAMP +/p62adipo mice, obesity and more aggressive PCa are shown. At the same time, energy expenditure pathways such as lipogenesis and OXPHOS in adipose tissue are inhibited to save energy substrates for FA β-oxidation gene-enriched PCa cells, with an up-regulated level of the rate-limiting enzyme of the transport of long-chain FAs for β-oxidation, CPT1A, thus promoting EMT and cancer aggressiveness (76).

We also found positive correlations between EMRGPI and many checkpoints, among which CD80, ADORA2A, CD160, and TNFRSF25 were highly associated with BCR-free survival. Adenosine mediates immune suppression in the TME by ADORA2A on immune cells. Drugs targeting ADORA2A have entered phase I clinical trials for the immunotherapy of patients with renal cell carcinoma (77). Serum CD80 is related to BCR (78). CD160 is essential for NK-mediated IFN-γ production (79). For hepatocellular carcinoma, the reduction in the number and function of CD160 + NK cells in TME contributes to the immune escape (80). Members of the TNF receptor superfamily (TNFRSF) are the key co-stimulators of T cells, and TNFRSF25 can promote $CD8^+$ T cell responses and anti-tumor immunity (81).

For the first time, our article proposed genes related to energy metabolism to predict BCR of PCa patients undergoing RP. It not only provided the latest insights to the correlations between cancer cells and TME cells, but most importantly, it proposed a method for screening high-risk BCR patients at the genetic level, which was helpful for individualized screening of early treatment patient groups, and ultimately helped to reduce PCa medical costs. However, the potential mechanism of the opposite difference between transcriptional and protein levels is needed to be further studied. Besides, the role of energy metabolism between tumor cells and immune cells still warranted to be investigated.

CONCLUSIONS

The EMRGPI established in this study might serve as an independent risk factor for PCa patients undergoing RP.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**.

AUTHOR CONTRIBUTIONS

DF proposed the project, conducted data analysis, interpreted the data, and wrote the manuscript. XS, FZ, QX, and QW, conducted data analysis, interpreted the data. LY supervised the project, and interpreted the data. All authors reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This program was supported by the National Natural Science Foundation of China (Grant Nos. 81974099, 82170785, 81974098, 82170784), programs from Science and Technology Department of Sichuan Province (Grant Nos. 21GJHZ0246), Young Investigator Award of Sichuan University 2017 (Grant No. 2017SCU04A17), Technology Innovation Research and Development Project of Chengdu Science and Technology

Bureau (2019-YF05-00296-SN), Sichuan University–Panzhihua science and technology cooperation special fund (2020CDPZH-4). The funders had no role in study design, data collection or analysis, preparation of the manuscript, or the decision to publish.

ACKNOWLEDGMENTS

The results showed here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.839362/full#supplementary-material

Supplementary Table 1 | The baselines of patients with prostate cancer from the TCGA database. BCR, biochemical recurrence; GS, Gleason score; IQR, interquartile range.

Supplementary Table 2 | Univariate and multivariate COX regression analysis of EMGPI and clinical indicators for the paitents with prostate cancer from the TCGA database. EMRGPI, energy metabolism-related gene prognositc index; GS, Gleason score.

REFERENCES

1. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A Nomogram Predicting Long-Term Biochemical Recurrence After Radical Prostatectomy. *Cancer* (2008) 112(6):1254–63. doi: 10.1002/cncr.23293
2. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining Prostate Specific Antigen Progression After Radical Prostatectomy: What Is the Most Appropriate Cut Point? *J Urol* (2001) 165(4):1146–51. doi: 10.1016/S0022-5347(05)66452-X
3. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining Biochemical Failure Following Radiotherapy With or Without Hormonal Therapy in Men With Clinically Localized Prostate Cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* (2006) 65(4):965–74. doi: 10.1016/j.ijrobp.2006.04.029
4. Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment With Curative Intent for Prostate Cancer: A Systematic Review. *Eur Urol* (2019) 75 (6):967–87. doi: 10.1016/j.eururo.2018.10.011
5. Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, et al. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. *Eur Urol Focus* (2020) 6(2):231–4. doi: 10.1016/j.euf.2019.06.004
6. Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, Ferro M, et al. Metabolomic Profiling for the Identification of Novel Diagnostic Markers in Prostate Cancer. *Expert Rev Mol Diagn* (2015) 15(9):1211–24. doi: 10.1586/14737159.2015.1069711
7. Lucarelli G, Loizzo D, Ferro M, Rutigliano M, Vartolomei MD, Cantiello F, et al. Metabolomic Profiling for the Identification of Novel Diagnostic Markers and Therapeutic Targets in Prostate Cancer: An Update. *Expert Rev Mol Diagn* (2019) 19(5):377–87. doi: 10.1080/14737159.2019.1604223
8. Clendinen CS, Gaul DA, Monge ME, Arnold RS, Edison AS, Petros JA, et al. Preoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy. *J Proteome Res* (2019) 18(3):1316–27. doi: 10.1021/acs.jproteome.8b00926
9. Luan J, Zhang Q, Song L, Wang Y, Ji C, Cong R, et al. Identification and Validation of a Six Immune-Related Gene Signature for Prediction of Biochemical Recurrence in Localized Prostate Cancer Following Radical Prostatectomy. *Transl Androl Urol* (2021) 10(3):1018–29. doi: 10.21037/tau-20-1231
10. Zhang L, Li Y, Wang X, Ping Y, Wang D, Cao Y, et al. Five-Gene Signature Associating With Gleason Score Serve as Novel Biomarkers for Identifying Early Recurring Events and Contributing to Early Diagnosis for Prostate Adenocarcinoma. *J Cancer* (2021) 12(12):3626–47. doi: 10.7150/jca.52170
11. Shao N, Tang H, Mi Y, Zhu Y, Wan F, Ye D. A Novel Gene Signature to Predict Immune Infiltration and Outcome in Patients With Prostate Cancer. *Oncoimmunology* (2020) 9(1):1762473. doi: 10.1080/2162402X.2020.1762473
12. Long X, Hou H, Wang X, Liu S, Diao T, Lai S, et al. Immune Signature Driven by ADT-Induced Immune Microenvironment Remodeling in Prostate Cancer Is Correlated with Recurrence-Free Survival and Immune Infiltration. *Cell Death Dis* (2020) 11(9):779. doi: 10.1038/s41419-020-02973-1
13. Luan JC, Zhang QJ, Zhao K, Zhou X, Yao LY, Zhang TT, et al. A Novel Set of Immune-Associated Gene Signature Predicts Biochemical Recurrence in Localized Prostate Cancer Patients After Radical Prostatectomy. *J Cancer* (2021) 12(12):3715–25. doi: 10.7150/jca.51059
14. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and Interpreting Cancer Genomics Data *via* the Xena Platform. *Nat Biotechnol* (2020) 38(6):675–8. doi: 10.1038/s41587-020-0546-8
15. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* (2018) 173(2):400–16.e11. doi: 10.1016/j.cell.2018.02.052
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. *PNAS* (2005) 102 (43):15545–50. doi: 10.1073/pnas.0506580102
17. Mortensen MM, Høyer S, Lynnerup AS, Ørntoft TF, Sørensen KD, Borre M, et al. Expression Profiling of Prostate Cancer Tissue Delineates Genes Associated With Recurrence After Prostatectomy. *Sci Rep* (2015) 5:16018. doi: 10.1038/srep16018
18. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI Gene Expression and Hybridization Array Data Repository. *Nucleic Acids Res* (2002) 30(1):207–10. doi: 10.1093/nar/30.1.207
19. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A Pathology Atlas of the Human Cancer Transcriptome. *Science* (2017) 357 (6352):eaan2507. doi: 10.1126/science.aan2507
20. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-Based Map of the Human Proteome. *Science* (2015) 347(6220):1260419. doi: 10.1126/science.1260419
21. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA Prediction Server: Biological Network Integration for Gene Prioritization and Predicting Gene Function. *Nucleic Acids Res* (2010) 38(Web Server issue):W214–20. doi: 10.1093/nar/gkq537
22. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular Signatures Database (MSigDB) 3.0. *Bioinformatics* (2011) 27(12):1739–40. doi: 10.1093/bioinformatics/btr260
23. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy. *Genome Biol* (2016) 17(1):174. doi: 10.1186/s13059-016-1028-7
24. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612
25. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends. *J Natl Cancer Inst* (2002) 94(13):981–90. doi: 10.1093/jnci/94.13.981
26. Hu XH, Cammann H, Meyer HA, Jung K, Lu HB, Leva N, et al. Risk Prediction Models for Biochemical Recurrence After Radical Prostatectomy Using Prostate-Specific Antigen and Gleason Score. *Asian J Androl* (2014) 16 (6):897–901. doi: 10.4103/1008-682X.129940

27. Poulakis V, Witzsch U, de Vries R, Emmerlich V, Meves M, Altmannsberger HM, et al. Preoperative Neural Network Using Combined Magnetic Resonance Imaging Variables, Prostate-Specific Antigen, and Gleason Score for Predicting Prostate Cancer Biochemical Recurrence After Radical Prostatectomy. *Urology* (2004) 64(6):1165–70. doi: 10.1016/j.urology.2004.06.030
28. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, et al. Retrospective Analysis of Prostate Cancer Recurrence Potential With Tissue Metabolomic Profiles. *Prostate* (2010) 70(7):710–7. doi: 10.1002/pros.21103
29. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, et al. Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. *PloS One* (2011) 6(8):e22486. doi: 10.1371/journal.pone.0022486
30. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* (2009) 324 (5930):1029–33. doi: 10.1126/science.1160809
31. Shao Y, Ye G, Ren S, Piao HL, Zhao X, Lu X, et al. Metabolomics and Transcriptomics Profiles Reveal the Dysregulation of the Tricarboxylic Acid Cycle and Related Mechanisms in Prostate Cancer. *Int J Cancer* (2018) 143 (2):396–407. doi: 10.1002/ijc.31313
32. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The Androgen Receptor Fuels Prostate Cancer by Regulating Central Metabolism and Biosynthesis. *EMBO J* (2011) 30(13):2719–33. doi: 10.1038/emboj.2011.158
33. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, et al. Androgens Regulate Prostate Cancer Cell Growth *via* an AMPK-PGC-1alpha-Mediated Metabolic Switch. *Oncogene* (2014) 33(45):5251–61. doi: 10.1038/onc.2013.463
34. Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, et al. Differential Regulation of Metabolic Pathways by Androgen Receptor (AR) and Its Constitutively Active Splice Variant, AR-V7, in Prostate Cancer Cells. *Oncotarget* (2015) 6(31):31997–2012. doi: 10.18632/oncotarget.5585
35. Nenu I, Gafencu GA, Popescu T, Kacso G. Lactate - A New Frontier in the Immunology and Therapy of Prostate Cancer. *J Cancer Res Ther* (2017) 13 (3):406–11. doi: 10.4103/0973-1482.163692
36. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The Reverse Warburg Effect: Aerobic Glycolysis in Cancer Associated Fibroblasts and the Tumor Stroma. *Cell Cycle* (2009) 8 (23):3984–4001. doi: 10.4161/cc.8.23.10238
37. Brooks GA. Lactate: Glycolytic End Product and Oxidative Substrate During Sustained Exercise in Mammals — The "Lactate Shuttle. In: R Gilles, editor. *Circulation, Respiration, and Metabolism*. Berlin Heidelberg: Springer Nature. (1985). p. 208–18.
38. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr Protoc Bioinf* (2016) 54:1.30.1–1.30.33. doi: 10.1002/cpbi.5
39. Seitz HK, Stickel F. Molecular Mechanisms of Alcohol-Mediated Carcinogenesis. *Nat Rev Cancer* (2007) 7(8):599–612. doi: 10.1038/nrc2191
40. Crabb DW, Edenberg HJ, Bosron WF, Li TK. Genotypes for Aldehyde Dehydrogenase Deficiency and Alcohol Sensitivity. The Inactive ALDH2(2) Allele Is Dominant. *J Clin Invest* (1989) 83(1):314–6. doi: 10.1172/JCI113875
41. Hidaka A, Sasazuki S, Matsuo K, Ito H, Sawada N, Shimazu T, et al. Genetic Polymorphisms of ADH1B, ADH1C and ALDH2, Alcohol Consumption, and the Risk of Gastric Cancer: The Japan Public Health Center-Based Prospective Study. *Carcinogenesis* (2015) 36(2):223–31. doi: 10.1093/carcin/bgu244
42. Chang JS, Straif K, Guha N. The Role of Alcohol Dehydrogenase Genes in Head and Neck Cancers: A Systematic Review and Meta-Analysis of ADH1B and ADH1C. *Mutagenesis* (2012) 27(3):275–86. doi: 10.1093/mutage/ger073
43. Wu M, Chang SC, Kampman E, Yang J, Wang XS, Gu XP, et al. Single Nucleotide Polymorphisms of ADH1B, ADH1C and ALDH2 Genes and Esophageal Cancer: A Population-Based Case-Control Study in China. *Int J Cancer* (2013) 132(8):1868–77. doi: 10.1002/ijc.27803
44. Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P. CYP2A13, ADH1B, and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk. *Pancreas* (2010) 39(2):144–8. doi: 10.1097/MPA.0b013e3181bab6c2
45. Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, et al. Alcohol Consumption and Prostate Cancer Incidence and Progression: A Mendelian Randomisation Study. *Int J Cancer* (2017) 140(1):75–85. doi: 10.1002/ijc.30436
46. Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, et al. Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results From an Equal-Access, Racially Diverse Biopsy Cohort. *Cancer Prev Res (Phila)* (2018) 11(10):621–8. doi: 10.1158/1940-6207.CAPR-18-0057
47. Hong S, Khil H, Lee DH, Keum N, Giovannucci EL. Alcohol Consumption and the Risk of Prostate Cancer: A Dose-Response Meta-Analysis. *Nutrients* (2020) 12(8):2188. doi: 10.3390/nu12082188
48. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is Alcohol Consumption a Risk Factor for Prostate Cancer? A Systematic Review and Meta-Analysis. *BMC Cancer* (2016) 16(1):845. doi: 10.1186/s12885-016-2891-z
49. de Menezes RF, Bergmann A, Thuler LC. Alcohol Consumption and Risk of Cancer: A Systematic Literature Review. *Asian Pac J Cancer Prev* (2013) 14 (9):4965–72. doi: 10.7314/APJCP.2013.14.9.4965
50. Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) Contributes to Prostate Cancer Progression by Stabilizing Tumour-Initiating Cells. *J Pathol* (2013) 231(4):495–504. doi: 10.1002/path.4271
51. Santos NJ, Barquilha CN, Barbosa IC, Macedo RT, Lima FO, Justulin LA, et al. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer. *Int J Mol Sci* (2021) 22(16):8669. doi: 10.3390/ijms22168669
52. Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, et al. Soluble Syndecan-1 (SDC1) Serum Level as an Independent Pre-Operative Predictor of Cancer-Specific Survival in Prostate Cancer. *Prostate* (2016) 76(11):977–85. doi: 10.1002/pros.23186
53. Szarvas T, Sevcenco S, Modos O, Keresztes D, Nyirády P, Kubik A, et al. Circulating Syndecan-1 Is Associated With Chemotherapy-Resistance in Castration-Resistant Prostate Cancer. *Urol Oncol* (2018) 36(6):312.e9–e15. doi: 10.1016/j.urolonc.2018.03.010
54. Garner H, de Visser KE. Immune Crosstalk in Cancer Progression and Metastatic Spread: A Complex Conversation. *Nat Rev Immunol* (2020) 20 (8):483–97. doi: 10.1038/s41577-019-0271-z
55. Hayashida K, Parks WC, Park PW. Syndecan-1 Shedding Facilitates the Resolution of Neutrophilic Inflammation by Removing Sequestered CXC Chemokines. *Blood* (2009) 114(14):3033–43. doi: 10.1182/blood-2009-02-204966
56. Laurent V, Toulet A, Attane C, Milhas D, Dauvillier S, Zaidi F, et al. Periprostatic Adipose Tissue Favors Prostate Cancer Cell Invasion in an Obesity-Dependent Manner: Role of Oxidative Stress. *Mol Cancer Res* (2019) 17(3):821–35. doi: 10.1158/1541-7786.MCR-18-0748
57. Regős E, Abdelfattah HH, Reszegi A, Szilák L, Werling K, Szabó G, et al. Syndecan-1 Inhibits Early Stages of Liver Fibrogenesis by Interfering With Tgfβ1 Action and Upregulating MMP14. *Matrix Biol* (2018) 68-69:474–89. doi: 10.1016/j.matbio.2018.02.008
58. Guan B, Pungaliya P, Li X, Uquillas C, Mutton LN, Rubin EH, et al. Ubiquitination by TOPORS Regulates the Prostate Tumor Suppressor NKX3.1. *J Biol Chem* (2008) 283(8):4834–40. doi: 10.1074/jbc.M708630200
59. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, et al. Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer. *Mol Cancer Res* (2008) 6(10):1639–48. doi: 10.1158/1541-7786.MCR-08-0052
60. Van Slambrouck S, Jenkins AR, Romero AE, Steelant WF. Reorganization of the Integrin Alpha2 Subunit Controls Cell Adhesion and Cancer Cell Invasion in Prostate Cancer. *Int J Oncol* (2009) 34(6):1717–26. doi: 10.3892/ijo_00000302
61. Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, et al. The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells. *Mol Cancer Res* (2019) 17(1):321–31. doi: 10.1158/1541-7786.MCR-18-0522
62. Bellelli E, Bracchi U, Tanzi ML, Benaglia G, Montanarini G. Poliomyelitis Immunity Status at Different Intervals From Vaccination. *Eur J Epidemiol* (1986) 2(3):197–204. doi: 10.1007/BF00211532
63. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-Like Growth Factor-I-Dependent Up-Regulation of ZEB1 Drives Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells. *Cancer Res* (2008) 68(7):2479–88. doi: 10.1158/0008-5472.CAN-07-2559
64. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-Like Growth Factor (IGF) Family and Prostate Cancer. *Crit Rev Oncol Hematol* (2006) 58(2):124–45. doi: 10.1016/j.critrevonc.2005.10.003

65. Odero-Marah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-Mesenchymal Transition (EMT) and Prostate Cancer. *Adv Exp Med Biol* (2018) 1095:101–10. doi: 10.1007/978-3-319-95693-0_6
66. Sandsmark E, Hansen AF, Selnaes KM, Bertilsson H, Bofin AM, Wright AJ, et al. A Novel Non-Canonical Wnt Signature for Prostate Cancer Aggressiveness. *Oncotarget* (2017) 8(6):9572–86. doi: 10.18632/oncotarget.14161
67. Hu M, Xie J, Liu Z, Wang X, Liu M, Wang J. Comprehensive Analysis Identifying Wnt Ligands Gene Family for Biochemical Recurrence in Prostate Adenocarcinoma and Construction of a Nomogram. *J Comput Biol* (2020) 27 (12):1656–67. doi: 10.1089/cmb.2019.0397
68. Gupta S, Roy A, Dwarakanath BS. Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. *Front Oncol* (2017) 7:68. doi: 10.3389/fonc.2017.00068
69. Marchiq I, Pouyssegur J. Hypoxia, Cancer Metabolism and the Therapeutic Benefit of Targeting Lactate/H(+) Symporters. *J Mol Med (Berl)* (2016) 94 (2):155–71. doi: 10.1007/s00109-015-1307-x
70. Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B, et al. Tumor-Derived Lactate Induces M2 Macrophage Polarization *via* the Activation of the ERK/STAT3 Signaling Pathway in Breast Cancer. *Cell Cycle* (2018) 17(4):428–38. doi: 10.1080/15384101.2018.1444305
71. Zhang L, Li S. Lactic Acid Promotes Macrophage Polarization Through MCT-HIF1alpha Signaling in Gastric Cancer. *Exp Cell Res* (2020) 388(2):111846. doi: 10.1016/j.yexcr.2020.111846
72. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, et al. Reciprocal Metabolic Reprogramming Through Lactate Shuttle Coordinately Influences Tumor-Stroma Interplay. *Cancer Res* (2012) 72 (19):5130–40. doi: 10.1158/0008-5472.CAN-12-1949
73. Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, et al. Cancer-Associated Fibroblasts Promote Prostate Cancer Malignancy *via* Metabolic Rewiring and Mitochondrial Transfer. *Oncogene* (2019) 38(27):5339–55. doi: 10.1038/s41388-019-0805-7
74. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, et al. Obesity Is Associated With Castration-Resistant Disease and Metastasis in Men Treated With Androgen Deprivation Therapy After Radical Prostatectomy: Results From the SEARCH Database. *BJU Int* (2012) 110 (4):492–8. doi: 10.1111/j.1464-410X.2011.10754.x
75. Muller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K, Aichler M, et al. P62 Links Beta-Adrenergic Input to Mitochondrial Function and Thermogenesis. *J Clin Invest* (2013) 123(1):469–78. doi: 10.1172/JCI64209
76. Huang J, Duran A, Reina-Campos M, Valencia T, Castilla EA, Müller TD, et al. Adipocyte P62/SQSTM1 Suppresses Tumorigenesis Through Opposite Regulations of Metabolism in Adipose Tissue and Tumor. *Cancer Cell* (2018) 33(4):770–84.e6. doi: 10.1016/j.ccell.2018.03.001
77. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, et al. Adenosine 2a Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. *Cancer Discov* (2020) 10(1):40–53. doi: 10.1158/2159-8290.CD-19-0980
78. Wang Q, Ye Y, Yu H, Lin SH, Tu H, Liang D, et al. Immune Checkpoint-Related Serum Proteins and Genetic Variants Predict Outcomes of Localized Prostate Cancer, a Cohort Study. *Cancer Immunol Immunother* (2021) 70 (3):701–12. doi: 10.1007/s00262-020-02718-1
79. Tu TC, Brown NK, Kim TJ, Wroblewska J, Yang X, Guo X, et al. CD160 Is Essential for NK-Mediated IFN-Gamma Production. *J Exp Med* (2015) 212 (3):415–29. doi: 10.1084/jem.20131601
80. Sun H, Xu J, Huang Q, Huang M, Li K, Qu K, et al. Reduced CD160 Expression Contributes to Impaired NK-Cell Function and Poor Clinical Outcomes in Patients With HCC. *Cancer Res* (2018) 78(23):6581–93. doi: 10.1158/0008-5472.CAN-18-1049
81. Slebioda TJ, Rowley TF, Ferdinand JR, Willoughby JE, Buchan SL, Taraban VY, et al. Triggering of TNFRSF25 Promotes CD8(+) T-Cell Responses and Anti-Tumor Immunity. *Eur J Immunol* (2011) 41(9):2606–11. doi: 10.1002/eji.201141477

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers in Immunology

ORIGINAL RESEARCH
published: 22 March 2022
doi: 10.3389/fimmu.2022.836939

Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer

Qiao Xiong[1,2†], Dechao Feng[1†], Ziwei Wang[2†], Yidie Ying[2], Chuanliang Xu[2], Qiang Wei[1], Shuxiong Zeng[2] and Lu Yang[1*]*

[1] Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China, [2] Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China

OPEN ACCESS

Edited by:
Dipyaman Ganguly,
Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Vivek Shukla,
Clinical Center (NIH), United States
Xian-Tao Zeng,
Wuhan University, China
Di Gu,
First Affiliated Hospital of Guangzhou Medical University, China

***Correspondence:**
Lu Yang
wycleflue@163.com
Shuxiong Zeng
zengshuxiong@126.com

[†]These authors have contributed equally to this work

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: 16 December 2021
Accepted: 16 February 2022
Published: 22 March 2022

Citation:
Xiong Q, Feng D, Wang Z, Ying Y, Xu C, Wei Q, Zeng S and Yang L (2022) Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer. Front. Immunol. 13:836939. doi: 10.3389/fimmu.2022.836939

Fatty acid metabolism (FAM) genes are potentially useful for predicting prognosis and immunotherapy response in bladder cancer (BC). To examine this, we constructed a prognostic model and identified key FAM genes in BC. Using transcriptional expression profiles and clinical data of BC patients from public datasets and Changhai (CH) hospital, we built and validated a risk-score model based on 13 prognostic FAM genes. Differential gene expression identified fatty acid synthase (*FASN*) as central to fatty acid metabolism in BC. FASN was differentially expressed between normal and tumor tissue, and was related to survival. In the CH dataset, FASN independently predicted muscle-invasive BC. FASN differential expression was significantly related to immune-cell infiltration and patients with low FASN expression responded better to immune checkpoint inhibitor (ICI) treatment. SREBF1 was predicted as the most significant transcription factor for *FASN*. Competing endogenous RNA network analysis suggested that lncRNA AC107027.3 may upregulate FASN by competitively binding miR-27A-3p, thereby regulating the immunotherapy response in BC. Dasatinib and temsirolimus are potential FASN-targeting drugs. Our model efficiently predicted prognosis in BC. FASN is central to fatty acid metabolism, and a potential indicator and regulator of ICI treatment.

Keywords: bladder cancer, fatty acid metabolism, FASN (fatty acid synthase), tumor immune microenvironment, immunotherapy, ceRNA network

INTRODUCTION

Bladder cancer (BC) is among the top 10 most common cancers globally, with an estimated 573 000 new diagnoses and 212 000 deaths in 2020 (1). It has two main subtypes, non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, requiring different diagnostic and treatment strategies. In recent decades, many potential biomarkers for BC diagnosis, prognosis, and therapy have been identified *via* advances in bioinformatics and sequencing (2). However, most of these have not been effective, and clinical strategies still depend mainly on pathology and imaging results (3). New approaches to identify new biomarkers for BC prognosis and therapy are urgently required.

Glucose, lipid, and protein metabolism regulates many important biological processes in cell proliferation and differentiation. Metabolic disorders can promote the tumor occurrence and progression by dysregulating the energy supply, molecular synthesis, and the microenvironment (4). Metabolomic analyses have revealed novel biomarkers related to diagnosis, prognosis and progression in many cancers, and novel antitumor strategies based on metabolism regulation have attracted attention (5). Lipids, one of the three major molecule types studied in metabolomics, are crucial in signal transduction and cellular membrane synthesis (6). The study of lipid metabolism in cancer has gone beyond classical cellular bioenergetics, opening new doors in tumor research (7). Fatty acids, the main intermediate products of lipid metabolism, participate in metabolic diseases as well as cancer genesis and development (8). For instance, reprogramming of fatty acid metabolism (FAM) by functional molecules promoted metastasis in gastric cancer (9), which is central to lipid metabolism. FAM has been targeted in chemotherapy, radiotherapy, and immunotherapy (10–12).

The energy-supply function of glucose, and the molecular functions of proteins, directly affect tumor-cell biological processes; this has increased the focus on glucose and amino acid metabolism. Glucose, proteins, and fatty acids influence each other *via* the tricarboxylic acid cycle, hence their metabolism in tumors is highly integrated. In terms of their metabolism, fatty acids, glucose, and amino acids are equally important (13). Lipid metabolism influences tumor growth and therapeutic response primarily by regulating the TME (14). Fatty acid metabolism can be catabolic or anabolic. Catabolism involves beta-oxidation, while anabolism involves biosynthesis, elongation, desaturation, and peroxidation (15). Enhancing fatty acid catabolism in multiple immune cells can re-establish antitumor function and improve the efficacy of immunotherapy (16).

Although FAM is significantly associated with BC tumor grade and stage (17, 18), prior studies have not addressed the prognostic value of FAM-related gene sets in BC. We therefore constructed a prognostic signature based on FAM genes in BC, and identified novel biomarkers for BC based on clinical features and treatment response.

MATERIALS AND METHODS

Data Acquisition

Transcriptional expression and corresponding clinical data were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, and were normalized and processed using the TCGAbiolinks package. FAM gene sets were collected from the Gene Set Enrichment Analysis (GSEA) website. The Changhai Hospital (CH) cohort (155 samples) was used to verify the protein expression and prognostic value of the key genes. Differential expression of the key gene was validated *via* RNA-seq of 10 paired normal and cancer tissues, and 5 tumor basal tissues, from the CH cohort. The sequencing results have been used in previous studies (19).

Prognostic FAM Gene Identification and Subgroup Analysis

We used Venn analysis of the KEGG, HALLMARK, and REACTOME gene sets in GSEA to obtain the FAM gene set. The ggplot2 and survival R packages were used to generate heatmap plots and evaluate prognostic FAM genes. A prognostic gene coexpression network was constructed using the igraph package. A protein–protein interaction (PPI) network was generated, and hub genes identified, using STRING and Cytoscape 3.8.0.

We used the ConsensusClusterPlus package to divide the BC patients into two subgroups *via* consensus clustering, according to the 68 prognostic FAM genes. We analyzed survival and clinicopathological relatedness, and conducted a PCA of the cluster subgroups, using R. An adjusted $P < 0.05$ was considered statistically significant.

Construction and Validation of the FAM-Related Gene Model

From the TCGA database, we randomly divided Urothelial Bladder Carcinoma (BLCA) sample patients into training and testing cohorts, then circularly performed least absolute shrinkage and selection operator (LASSO) regression and stepwise multivariate Cox regression, to develop an efficient signature. The samples were classified into high- or low-risk groups, using the median risk score. To assess the efficiency of the risk-score model, we analyzed the area under the ROC curve, performed Kaplan–Meier (KM) analysis, and generated risk plots using the training, testing, and combined cohorts. We used univariate and multivariate Cox regression analyses, with risk, cluster, age, sex, stage, and grade as factors, and constructed a nomogram. To evaluate the net benefit of the nomogram, we used the C-index, ROC curve, calibration curve, and decision curve analysis.

After validating the risk-score model, we applied copy number variation (CNV) and tumor burden mutation analysis. Standard CNV data were obtained from the NCI Center for Cancer Genomics (GDC)-TCGA cohort, and were analyzed using strawberry Perl and the RCircos package. The correlation between CNV and immune infiltration was analyzed *via* TIMER. The BC patients' somatic mutation data were downloaded from the TCGA-BLCA database and analyzed using the maftools package.

Identification and Validation of the Key Gene

To screen key FAM genes, we used a Venn plot to analyse PPI hub genes, our model-identified genes, and TCGA DEGs. The mutation atlas of the key gene was downloaded from the cBioPortal database (https://www.cbioportal.org/). The three dimensional structure of the protein translated by the key gene, and the location atlas, were obtained from the Protein Data Bank (https://www.rcsb.org/structure/6NNA).

Immunohistochemistry and immunofluorescence data were acquired from the Human Protein Atlas database (https://www.proteinatlas.org).

We first confirmed the differential expression, pathological correlation, and prognostic value of the key genes using six public datasets (TCGA, GSE13507, GSE3167, GSE40355, GSE32548, and GSE32894) (20–24). External validation was performed using the CH cohort. Ten paired samples of RNA-seq and IHC data were used to verify differential expression, and another 155 IHC-stained cancer samples were used to evaluate the clinical prognostic value of the key gene. IHC staining chips for the key gene were visualized using Image-Pro Plus (IPP) software, and assessed by a professional pathologist.

GSEA and Gene Set Variation Analysis (GSVA)

We divided TCGA BC patients into low- and high key-gene expression groups, and conducted Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses. GSVA was applied to estimate pathway scores for the low and high expression groups (25). We used the R packages GSEABase, GSVA, and limma, and considered $P < 0.05$ as statistically significant. GSEA was used to identify significantly upregulated and downregulated pathways (26), using software downloaded from the Broad Institute, as well as the R packages org.Hs.eg.db, GOplot, digest, and enrichplot. Statistical significance was set at a |normalized enrichment score| > 1, nominal $P < 0.05$, and FDR $q < 0.25$.

Immune Function of the Key Gene

On the basis of GSVA and GSEA, we selected immune infiltration as the process for further analysis, and downloaded original immune infiltration data from TIMER2.0. We then applied seven algorithms (TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCPCOUNTER, XCELL, and EPIC) in the limma package, using the Wilcoxon test ($P < 0.05$). We further compared the high- and low-expression groups in terms of immune cell infiltration, immune function, immune microenvironment, and immune checkpoints. We downloaded information on the therapeutic responses of PD-1 and CTLA-4, crucial targets of immune checkpoint inhibitor (ICI) therapy, from The Cancer Immunome Atlas (TCIA) database (https://tcia.at/home/).

Molecular Regulation Mechanism of the Key Gene

To determine the pathway potentially regulating the transcription and translation of the key gene in BC, we analyzed transcription factors (TFs) and competing endogenous RNA (ceRNA) networks. Sequence information about the key gene was obtained from the Gene Module in the National Center for Biotechnology Information (NCBI). The region from 2000 bp before to 100 bp after the transcription start point served as the potential binding region. We predicted the potential TFs using the Genome Database of the University of California (Santa Cruz), and obtained the TF binding sequence logo and the transcription factor flexible model nucleotide correlation logo from the JASPAR database (27, 28). Next, we selected microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) that may regulate the key gene from the STARBASE database, and constructed a ceRNA network using the reshape2 package and Cytoscape (29). The expression of the selected TFs, miRNAs, and lncRNAs, and their prognostic relevance, were validated using the TCGA or CH cohorts.

Drugs Targeting the Key Gene

Based on the regulatory pathway, we screened drugs targeting the key gene. Drug sensitivity information was obtained from the CellMiner database and Gene Set Cancer Analysis (GSCA) database, which collects drug-sensitivity data from the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC) database (30, 31). We used Venn analysis to select specific drugs targeting the key gene, and applied the pRRophetic package to compare the high- and low-expression groups in terms of their IC_{50} values. We obtained the chemical structure and clinical study information for the predicted drugs from the canSAR Black database.

Statistical Analysis

R software v. 4.1.1 (https://www.r-project.org) and GraphPad Prism 7.0 (https://www.graphpad.com/) were used for statistical analysis. $P < 0.05$ was defined as statistically significant. We used unpaired Student's *t*-tests and Wilcoxon tests to analyse normally and nonnormally distributed variables, respectively. The paired Student's *t*-test was used to analyse key-gene differential expression in paired samples. Univariate, multivariate, and Lasso-penalized regression analyses were used to identify the important genes and characterize the prognostic signature.

RESULTS

Selection of a Potential Prognostic Signature Based on FAM Genes in BC

A flow chart of this study including two main parts was provided in **Scheme 1**. In total, 309 FAM genes were identified *via* Venn analysis of three functional gene sets, and 52 differentially expressed FAM genes were identified (**Figures 1A, B**). PPI analysis revealed the interactions among 68 prognostic FAM genes, *via* univariate Cox regression. The Cyto-Hubba algorithm, which is based on the degree method, revealed the top 10 hub genes (FASN, HADH, ACLY, ACADVL, SCD, ACADS, SCP2, HMGCS2, ACSL5, and ACAT1), of which FASN was the most noteworthy (**Figure 1C**). The FAM gene analysis process and co-expression network is shown in **Figures S1A–D**. Primary function analysis confirmed that the selected genes were enriched mainly in FAM pathways (**Figures S1E–H**). Consensus clustering separated the samples into two distinct subgroups (**Figure S2**).

To construct the FAM-related signature, we selected 13 genes (CPT1B, FASN, MID1IP1, ACOT13, ACLY, NUDT19, TECR,



SCHEME 1 | Flowchart of the analysis process.

PTGIS, ADH4, PRDX6, IL4I1, EPHX1, and METAP1) using LASSO regression and multivariate Cox regression (**Figures 1D, E** and **Table S1**). The nomogram suggested that the signature was an independent prognostic factor in BC patients (**Figure 1F**). The process for building and validating the risk-score model is provided in the supplementary materials (**Figures S3**, **S4**). For further analysis, we assigned these candidate genes to catabolism and anabolism groups based on GeneCard annotation, and performed function and survival analysis (**Figures 1G, H**, **S5, S6**).

Identification and Validation of FASN in FAM

Venn analysis of the 13 model-identified genes, 10 PPI hub genes, and 52 DEGs, identified fatty acid synthase (FASN) as the key FAM gene in BC patients (**Figure 2A**). Its primary function and 3D structure were obtained from the GeneCard and Protein Data Bank databases (**Figures 2B, C**). IHC staining revealed that FASN expression was higher in tumor tissues than in normal tissues, and was mainly located in the cytoplasm (**Figures 2D–F**). FASN mutation data and immunofluorescence images are presented in **Figures S7A, B**.

Based on analysis of the TAGA, GSE13507, GSE3167, and GSE40355 datasets, FASN was differentially expressed between cancer and normal tissue (**Figures 2G–J**). Clinicopathology grouping analysis, using the GSE3167, GSE40355, GSE32548, and GSE32894 datasets, indicated that FASN was highly expressed in patients with high tumor grades (**Figures 2K, L**, **S7C, D**). Kaplan-Meier analysis of TCGA data revealed that FASN showed prognostic significance, regardless of whether grouping was based on the median or optimal cutoff value (**Figures 2M**, **S7E**). Using the GSE13507 dataset, FASN expression was valuable in predicting both overall and disease-free survival of BC patients (**Figures 2N**, **S7F**).

External Validation of FASN

External validation of FASN (in the CH cohort) used 25 sequencing samples and 155 tissue samples. Based on RNA-seq data, FASN expression appeared to be lower in normal tissues than basal and tumor tissues (**Figure 3A**). Paired-sample analysis revealed higher FASN expression in tumor than normal tissues, in all 10 patients (**Figure 3B**). The volcano plot further indicates that FASN was significantly upregulated in tumor tissues (**Figure 3C**). IHC staining of the 10 paired tissue samples confirmed that FASN expression was higher in tumor tissues (**Figures 3D–F**, **S8A**).

IHC staining of FASN was conducted using 155 tissue chips. The IHC score was calculated as the product of the staining intensity (0–3) and proportion (0–100) (**Figure S8B, C**). The patients were divided into FASN-negative and -positive groups by IHC score, for further analysis (**Table S2**). Kaplan-Meier analysis of overall survival showed that FASN was prognostic in muscle-invasive bladder cancer (n = 92) but not in non-muscle-



FIGURE 1 | Identification of prognostic FAM genes and risk score model. **(A)** Venn diagram of 309 FAM genes from KEGG, HALLMARK and REACTOME. **(B)** Volcano plot of 52 fatty acid metabolism-related DEGs (p<0.05). **(C)** PPI network and hub genes of 68 prognostic FAM genes. **(D)** Cross-validation for tuning the parameter selection in the LASSO regression. **(E)** Kaplan–Meier survival curve of the patients between the high- and low-risk groups. **(F)** Nomogram containing risk, cluster and clinicopathological features. **(G)** Differential expression of the 13 model genes between different risk groups. **(H)** Risk and functional groups of the 13 model genes. (*p < 0.05, **p < 0.01, ***p < 0.001).

invasive bladder cancer (n = 63) (**Figures 3G**, **S8F**). For muscle-invasive bladder cancer patients, the median survival time of the FASN-positive group was 47.93 months (that of the FASN-negative group was not available). We found no correlation between FASN expression and tumor invasion and grade (**Figure S8D, E**), although multivariate Cox regression analysis revealed that FASN and invasion were both independent prognostic factors (**Table 1**). We further constructed nomograms to predict the 1-, 3- and 5-year BC survival. Adding FASN to the nomogram increased its accuracy from 0.738 to 0.762, suggesting that FASN is an important prognostic factor (**Figure 3H**).

GSEA and GSVA

In the KEGG analysis, GSVA and GSEA identified 53 and 39 enriched functional pathways, respectively. In the high-FASN group, most of the functional pathways were related to metabolism, whereas in the low-FASN group, they were mostly immune-related (**Figures 4A–C**). Intriguingly, 11 of the 22 immune system KEGG pathways were significantly enriched in the low-FASN group, both *via* GSEA and GSVA (**Figures 4D, E**). GO analysis yielded similar results (**Figure S9**). As both KEGG and GO analysis indicated that low FASN expression is associated with immune function, we conducted a correlation analysis between immune-cell infiltration and FASN expression.



FIGURE 2 | Identification and validation of FASN. **(A)** Venn diagram of the top 10 PPI hub genes, 52 differentially expressed genes and 13 model genes. **(B)** Mechanism diagram of the role of FASN in fatty acid metabolism. **(C)** 3D structure of the protein translated by FASN and NADPH ligand from the PDB database. **(D–F)** IHC staining of FASN in tumor and normal tissues of BC patients from the HPA database. **(G–J)** Differential expression of FASN between the tumor and normal groups in TAGA, GSE13507, GSE3167 and GSE40355. **(K, L)** Differential expression of FASN between low- and high-grade patients in GSE13507 and GSE40355. **(M, N)** Overall survival probability between the low- and high-FASN groups in TCGA and GSE13507 (patients grouped by median value).

The heatmap revealed significant differences in immune-cell infiltration between the low- and high-FASN groups, for multiple databases (**Figure 4F**).

Immune Function of FASN

The functional analysis indicated that many immune pathways were enriched in the low-FASN group. We therefore also analyzed immune cell infiltration, immune function, immune microenvironment, and immune checkpoints, to explore the role of FASN in cancer immune infiltration and responses.

CIBERSORT analysis revealed that five types of immune cells were differentially infiltrated between the low- and high-FASN groups and FASN CNV significantly affects the infiltration of CD4 + T cells, dendritic cells, and neutrophils (**Figures 5A**, **S10A**).



FIGURE 3 | External validation of FASN. **(A)** Differential expression of FASN in normal, basal and tumor tissues. **(B)** Differential expression of FASN in 10 paired normal and tumor tissues. **(C)** Volcano plot of paired tissue RNA-seq matrix (logFC>1, p<0.05). **(D–F)** IHC staining of the 10 paired normal and tumor tissues. **(G)** Overall survival curve between the positive and negative FASN groups of MIBC patients in the CH cohort. **(H)** Nomogram with FASN and clinicopathologic features for the prediction of outcome in the CH cohort.

Further correlation analysis of the expression of FASN and immune cell marker genes indicated that six types of immune-cell infiltrate were associated with FASN expression (**Figures S10B, C**). Single-sample GSEA scores of immune function revealed that all of the immune function indicators were significantly higher in the low-FASN group, except for the type II INF response (**Figure 5B**). The low-FASN group had higher stromal, immune, and ESTIMATE TME scores (**Figures 5C–E**). In particular, most of the immune checkpoints (39/48), including CD274 (PD-L1) and CTLA4, were differentially expressed between the high-and low-FASN groups (**Figure 5F**). Evaluation of immune checkpoint therapy, based on the TCIA database, revealed that patients with low FASN levels responded better to anti- PD-1 and CTLA4 treatments than those with high FASN levels (**Figures 5G–L**)

TABLE 1 | The results of univariate and multivariate COX regression analysis in BC patients in the CH cohort.

Features	Univariate analysis				Multivariate analysis			
	HR	HR.95L	HR.95H	P value	HR	HR.95L	HR.95H	P value
Age (<=65 vs >65)	1.04	1.00	1.07	0.0271	1.02	0.99	1.06	0.1718
Gender (male vs female)	0.95	0.37	2.42	0.9176	0.60	0.22	1.61	0.3083
Recurrence (re vs non-re)	1.12	0.60	2.08	0.7314	1.29	0.68	2.47	0.4380
Size (<3 vs >=3)	1.70	0.90	3.22	0.1012	1.25	0.64	2.44	0.5075
Grade (high vs low)	1.01	0.62	1.67	0.9561	0.82	0.45	1.51	0.5271
Invasion (NMIBC vs MIBC)	7.96	3.13	20.27	0.0000	7.85	2.98	20.70	0.0000
FASN (negative vs positive)	1.89	0.93	3.83	0.0775	2.55	1.19	5.49	0.0164

Molecular Regulation of FASN

TF analysis revealed a potential regulatory mechanism of FASN in the nucleus. Fifteen TFs in the JASPAR CORE collection (2022) were predicted to be associated with FASN transcription, with a minimum score > 600. Correlation analysis suggested that sterol regulatory element binding transcription factor 1 (SREBF1) was the TF most significantly related to FASN (**Figure 6A**). SREBF1 and FASN are both located on chromosome 17; the TF binding site is shown in **Figure 6B**. The binding sequence logo and nucleotide correlation logo generated by transcription factor flexible models are presented in **Figures 6C, D**. Our analysis of association, expression, and prognosis revealed that SREBF1 was highly correlated with FASN, and was also prognostic in BC patients (**Figures 6E–G**). Analysis of RNA-seq data from the CH cohort validated that SREBF1 was associated with FASN, and was differentially expressed in normal and tumor tissues (**Figures 6H–J**).

We constructed an mRNA–miRNA–lncRNA network to examine the translational regulation of FASN in the cytoplasm (**Figures 7A, B**). First, 26 miRNAs potentially targeting FASN were obtained from the STARBASE database, and miR-27a-3p was identified *via* Spearman correlation analysis (**Figure 7C**). The expression boxplot and overall survival curves indicate that miR-27a-3p was differentially expressed between the normal and tumor groups, and had prognostic value (**Figures 7D, E**). Then, 136 emulative lncRNAs targeting miR-27a-3p were obtained from STARBASE; of these, AC107027.3 was the most significant (**Figure 7F**). In contrast to FASN, AC107027.3 expression was low in tumor tissues, and was positively correlated with overall survival (**Figures 7G, H**).

Prediction of FASN-Targeting Drugs

Based on these molecular mechanism findings, we screened drugs targeting FASN and SREBF1 from the Cancer Therapeutics Response Portal (CTRP), Genomics of Drug Sensitivity in Cancer (GDSC), and CellMiner databases. In total, 23 and 61 drugs targeting FASN and SREBF1, respectively, were selected (correlation coefficient > 0 and $P < 0.05$; **Figure S11A**). Venn analysis between the different databases revealed that dasatinib and temsirolimus targeted FASN (**Figures 7I**, **S11B**), whereas navitoclax and PI-103 targeted SREBF1 (**Figure S11C**). Eight drugs targeted both FASN and SREBF1 (**Figure S10D**). Based on their IC_{50} scores, samples with different FASN expression responded differently to dasatinib and temsirolimus (**Figures 7J, K**). Based on information from canSAR Black, dasatinib and temsirolimus are FDA-approved drugs that are used mainly for tumor therapy (**Figures 7L, M**, **S10E, F**, **Table S3**).

DISCUSSION

The global incident cases of bladder cancer have increased by more than 100 percent in the past few decades (32). Many gene signatures, including those for ferroptosis-related genes, autophagy-related genes, and hypoxia-related genes (33–35), have shown value in BC; nonetheless, we could find no prior studies using FAM-related models in BC prognosis and diagnosis. To address this gap, we evaluated the role of FAM genes in BC prognosis and immune infiltration. Our model identified 13 FAM genes (CPT1B, ACOT13, NUDT19, ADH4, EPHX1, and PRDX6, all catabolic; and FASN, MID1IP1, ACLY, PTGIS, METAP1, IL4I1, and TECR, all anabolic). The catabolic and anabolic FAM genes work together to regulate fatty acid metabolism and their FAM functions are shown in the schematic diagram (**Figure 8A**). Some of those genes have been reported to be involved in multiple cancers and others remain to be explored. For example, CPT1B, a protein for transporting pre-metabolites of fatty acids on the mitochondrial membrane, is a key target for controlling fatty acid beta-oxidation in mitochondria and has been reported as a therapeutic and grading target (18, 36). ACLY catalyzes the cleavage of citrate into the fatty acid synthesis substrate acetyl-CoA and is also a novel therapeutic target because of its function of glucose-to-acetate switch (37, 38). Because our model included the entire process of fatty acid synthesis and decomposition, it could effectively predict survival in BC.

We selected FASN, an important regulator in fatty acid anabolism, based on its prognostic signature. FASN was differentially expressed in tumor and normal tissues, was associated with tumor grade, and showed prognostic value in both the public and private databases that we studied. Its main function is to condense 7 malonyl-CoA molecules and 1 acetyl-CoA in series, to form the initial product of fatty acid synthesis, namely palmitate (15). FASN-dependent lipid metabolism influences neural stem cell proliferation and development (39). In recent years, increasing evidence has highlighted its important role in many cancers. High FASN expression is related to poor prognosis and metastasis in breast cancer (40, 41). In contrast, FASN inhibition both limits tumor–cell migration and



FIGURE 4 | Function analysis of FASN. **(A)** Heatmap of KEGG enrichment for the low- and high-FASN groups in GSVA ($p<0.05$). **(B)** Types of KEGG pathways enriched in the high-FASN group. **(C)** Types of KEGG pathways enriched in the low-FASN group. **(D)** Venn plot of pathways enriched in low-FASN group. **(E)** Gene enrichment of the 11 selected immune pathways in GSEA. **(F)** Heatmap of immune infiltration between low- and high-FASN groups by seven algorithms ($p<0.05$).



FIGURE 5 | Immune function of FASN. **(A)** Effect of FASN CNV status on immune cell infiltration. **(B)** ssGSEA scores of immune function between the low- and high-FASN groups. **(C–E)** Boxplot of TME score between low- and high-FASN groups. **(F)** Differential expression of 39 immune checkpoints between low- and high-FASN groups. **(G, H)** Scatter plot of correlation between CD274 (PD-L1), CTLA4 and FASN. **(I–L)** ICI treatment response of low and high-FASN groups. (ns $p > 0.05$, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$).



FIGURE 6 | Transcription factors regulating FASN. **(A)** Correlation network of FASN and TFs. **(B)** Diagram of gene location and transcription of FASN and SREBF1. **(C)** TFBS sequence logos of SREBF1 (the ordinate represents the amount of base information, and the abscissa represents the base location). **(D)** Base correlation logos of TFBS by TFFM. **(E)** Scatter plot of association between FASN and SREBF1 in TCGA. **(F)** Boxplot of SREBF1 expression in normal and tumor patients in TCGA. **(G)** Overall survival curve of low- and high-SREBF1 groups in TCGA. **(H)** Scatter plot of association between FASN and SREBF1 in CH database. **(I)** Differential expression of FASN in normal, basal and tumor tissues. **(J)** Differential expression of FASN in 10 paired normal and tumor tissues.



FIGURE 7 | CeRNA network and drugs prediction of FASN. **(A)** mRNA-miRNA-lncRNA interaction network of FASN in BC. **(B)** AC107027.3 competitively binds miR-27a-3p to decrease its inhibition on FASN. **(C)** Scatter plot of association between FASN and miR-27a-3p in TCGA. **(D)** Boxplot of miR-27a-3p in normal and tumor patients in TCGA. **(E)** Overall survival curve of low- and high- miR-27a-3p groups in TCGA. **(F)** Scatter plot of association between FASN and AC107027.3 in TCGA. **(G)** Boxplot of AC107027.3 in normal and tumor patients in TCGA. **(H)** Overall survival curve of low- and high- AC107027.3 groups in TCGA. **(I)** Drugs targeting FASN in the CTRP, GDSC, and CellMiner databases. **(J, K)** IC50 of dasatinib and temsirolimus in low- and high-FASN groups. **(L, M)** Chemical structure of dasatinib and temsirolimus from canSARblack.



FIGURE 8 | Schematic diagram of FAM genes **(A)** and FASN regulation **(B)**.

invasiveness, and increases tumor sensitivity to drug therapy (42–44).This evidence, along with our findings, suggests that, while CPT1B is rate-limiting in fatty acid catabolism, FASN is the key regulator of fatty acid anabolism; together, they regulate the fatty acid metabolic pool and may play important role in progression and treatment of cancers.

Regulation analysis of FASN provides us more methods to modify fatty acid metabolism in BC (**Figure 8B**). Importantly, the TF most significantly involved in FASN regulation, SREBF1, also plays an important role in lipid metabolism (45, 46). Recent studies also reported that multiple lncRNAs competitively bind miRNAs to regulate FASN expression in nasopharyngeal and endometrial cancer (47, 48). For drugs targeting FASN, a phase II clinical trial revealed that temsirolimus show potential benefit in bladder cancer patients who are refractory to first line platinum-based chemotherapy (49). Our drug screening also revealed several drugs that target both SREBF1 and FASN, which may have better effects in BC patients.

Disrupted immunity in the TME plays an important role in cancer development and progression. Further, FAM is closely associated with immune-cell regulation in the TME (50, 51). In ovarian cancer, for instance, a FASN-related pathway was reported to disrupt dendritic cells and induce an impaired antitumor immune response *via* lipid accumulation (52). In our study, FASN was significantly associated with the immune microenvironment, immune-cell infiltration, and immune function in BC, and its CNV affected infiltration by CD4+ T cells, neutrophils, and dendritic cells. Most of the immune checkpoint genes (39/44) that we screened were differentially expressed between the high- and low-FASN groups. Further, ICI analysis revealed significant FASN expression in the CTLA4- and PD1-positive groups, with no significant effects in the double-negative groups. This suggests that, in BC patients, FASN expression is an indicator for anti-CTLA4 and anti-PD1 treatment. Prior studies (53–55) have indicated that many of the metabolic genes identified by our model, such as IL4I1,

ACLY, and PTGIS, are involved in immune responses; however, while those studies considered gene expression and immune-cell infiltration, and its mechanisms, they did not consider immunotherapy. Our work addresses this gap.

CONCLUSION

We constructed a prognostic risk-score model based on 13 FAM genes. The model effectively predicted prognosis in BC, independently of other clinicopathological features. It identified FASN as the key FAM gene in BC. FASN showed value in prognosis, and as an immunotherapy indicator and regulator, especially in anti-CTLA4 and anti-PD1 treatments. These findings present a novel way to predict prognosis in BC, and a novel target for ICI treatment. By describing the potential molecular mechanism whereby FASN functions, we provide support for further interventions using this target gene.

Limitation

Although it revealed encouraging results, there are still several limitations in our study. First, the model was constructed and validated in a single data source (TCGA). It would be better if its prognostic value was tested in another independent patient cohort. Second, the original row data of the CH cohort used for validating the expression of the key gene was lost due to our lack of preservation awareness several years ago. However, we can provide all the data processing forms and previous studies based on these data. Last, the molecular mechanism used to regulate the key gene was not tested by more experiments, and we will continue to work on this in further studies.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Ethical Board of Changhai Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

QX proposed the project, conducted data analysis, interpreted the data, and wrote the manuscript. DF, ZW, YY, CX, and QW conducted data analysis, interpreted the data. SZ and LY supervised the project, and interpreted the data. All authors reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This research was financed by grants from Qihang program of Naval Medical University, National Natural Science Foundation of China (81772720, 81802515, 81801854, 82172871, 81974099, 82170785, 81974098, 82170784).

ACKNOWLEDGMENTS

We are grateful to the public databases, the datasets used in this study, and their providers and maintainers.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.836939/full#supplementary-material

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2021) 71:209–49. doi: 10.3322/caac.21660
2. Zeng S, Ying Y, Xing N, Wang B, Qian Z, Zhou Z, et al. Noninvasive Detection of Urothelial Carcinoma by Cost-Effective Low-Coverage Whole-Genome Sequencing From Urine-Exfoliated Cell DNA. *Clin Cancer Res* (2020) 26:5646–54. doi: 10.1158/1078-0432.CCR-20-0401
3. Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and Staging of Bladder Cancer. *Hematol Oncol Clin North Am* (2021) 35:531–41. doi: 10.1016/j.hoc.2021.02.004
4. Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, et al. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. *Mol Cell* (2015) 60:571–83. doi: 10.1016/j.molcel.2015.09.025
5. Martínez-Reyes I, Chandel NS. Cancer Metabolism: Looking Forward. *Nat Rev Cancer* (2021) 21:669–80. doi: 10.1038/s41568-021-00378-6
6. Yoon H, Shaw JL, Haigis MC, Greka A. Lipid Metabolism in Sickness and in Health: Emerging Regulators of Lipotoxicity. *Mol Cell* (2021) 81:3708–30. doi: 10.1016/j.molcel.2021.08.027
7. Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid Metabolism in Cancer: New Perspectives and Emerging Mechanisms. *Dev Cell* (2021) 56:1363–93. doi: 10.1016/j.devcel.2021.04.013
8. Currie E, Schulze A, Zechner R, Walther TC, Farese RJ. Cellular Fatty Acid Metabolism and Cancer. *Cell Metab* (2013) 18:153–61. doi: 10.1016/j.cmet.2013.05.017
9. Tan Y, Lin K, Zhao Y, Wu Q, Chen D, Wang J, et al. Adipocytes Fuel Gastric Cancer Omental Metastasis *via* PITPNC1-Mediated Fatty Acid Metabolic Reprogramming. *Theranostics* (2018) 8:5452–68. doi: 10.7150/thno.28219
10. Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, et al. Inhibiting Fatty Acid Synthase With Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients With Operable TNBC. *Clin Cancer Res* (2021) 21:5810–7. doi: 10.1158/1078-0432.CCR-21-0493
11. Chuang HY, Lee YP, Lin WC, Lin YH, Hwang JJ. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to

Radiotherapy *via* FASN/NF-κb Pathway. *Sci Rep* (2019) 9:13284. doi: 10.1038/s41598-019-49486-2
12. Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism Within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. *Cancer Cell* (2017) 32:377–91. doi: 10.1016/j.ccell.2017.08.004
13. Biswas S, Lunec J, Bartlett K. Non-Glucose Metabolism in Cancer Cells–Is It All in the Fat? *Cancer Metastasis Rev* (2012) 31:689–98. doi: 10.1007/s10555-012-9384-6
14. Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, et al. Contradictory Roles of Lipid Metabolism in Immune Response Within the Tumor Microenvironment. *J Hematol Oncol* (2021) 14:187. doi: 10.1186/s13045-021-01200-4
15. Bogie J, Haidar M, Kooij G, Hendriks J. Fatty Acid Metabolism in the Progression and Resolution of CNS Disorders. *Adv Drug Deliv Rev* (2020) 159:198–213. doi: 10.1016/j.addr.2020.01.004
16. Gu Y, Niu X, Yin L, Wang Y, Yang Y, Yang X, et al. Enhancing Fatty Acid Catabolism of Macrophages Within Aberrant Breast Cancer Tumor Microenvironment Can Re-Establish Antitumor Function. *Front Cell Dev Biol* (2021) 9:665869. doi: 10.3389/fcell.2021.665869
17. Piyarathna D, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, et al. Distinct Lipidomic Landscapes Associated With Clinical Stages of Urothelial Cancer of the Bladder. *Eur Urol Focus* (2018) 4:907–15. doi: 10.1016/j.euf.2017.04.005
18. Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, et al. Multi-Omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. *Clin Cancer Res* (2019) 25:3689–701. doi: 10.1158/1078-0432.CCR-18-1515
19. Zeng S, Liu A, Dai L, Yu X, Zhang Z, Xiong Q, et al. Prognostic Value of TOP2A in Bladder Urothelial Carcinoma and Potential Molecular Mechanisms. *BMC Cancer* (2019) 19:604. doi: 10.1186/s12885-019-5814-y
20. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors. *J Clin Oncol* (2010) 28:2660–7. doi: 10.1200/JCO.2009.25.0977
21. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, et al. Gene Expression in the Urinary Bladder: A Common Carcinoma *in Situ* Gene Expression Signature Exists Disregarding Histopathological Classification. *Cancer Res* (2004) 64:4040–8. doi: 10.1158/0008-5472.CAN-03-3620
22. Hecker N, Stephan C, Mollenkopf HJ, Jung K, Preissner R, Meyer HA. A New Algorithm for Integrated Analysis of miRNA-mRNA Interactions Based on Individual Classification Reveals Insights Into Bladder Cancer. *PloS One* (2013) 8:e64543. doi: 10.1371/journal.pone.0064543
23. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, et al. Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma. *Plos One* (2012) 7:e38863
24. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, et al. A Molecular Taxonomy for Urothelial Carcinoma. *Clin Cancer Res* (2012) 18:3377–86.
25. Hänzelmann S, Castelo R, Guinney J. GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. *Proc Natl Acad Sci USA* (2005) 102:15545–50. doi: 10.1073/pnas.0506580102
27. Lee BT, Barber GP, Benet-Pagès A, Casper J, Clawson H, Diekhans M, et al. The UCSC Genome Browser Database: 2022 Update. *Nucleic Acids Res* (2021) 50:1115–22. doi: 10.1093/nar/gkab959
28. Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: Update of the Open-Access Database of Transcription Factor Binding Profiles. *Nucleic Acids Res* (2020) 48:D87–92. doi: 10.1093/nar/gkz1001
29. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. Starbase: A Database for Exploring microRNA-mRNA Interaction Maps From Argonaute CLIP-Seq and Degradome-Seq Data. *Nucleic Acids Res* (2011) 39:D202–9. doi: 10.1093/nar/gkq1056
30. Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: A Web Server for Gene Set Cancer Analysis. *Bioinformatics* (2018) 34:3771–2. doi: 10.1093/bioinformatics/bty411
31. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. *Cancer Res* (2012) 72:3499–511. doi: 10.1158/0008-5472.CAN-12-1370
32. Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, et al. Global, Regional, and National Burden of Kidney, Bladder, and Prostate Cancers and Their Attributable Risk Factors, 1990-2019. *Mil Med Res* (2021) 8:60. doi: 10.1186/s40779-021-00354-z
33. Sun J, Yue W, You J, Wei X, Huang Y, Ling Z, et al. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer. *Front Oncol* (2021) 11:730716. doi: 10.3389/fonc.2021.730716
34. Zhou C, Li AH, Liu S, Sun H. Identification of an 11-Autophagy-Related-Gene Signature as Promising Prognostic Biomarker for Bladder Cancer Patients. *Biology (Basel)* (2021) 10:375. doi: 10.3390/biology10050375
35. Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, et al. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. *Front Immunol* (2021) 12:725223. doi: 10.3389/fimmu.2021.725223
36. Abudurexiti M, Zhu W, Wang Y, Wang J, Xu W, Huang Y, et al. Targeting CPT1B as a Potential Therapeutic Strategy in Castration-Resistant and Enzalutamide-Resistant Prostate Cancer. *PROSTATE* (2020) 80:950–61. doi: 10.1002/pros.24027
37. Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, et al. Acetylation Stabilizes ATP-Citrate Lyase to Promote Lipid Biosynthesis and Tumor Growth. *Mol Cell* (2013) 51:506–18. doi: 10.1016/j.molcel.2013.07.002
38. Zhao S, Torres A, Henry RA, Trefely S, Wallace M, Lee JV, et al. ATP-Citrate Lyase Controls a Glucose-To-Acetate Metabolic Switch. *Cell Rep* (2016) 17:1037–52. doi: 10.1016/j.celrep.2016.09.069
39. Knobloch M, Braun SM, Zurkirchen L, von Schoultz C, Zamboni N, Araúzo-Bravo MJ, et al. Metabolic Control of Adult Neural Stem Cell Activity by Fasn-Dependent Lipogenesis. *NATURE* (2013) 493:226–30. doi: 10.1038/nature11689
40. Breast Cancer Brain Metastases Rely on FASN-Mediated Lipid Biosynthesis. *Cancer Discov* (2021) 11:1315. doi: 10.1158/2159-8290.CD-RW2021-051
41. Jiang W, Xing XL, Zhang C, Yi L, Xu W, Ou J, et al. MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study. *Front Oncol* (2021) 11:604801. doi: 10.3389/fonc.2021.604801
42. Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, et al. FASN Inhibition as a Potential Treatment for Endocrine-Resistant Breast Cancer. *Breast Cancer Res Treat* (2021) 187:375–86. doi: 10.1007/s10549-021-06231-6
43. Humbert M, Seiler K, Mosimann S, Rentsch V, Sharma K, Pandey AV, et al. Reducing FASN Expression Sensitizes Acute Myeloid Leukemia Cells to Differentiation Therapy. *Cell Death Differ* (2021) 28:2465–81. doi: 10.1038/s41418-021-00768-1
44. Papaevangelou E, Almeida GS, Box C, DeSouza NM, Chung YL. The Effect of FASN Inhibition on the Growth and Metabolism of a Cisplatin-Resistant Ovarian Carcinoma Model. *Int J Cancer* (2018) 143:992–1002. doi: 10.1002/ijc.31392
45. Li LY, Yang Q, Jiang YY, Yang W, Jiang Y, Li X, et al. Interplay and Cooperation Between SREBF1 and Master Transcription Factors Regulate Lipid Metabolism and Tumor-Promoting Pathways in Squamous Cancer. *Nat Commun* (2021) 12:4362. doi: 10.1038/s41467-021-24656-x
46. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, A Membrane-Bound Transcription Factor Released by Sterol-Regulated Proteolysis. *Cell* (1994) 77:53–62. doi: 10.1016/0092-8674(94)90234-8
47. Liu F, Wei J, Hao Y, Lan J, Li W, Weng J, et al. Long Intergenic Non-Protein Coding RNA 02570 Promotes Nasopharyngeal Carcinoma Progression by Adsorbing microRNA miR-4649-3p Thereby Upregulating Both Sterol Regulatory Element Binding Protein 1, and Fatty Acid Synthase. *Bioengineered* (2021) 12:7119–30. doi: 10.1080/21655979.2021.1979317
48. He Y, Xu S, Qi Y, Tian J, Xu F. Long Noncoding RNA SNHG25 Promotes the Malignancy of Endometrial Cancer by Sponging microRNA-497-5p and

Increasing FASN Expression. *J Ovarian Res* (2021) 14:163. doi: 10.1186/s13048-021-00906-w
49. Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, et al. Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients With Recurrent Bladder Cancer. *BMC Cancer* (2018) 18:194. doi: 10.1186/s12885-018-4059-5
50. Lochner M, Berod L, Sparwasser T. Fatty Acid Metabolism in the Regulation of T Cell Function. *Trends Immunol* (2015) 36:81–91. doi: 10.1016/j.it.2014.12.005
51. Wu H, Han Y, Rodriguez SY, Deng H, Siddiqui S, Treese C, et al. Lipid Droplet-Dependent Fatty Acid Metabolism Controls the Immune Suppressive Phenotype of Tumor-Associated Macrophages. *EMBO Mol Med* (2019) 11:e10698. doi: 10.15252/emmm.201910698
52. Jiang L, Fang X, Wang H, Li D, Wang X. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-Tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells. *Front Immunol* (2018) 9:2927. doi: 10.3389/fimmu.2018.02927
53. Romagnani S. IL4I1: Key Immunoregulator at a Crossroads of Divergent T-Cell Functions. *Eur J Immunol* (2016) 46:2302–5. doi: 10.1002/eji.201646617
54. Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and Integrative Analysis of ACLY and Related Gene Panels Associated With Immune Microenvironment Reveal Prognostic Significance in Hepatocellular Carcinoma. *Cancer Cell Int* (2021) 21:409. doi: 10.1186/s12935-021-02108-2
55. Dai D, Chen B, Feng Y, Wang W, Jiang Y, Huang H, et al. Prognostic Value of Prostaglandin I2 Synthase and Its Correlation With Tumor-Infiltrating Immune Cells in Lung Cancer, Ovarian Cancer, and Gastric Cancer. *Aging (Albany NY)* (2020) 12:9658–85. doi: 10.18632/aging.103235

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

frontiers | Frontiers in Immunology

ORIGINAL RESEARCH
published: 12 May 2022
doi: 10.3389/fimmu.2022.799636

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

Lien De Beck[1,2†], Robin Maximilian Awad[1†], Veronica Basso[3†], Noelia Casares[4†], Kirsten De Ridder[1†], Yannick De Vlaeminck[1†], Alessandra Gnata[3†], Cleo Goyvaerts[1†], Quentin Lecocq[1], Edurne San José-Enériz[5†], Stefaan Verhulst[6†], Ken Maes[2,7†], Karin Vanderkerken[2†], Xabier Agirre[5,8†], Felipe Prosper[5,8,9†], Juan José Lasarte[4†‡], Anna Mondino[3†‡] and Karine Breckpot[1†‡]*

[1] Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium, [2] Laboratory of Hematology and Immunology, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium, [3] Lymphocyte Activation Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy, [4] Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain, [5] Hemato-Oncology Program, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, Pamplona, Spain, [6] Liver Cell Biology Research Group, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium, [7] Center for Medical Genetics, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium, [8] Laboratory of Cancer Epigenetics, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, [9] Hematology and Cell Therapy Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain

Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the immunogenic potential of a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) in the preclinical B16-OVA melanoma model. Making use of tumor transcriptomic and functional analyses, methylation-targeted epigenetic reprogramming was shown to induce tumor cell cycle arrest and apoptosis *in vitro* coinciding with transient tumor growth delay and an IFN-I response in immune-competent mice. In consideration of a potential impact on immune cells, the drug was shown not to interfere with dendritic cell maturation or T-cell activation in vitro. Notably, the drug promoted dendritic cell and, to a lesser extent, T-cell infiltration in vivo, yet failed to sensitize tumor cells to programmed cell death-1 inhibition. Instead, it increased therapeutic efficacy of TCR-redirected T cell and dendritic cell vaccination, jointly increasing overall survival of B16-OVA tumor-bearing mice. The reported data confirm the prospect of methylation-targeted epigenetic reprogramming in melanoma and sustain dual G9a and DNMT inhibition as a strategy to tip the cancer-immune set-point towards responsiveness to active and adoptive vaccination against melanoma.

Keywords: melanoma, cancer vaccination, dendritic cell vaccination, adoptive T cell therapies, epigenetic targeted therapy, histone and DNA methylation/demethylation, histone methyltransferase G9a, DNA methyltransferase (DNMT)

OPEN ACCESS

Edited by:
Irina Apostolou, Sumitomo Dainippon Pharma Oncology, United States

Reviewed by:
Anne-Marie Schmitt-Verhulst, U1104 Centre d'immunologie de Marseille-Luminy (CIML) (INSERM), France
Ying Ma, Tianjin Medical University Cancer Institute and Hospital, China

***Correspondence:**
Karine Breckpot
karine.breckpot@vub.be

†These authors have contributed equally to this work and share last authorship

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *21 October 2021*
Accepted: *28 March 2022*
Published: *12 May 2022*

Citation:
De Beck L, Awad RM, Basso V, Casares N, De Ridder K, De Vlaeminck Y, Gnata A, Goyvaerts C, Lecocq Q, San José-Enériz E, Verhulst S, Maes K, Vanderkerken K, Agirre X, Prosper F, Lasarte JJ, Mondino A and Breckpot K (2022) Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Front. Immunol. 13:799636. doi: 10.3389/fimmu.2022.799636

INTRODUCTION

Melanoma is a malignant skin cancer with an estimated worldwide increase of 57% and 68% in the number of new cases and deaths by 2040, respectively. Despite a four-fold lower incidence compared to non-melanoma skin cancers, melanoma accounts for half of skin cancer-related deaths (1). Conventional therapies include surgery and chemo-radiotherapy, while targeted therapies and immunotherapy represent novel treatment options. Immunotherapy has gained attention owing to the potential of melanoma-specific cytotoxic T cells to kill melanoma cells irrespective of their location while ensuring long-term protection (2). Immune checkpoint blockade has indeed become standard-of-care for melanoma (3, 4), while active (5) and adoptive (6) vaccination have shown promising results in clinical trials. The yet low overall clinical response rates have prompted research on combination strategies.

Epigenetic modifying drugs pledge promising, as epigenetic events shape cell transformation of both cancer cells and cancer-supportive cells within the tumor micro-environment. Aberrations in both histone and DNA methylation patterns, in part due to histone methyltransferase G9a (7, 8) and DNA methyltransferase (DNMT) 1/3b overexpression (9, 10), have indeed been identified in melanoma. G9a promotes gene expression *via* monomethylation of histone 3 on lysine 9 (H3K9me1) (11). G9a together with DNMT1 represses gene expression by dimethylation of histone H3 on lysine 9 (H3K9me2) and DNA cytosine methylation (5mC), respectively (12). Together with *de novo* methylation implemented by DNMT3b, these processes cooperate to govern cellular integrity and to commit cells to a specific expression profile (13). Distinct promotor CpG hypermethylation patterns in melanoma patients have been recently identified to drive tumor immune cell exclusion, thereby linking aberrant methylation patterns to melanoma immune evasion, and as such suggestive of a correlation between prognosis and epigenetic immune regulation (14). The involvement of these epigenetic processes in melanoma initiation and progression renders them valuable targets for combined inhibition in the melanoma context (15–25).

CM-272 is a dual G9a/DNMT inhibitor with proven efficacy in hematological and solid cancer models. The drug inhibited tumor growth while promoting immunogenic cell death and IFN responses (26–28), as such facilitating synergism with programmed death ligand-1 (PD-L1) blockade in a preclinical bladder cancer model (28). This brings forth CM-272 as a prime candidate for combination with immunotherapy in melanoma.

To evaluate the combination of CM-272 with immunotherapy, we exploited the B16-OVA (MO4) melanoma model, which expresses ovalbumin (OVA) as a model antigen (29). This enables the evaluation of tumor/OVA-targeted active and adoptive immunotherapy. This model is representative of BRAF wild-type patients lacking $p16^{Ink4a}$ and $p14^{Arf}$ tumor suppressor proteins (29–33). From an immunological perspective, it also represents the so-called immunotype B patients, existing among both primary and metastatic melanoma patients that have a limited number of tumor-infiltrating lymphocytes, which has been identified as a poor prognostic factor (34–36). This compromised immune set-point manifests in the MO4 model as an inherent resistance to immune checkpoint blockade therapy (37–40). These features render this preclinical model relevant for evaluating more powerful combination strategies.

Abbreviations: 5mC, cytosine methylation; BD, Becton Dickinson; CFSE, carboxyfluorescein diacetate succinimidyl ester; DC, dendritic cell; DNMT, DNA methyltransferase; GSEA, gene set enrichment analysis; H3K9me2, di-methylated lysine 9 on histone H3; m.p.c., mice per condition; NES, normalized enrichment score; OVA, ovalbumin; PD-1, programmed cell death-1; PD-L1, programmed death ligand-1; *q*-value, adjusted *p*-value; SD, standard deviation; SEM, standard error of the mean; s.p.c., samples per condition; TGF-β, transforming growth factor-β; TIL, tumor-infiltrating leukocyte; TP53, tumor suppressor 53.

MATERIALS AND METHODS

Mice, Cell Lines and Primary Cell Culture

Female 6-12 week old C57Bl6J, Crl:NU-Foxn1^{nu} or C57BL/6-Tg$^{(TcraTcrb)1100Mjb/J}$ (OT-I) mice were purchased from Charles River (Saint-Germain-Nuelles, France; Calco, Italy). C57Bl6J mice for programmed cell death-1 (PD-1) blockade therapy were purchased from Harlan (Barcelona, Spain).

Cells were cultured at 37°C under humidified 5% CO_2 atmosphere and tested negative for mycoplasma using VenorGeM Classic and MB Taq Polymerase (Minerva Biolabs, Berlin, Germany). MO4 cells were gifted by Ken Rock (Division of Lymphocyte Biology, Dana Farber Cancer Institute, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts), authenticated by Eurofins Scientific (Luxemburg, Belgium), and cultured in DMEM (Sigma-Aldrich, Overijse, Belgium) supplemented with 10% fetal bovine serum (TICO, Amstelveen, The Netherlands), 2mM L-Glutamine (Sigma-Aldrich), 100U/mL penicillin (Sigma-Aldrich), and 100μg/mL streptomycin (Sigma-Aldrich).

Dendritic cells (DCs) were generated from bone marrow cells of C57Bl6J mice, matured with lipopolysaccharide and pulsed with $OVA_{257-264}$, as previously described (41). Where indicated, CD4+ or CD8+ T cells were isolated from C57Bl6J, OT-I or OT-II TCR transgenic mice. OVA-specificity was inherent to OT-I (OVA-derived SIINFEKL [OVA257-264] in H2-kb) and OT-II (OVA-derived ISQAVHAAHAEINEAGR [OVA323-339] in I-Ab) T cells, or was genetically engineered. For T cell isolation, spleens were isolated and passed through a 40μm cell strainer (Corning, New York, New York) before red blood cells were lysed. Single cell suspensions were subsequently enriched for the $CD8^+$ fraction using negative MACS-selection (from OT-I mice for DC co-culture assays), or for the $CD4^+$ or $CD8^+$ fraction using negative and positive selection (from C57Bl6J, OT-I or OT-II mice for *in vitro* T cell sensitivity assays), according to manufacturer instructions (Miltenyi Biotec, Gladbach, Germany). For *in vitro* experiments on MO4-mediated T-cell stimulation, OVA-specific T cells were genetically engineered. To this end, a retrovirus encoding the OT-I TCR was produced as previously described (42), and used to transduce Concanavalin A/IL-7-activated mouse splenocytes by spin infection in retronectin (Takara)-coated plates (43).

Therapeutic Reagents

CM-272 was developed at Clinica Universidad de Navarra (26), dissolved at 10mM in DMSO (Sigma-Aldrich), and diluted in culture medium (*in vitro)* or 0.9% NaCl infusion solution (*in vivo*) (Baxter, Lessines, Belgium). Combination therapy included: (1) anti-PD-1 (clone RMPI-14) or isotype-matched antibody (BioXcel, New Haven, Connecticut) at 0.5mg/mL in 0.9% NaCl-solution, (2) $1x10^6$ OT-I TCR-engineered or untransduced T cells, (3) $5x10^6$ DCs/mL in phosphate buffered saline (PBS) or PBS (Sigma-Aldrich).

Experimental Set-Up - *In Vivo* Experiments

C57Bl6J mice were subcutaneously injected in the flank with $3x10^5$ MO4 cells in 50µL PBS. Treatment regimen was started on day 3 (unless stated otherwise), as an intraperitoneal CM-272 (5mg/kg)/vehicle injection for 5 consecutive days a week, until 1000 mm^3 tumor volume endpoint was reached. Combination treatment included: (1) 3 intraperitoneal injections of 50µg anti-PD-1/isotype once a week starting from day 1 of treatment cycle 1 (day 7-10); (2) $1x10^6$ OT-I TCR-engineered/untransduced T cells (day 13). Treatment cycle 1 started on day 5; (3) 3-4 intravenous injections of $5x10^5$ DCs/vehicle once a week, starting from day 1 of treatment cycle 1. Tumor volume was measured 3-5 times per week and calculated as: (length x $width^2$)/2, width being the smallest value. The ethical endpoint of the experiment allowed a maximum tumor volume of 1500 mm^3. For evaluation of therapy efficacy, we plotted the time to reach a volume of 1000 mm^3 (experimental endpoint) in a Kaplan-Meier curve, using an algorithm build on the following criteria. If on the day of monitoring the tumor volume reached 1000 ± 50 mm^3, this day was plotted as experimental endpoint (criterium a). If (a) was not met, the day at which the tumor volume reached a volume closest to 1000 ± 150 mm^3 was used (criterium b). If (b) was never met, the first day at which the tumor volume exceeded 1150 mm^3 was used (criterium c). In case tumor volumes remained <850 mm^3, mice were censored, i.e., scored as 'alive' (criterium d). Censoring was required when mice had to be taken out of the experiment for ethical reasons, e.g., ulcers of tumors combined with physical signs of declined health status. Outlier removal analysis was subsequently performed. The time to reach 1000 mm^3 was plotted until the last mouse in the vehicle group reached this endpoint. With regard to tumor growth curves, mean tumor volume in time was plotted for each experimental group, until the first mouse of the concerning group had reached the experimental endpoint tumor volume.

For *ex vivo* tumor tissue analysis, tumors were processed to single cell suspensions either by application of the GentleMACS isolation protocol (Miltenyi Biotec) in case of downstream flow cytometry (at experimental endpoint), or by immediate lyses in case of downstream multiplex analysis (at 706.9 ± 194.8 mm^3).

Experimental Set-Up - *In Vitro* Sensitivity MO4 Cells

Quantification of epigenetic marks was performed as previously described (28), upon 48 hours (H3K9me2) or 5 days (5mC) exposure to 1.9µM CM-272. Furthermore, $1x10^4$ MO4 cells were exposed to 0.05-1µM CM-272 in 200µL in a flat-bottom 96-well plate (Sarstedt, Nümbrecht, Germany). Confluence, cytotoxicity and apoptosis were monitored with the IncuCyte Zoom (Essen BioScience, Welwyn Garden City, UK), and the number of viable cells was determined with CellTiter-Glo, as instructed (Promega, Leiden, The Netherlands). IC50 value was determined based on four-parameter nonlinear regression of vehicle-normalized CellTiter-Glo data. Concerning RNA sequencing and validation, $5x10^5$ MO4 cells were exposed to 0.05-1µM CM-272 in 5mL in a 6-well plate (Corning) for indicated timeframe. Cells were harvested for flow cytometry, snap-frozen awaiting western blot analysis, or processed for RNA sequencing.

Experimental Set-Up - *In Vitro* Sensitivity T Cells

Purified $CD4^+$/$CD8^+$ or OT-I/-II T cells were labelled with carboxyfluorescein diacetate succinimidyl ester (CFSE) (Becton Dickinson [BD], Franklin Lakes, New Jersey) and stimulated with 0.5µg/mL plate-coated anti-CD3 (clone 145-2C11; Biolegend, San Diego, California) and 1µg/mL soluble anti-CD28 (clone 37.51; Biolegend), or 10µg/mL OVA-derived peptides (AnaSpec, Fremont, California) for 3 days, respectively. Non-mitogenic IL-7 (5ng/mL) served as a negative control (PeproTech, Cranbury, New Jersey). T cells were treated with 0.125-1µM CM-272. Cells were collected for flow cytometry at 72 hours and IFN-γ was measured in culture supernatants at 48 hours. MO4 cells were co-cultured for 48 hours with OT-I TCR-engineered T cells at 1:2 effector/target ratio, while exposed to 0.125-0.5µM CM-272, before IFN-γ measurement.

Experimental Set-Up - *In Vitro* Sensitivity DCs

$5x10^5$ DCs were exposed to 0.05-1µM CM-272 for 24 hours in a 48-well plate in 500µL complete RPMI-1640 (Sigma-Aldrich) and cultured for an additional 24 hours with/without 1µg/mL lipopolysaccharide (E. coli serotype O55:B5; Sigma-Aldrich). DCs were collected for flow cytometry and IL-12p70 was measured in culture supernatants. DCs pulsed with 10µg/mL $OVA_{257-264}$ were co-cultured at 1:10 ratio with OT-I T cells for 72 hours before IFN-γ measurement. Unstimulated and CD3/CD28-stimulated (ThermoFisher, Waltham, Massachusetts) T cells served as negative and positive controls, respectively.

RNA Extraction From MO4 Cells or *Ex Vivo* Tumor Tissue

Upon cell harvesting, cell integrity was evaluated using cell cycle analysis and sub-G1-phase quantification. MO4 cells in the sub-G1 phase amounted to 1.78% (± 0.67 SD) and 6.92% (± 2.32 SD) in vehicle and CM-272 treatment conditions, respectively. RNA was extracted from *in vitro* treated MO4 cells or *ex vivo* tumor tissue using the RNeasy plus mini kit, according to manufacturer instructions (Qiagen, Hilden, Germany). RNA quality control was based on the RNA integrity number score and DV200 score as determined on the 2100 Bioanalyzer (Agilent, Santa Clara,

California). The RNA integrity number ranged from 8.7 to 7.1 and the DV200 score from 90 to 95%, indicating that the RNA was of sufficient (undegraded) quality to perform RNA sequencing on. Concentration was determined using Qubit RNA HS Assay (Invitrogen, Carlsbad, California). RNA was subsequently used for RNA sequencing (*in vitro* MO4 cells) or multiplex analysis (*ex vivo* tumor tissue).

RNA Sequencing Analysis on MO4 Cells

MO4 cells were treated for 24 hours with 1μM CM-272 or vehicle, and further processed as to extract the RNA. 150ng RNA per condition was used to construct an RNA library upon ribosomal RNA depletion using the KAPA Ribo Erase (HMR) kit (Kapa Biosystems, Basel, Switzerland), followed by sequencing on the Illumnia NovaSeq 6000 (Illumnia, San Diego, California). Gene expression counts were generated upon read alignment against the mus musculus reference genome version GRCm38-83 using STAR software (44), and subsequent analysis using HTSeq script in Python (45). Normalized gene expression counts and $\log_2$-fold change of gene expression were generated using DESeq2 script in R. Genes, as calculated by DESeq2 on single-gene level, in compliance with *p*-value <0.0005, *q*-value <0.002, and $|\log_2$-fold change$|$ >1 were listed (**Supplementary Table 1**). Principal component analysis plot comparing vehicle and CM-272 samples was provided (**Supplementary Figure 1C**). Normalized counts from DESeq2 analysis were subjected to gene set enrichment analysis (GSEA) making use of GSEA v4.1.0 software and the Canonical Pathways (KEGG, PID, REACTOME and WikiPathways) gene set collections from the Molecular Signatures Database, as previously described (46–48). As such, gene sets were pre-filtered to a minimum of 15 and maximum of 500 number of genes, rendering 1776 gene sets (composed of 17870 gene markers) out of 2523 to be evaluated. Using 17870 gene markers for the CM-272 versus vehicle comparison, 1255 and 521 gene sets were identified as up- or downregulated in CM-272 condition, respectively. Significantly changed gene sets were defined as nominal p-value <0.005, *q*-value <0.1, |Normalized Enrichment Score (NES)| >1 (**Supplementary Table 2**). Results from **Supplementary Table 2** were visually presented using the EnrichmentMap Cytoscape application, as previously described (**Figure 1B**) (49).

Multiplex Analysis on *Ex Vivo* Tumor Tissue

Tumors were resected from 6 mice (total 12) treated with CM-272 or vehicle, and further processed as to extract the RNA. RNA of each individual tumor was then analyzed with the nCounter PanCancer Mouse Immune Profiling Panel on the nCounter MAX Analysis System (Nanostring, Seattle, Washington). Quality control was performed using nSolver software. Expression counts (transcripts per million) were normalized making use of the Nanostring analysis-adjusted RuvSeq method (50). Principal component analysis plot comparing vehicle and CM-272 samples was provided (**Supplementary Figure 3A**). Normalized counts were subjected to GSEA, using Canonical Pathways (BIOCARTA, KEGG, PID, REACTOME and WikiPathways) gene set collections, as previously described (46–48). As such, gene sets were pre-filtered to a minimum of 15 and maximum of 500 number of genes, rendering 106 gene sets out of 2871 to be analyzed. Using 359 gene markers for the CM-272 versus vehicle comparison, 70 and 36 gene sets were identified as up- or downregulated in CM-272 condition, respectively. Significantly changed gene sets were defined as nominal *p*-value <0.005; FDR-value <0.1; |NES| >1 (**Supplementary Table 3**) and visualized using the EnrichmentMap Cytoscape application (**Figure 4D**). Tumor-infiltrating leukocyte (TIL)-scoring was performed in R as previously described (51), using cell type specific marker genes as specified by the PanCancer Mouse Immune Profiling Panel (Nanostring). Briefly, cell scores were calculated as the mean of $\log_2$-normalized gene expression value of all marker genes. Total TIL score per sample were calculated as the mean of all cell scores whose correlation with CD45 exceeded 0.6. Cell type enrichment score was calculated as the residual from the linear regression curve simulating cell score from total TIL score, combining all samples data for each cell type separately.

IncuCyte Zoom Live Cell Imaging

The IncuCyte Zoom live cell imaging device was used to monitor cell confluence, cytotoxicity - 1:800 dilution of Incucyte Cytotox Red Dye (Sartorius, Göttingen, Germany), and expression of caspase-3/7 – 1:1500 dilution of Incucyte Caspase-3/7 Dye, according to manufacturer instructions (Sartorius).

ELISA

Supernatant was collected from cell culture of DCs, T cells, DC/T cell co-cultures, or MO4/T cell co-cultures at indicated time-points. IL-12p70 and IFN-γ levels were measured according to manufacturer instructions (Invitrogen, BD Pharmingen).

Flow Cytometry

Antibody staining was performed in 0.02% sodium azide/1% PBS supplemented with bovine serum albumin (prepared in-house), unless stated otherwise, for 1 hour at 4°C. Cells were acquired on the LSR Fortessa/Canto (BD) and data was analyzed with FlowJo v10 software (BD). Forward- and side-scatter properties were used to gate-out debris and aggregating cells before viable cells were selected using a viability dye. Cell cycle analysis included dead cells. MO4 cells were analyzed for: (1) cell cycle distribution: $3x10^5$ cells in 500μL PBS were fixated by addition to 4,5mL of a -20°C pre-cooled 70% Ethanol solution while vortexing. After 2 hours of incubation at -20°C, cells were washed twice and rehydrated for 15 minutes in PBS. DNA was stained by 10 minutes incubation with 200μL propidium iodide solution: 1 mg/mL sodium nitrate (Merck KGaA, Darmstadt, Germany), 0.1% Triton-X (Merck), 100 μg/mL RNase A (Boehringer, Ingelheim, Germany), and 50 μg/mL propidium iodide (Sigma-Aldrich). Gating strategy was provided (**Supplementary Figure 1F**). (2) Expression of SIINFEKL/H-$2K^b$ (phycoerythrin [PE], clone eBio25-D1.16; eBioscience, San Diego, California) and PD-L1 (brilliant violet 421 [BV421], clone MIH5; Novus, Centennial, Colorado). The DC phenotype was analyzed based on surface expression of: CD11c (peridinin chlorophyll protein cyanine 5.5 [PerCP-Cy5.5], clone N418; Biolegend), CD40 (PE-cyanine 7 [PE-Cy7], clone 3.23; Biolegend), CD80 (BV421,



FIGURE 1 | Dual G9a and DNMT inhibition shapes the transcriptional profile of melanoma cells, impacting on cell cycle progression and immunogenicity. **(A)** H3K9me2- and 5mC-levels upon 1.9μM CM-272 treatment (2 or 5 days respectively), relative to vehicle-treated cells (mean ± SD; *n*=3/4). **(B, C)** Gene expression changes in MO4 cells upon treatment with 1μM CM-272 for 24 hours (*n*=1, 2 s.p.c.). The percentage of cells with fractionated DNA (sub-G1-phase, indicative of cell death) amounted to 1.78 ± 0.67 and 6.92 ± 2.32 (SD) in vehicle and CM-272 treated conditions, respectively. **(B)** Graphical representation of GSEA on gene expression changes in MO4 cells. **(C)** Enrichment plot of a gene set involving epigenetic regulation of gene expression. Heatmap lists row-normalized gene expression of leading-edge genes. Vehicle and CM-272 conditions were compared using unpaired two-tailed student *t*-test **(A)**. Asterisks indicate statistical significance: **p ≤ 0.01; ****p ≤ 0.0001.

clone 16-1OA1; BD), CD86 (fluorescein isothiocyanate [FITC], clone GL1; BD), I-A/I-E [I-A^d] (allophycocyanin [APC], clone M5.114.15.2; Biolegend). Gating strategy was provided (**Supplementary Figure 4A**). *Ex vivo* tumor T-cell infiltrate of vehicle or CM-272-treated mice was analyzed based on: 7-AAD (Biolegend), PD-1 (PE, clone J43; BD), CD8a (Pacific Blue, clone 53-6.7; BD), CD4 (Alexa Fluor 700 [AF700], clone RM4-5; BD), CD3e (PE-Cy7, clone 17A2; Biolegend), CD45.2 (APC-eFluor 780 [APC-eFluor 780], clone 104; Invitrogen). *Ex vivo* tumor T-cell infiltrate of DC vaccine alone or DC vaccine and CM-272-treated mice was analyzed based on: Fixable viability dye eFluor506 (eBioscience), PD-1 (PE-Cy7, clone J43; Invitrogen), CD8a (Horizon v450, clone 53-6.7; BD), CD4 (alexa fluor 700 [AF700], clone RM4-5; BD), CD3e (PerCP-Cy5.5, clone 145-2C11; BD), CD45.2 (APC-cyanin 7 [APC-Cy7], clone 104; BD). For *ex vivo* tumor tissue analysis, cells were pre-stained with anti-CD16/32 (unconjugated, clone 93; Biolegend) and samples were fixed with Cytofix/cytoperm (BD), according to manufacturer instructions. Gating strategy was provided (**Supplementary Figure 4F**). T-cell proliferation was measured based on CFSE dilution in viable $CD4^+$ or $CD8^+$ T cells.

Western Blot

Western blot-mediated quantification of epigenetic marks was performed as previously described (28). For the detection of p21 protein, MO4 cells were lysed in 400µL buffer (5% ß-mercaptoethanol laemmli buffer; prepared in-house) and boiled at 95°C for 10 minutes. 20µg of protein was size-separated on a SDS-PAGE gel next to size-reference (PageRuler; ThermoFisher) and transferred to a nitrocellulose membrane (Amersham, Little Chalfont, United Kingdom). The membrane was blocked in 5% low-fat milk TTBS (prepared in-house) before overnight incubation at 4°C with 5mL of 1:500 rabbit polyclonal IgG $p21^{Waf1/Cip1}$ (clone C-19; SantaCruz, Dallas, Texas) or 1:1000 rabbit polyclonal ß-actin (Cell Signaling, Danvers, Massachusetts). Blots were incubated for 1 hour at room temperature with anti-rabbit horseradish peroxidase-linked IgG (Cell signaling). Proteins were detected using WesternBright chemiluminescent reagent (Advansta, San Jose, California), visualized on the Odyssey FC (LI-COR, Lincoln, Nebraska), and quantified relative to background making use of Image Studio Lite software (LI-COR).

Statistical Analysis

Statistical analysis was performed using GraphPad Prism v9.1.0 or RStudio v1.3.1093. Outliers were selected using ROUT method at 0.1% (*in vivo*) or 1% (*in vitro/ex vivo*). Normality was tested using Shapiro-Wilk test. Sample sizes ≤ 4 were tested assuming normality. Asterisks or symbols indicate statistical significance: * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$; **** $p \leq 0.0001$. Only significant differences were indicated in graphs. Statistical tests, sample sizes (mice per condition [m.p.c.] or samples per condition [s.p.c.]), data variability (standard deviation [SD] or standard error of the mean [SEM]), and number of repeats (n) were indicated in figure legends.

RESULTS

Dual G9a and DNMT Inhibition Results in Melanoma Cell Cycle Arrest and Cell Death

To study melanoma-intrinsic CM-272 effects, MO4 cells were first exposed to the drug *in vitro*. H3K9me2- and 5mC-levels were significantly reduced upon treatment, suggesting G9a and DNMT1 to be active in MO4 tumors and inhibitable by CM-272 (**Figure 1A**). Also, cell number and viability were significantly reduced by CM-272 doses above 0.25µM, reaching IC50 at 0.3844µM after exposure for 72 hours (**Supplementary Figures 1A, B**). These data show that MO4 cells are sensitive to epigenetic modulation by CM-272 *in vitro*.

To gain further insights and study transcriptional consequences, MO4 cells were treated for 24 hours with 1µM CM-272 and subjected to RNA sequencing. A total number of 1595 and 823 genes were identified as significantly up- or downregulated respectively in CM-272-treated MO4 cells, at single-gene level (**Supplementary Table 1**). Since the net consequence of single-gene expression changes in big data is generally considered difficult to assess, we made use of the GSEA method to evaluate net effect on pre-established signaling pathways (further referred to as 'gene sets'). Significantly changed gene sets with associated gene set enrichment score and significance were listed in **Supplementary Table 2**. In addition, we visually represented significantly changed gene sets using the EnrichmentMap Cytoscape application (**Figure 1B**). Each significantly changed gene set is presented as a node, whose size and color indicated the number of associated genes and the associated enrichment score. Edges between nodes indicate gene overlap and overlap size. Biologically associated nodes are visually grouped and annotated with an appropriate term, indicating various biological processes. Finally, biological processes are also visually grouped according to whether they pertained to cell metabolism, immune response, or other biological pathways. Some relevant gene sets were further disclosed, showing normalized gene expression of leading-edge genes (**Figure 1C**) or of the top 20 up- and down-regulated genes (**Supplementary Figures 1D, E**). GSEA identified 218 and 100 gene sets as significantly down- or upregulated respectively in CM-272-treated MO4 cells (**Figure 1B** and **Supplementary Table 2**). Among the downregulated gene sets, those pertaining to cell metabolism, particularly cell cycle regulation, were most represented. In addition, CM-272 downregulated gene sets critical for cell functioning, such as mRNA processing, translation and degradation; the DNA damage response; protein SUMOylation; and epigenetic regulation, including DNMT1/3 (*dnmt1/3*) and G9a (*ehmt2*). (**Figure 1C**). Also, gene sets involving tumor suppressor 53 (TP53) regulation were downregulated, apart from one upregulated gene set, pointing toward cyclin-dependent kinase inhibitor protein p21 (*cdkn1a*)-induced cell cycle arrest and apoptosis (**Figure 1B**; **Supplementary Figure 1D**). GSEA also identified upregulation of gene sets linked to carcinogenesis (TP53 regulation, neural cell adhesion molecule signaling and extracellular matrix metabolism) and immune responses (antigen presentation, complement system, inflammatory response through IL-10 signaling, and IL-4/12/13/23/27, IFN-I/II, transforming growth factor-β [TGF-β] and toll-like receptor signaling) (**Figure 1B** and **Supplementary Figure 1E**).

Next, we validated selected pathways possibly causing acute cytostatic or cytotoxic events. Using flow cytometry, CM-272 was shown to cause cells to arrest in the G1-phase of cell cycle by 24 hours of treatment in a dose-dependent manner (**Figure 2A**), and the accumulation of sub-G1 cells, representative of apoptotic cells with fractionated DNA, by 48 and 72 hours (**Figure 2B** and **Supplementary Figure 1G**) (52). At transcriptional level, the upregulation of cyclin D1 (*ccnd1*) at 24 hours accompanied the G1-arrest (**Supplementary Table 1**), along with that of *cdkn1a* (**Supplementary Table 1**) and concomitant accumulation of p21 (**Figure 2C** and **Supplementary Figure 1H**). These events were concomitant to a rise in cytotoxicity and caspase-3/7 activation, significantly detected at 1-2µM CM-272 (**Figures 2D, E**). These results suggest that CM-272-treated MO4 cells undergo cell cycle arrest followed by cell death. Notably, the finding that CM-272 concomitantly reduced cell growth while causing an upregulation of immune-related gene sets suggested that CM-272-treated



FIGURE 2 | Dual G9a and DNMT inhibition causes MO4 cell cycle arrest and cell death. **(A, B)** Percentage of MO4 cells in cell cycle phases (mean ± SD; *n* = 4). Asterisks represent significant differences in **(A)** G1-phase at 24 hours or **(B)** sub-G1-phase at 48 hours. **(C)** p21 protein expression and ß-actin loading control (representative blot; *n* = 3). **(D, E)** Cell death induction: **(D)** Loss of cell membrane integrity and **(E)** caspase-3/7 activity in time (mean ± SD; *n* = 3). Vehicle and CM-272 conditions were compared using ordinary one-way Anova and *post-hoc* Dunnett's multiple comparison tests **(A, B)** or REML modeling with Geisser-Greenhouse correction and *post-hoc* Sidak multiple comparison test **(D, E)**. Asterisks indicate statistical significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

tumors *in vivo* might develop a different sensitivity to immune recognition.

Dual G9a and DNMT Inhibition Favors Tumor Cell Recognition by Tumor-Specific T Cells *In Vitro*

To address effects on tumor/T-cell recognition, we first investigated if CM-272 promoted MO4 antigen presentation. SIINFEKL/H-2K^b complexes were found to be upregulated by CM-272 in a dose-dependent manner (**Figure 3A**). Notably, CM-272 also increased PD-L1 expression (**Figure 3B**), questioning net effects on T-cell activation.

We also investigated putative T-cell intrinsic effects of CM-272. T-cell expansion to polyclonal (**Figure 3C**; **Supplementary Figure 1I**) and antigen-driven (**Figure 3D**) stimulation as well as IFN-γ production (**Figure 3E**) were comparable in the absence or presence of CM-272. In addition, in MO4 and OVA-specific TCR-engineered T cell co-cultures, IFN-γ production (**Figure 3F**) was significantly increased upon CM-272 exposure. These results indicate that CM-272 promotes tumor/T cell recognition.

Dual G9a and DNMT Inhibition Transiently Delays Melanoma Growth in Immune-Competent Mice

CM-272's therapeutic activity was evaluated in immune-competent and -deficient mice bearing subcutaneous MO4 tumors. CM-272 or vehicle were injected intraperitoneally starting at day 3, and tumor growth was monitored in time (**Figure 4A**, treatment scheme). Of note, MO4 tumors developed faster in immune-deficient mice compared to immune-competent ones (**Figure 4B** and **Supplementary Figure 2A**). CM-272 delayed tumor growth only in immune-competent mice and only transiently. Indeed, effects were most evident at day 12 (**Figure 4C**) and omitted to significantly impact survival (data not shown). As the tumor delay effect of CM-272 *in vivo* was prone to variability (50% efficacy across 6 independent experiments, conducted at independent sites), further investigation into transcriptional reprogramming by CM-272 *in vivo* was deemed necessary. By extension thereof, these data support the possibility that, in context of melanoma, CM-272 exerts anti-tumor activity mainly *via* immune-mediated mechanisms.

To address this, we performed multiplex gene expression analysis on MO4 tumors from immune-competent mice to study the tumor immune-contexture. CM-272 upregulated toll-like receptor and IFN-I signaling, as identified by GSEA (**Figure 4D**). Although this corroborated *in vitro* findings on CM-272's ability to fuel immune-signaling, at present we cannot discriminate whether *in vivo* effects are due only to tumor-intrinsic effects or also to effects on other tumor-infiltrating/resident cells. Enrichment of a TCR-signaling gene set was also observed, potentially reflecting the upward trend in (CD8$^+$) T-cell representation (including cytotoxic and exhausted T cells as well as T helper 1 cells) and the downward trend in regulatory T cells, as identified by TIL-scoring (**Supplementary Figures 3B–D**). Although the CD8$^+$ T cell/regulatory T cell ratio remained unchanged, DCs were significantly increased within CM-272-



FIGURE 3 | Dual G9a and DNMT inhibition favors tumor cell recognition by tumor-specific T cells in vitro. **(A, B)** MO4 cell surface presentation of **(A)** SIINFEKL/H2-K^b or **(B)** PD-L1 after CM-272 treatment for 24 hours (mean ± SD; *n* = 4). **(C, D)** T-cell proliferation upon 72 hours of polyclonal (anti-CD3/CD28) or peptide (SIINFEKL/ISQAVH) stimulation of **(C)** $CD4^+$ and $CD8^+$ T cells or **(D)** OT-I and OT-II T cells, respectively, in the presence or not of CM-272 (representative histograms; *n*=4 [B]/*n*=2 [C]). **(E, F)** IFN-γ production upon 48 hours of **(E)** polyclonal stimulation of T cells (mean ± SD; *n* = 2, total 4 s.p.c.) or **(F)** MO4-mediated stimulation of (un)transduced T cells (mean ± SD; *n*=2/3). Vehicle and CM-272 conditions were compared using ordinary one-way Anova and *post-hoc* Dunnett's multiple comparison test (A,B,F). Asterisks indicate statistical significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

treated tumors (**Figure 4E**). These data support CM-272-driven immunomodulation *in vivo*.

Dual G9a and DNMT Inhibition Promotes the Therapeutic Efficacy of DC Vaccination

Given that CM-272 impacts on antigenicity (SIINFEKL/H-$2K^b$ complexes, **Figure 3A**) and immunogenicity (PD-L1, **Figure 3B**) *in vitro*, and on the immune-contexture *in vivo* (**Figures 4D, E**), we investigated possible cooperation with various immunotherapy strategies. We studied the combination of CM-272 with PD-1 blockade therapy (2.5mg/kg intraperitoneal, on day 7, 14 and 21), which we reasoned could counteract CM-272-induced PD-L1 upregulation and thereby ameliorate the narrow therapeutic window for PD-1/PD-L1 blockade in melanoma subsets (37–39, 53). However, no benefit was observed as PD-1 blockade failed to delay tumor growth when administered alone and in combination with CM-272 (**Figure 4F** and **Supplementary Figure 2B**).

We then reasoned that T-cell representation might be insufficient and therefore tested the combination with adoptive T-cell therapy in the form of SIINFEKL-specific TCR-engineered T cells (**Figure 5A**, treatment scheme). Provision of T cells improved the therapeutic effects of CM-272, allowing the survival of 69.2% of mice at the time all vehicle controls reached endpoint (survival proportion 0%) (**Figure 5B**). Yet, the combination of CM-272 and T-cell therapy was not sufficient for durable responses.

We thus reasoned that T-cell priming might be a limiting factor. We therefore investigated active DC-mediated vaccination as to better instigate tumor-directed $CD8^+$ T-cell responses *in vivo*. DCs of bone marrow origin were matured with lipopolysaccharide and pulsed with SIINFEKL. Lipopolysaccharide-matured DCs expressed CD40, CD80 and CD86 co-stimulatory molecules (**Supplementary Figures 4A–C**) and secreted IL-12p70 (**Supplementary Figure 4D**) to comparable extent in the absence or the presence of CM-272. Likewise, mature DCs induced comparable IFN-γ secretion by SIINFEKL-specific $CD8^+$ T cells (**Supplementary Figure 4E**). *In vivo*, DC vaccination delayed tumor growth compared to vehicle- and CM-272-only treatments (**Figure 5C**). Adding CM-272 to DC vaccination further increased tumor growth control. This was best found on day 10, 13, 17, and 18 (**Figures 5C, D**). Flow cytometry analysis of the tumor at end-stage confirmed that DC vaccination caused tumor infiltration by both $CD4^+$ and $CD8^+$ T cells, which remained unchanged in combination with CM-272 (**Figure 5E**). A significant fraction of T cells upregulated PD-1, indicative of acute tumor recognition (**Figure 5F**). The combination of CM-272 and DC vaccination best promoted mouse survival, with 100% of treated mice being alive at the time all vehicle mice had reached endpoint (survival proportion 22.5%), compared to 63.5% upon DC vaccination only (**Figure 5G**). These data indicate that the dual G9a and DNMT inhibitor CM-272 promotes the therapeutic effect of cancer vaccination against melanoma.

DISCUSSION

We report that the dual G9a and DNMT inhibitor CM-272 can be used in combination with adoptive T cell therapy and active



FIGURE 4 | Dual G9a and DNMT inhibition transiently delays MO4 tumor growth in immune-competent mice. **(A, C)** CM-272 therapy in immune-deficient (NUDE) and -competent (C57Bl6J) MO4-bearing mice. **(A)** Schematic representation of treatment regimen (n=1, 11 m.p.c.). **(B, C)** Tumor volume in time (mean ± SEM [B]/ mean ± SD [C]). **(D, E)** Multiplex tumor analysis (706.9 ± 193.8 mm^3; n=1, 12 m.p.c.). **(D)** Graphical representation of GSEA. **(E)** TIL-scoring (10-90 percentile Box&Whiskers). **(F)** Mice survival (Kaplan-Meier curve) upon CM-272 combination with PD-1 blockade (aPD-1; n=1, 6-8 m.p.c.). Vehicle and CM-272 conditions were compared using REML modeling and *post-hoc* Sidak multiple comparison test **(B)**; unpaired one-tailed student t-test with Welsh correction or Mann-Whitney test **(C)**; Wilcoxon rank sum test **(E)**; Log-rank test **(F)**. Asterisks indicate statistical significance: *p ≤ 0.05; **p ≤ 0.01.

cancer vaccination against melanoma. The data support the notion that both tumor cell-intrinsic and -extrinsic events shape *in vivo* responses to such combination therapies, and that counteractive effects might be concomitantly induced, possibly hindering full efficacy of such combined strategies.

In vitro, CM-272 caused MO4 cell cycle arrest and cell death. This corroborates recent findings that correlated G9a- and DNMT1-activity to melanoma cell proliferation (7–9). Also, restoring wild-type TP53 transcriptional activity, or at least tipping the balance away from oncogenic mutant isoforms, has been receiving attention as a means to tackle melanoma cell proliferation and therapy resistance (54). Our results advocate for epigenetic regulation of isoform expression, as CM-272 induced TP53 signaling toward p21-mediated cell cycle arrest and apoptosis. Though p21 effects are ambiguous, it is considered to mediate G1 arrest at high concentrations (55). This substantiates the anti-proliferative effect of CM-272 on MO4 cells. Notably, p21 upregulation has been shown to sensitize melanoma cells to T-cell cytotoxicity (56). Accordingly, we found improved recognition of CM-272-treated tumors by T cells *in vitro*.

We also found evidence of CM-272 having immune-modulatory consequences both *in vitro* and within the TME *in vivo*, suggesting that it might help shifting the cancer-immune set-point beyond the activation threshold (57). Indeed, in transcriptomic analyses we found that CM-272 induced the upregulation of several gene sets related to immune responses, including toll-like receptor and IFN-I signaling. We appreciate that IFN-I signaling could be due to MYD88 signaling resulting from epigenetic re-expression of retroviral elements or from the response to genetic material from dying cells (58), and operates



FIGURE 5 | DC vaccination best cooperates with dual G9a and DNMT inhibition in prolonging mouse survival. **(A–G)** CM-272 combination therapy with **(B)** adoptive T-cell therapy (n = 3, total 7-14 m.p.c.) or **(C–G)** DC vaccination (n = 2, total 12 m.p.c.). **(A)** Treatment regimen. **(B, G)** Survival (Kaplan-Meier curve) upon CM-272 combination with **(B)** T-cell therapy or **(G)** DC vaccination. **(C, D)** Tumor volume in time (mean ± SEM [C]/mean ± SD [D]). **(E, F)** Tumor-contexture upon CM-272 combination with DC vaccination (n = 1, 4-8 m.p.c.). **(E)** $CD4^+/CD8^+$ T-cell abundance. **(F)** PD-1 expression on $CD4^+/CD8^+$ T cells. Vehicle and experimental conditions were compared using Log-rank test (B,G); REML modeling with Geisser-Greenhouse correction and *post-hoc* Sidak multiple comparison test **(C)**; unpaired one-tailed student t-test or Mann-Whitney test **(D)**; ordinary one-way Anova and *post-hoc* Tukey's multiple comparison test **(E, F)**. Asterisks indicate statistical significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. Statistical significance of panel C is supplemented in **Table S4**.

as a bridge between innate and adaptive anti-tumor immunity. IFN-I has been previously shown to promote DC maturation and IL-12p70 production, instruct the local release of chemo-attractants for monocyte and lymphocyte recruitment, and induce antigen and co-stimulatory ligand expression, as such facilitating T cell reactivation and tumor recognition (59–62). Although not all transcriptional changes defined *in vitro* were validated in explanted tumors, we appreciate that they could all participate in establishing a more favorable immune contexture *in vivo*. Accordingly, CM-272 caused DC enrichment in the tumor, thus supporting the promise for synergistic activity in combination with immunotherapy. Nevertheless, it should be noted that CM-272 also caused PD-L1 upregulation on tumor cells, a known IFN-I feedback mechanism protecting tumors from IFN-mediated toxicity (63). In addition, tolerogenic signals including IL-10 (64) and TGF-β (65) were also upregulated by

CM-272. GSEA thus identified CM-272's epigenetic reprogramming as a putative *in vivo* double-edged sword. We believe that such dual activity is consistent with the transient therapeutic effects reported *in vivo*. The fact that CM-272 depends on an intact immune system to exert an anti-tumor effect suggests that the direct tumor inhibition observed *in vitro* is not as prominent *in vivo*. This may be due to insufficient drug penetration into the tumor site *in vivo* to confer direct tumor-cell intrinsic cytotoxic effects. Ensuing this notion, suboptimal CM-272 tumor-cell intrinsic effects *in vivo* could also explain its failure to confer a significant survival improvement when provided as a single agent. Regardless, *in vivo* tumor transcriptional changes upon CM-272 treatment suggest the drug to be active at the tumor site, and able to instigate a signaling cascade toward immune activation. In line with our statement above, we contend that the reported results reflect some tumor cells being affected by CM-272 *in vivo*, e.g., by cell death induction or cellular stress as observed *in vitro*, and this to be sufficient to initiate transcriptional events reflective of reprogramming of the tumor microenvironment and of immune-mediated destruction.

Since PD-L1 levels were augmented by CM-272, and DC influx and TCR-signaling (local T-cell activity) were induced by CM-272 *in vivo* administration, we first tested possible synergy with PD-1 blockade therapy. The decision to target PD-1 rather than PD-L1 was based on previous published results. Indeed, a meta-analysis of melanoma patients treated with PD-1 or PD-L1 blockade reported a 37% response rate in former compared to 16% in the latter (66). In addition, while anti-PD-1/PD-L1 blocking antibodies were proven similarly efficacious in B16 melanoma-bearing mice, even at elevated PD-L1 levels (37), the potency of anti-PD-L1 and not that of anti-PD-1 was found to decline with age in the B16 model (67). Thus, both for putative translational purposes and to avoid confounding effects, the synergy with anti-PD-1 was first investigated. We found that CM-272 failed to sensitize MO4 tumors to PD-1 blockade. This contradicts the successful combination of anti-PD-L1/CM-272 in a bladder cancer model (28) and of anti-PD-1/UNC0642 (G9a inhibitor) in the parental B16F10 model (68), as well as other preclinical reports on G9a or DNMT inhibition across different tumor models (8, 69, 70), and yet can be explained by diverse immune contextures or pharmacokinetics of epigenetic remodeling. In agreement with our findings, clinical trials have reported on a significant patient subgroup that does not respond to such combined treatments. While phase I/II clinical trials in melanoma patients testing DNMTi's in combination with anti-CTLA-4 or anti-PD-1 mAbs are still ongoing (71), a phase II trial in acute myeloid leukemia reported on the combination of the DNMTi Azacitidine and PD-1 inhibitor Nivolumab. Here, despite an encouraging overall response rate of 33%, low pre-therapy tumor infiltration by T cells remained a limiting factor for therapeutic response (72). Still, we acknowledge that implementation of PD-1 blockade, albeit increased PD-L1 expression upon CM-272 treatment, could be subject to discussion. As stated before, the decision to target PD-1 was made to avoid confounding effects in the B16 model as well as for translational purposes, based on previous published results (37, 66, 67). Notwithstanding the grounds for testing PD-1 blockade, future studies might address the blockade of PD-L1 or of other immune checkpoints when of relevance. Also, using anti-PD-L1 as a single agent or in combination with anti-PD-1 might further improve therapeutic efficacy of the combined vaccination treatment. Future studies are needed to address this possibility.

On these grounds, and with the aim of promoting T-cell responses, we moved to adoptive T-cell therapy and active vaccination. Adoptive T-cell therapy showed capable of some cooperative effects in the MO4 model. Indeed, the combination of CM-272 and TCR-redirected T cells promoted longer survival in a significant fraction of tumor-bearing mice, although tumors eventually escaped control. Cooperative activity could be explained by the ability of CM-272 to promote direct peptide/MHC-complex presentation, rendering melanoma cells better targets for adoptively transferred effector T cells (73). Pursuant to this, we reasoned that CM-272-induced sustained IFN-I/II signaling and/or factors like IL-10 and TGF-β could indeed hinder tumor antigen presentation by tumor-resident DCs, thereby restraining successful combination therapy of CM-272 and PD-1 inhibition (60, 74–81). We also found *cd209* expression to be increased by CM-272, potentially reflecting monocyte-derived DCs, known to have paradoxical effects on T-cell responses (82). Directly improving *in situ* tumor antigen presentation by DCs should thus enable the generation of a successful anti-tumor T-cell response if indeed it is the limiting factor. To test this, we vaccinated mice with antigen-loaded mature DCs, known to promote protective immunity in preclinical models and clinical trials (38, 83). Combining CM-272 with DC vaccination prolonged tumor growth control and increased survival compared to individual therapies to extents that surmised those evoked by the combination of adoptive T-cell therapy and CM-272. We attribute this to the ability of mature DCs to express co-stimulatory ligands and to secrete IL-12p70, key for cytotoxic T-cell induction (84), and local reactivation of T cells combined with the cytotoxic and immune-shaping support from CM-272.

Thus, our work extends previous *in vitro* reports on increased melanoma antigenicity upon methylation-targeted epigenetic treatment in cancer vaccination context (73, 85) and underlines epigenetic reprogramming as a strategy to tip the cancer-immune set-point toward responsiveness to immunotherapeutic strategies. We expect additional studies to stem from this proof-of-principle report as to include the validation of the therapeutic robustness of this combined strategy when targeting unmutated tumor-associated self-antigens, the selection of the most appropriate vaccination platform (e.g., mRNA vaccination), and the definition of markers of epigenetic reprogramming capable of predicting sensitivity to the most appropriate immunotherapy.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and

accession number(s) can be found below: Mendeley; 10.17632/x26nbkdjj3.1, 10.17632/pzvxcmhxb7.1, 10.17632/4zgd4ssrv2.1.

ETHICS STATEMENT

All animal experiments were reviewed and approved by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel (16-214-11 and 19-214-7); the Ethical Committee for Animal Experiments of the San Raffaele Scientific Institute (IACUC 858, Authorization 839/2017-PR); the Ethical Committee for Animal Experiments of the Universidad de Navarra (R-018-19).

AUTHOR CONTRIBUTIONS

LDB: conceptualization (equal), investigation (lead), data curation (lead), formal analysis (lead), project administration (equal), validation (equal), writing – original draft (equal), writing – review and editing (equal), visualization (lead), supervision (equal); KB: conceptualization (equal), funding acquisition (equal), project administration (equal), formal analysis (supporting), validation (equal), writing – original draft (equal), writing – review and editing (equal), supervision (equal); AM: conceptualization (equal), funding acquisition (equal), project administration (supportive), formal analysis (supporting), validation (equal), writing – review and editing (equal), supervision (equal); JJL: conceptualization (equal), Funding acquisition (equal), project administration (supporting), validation (supporting), writing – review and editing (equal), supervision (equal); XA: conceptualization (equal), funding acquisition (equal), writing – review and editing (supporting); FP: conceptualization (equal), funding acquisition (equal), writing – review and editing (supporting); CG: investigation (supporting), writing – review and editing (supporting); SV: software (equal), writing – review and editing (supporting); RMA: investigation (supporting); VB: investigation (supporting); NC: investigation (supporting); KDR: software (equal); YDV: investigation (supporting); AG: investigation (supporting); QL: investigation (supporting); ESJ-E: investigation (supporting); KM: writing – review and editing (supporting); KV: writing – review and editing (supporting). All authors contributed to the article and approved the submitted version.

FUNDING

LDB, RMA, KDR, YDV, CG, QL, SV, KM, KV, and KB: This research was performed with financial support from the Vrije Universiteit Brussel (VUB) under the strategic research program scheme (SRP48) and from ERA-NET TRANSCAN 2 JTC 2015 (EPICA project; G0H7216N). LDB, RMA, YDV, QL, and SV received funding from het Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO) under the predoctoral FWO-FR research grant (1164918N), pre-doctoral FWO-SB research grants (1S53719N, 1S24817N, and 1S24218N), and the junior post-doctoral research grant (1243121N), respectively. CG received funding from the research council of the Vrije Universiteit Brussel (VUB; OZR3458). FP, XA, and JJL: This research was performed with financial support from the Foundation for Applied Medical Research, the University of Navarra, Fundación Fuentes Dutor, Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER (PI20/01308, PI20/01306), CIBERONC (CB16/12/00489), ERA-NET TRANSCAN-2 JTC 2015 (EPICA project; AC16/00041), Spanish Ministry of Economy, Industry and Competitiveness (RTHALMY SAF2017-92632-EXP), Ministerio de Ciencia e Innovación (PID2019-108989RB-I00), and Gobierno de Navarra (strategic projects DIANA, DESCARTHeS and AGATA). AM: This research was performed with financial support from ERA-NET TRANSCAN-2 JTC 2015 (EPICA project; AC16/00041) and Associazione Italiana per la Ricerca sul Cancro (AIRC IG 2014 Id.15883 and AIRC IG 2018 Id.21763).

ACKNOWLEDGMENTS

The authors would like to thank Dorien Autaers for performing the measurements on RNA integrity, Lotte Jacobs for the intravenous injections of the DC vaccine and the BRIGHTcore facility at the UZ Brussels for the technical assistance regarding RNA sequencing and Nanostring. The authors also wish to thank Dr. Gerlanda Vella (San Raffaele Institute) for participating in the initial set-up of tumor/T cell co-cultures. Graphics were created with BioRender.com and Inkscape v1.1.0.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.799636/full#supplementary-material

REFERENCES

1. Cancer Tomorrow Estimated number of new cases from 2020 to 2040. World Health Organization. (2020) [cited 08.04.2021]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/bars?mode=cancer&group_populations=1&multiple_cancers=1&cancers=16_17&key=total&show_bar_mode_prop=1&types=0&bar_mode=stacked&years=2040&sort_by=value0&sexes=0&populations=903_904_905_908_909_935.
2. Krohn IK, Aerts JL, Breckpot K, Goyvaerts C, Knol E, Van Wijk F, et al. T-Cell Subsets in the Skin and Their Role in Inflammatory Skin Disorders. *Allergy*. (2022) 77(3):827–42. doi: 10.1111/all.15104
3. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. *J Clin Oncol* (2014) 32(10):1020–+. doi: 10.1200/JCO.2013.53.0105
4. Gomes F, Serra-Bellver P, Lorigan P. The Role of Nivolumab in Melanoma. *Future Oncol* (2018) 14(13):1241–52. doi: 10.2217/fon-2017-0484
5. Maurer DM, Butterfield LH, Vujanovic L. Melanoma Vaccines: Clinical Status and Immune Endpoints. *Melanoma Res* (2019) 29(2):109–18. doi: 10.1097/CMR.0000000000000535
6. Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, et al. Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic

Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2. *Cancer Immunol Immunother* (2019) 68(5):773–85. doi: 10.1007/s00262-019-02307-x
7. Dang NN, Jiao J, Meng XG, An YH, Han C, Huang SH. Abnormal Overexpression of G9a in Melanoma Cells Promotes Cancer Progression *via* Upregulation of the Notch1 Signaling Pathway. *Aging-Us* (2020) 12 (3):2393–407. doi: 10.18632/aging.102750
8. Kato S, Weng QY, Insco ML, Chen KY, Muralidhar S, Pozniak J, et al. Gain-Of-Function Genetic Alterations of G9a Drive Oncogenesis. *Cancer Discover* (2020) 10(7):980–97. doi: 10.1158/2159-8290.CD-19-0532
9. Gassenmaier M, Rentschler M, Fehrenbacher B, Eigentler TK, Ikenberg K, Kosnopfel C, et al. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating With Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. *Am J Pathol* (2020) 190(10):2155–64. doi: 10.1016/j.ajpath.2020.07.002
10. Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu XN, Meeth K, et al. DNMT3b Modulates Melanoma Growth by Controlling Levels of Mtorc2 Component RICTOR. *Cell Rep* (2016) 14(9):2180–92. doi: 10.1016/j.celrep.2016.02.010
11. Ding J, Li T, Wang XW, Zhao EH, Choi JH, Yang LQ, et al. The Histone H3 Methyltransferase G9A Epigenetically Activates the Serine-Glycine Synthesis Pathway to Sustain Cancer Cell Survival and Proliferation. *Cell Metab* (2013) 18(6):896–907. doi: 10.1016/j.cmet.2013.11.004
12. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, et al. Direct Interaction Between DNMT1 and G9a Coordinates DNA and Histone Methylation During Replication. *Genes Dev* (2006) 20(22):3089–103. doi: 10.1101/gad.1463706
13. Jaenisch R, Bird A. Epigenetic Regulation of Gene Expression: How the Genome Integrates Intrinsic and Environmental Signals. *Nat Genet* (2003) 33:245–54. doi: 10.1038/ng1089
14. Mitra S, Lauss M, Cabrita R, Choi J, Zhang TW, Isaksson K, et al. Analysis of DNA Methylation Patterns in the Tumor Immune Microenvironment of Metastatic Melanoma. *Mol Oncol* (2020) 14(5):933–50. doi: 10.1002/1878-0261.12663
15. Davis LE, Shalin SC, Tackett AJ. Current State of Melanoma Diagnosis and Treatment. *Cancer Biol Ther* 14 (2019) 20(11):1366–79. doi: 10.1080/15384047.2019.1640032
16. Romano G, Kwong LN. miRNAs, Melanoma and Microenvironment: An Intricate Network. *Int J Mol Sci* (2017) 18(11):16. doi: 10.3390/ijms18112354
17. Venza M, Visalli M, Catalano T, Biondo C, Beninati C, Teti D, et al. DNA Methylation-Induced E-Cadherin Silencing Is Correlated With the Clinicopathological Features of Melanoma. *Oncol Rep* (2016) 35(4):2451–60. doi: 10.3892/or.2016.4618
18. Molognoni F, de Melo FHM, da Silva CT, Jasiulionis MG. Ras and Rac1, Frequently Mutated in Melanomas, Are Activated by Superoxide Anion, Modulate Dnmt1 Level and Are Causally Related to Melanocyte Malignant Transformation. *PloS One* (2013) 8(12):e81937. doi: 10.1371/journal.pone.0081937
19. Venza M, Visalli M, Biondo C, Lentini M, Catalano T, Teti D, et al. Epigenetic Regulation of P14(ARF) and P16(INK4A) Expression in Cutaneous and Uveal Melanoma. *Biochim Et Biophys Acta Gene Regul Mechanisms* (2015) 1849 (3):247–56. doi: 10.1016/j.bbagrm.2014.12.004
20. Cannuyer J, Van Tongelen A, Loriot A, De Smet C. A Gene Expression Signature Identifying Transient DNMT1 Depletion as a Causal Factor of Cancer-Germline Gene Activation in Melanoma. *Clin Epigenetics* (2015) 7:17. doi: 10.1186/s13148-015-0147-4
21. Yu HZ, Yang WX. MiR-211 is Epigenetically Regulated by DNMT1 Mediated Methylation and Inhibits EMT of Melanoma Cells by Targeting RAB22A. *Biochem Biophys Res Commun* (2016) 476(4):400–5. doi: 10.1016/j.bbrc.2016.05.133
22. Uzdensky A, Demyanenko S, Bibov M, Sharifulina S, Kit O, Przhedetski Y, et al. Expression of Proteins Involved in Epigenetic Regulation in Human Cutaneous Melanoma and Peritumoral Skin. *Tumor Biol* (2014) 35(8):8225–33. doi: 10.1007/s13277-014-2098-3
23. Tan YH, Tajik A, Chen JW, Jia QO, Chowdhury F, Wang LL, et al. Matrix Softness Regulates Plasticity of Tumour-Repopulating Cells *via* H3K9 Demethylation and Sox2 Expression. *Nat Commun* (2014) 5:12. doi: 10.1038/ncomms5619
24. Maric H, Supic G, Kandolf-Sekulovic L, Maric V, Mijuskovic Z, Radevic T, et al. DNMT1 and DNMT3B Genetic Polymorphisms Affect the Clinical Course and Outcome of Melanoma Patients. *Melanoma Res* (2019) 29(6):596–602. doi: 10.1097/CMR.0000000000000612
25. Chiappinelli KB, Strissel PL, Desrichard A, Li HL, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer *via* dsRNA Including Endogenous Retroviruses. *Cell* (2015) 162(5):974–86. doi: 10.1016/j.cell.2015.07.011
26. Jose-Eneriz ES, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, et al. Discovery of First-in-Class Reversible Dual Small Molecule Inhibitors Against G9a and DNMTs in Hematological Malignancies. *Nat Commun* (2017) 8:15424. doi: 10.1038/ncomms15424
27. Barcena-Varela M, Caruso S, Llerena S, Alvarez-Sola G, Uriarte I, Latasa MU, et al. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. *Hepatology* (2019) 69(2):587–603. doi: 10.1002/hep.30168
28. Segovia C, San Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, Garate L, Miranda E, et al. Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression. *Nat Med* (2019) 25(7):1073–+. doi: 10.1038/s41591-019-0499-y
29. Falo LD, Kovacsovicsbankowski M, Thompson K, Rock KL. Targeting Antigen Into the Phagocytic Pathway *In-Vivo* Induces Protective Tumor-Immunity. *Nat Med* (1995) 1(7):649–53. doi: 10.1038/nm0795-649
30. Bishop JAN, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, et al. Mutation Testing in Melanoma Families: INK4A, CDK4 and INK4D. *Br J Cancer* (1999) 80(1-2):295–300. doi: 10.1038/sj.bjc.6690354
31. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, et al. Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma. *J Natl Cancer Institute* (2002) 94(12):894–903. doi: 10.1093/jnci/94.12.894
32. Sharpless NE. INK4a/ARF: A Multifunctional Tumor Suppressor Locus. *Mutat Res Fundamental Mol Mech Mutagenesis* (2005) 576(1-2):22–38. doi: 10.1016/j.mrfmmm.2004.08.021
33. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN. Genomic Alterations in Spontaneous and Carcinogen-Induced Murine Melanoma Cell Lines. *Oncogene* (2004) 23(13):2347–56. doi: 10.1038/sj.onc.1207405
34. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma. *J Clin Oncol* (2007) 25(7):869–75. doi: 10.1200/JCO.2006.08.9755
35. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated With Clinical Outcome in Metastatic Melanoma. *Cancer Res* (2012) 72(5):1070–80. doi: 10.1158/0008-5472.CAN-11-3218
36. Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, et al. Patterns of Immune-Cell Infiltration in Murine Models of Melanoma: Roles of Antigen and Tissue Site in Creating Inflamed Tumors. *Cancer Immunol Immunother* (2019) 68(7):1121–32. doi: 10.1007/s00262-019-02345-5
37. Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, et al. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. *Cancer Immunol Res* (2015) 3(6):631–40. doi: 10.1158/2326-6066.CIR-14-0190
38. Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, et al. Overcoming Primary and Acquired Resistance to Anti-PD-L1 Therapy by Induction and Activation of Tumor-Residing Cdc1s. *Nat Commun* (2020) 11 (1):20. doi: 10.1038/s41467-020-19192-z
39. Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. *Cancer Res* (2018) 78(17):5011–22. doi: 10.1158/0008-5472.CAN-18-0118
40. Albershardt TC, Leleux J, Parsons AJ, Krull JE, Berglund P, ter Meulen J. Intratumoral Immune Activation With TLR4 Agonist Synergizes With Effector T Cells to Eradicate Established Murine Tumors. *NPJ Vaccines* (2020) 5(1):50. doi: 10.1038/s41541-020-0201-x
41. Breckpot K, Dullaers M, Bonehill A, Van Meirvenne S, Heirman C, De Greef C, et al. Lentivirally Transduced Dendritic Cells as a Tool for Cancer Immunotherapy. *J Gene Med* (2003) 5(8):654–67. doi: 10.1002/jgm.400

42. de Witte MA, Coccoris M, Wolkers MC, van den Boom MD, Mesman EM, Song JY, et al. Targeting Self-Antigens Through Allogeneic TCR Gene Transfer. *Blood* (2006) 108(3):870–7. doi: 10.1182/blood-2005-08-009357
43. Manzo T, Sturmheit T, Basso V, Petrozziello E, Michelini RH, Riba M, et al. T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF Alpha Expression and Empower Adoptive Cell Therapy for Solid Tumors. *Cancer Res* (2017) 77(3):658–71. doi: 10.1158/0008-5472.CAN-16-0725
44. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast Universal RNA-Seq Aligner. *Bioinformatics* (2013) 29(1):15–21. doi: 10.1093/bioinformatics/bts635
45. Anders S, Pyl PT, Huber W. HTSeq-A Python Framework to Work With High-Throughput Sequencing Data. *Bioinformatics* (2015) 31(2):166–9. doi: 10.1093/bioinformatics/btu638
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. *Proc Natl Acad Sci U States A* (2005) 102(43):15545–50. doi: 10.1073/pnas.0506580102
47. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular Signatures Database (MSigDB) 3. 0. *Bioinf* (2011) 27 (12):1739–40. doi: 10.1093/bioinformatics/btr260
48. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1 Alpha-Responsive Genes Involved in Oxidative Phosphorylation are Coordinately Downregulated in Human Diabetes. *Nat Genet* (2003) 34 (3):267–73. doi: 10.1038/ng1180
49. Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway Enrichment Analysis and Visualization of Omics Data Using G: Profiler, GSEA, Cytoscape and EnrichmentMap. *Nat Protoc* (2019) 14(2):482–517. doi: 10.1038/s41596-018-0103-9
50. Bhattacharya A, Hamilton AM, Furberg H, Pietzak E, Purdue MP, Troester MA, et al. An Approach for Normalization and Quality Control for NanoString RNA Expression Data. *Briefings Bioinf* (2021) 22(3):bbaa163. doi: 10.1093/bib/bbaa163
51. Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, et al. Gene Expression Markers of Tumor Infiltrating Leukocytes. *J Immunother Cancer* (2017) 5:15. doi: 10.1186/s40425-017-0215-8
52. Plesca D, Mazumder S, Almasan A. DNA Damage Response and Apoptosis. *Programmed Cell Death Biol Ther Implications Cell Death Part B* (2008) 446:107–22. doi: 10.1016/S0076-6879(08)01606-6
53. Spranger S, Bao RY, Gajewski TF. Melanoma-Intrinsic Beta-Catenin Signalling Prevents Anti-Tumour Immunity. *Nature* (2015) 523(7559):231–U61. doi: 10.1038/nature14404
54. Joruiz SM, Bourdon JC. P53 Isoforms: Key Regulators of the Cell Fate Decision. *Cold Spring Harbor Perspect Med* (2016) 6(8):20. doi: 10.1101/cshperspect.a026039
55. Li W, Sanki A, Karim RZ, Thompson JF, Lee CS, Zhuang LQ, et al. The Role of Cell Cycle Regulatory Proteins in the Pathogenesis of Melanoma. *Pathology* (2006) 38(4):287–301. doi: 10.1080/00313020600817951
56. Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, et al. Aurora Kinase Inhibition Sensitizes Melanoma Cells to T-Cell-Mediated Cytotoxicity. *Cancer Immunol Immunother* (2021) 70(4):1101–13. doi: 10.1007/s00262-020-02748-9
57. Chen DS, Mellman I. Elements of Cancer Immunity and the Cancer-Immune Set Point. *Nature* (2017) 541(7637):321–30. doi: 10.1038/nature21349
58. Al Emran A, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. *Trends Immunol* (2019) 40(4):328–44. doi: 10.1016/j.it.2019.02.004
59. Lamberti MJ, Mentucci FM, Roselli E, Araya P, Rivarola VA, Vittar NBR, et al. Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation. *Front Immunol* (2019) 10:12. doi: 10.3389/fimmu.2019.02614
60. Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-Tumor Immunity to Resistance. *Front Oncol* (2018) 8:16. doi: 10.3389/fonc.2018.00322
61. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, et al. Immune Cell-Poor Melanomas Benefit From PD-1 Blockade After Targeted Type I IFN Activation. *Cancer Discover* (2014) 4(6):674–87. doi: 10.1158/2159-8290.CD-13-0458
62. Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. *Cancers* (2021) 13(5):1037. doi: 10.3390/cancers13051037
63. Gato-Canas M, Zuazo M, Arasanz H, Ibanez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 Signals Through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. *Cell Rep* (2017) 20(8):1818–29. doi: 10.1016/j.celrep.2017.07.075
64. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. IL-10 Expression by Primary Tumor Cells Correlates With Melanoma Progression From Radial to Vertical Growth Phase and Development of Metastatic Competence. *Modern Pathol* (2011) 24(6):801–9. doi: 10.1038/modpathol.2011.5
65. Angioni R, Sanchez-Rodriguez R, Viola A, Molon B. TGF-Beta in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment. *Cancers* (2021) 13(3):401. doi: 10.3390/cancers13030401
66. Zhao B, Zhao H, Zhao JX. Efficacy of PD-1/PD-L1 Blockade Monotherapy in Clinical Trials. *Ther Adv Med Oncol* (2020) 12:1758835920937612. doi: 10.1177/1758835920937612
67. Padron A, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, et al. Age Effects of Distinct Immune Checkpoint Blockade Treatments in a Mouse Melanoma Model. *Exp Gerontol* (2018) 105:146–54. doi: 10.1016/j.exger.2017.12.025
68. Kelly GM, Al-Ejeh F, McCuaig R, Casciello F, Ahmad Kamal N, Ferguson B, et al. G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. *Clin Cancer Res* (2021) 27(9):2624–35. doi: 10.1158/1078-0432.CCR-20-3463
69. Yu GJ, Wu YF, Wang WY, Xu J, Lv XP, Cao XT, et al. Low-Dose Decitabine Enhances the Effect of PD-1 Blockade in Colorectal Cancer With Microsatellite Stability by Re-Modulating the Tumor Microenvironment. *Cell Mol Immunol* (2019) 16(4):401–9. doi: 10.1038/s41423-018-0026-y
70. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing DY, Orsulic S, et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes With CTLA-4 Blockade in a Murine Ovarian Cancer Model. *Cancer Immunol Res* (2015) 3(9):1030–41. doi: 10.1158/2326-6066.CIR-15-0073
71. Giunta EF, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, et al. Epigenetic Regulation in Melanoma: Facts and Hopes. *Cells* (2021) 10 (8):2048. doi: 10.3390/cells10082048
72. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. *Cancer Discover* (2019) 9(3):370–83. doi: 10.1158/2159-8290.CD-18-0774
73. Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, et al. MAGE-C2-Specific TCRs Combined With Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. *J Immunol* (2016) 197(6):2541–52. doi: 10.4049/jimmunol.1502024
74. Chen C, Gao FH. Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy. *Front Immunol* (2019) 10:8. doi: 10.3389/fimmu.2019.00187
75. Oh E, Hong J, Yun CO. Regulatory T Cells Induce Metastasis by Increasing Tgf-Beta and Enhancing the Epithelial-Mesenchymal Transition. *Cells* (2019) 8(11):15. doi: 10.3390/cells8111387
76. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of Human Th17 Cells and Itregs is Orchestrated by Different Subsets of Myeloid Cells. *Blood* (2011) 117(24):6532–41. doi: 10.1182/blood-2010-11-317321
77. Teixeira AF, ten Dijke P, Zhu HJ. On-Target Anti-TGF-Beta Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges? *Front Cell Dev Biol* (2020) 8. doi: 10.3389/fcell.2020.00605
78. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, et al. Macrophage IL-10 Blocks CD8(+) T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. *Cancer Cell* (2014) 26(5):623–37. doi: 10.1016/j.ccell.2014.09.006
79. Benci JL, Xu BH, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell* (2016) 167(6):1540–+. doi: 10.1016/j.cell.2016.11.022
80. Nakahara T, Oba J, Shimomura C, Kido-Nakahara M, Furue M. Early Tumor-Infiltrating Dendritic Cells Change Their Characteristics Drastically in Association With Murine Melanoma Progression. *J Invest Dermatol* (2016) 136(1):146–53. doi: 10.1038/JID.2015.359

81. Mpakali A, Stratikos E. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. *Cancers* (2021) 13(1):30. doi: 10.3390/cancers13010134
82. Lucarini V, Melaiu O, Tempora P, D'Amico S, Locatelli F, Fruci D. Dendritic Cells: Behind the Scenes of T-Cell Infiltration Into the Tumor Microenvironment. *Cancers* (2021) 13(3):21. doi: 10.3390/cancers13030433
83. Murgaski A, Bardet PMR, Arnouk SM, Clappaert EJ, Laoui D. Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A's: Abundance, Activation and Antigen-Delivery. *Cancers* (2019) 11(5):16. doi: 10.3390/cancers11050670
84. Wilgenhof S, Van Nuffel AMT, Corthals J, Heirman C, Tuyaerts S, Benteyn D, et al. Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. *J Immunother* (2011) 34(5):448–56. doi: 10.1097/CJI.0b013e31821dcb31
85. Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, et al. Epigenetic Reprogramming of Tumor Cell-Intrinsic STING Function Sculpts Antigenicity and T Cell Recognition of Melanoma. *Proc Natl Acad Sci USA* (2021) 118(15):e2013598118. doi: 10.1073/pnas.2013598118

Conflict of Interest: The dual G9a/DNMT inhibitor CM-272 pertains to patent WO2015192981A1, on which XA, FP, and ESJ-E are filed as inventors.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

†***ORCID:***
Lien De Beck, orcid.org/0000-0002-8445-0441; Robin Maximilian Awad, orcid.org/0000-0001-5434-494X; Veronica Basso, orcid.org/0000-0003-1880-8406; Noelia Casares, orcid.org/0000-0003-3817-6434; Kirsten De Ridder, orcid.org/0000-0003-1482-1742; Yannick De Vlaeminck, orcid.org/0000-0002-1882-4740; Alessandra Gnata, orcid.org/0000-0002-5176-9106; Cleo Goyvaerts, orcid.org/0000-0002-1725-7772; Edurne San José-Enériz, orcid.org/0000-0001-5786-5273; Stefaan Verhulst, orcid.org/0000-0001-6566-6071; Ken Maes, orcid.org/0000-0001-8906-2790; Karin Vanderkerken, orcid.org/0000-0002-2137-7179; Xabier Agirre, orcid.org/0000-0002-6558-9560; Felipe Prosper, orcid.org/0000-0001-6115-8790; Juan José Lasarte, orcid.org/0000-0003-1641-3881; Anna Mondino, orcid.org/0000-0003-0833-6927; Karine Breckpot, orcid.org/0000-0003-4331-3480

frontiers | Frontiers in Immunology

ORIGINAL RESEARCH
published: 17 June 2022
doi: 10.3389/fimmu.2022.818120

Comprehensive Evaluation of the m^{6}A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma

Mingke Yu[1,2†], Xuefei Liu[3†], Han Xu[4†], Sangyu Shen[2], Fajiu Wang[5], Dajin Chen[6], Guorong Li[7], Zongping Wang[8], Zhixiang Zuo[3*] and An Zhao[1,9*]*

[1] Experimental Research Center, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, [2] The Second School of Clinical Medicine , Zhejiang Chinese Medical University, Hangzhou, China, [3] State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, [4] Department of Pediatrics, The Affiliated Children's Hospital of Nanchang University (Jiangxi Provincial Children's Hospital), Nanchang, China, [5] Department of Cardiothoracic Surgery, Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China, [6] Kidney Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, [7] Department of Urology, North Hospital, Centre Hospitalier Universitaire (CHU) of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France, [8] Department of Urology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, [9] Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China

Background: Clear cell renal cell carcinoma (ccRCC) is known for its high drug resistance. The tumor-immune crosstalk mediated by the epigenetic regulation of N6-methyladenosine (m^{6}A) modification has been demonstrated in recent studies. Therefore, m^{6}A modification-mediated immune cell infiltration characteristics may be helpful to guide immunotherapy for ccRCC.

Methods: This study comprehensively analyzed m^{6}A modifications using the clinical parameters, single-cell RNA sequencing data, and bulk RNA sequencing data from the TCGA-ccRC cohort and 13 external validation cohorts. A series of bioinformatic approaches were applied to construct an m^{6}A regulator prognostic risk score (MRPRS) to predict survival and immunotherapy response in ccRCC patients. Immunological characteristics, enriched pathways, and mutation were evaluated in high- and low-MRPRS groups.

Results: The expressional alteration landscape of m^{6}A regulators was profiled in ccRCC cell clusters and tissue. The 8 regulator genes with minimal lambda were integrated to build an MRPRS, and it was positively correlated with immunotherapeutic response in extent validation cohorts. The clinicopathological features and immune infiltration characteristics could be distinguished by the high- and low-MRPRS. Moreover, the MRPRS-mediated mutation pattern has an enhanced response to immune checkpoint blockade in the ccRCC and pan-cancer cohorts.

Conclusions: The proposed MRPRS is a promising biomarker to predict clinical outcomes and therapeutic responses in ccRCC patients.

Keywords: clear cell renal cell carcinoma, N6-methyladenosine, immune infiltration characteristic, mutation, immunotherapy, prognosis

OPEN ACCESS

Edited by:
Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Cheng Zhang, First Affiliated Hospital of Harbin Medical University, China
Kang Li, Harbin Medical University, China

***Correspondence:**
An Zhao
zhaoan@zjcc.org.cn

Zhixiang Zuo
zuozhx@sysucc.org.cn

Zongping Wang
wangzp@zjcc.org.cn

†These authors have contributed equally to this work and share first authorship

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *19 November 2021*
Accepted: *11 May 2022*
Published: *17 June 2022*

Citation:
Yu M, Liu X, Xu H, Shen S, Wang F, Chen D, Li G, Wang Z, Zuo Z and Zhao A (2022) Comprehensive Evaluation of the m^{6}A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Front. Immunol. 13:818120. doi: 10.3389/fimmu.2022.818120

INTRODUCTION

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer and accounts for nearly 3% of adult malignant tumors (1). Approximately 30% of patients already have advanced ccRCC or metastases when they are first diagnosed, and have missed the opportunity for surgical intervention (2). Although targeted therapy and immunotherapy have become the main adjuvant therapy for advanced ccRCC, the complete response rate and partial response rate remained low (3, 4). So far, the biomarker-based therapeutic strategies for advanced ccRCC have been missing.

N6-methyladenosine (m^6A) modification is an important factor for messenger RNA (mRNA) stability, splicing, and translation (5–7). Serval m^6A-sequencing studies have revealed that abnormal m^6A regulatory enzymes are involved in mutagenesis, proliferation, and tumorigenesis through the dysregulation of the m^6A pathway (8, 9). Recently, m^6A modifications have been shown to play a role in the regulation of immune cells, such as the following: METTL3-mediated m^6A modification increased the translation of certain immune transcripts and physiologically promoted the activation of dendritic cells (DCs) and DC-based T-cell responses (10), and ALKBH5 regulated m^6A modification in the 3'UTR region of PD-L1 mRNA and inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression (11). The potential relationship between RNA m^6A dysregulation and tumor-infiltrating immune cells (TIICs) has motivated us to investigate and find the potential biomarkers for predicting immune checkpoint therapy outcomes. Herein, we systematically evaluated the m^6A regulator-based risk score and its associated gene mutation with the TIICs and revealed a new predictive method that could be used to predict the immunotherapy response in ccRCC and pan-cancer.

MATERIALS AND METHODS

Data Collection and Processing

The RNA sequencing (RNA-seq) transcriptome data of patients with ccRCC and the corresponding clinical data and mutation profiles were downloaded from The Cancer Genome Atlas (TCGA) database. The validation datasets (GSE53757, GSE40435, GSE29609, and E-MTAB-3267) were included for analysis from the Gene Expression Omnibus (GEO) database and the European Molecular Biology Laboratory (12–15). The relative transcriptomic and clinical data of three immunotherapeutic cohorts of patients with ccRCC were obtained from the online supplementary data (16–18). RNA-seq data of the immunotherapy cohort of bladder cancer (19) and melanoma (PRJEB23709 and phs000452) were collected for testing (20, 21). The annotated response and mutational data of patients from a discovery cohort receiving ICB treatment from 4 studies were collected and consolidated to study the relationship between mutated genes and immunotherapy (17, 22–24). The single-cell dataset of ccRCC ICB treatment was obtained from PMID33861994 (25). The information for all collected data is presented in **Table S1**.

Single-Cell RNA Sequencing Analysis

The association with m^6A regulators was established by analyzing the genes related to the immune response in the scRNA-seq results of ccRCC (25). The CellRanger software (version 5.0.0) and STAR were used for preprocessing. Principal component analysis (PCA) was run using the "RunPCA" function on the variable genes identified, and the k-nearest neighbor graph was constructed by the "FindNeighbors" function. Uniform manifold approximation and projection (UMAP) was used to visualize single-cell transcriptional profiles and clusters. Marker genes were visualized on UMAP plots using log-normalized counts.

Cell–Cell Communication Analysis

CellPhoneDB applies an algorithm that considers only receptors and ligands with broad expression among the tested cell types, followed by calculating the likelihood of cell-type specificity of a given receptor–ligand complex with a sufficient number of permutations (26).

Selection of m^6A RNA Methylation Regulators

Based on previous studies (5, 27–30), 23 m^6A RNA methylation regulators, namely, ALKBH5, CBLL1, FMR1, IGF2BP1/2/3, FTO, YTHDC1/2, YTHDF1/2/3, HNRNPC, LRPPRC, METTL3/14/16, WTAP, KIAA1429, RBM15/15B, ZC3H13, and HNRNPA2B1, were used for our analysis. Immunohistochemistry (IHC) images of m^6A regulators have been used in the tissue atlas and pathology atlas panels in the Human Protein Atlas. The protein and gene expression of m^6A regulators in normal individuals and ccRCC patients were analyzed on University of Alabama Cancer Database (UALCAN) portal.

Immune Infiltration Analysis in RCC

CIBERSORT and MCP counter were used to transform the RNA-seq data into the proportion of TIICs. The MCP counter R package was used to evaluate the expression of nine TIICs types. CIBERSORT (https://cibersort.stanford.edu/) was used to quantify the 22 infiltrated immune cells according to normalized gene expression profiles, which included different types of B cells, T cells, NK cells, DC cells, and mast cells. As a verification

Abbreviations: ccRCC, clear cell renal cell carcinoma; m^6A, N6-methyladenosine; MRPRS, m^6A regulator prognostic risk score; TMB, tumor mutational burden; mRNAs, messenger RNAs; DCs, dendritic cells; TIICs, tumor-infiltrating immune cells; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; ICB, immune checkpoint blockade; WES, whole-exome sequencing; IHC, immunohistochemistry; scRNA-Seq, single-cell RNA sequencing; PCA, principal component analysis; UMAP, uniform manifold approximation and projection; MsigDB, molecular signature database; TME, tumor microenvironment; ssGSEA, single-sample gene-set enrichment analysis; LASSO, least absolute shrinkage and selection operator; DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein–protein interaction; MHC, major histocompatibility complex; TCR, T-cell receptor; SNV, single-nucleotide variant; OS, overall survival; PFS, progression-free survival; TLSs, tertiary lymphoid structures; VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; ESCA, esophageal carcinoma; LUAD, lung adenocarcinoma; PAAD, pancreatic adenocarcinoma; ACC, adrenocortical carcinoma; BLCA, bladder cancer; COAD, colon adenocarcinoma; GBM, glioblastoma multiforme; NSCLC, non-small-cell lung cancer; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain low-grade glioma; LIHC, liver hepatocellular carcinoma; MESO, mesothelioma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma.

method, the single-sample gene-set enrichment analysis (ssGSEA) and xCell algorithm were applied.

Construction and Validation of the m^{6}A Gene Signature

The significant m^{6}A RNA methylation regulators were established by the least absolute shrinkage and selection operator (LASSO) Cox regression (with the penalty parameter estimated by 20-fold cross-validation). Those regulator genes with minimal lambda were integrated to build an MRPRS, and it was developed according to the expression level using univariate Cox. The "glmnet" package was used to perform the LASSO Cox regression model analysis.

The limma R package's empirical Bayesian approach was applied to determine differentially expressed genes (DEGs) between high and low m^{6}A scores. The significance criteria for determining DEGs were set as the adjusted $p < 0.05$ and $|\log FC| > 1$. Finally, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses using the ClusterProfiler R package based on these DEGs. A protein–protein interaction (PPI) network was constructed by STRING (https://string-db.org/) and evaluated using the Cytoscape software (31).

Statistical Analysis

Statistical tests were carried out using R version 4.0.4, SPSS 25.0 (IBM, NY, USA) and GraphPad Prism 8.0. The expression levels of the m^{6}A RNA regulators were compared with the Mann–Whitney *U* test in ccRCC versus normal tissues. Survival curves were generated using the Kaplan–Meier method, and the difference was compared with the log-rank test. Pearson correlation coefficient was used to compare the correlation between MRPRS and gene expression values. The "oncoplot" function of the R package "maftools" was used to determine the mutation landscape of the TCGA ccRCC cohort and immunotherapeutic cohort. The high- and low-group was divided based on the optimal cut-off value calculated by the function "surv_cutpoint" in the R package "survminer". All the R package used in this study is listed in **Table S2**. $p < 0.05$ indicated statistical significance.

RESULTS

The Expressional Alteration Landscape of m^{6}A Regulators in ccRCC Tissues and Cell Clusters

On reviewing the literature (5, 27–30), 23 genes were found that mainly regulate m^{6}A modification including 9 writers (METTL3, METTL14, METTL16, RBM15, RBM15B, CBLL1, ZC3H13, KIAA1429, and WTAP), 12 readers (FMR1, HNRNPA2B1, HNRNPC, YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3, and LRPPRC), and 2 erasers (FTO and ALKBH5). We utilized the bulk TCGA-ccRCC data (529 cases of ccRCC and 74 cases of normal tissues) to analyze the expression of these m^{6}A regulators, revealing that 15 out of 23 m^{6}A regulators were differentially expressed (**Figure 1A**; **Table S3**), and this phenomenon was also found in two other GEO datasets (GSE53757 and GSE40435) (**Figure S1A**). In addition, the protein levels of these regulators were also evaluated from the IHC results (**Figure S1B**; **Table S4**).

We next used the scRNA-seq data (25) (PMID33861994) to evaluate the expression of m^{6}A regulators in different subsets of ccRCC cells. A total of 65,535 cells were divided into 7 cell clusters, a total of 6,539 epithelial cells from ccRCC multiple regions (Near, Far, Center, and Lymph node) and normal tissues of 6 ICB-treated and untreated patients were extracted, and 6 ccRCC cell clusters were identified based on AQP3, GPX3, CCNI, STMN1, VCAM1, and VCAN expression (**Figures 1B, C**; **Figures S1C, D**; **Table S5**). The genes with the most significant differential expression in each cell cluster were described in the heatmap (**Figure 1E**; **Table S6**), and significant functional heterogeneity was found among the 7 cell clusters (**Figure 1F**). As shown in **Figure 1G**, m^{6}A regulators also presented the expression heterogeneity between normal cell clusters and tumor cell clusters, as well as between the 6 ccRCC cell clusters. Moreover, the expression of WTAP, YTHDC1, YTHDC2, HNRNPC, and HNRNPA2B1 was significantly different between the ICB-resistant-related GPX3$^+$ epithelial cells and ICB-response-related VCAM1$^+$ epithelial cells (**Figure 1D**), indicating that the differential expression level of m^{6}A regulators in ccRCC tissue and cell clusters may be related to the efficacy of immunotherapy.

Construction, Validation, and Immunotherapy Response Evaluation of the m^{6}A Regulator Prognostic Risk Score

To systematically evaluate these differences in m^{6}A regulators, the MRPRS was established by the LASSO Cox algorithm, the 8 regulator genes with minimal lambda were integrated to build an MRPRS (**Figures 2A, B**) (**Figure S2A**), and it was developed according to the expression level using univariate Cox (**Figure S2B**). The ccRCC patients in the TCGA database were divided into the high-MRPRS group ($N = 134$) and the low-MRPRS group ($N = 395$) based on the optimal cut-off value calculated by the function "surv_cutpoint" in the R package "survminer", and the ccRCC patients in the high-MRPRS group had a significantly shorter overall survival time than that in the low-MRPRS group ($p < 0.001$; **Figure 2C**). The prognostic value of MRPRS was also validated in an independent cohort (GSE29609, $p = 0.037$; **Figure 2D**). We continued to extend the MRPRS signature to 16 other tumor types, such as esophageal carcinoma (ESCA), lung adenocarcinoma (LUAD), and pancreatic adenocarcinoma (PAAD) (**Figure S2C**). These results present that MRPRS is negatively associated with survival outcomes.

Next, we investigated the correlation between MRPRS and immunotherapy response in three independent ccRCC cohorts (PMID29301960, PMID32472114, and PMID32895571) (16, 18, 22), and found that the MRPRS was significantly higher in the response group than in the non-response group; the high-MRPRS group presented a markedly prolonged survival (**Figures 2F–I**). Moreover, the increased MRPRS in the VCAM1$^+$ cell cluster was positively correlated with the patients who experienced complete and mixed responses (**Figure 2E**). Similar results were also obtained in the extended dataset of bladder cancer (IMvigor210) and melanoma (PRJEB23709) (**Figures S3A–E**).

In addition, we analyzed the expression of targeted therapy- and chemotherapy-related genes between high- and low-MRPRS groups (**Figure 2J**). Interestingly, VEGF and mTOR pathway-related genes were found to be highly expressed in



FIGURE 1 | **(A)** Expression of 23 m^{6}A RNA methylation regulators between renal cancer and normal tissues in the TCGA-ccRCC cohort. **(B, C)** The UMAP plot and overview of epithelial cells by the origin and cell type of the cells. **(D)** Composition of various epithelial cells in different immunotherapeutic responses. **(E)** The heatmap of marker gene expression in 7 identified epithelial cell subsets. **(F)** Dot plot analysis of KEGG pathway enrichment of 7 epithelial cell subsets. **(G)** Violin plots showing the partial expression of m^{6}A regulators for each epithelial cell type (**p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant).

the low-MRPRS group, and MRPRS was negatively correlated with the expression level of angiogenesis-related genes including PECAM, FLT1/4, VWF, and CDH5 (**Figures 2J, K**). In the E-MTAB-3267 cohort of ccRCC patients treated with sunitinib, the MRPRS was significantly lower in the response group than in the non-response group, and the low-MRPRS group showed a markedly prolonged survival (**Figures 2L, M**). Collectively, our data suggest that the patients with high MRPRS may benefit from immunotherapy and those with low MRPRS may benefit from targeted therapy.

The Clinicopathological Features and Immune Infiltration Characteristics in Distinct MRPRS

We examined the correlation between the MRPRS and the clinical parameters. No significant association was found between the MRPRS and gender and age, but significant associations in terms of TNM stages, grade, and survival status were observed (**Figure S4A**), and MRPRS is positively correlated with TNM stages and grades ($p < 0.001$; **Figure 3A**). Moreover, each of the four different T stages including stage I had significantly higher MRPRS when compared with the control subjects, and MRPRS in the metastasis group was significantly higher than that in the non-metastasis group ($p < 0.001$, respectively; **Figure 3A**).

To investigate the effects of MRPRS on the immune infiltration characteristic of ccRCC, we evaluated the expression of immunomodulators and the infiltration levels between high- and low-MRPRS groups in ccRCC, as shown in **Figure 3B**; 5 immunomodulators (chemokine, receptor, immunostimulator, inhibitory immune checkpoint, and MHC) and the infiltration levels of 4 types of TIICs (CD8+ T cells, DC, macrophages, and Th1 cells) were positively correlated with the high-MRPRS group ($p < 0.05$). The MCP counter, xCell, CIBERSORT, and ssGSEA algorithm were used to calculate an immune score and to estimate the abundance of various types of immune cells. We found significantly higher estimates of Tregs, CD8$^+$T cells, NK cells, and B cells in ccRCC with



FIGURE 2 | **(A)** LASSO coefficient profiles of the 23 m^{6}A RNA methylation regulators in the TCGA-ccRCC cohort. **(B)** The prognostic analyses for 23 m^{6}A RNA methylation regulators in the TCGA-ccRCC cohort using the univariate Cox regression model. **(C)** Kaplan–Meier analysis of patients between high- and low-MRPRS groups in the TCGA-ccRCC cohort. **(D)** Validation cohort of MRPRS from GSE29609. **(E)** Box plot of different MRPRSs in 3 epithelial cell subsets. **(F)** The MRPRS between response and non-response groups in PMID32472114. **(G–I)** Kaplan–Meier analysis of three validation cohorts of immunotherapy in ccRCC (PMID32472114, PMID29301960, and PMID32895571). **(J)** Heatmap of chemotherapy and targeted drug-related genes between high- and low-MRPRS groups. **(K)** The correlation of MRPRS and genes associated with angiogenesis. **(L)** The MRPRS between response and non-response groups in ccRCC with sunitinib (E-MTAB-3267). **(M)** Kaplan–Meier analysis between high- and low-MRPRS groups in ccRCC with sunitinib (E-MTAB-3267) (*p < 0.05; **p < 0.01; ***p < 0.001).

high MRPRS (**Figure 3C** and **Figures S5A–C**; **Table S7**). Moreover, the VCAM1$^+$ cell cluster presented upregulation of HLA-A and HLA-B (**Figure 1E**), and it was also the cell cluster that communicates most frequently with immune cells (**Figure 3E**; **Table S8**).

We performed volcano plots based on the DEGs from the high- and low-MRPRS groups. The results of the volcano plots showed that 1,780 genes were significantly upregulated in the comparison of the high- and low-MRPRS groups (**Table S9**). In the PPI network from the STRING database with the Cytoscope software, we constructed a co-expression network consisting of 45 nodes and 169 edges (**Figure S4C**). These included immune-related genes, CD19 and CD79A, and membrane proteins on the surface of B cells, which participate in the proliferation and differentiation of B cells. FOXP3 and IL2RA (CD25) are the characteristic markers of Treg cells. We also found that the expression of many costimulatory factors, such as TNFSF14, TNFRSF18, and a large amount of interleukins such as IL2 and IL6, promotes T-cell proliferation and T-cell-mediated killing (**Figure S4B**). GO enrichment analysis and KEGG analysis of these signature genes revealed that these DEGs were enriched in several biological processes and pathways related to immune regulation (**Figures S4D, E**; **Table S10**). Moreover, the number and diversity of T-cell receptors (TCRs) were higher in the high-MRPRS group than in the low-MRPRS group ($p < 0.01$) (**Figure 3D**). These findings suggest that the regulation of TCR gene expression may be influenced by the specific tumor cell cluster with abnormal m^{6}A modifications.

The Landscape of Genetic Variation of MRPRS Groups in ccRCC

The somatic mutation profile between the high- and low-MRPRS groups in the TCGA-ccRCC cohort used the maftools package, and the top 10 most frequently mutated genes in each group are shown in **Figure 4A**. Notably, SETD2, TRIOBP, RYR2, ZFPM2, and ABCC6 occupy the top 5 positions among differently mutated genes between the high- and low-MRPRS group (**Figure 4B**), and a lollipop plot showed the different mutation spots of these mutated genes between two groups (**Figure 4C**). Interestingly, the mutation rate of SETD2 was 23.18% in the high-MRPRS group and 3.87% in the low-MRPRS group, and the remaining four genes were mutated only in the high-MRPRS group. In addition, the distribution of variants according to variant classification, variant type, and single-nucleotide variant (SNV) class was displayed as a cohort summary plot, and among all the genomic alterations, missense mutations were the predominant type, with C>T and C>G representing the most common SNV classes (**Figures S6A, B**). Somatic mutation



FIGURE 3 | **(A)** Box plot of the relationship between stage T, N, M, grade, and MRPRS. **(B)** The heatmap of markers on multiple immune infiltrates. **(C)** The MCP_counter algorithm was used to estimate the abundance of various types of immune cells between high- and low-MRPRS groups. **(D)** The abundance and diversity of TCR clone in high- and low-MRPRS groups. **(E)** Crosstalk between immune cells and epithelial cells (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).

gene interaction networks showed a high correlation between VHL and PBRM1, PBRM1 and SETD2, and TTN and MUC16 in the high MRPRS score group (**Figures S6C, D**).

We also applied the MCP counter and ssGSEA algorithm to estimate the tumor-infiltrating immune cells between the group defined by patients with at least one mutation in these five genes or without mutation. As shown in **Figures 4D, E**, the infiltrating immune cells of T cells, DC cells, and B cells in the mutation status group were higher than those in the non-mutation status group ($p < 0.01$).

The Role of the MRPRS-Mediated Mutation Pattern in Predicting the Response to Immunotherapy

We next investigated whether the MRPRS-mediated mutation pattern could predict patients' response to immunotherapy. We constructed a pan-cancer cohort with anti-PD-1/PDL1 immunotherapy consisting of 1,959 cases based on four cohorts (17, 22–24) (**Table S11**), and patients with mutation exhibited a significantly clinical response to immunotherapy and markedly prolonged survival in ccRCC (**Figures 5A, B**). Immunotherapy represented by PD-L1 and PD-1 blockade is a breakthrough in tumor therapy. We continued to extend the potential role of MRPRS-mediated mutation pattern in predicting responses to immunotherapy in pan-cancer (**Figure 5C**) and revealed that the OS and PFS in patients with mutations were significantly higher than in those without mutations (**Figures 5D, E**). However, the MRPRS-mediated mutation pattern had no significance in OS of either TCGA-ccRCC or TCGA-pan-cancer (**Figures S7A, B**); by contrast, the PFS of the mutation group was worse than that of the non-mutation group in the TCGA-ccRCC ($p = 0.049$, **Figure S7C**), and the PFS in the TCGA-pan-cancer was not significant (**Figure S7D**).

In addition, tumor mutation burden (TMB) may serve as a biomarker for predicting the response to ICB treatment. We next



FIGURE 4 | **(A)** Waterfall plot of the distribution of mutations found in the high- and low-MRPRS groups of the TCGA-ccRCC cohort. **(B)** The top 5 genes of high- vs. low-MRPRS group mutation status. **(C)** Lollipop plot of somatic mutations in SETD2, TRIOBP, RYR2, ZFPM2, and ABCC6. **(D, E)** MCP_counter and ssGSEA algorithm were used to estimate the abundance of various types of immune cells in high- and low-MRPRS groups (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant).

divided the pan-cancer cohort patients into three groups according to TMB and MRPRS-mediated mutations and found that the OS of patients with low TMB and mutations was significantly better than that of the patients with high TMB and the patients with low TMB and non-mutations (P < 0.0001, **Figure 5F**).

DISCUSSION

The TME of ccRCC is known to be highly immunosuppressive (32). In the TME, T cells are continuously exposed to antigens, which leads to the impairment of T-cell function and ultimately to a dysfunctional state called "exhaustion" (33). The use of monoclonal antibodies or small molecules to reverse T-cell exhaustion is the basic strategy of immunotherapy (34). Since the results of the Checkmate-025 study, the immunotherapy of ccRCC has been the focus of attention, and now, combined targeted and immunotherapy has become a key component of the adjuvant treatment of advanced ccRCC (35). However, the complete or mixed response rate of immunotherapy in ccRCC is still low. Relying on biomarkers to screen patients who benefit from immunotherapy and to avoid overtreatment has long been expected in clinical practice.

Increasing evidence has demonstrated that m^6A modification plays an indispensable role in immunity, inflammation, and therapy resistance through various m^6A regulators (36). In this study, we systematically evaluated the expression level of m^6A regulators in the ccRCC tissue and cell clusters and focused on the detailed relationship between m^6A modification and TME to enhance our understanding of the ccRCC-immune crosstalk. We constructed an MRPRS comprising 8 m^6A regulators by the LASSO algorithm to provide reliable biomarkers able to predict the prognosis and immunotherapy efficacy. For the first time, we analyzed the MRPRS levels in ccRCC cell clusters and found that the increased MRPRS in the $VCAM^1$+ cell cluster was positively correlated with patients who experienced complete and mixed responses. This is consistent with our finding that the positive correlation between MRPRS and immunotherapy benefits the bulk tissue datasets. It is interesting to note that the spatial localization of this immunotherapy-related ccRCC cell cluster is worthy of further investigation.



FIGURE 5 | **(A)** Different distribution ratio of response and non-response in the immunotherapeutic cohort of ccRCC. **(B)** Kaplan–Meier analysis of patients in the mutated and non-mutated groups in the immunotherapeutic cohort of ccRCC (Van_2018, Morris_2019, PMID29337640 and PMID29301960). **(C)** The composition of major cancer types in the immunotherapeutic cohort contains mutations of pan-cancer. **(D, E)** Kaplan–Meier analysis (OS and PFS) of patients in the mutation and non-mutation groups in the immunotherapeutic cohort of pan-cancer. **(F)** Kaplan–Meier analysis of patients in the low TMB of mutated, low TMB of non-mutated, and high TMB groups.

We further explored the detailed role of m^{6}A modification in modifying immune characteristics in ccRCC. The results of the GO and KEGG pathway analyses revealed a significant enrichment of genes in immune-related pathways. GO enrichment analysis showed that these DEGs were enriched in the humoral immune response, immunoglobulin complex, and antigen binding. The results of the KEGG analysis indicated these enriched pathways such as neuroactive ligand–receptor interaction, cytokine–cytokine receptor interaction, and the calcium signaling pathway. These results indicated that DEGs in the ccRCC are enriched in immune-related genes distinguished by the MRPRS. Among these DEGs, numerous immune-related genes were found, such as CD19, CD79A, FOXP3, CXCL13, IL2, and TNFRSF13B. FOXP3 is a hallmark of regulatory T cells, CXCL13 is related to CD8 T cells, and CD79A, CD19, and TNFRSF13B are markers of neoplastic B cells. This was in accordance with results from the single-cell sequencing analysis of ccRCC (25). Moreover, these immune cells comprise the main part of tertiary lymphoid structures (TLSs), which have recently been associated with effective antitumor immune responses in cancer patients (37, 38). These findings suggest that m^{6}A modification may influence the formation of tertiary lymphatic structures.

The patient with a high MRPRS has a poor prognosis, and this could be due to the observation that several critical inhibitor immune checkpoints were significantly highly expressed in the high-MRPRS group, which may limit cytotoxic immune cell activities in the TME, such as CD8 T cells, causing cytotoxic cells to be in an exhausted functional state (39). Therefore, patients with high MRPRS may be more sensitive to immunotherapy. Several studies have also demonstrated that inflammatory tumor phenotypes are more sensitive to ICB (40, 41). We next compared the prognostic value of the MRPRS based on ccRCC immunotherapeutic cohorts, and the high-MRPRS group presented a prolonged survival. These findings suggest that MRPRS could be used as a new predictive biomarker for immunotherapy response in ccRCC.

Furthermore, we identified 5 genes (SETD2, TRIOBP, RYR2, ZFPM2, and ABCC6) that show the most significant differences in the comparison of mutated genes between two MRPRS groups. We found that the patients with mutated genes had worse PFS outcomes than the non-mutated group, and this was consistent with the high-MRPRS group showing worse survival than those with lower MRPRS. The potential association of TMB with sensitivity to ICB is based on the hypothesis that in tumors with high TMB, there is an increased production of surface neoantigens, thus stimulating the anti-tumor immune system response (42). The TMB has been investigated in several tumor settings, mainly in NSCLC and melanoma, as a stratification marker to predict the response to immune agents, showing promising yet inconclusive results (43, 44). In contrast, it has also been reported that high TMB fails to

predict immune checkpoint blockade response across all cancer types (45). Herein, we applied the prediction of immunotherapeutic efficacy with the MRPRS-mediated mutation pattern and TMB in pan-cancer cohort and found that the MRPRS-mediated mutation pattern was a better predictor of immunotherapy outcome than the TMB. The regulatory relationship between the m6A modification and the gene mutation still needs to be studied.

Consequently, we provided a new perspective on the immune characteristics and immunotherapy strategies of ccRCC. However, several limitations should be recognized. Although we analyzed immune cell characteristics in a scRNA-seq dataset, the tumor-infiltrating immune cells were obtained based on algorithms, and thus, further experimental validation *in vitro*/*in vivo* is needed. Our study was also limited by the lack of clinical datasets to verify the relationship between the MRPRS and patients receiving targeted treatment or ICB combined targeted treatment. The combination of an MRPRS-based panel with prospective clinical trials is worth carrying out in the future.

CONCLUSION

This study revealed a significant association between MRPRS and TIICs of ccRCC. The proposed MRPRS is a promising biomarker to predict clinical outcomes and therapeutic responses in ccRCC patients.

DATA AVAILABILITY STATEMENT

All data used in this work can be acquired from the Gene-Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) under the accession numbers GSE53757, GSE40435 and GSE29609, The Cancer Genome Atlas (TCGA) data portal (https://portal.gdc.cancer.gov/), The European Molecular Biology Laboratory (https://www.embl.org/), UALCAN (http://ualcan.path.uab.edu/), HumanProtein Atlas (HPA, https://www.proteinatlas.org/) and https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3267/. The authors would like to thank the above database for the data provided.

AUTHOR CONTRIBUTIONS

AZ and ZZ designed this work. MY, XL, HX, SS, FW, DC, and ZW integrated and analyzed the data. AZ, MY, and XL wrote this manuscript. AZ, ZZ, ZW, and GL edited and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (Reference number: 81402117) and the Qianjiang Talent Project of Zhejiang Province (Reference number: QJD1602025)

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.818120/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. *CA Cancer J Clin* (2020) 70(1):7–30. doi: 10.3322/caac.21590
2. Li QK, Pavlovich CP, Zhang H, Kinsinger CR, Chan DW. Challenges and Opportunities in the Proteomic Characterization of Clear Cell Renal Cell Carcinoma (ccRCC): A Critical Step Towards the Personalized Care of Renal Cancers. *Semin Cancer Biol* (2019) 55:8–15. doi: 10.1016/j.semcancer.2018.06.004
3. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* (2019) 380(12):1116–27. doi: 10.1056/NEJMoa1816714
4. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab Plus Bevacizumab Versus Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. *Lancet* (2019) 393 (10189):2404–15. doi: 10.1016/S0140-6736(19)30723-8
5. Zaccara S, Ries RJ, Jaffrey SR. Reading, Writing and Erasing mRNA Methylation. *Nat Rev Mol Cell Biol* (2019) 20(10):608–24. doi: 10.1038/s41580-019-0168-5
6. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-Methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation. *Nat Cell Biol* (2018) 20(3):285–95. doi: 10.1038/s41556-018-0045-z
7. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, et al. FTO-Dependent Demethylation of N6-Methyladenosine Regulates mRNA Splicing and is Required for Adipogenesis. *Cell Res* (2014) 24(12):1403–19. doi: 10.1038/cr.2014.151
8. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The M(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. *Mol Cell* (2016) 62 (3):335–45. doi: 10.1016/j.molcel.2016.03.021
9. Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, et al. M(6)A mRNA Methylation Regulates AKT Activity to Promote the Proliferation and Tumorigenicity of Endometrial Cancer. *Nat Cell Biol* (2018) 20(9):1074–83. doi: 10.1038/s41556-018-0174-4
10. Wang H, Hu X, Huang M, Liu J, Gu Y, Ma L, et al. Mettl3-Mediated mRNA M (6)A Methylation Promotes Dendritic Cell Activation. *Nat Commun* (2019) 10(1):1898. doi: 10.1038/s41467-019-09903-6
11. Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. *Cancer Res* (2021) 81(18):4778–93. doi: 10.1158/0008-5472.CAN-21-0468
12. von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, et al. Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. *Cancer Res* (2014) 74(17):4796–810. doi: 10.1158/0008-5472.CAN-14-0210
13. Wozniak MB, Le Calvez-Kelm F, Abedi-Ardekani B, Byrnes G, Durand G, Carreira C, et al. Integrative Genome-Wide Gene Expression Profiling of Clear Cell Renal Cell Carcinoma in Czech Republic and in the United States. *PLoS One* (2013) 8(3):e57886. doi: 10.1371/journal.pone.0057886
14. Edeline J, Mottier S, Vigneau C, Jouan F, Perrin C, Zerrouki S, et al. Description of 2 Angiogenic Phenotypes in Clear Cell Renal Cell Carcinoma. *Hum Pathol* (2012) 43(11):1982–90. doi: 10.1016/j.humpath.2012.01.023
15. Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma are Associated With Sunitinib Response in the Metastatic Setting. *Clin Cancer Res* (2015) 21 (6):1329–39. doi: 10.1158/1078-0432.CCR-14-1128

16. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, et al. Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma. *Nat Med* (2020) 26(6):909–18. doi: 10.1038/s41591-020-0839-y
17. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic Correlates of Response to Immune Checkpoint Therapies in Clear Cell Renal Cell Carcinoma. *Science* (2018) 359(6377):801–6. doi: 10.1126/science.aan5951
18. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab Plus Axitinib Versus Sunitinib in Advanced Renal Cell Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Renal 101 Trial. *Nat Med* (2020) 26(11):1733–41. doi: 10.1038/s41591-020-1044-8
19. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. *Nature* (2018) 554(7693):544–8. doi: 10.1038/nature25501
20. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. *Cancer Cell* (2019) 35(2):238–55.e6. doi: 10.1016/j.ccell.2019.01.003
21. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma. *Science* (2015) 350(6257):207–11. doi: 10.1126/science.aad0095
22. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, et al. Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors. *Nat Genet* (2018) 50(9):1271–81. doi: 10.1038/s41588-018-0200-2
23. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types. *Nat Genet* (2019) 51(2):202–6. doi: 10.1038/s41588-018-0312-8
24. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. *J Clin Oncol* (2018) 36(7):633–41. doi: 10.1200/JCO.2017.75.3384
25. Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, et al. Single-Cell Sequencing Links Multiregional Immune Landscapes and Tissue-Resident T Cells in ccRCC to Tumor Topology and Therapy Efficacy. *Cancer Cell* (2021) 39(5):662–77.e6. doi: 10.1016/j.ccell.2021.03.007
26. Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: Inferring Cell-Cell Communication From Combined Expression of Multi-Subunit Ligand-Receptor Complexes. *Nat Protoc* (2020) 15(4):1484–506. doi: 10.1038/s41596-020-0292-x
27. Li H, Hu J, Yu A, Othmane B, Guo T, Liu J, et al. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. *Front Oncol* (2021) 11:642159. doi: 10.3389/fonc.2021.642159
28. Chen L, Hu B, Song X, Wang L, Ju M, Li Z, et al. M(6)A RNA Methylation Regulators Impact Prognosis and Tumor Microenvironment in Renal Papillary Cell Carcinoma. *Front Oncol* (2021) 11:598017. doi: 10.3389/fonc.2021.598017
29. Huang H, Weng H, Chen J. M(6)A Modification in Coding and Non-Coding RNAs: Roles and Therapeutic Implications in Cancer. *Cancer Cell* (2020) 37 (3):270–88. doi: 10.1016/j.ccell.2020.02.004
30. Chen XY, Zhang J, Zhu JS. The Role of M(6)A RNA Methylation in Human Cancer. *Mol Cancer* (2019) 18(1):103. doi: 10.1186/s12943-019-1033-z
31. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING V10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. *Nucleic Acids Res* (2015) 43:D447–52. doi: 10.1093/nar/gku1003
32. Diaz-Montero CM, Rini BI, Finke JH. The Immunology of Renal Cell Carcinoma. *Nat Rev Nephrol* (2020) 16(12):721–35. doi: 10.1038/s41581-020-0316-3
33. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. *Cancer Cell* (2018) 33(4):547–62. doi: 10.1016/j.ccell.2018.03.012
34. He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X. CD8+ T-Cell Exhaustion in Cancer: Mechanisms and New Area for Cancer Immunotherapy. *Brief Funct Genomics* (2019) 18(2):99–106. doi: 10.1093/bfgp/ely006
35. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* (2015) 373(19):1803–13. doi: 10.1056/NEJMoa1510665
36. Shulman Z, Stern-Ginossar N. The RNA Modification N(6)-Methyladenosine as a Novel Regulator of the Immune System. *Nat Immunol* (2020) 21(5):501–12. doi: 10.1038/s41590-020-0650-4
37. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response. *Nature* (2020) 577(7791):549–55. doi: 10.1038/s41586-019-1922-8
38. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma. *Nature* (2020) 577(7791):561–5. doi: 10.1038/s41586-019-1914-8
39. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. *Cell* (2018) 175(2):313–26. doi: 10.1016/j.cell.2018.09.035
40. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An Immune-Active Tumor Microenvironment Favors Clinical Response to Ipilimumab. *Cancer Immunol Immunother* (2012) 61(7):1019–31. doi: 10.1007/s00262-011-1172-6
41. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. *Adv Exp Med Biol* (2017) 1036:19–31. doi: 10.1007/978-3-319-67577-0_2
42. Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of Response to Immune Checkpoint Therapies for Cancer: Implications for Precision Medicine. *Genome Med* (2018) 10(1):93. doi: 10.1186/s13073-018-0605-7
43. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden. *N Engl J Med* (2018) 378(22):2093–104. doi: 10.1056/NEJMoa1801946
44. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. *N Engl J Med* (2014) 371(23):2189–99. doi: 10.1056/NEJMoa1406498
45. McGrail DJ, Pilie PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across All Cancer Types. *Ann Oncol* (2021) 32(5):661–72. doi: 10.1016/j.annonc.2021.02.006

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

frontiers | Frontiers in Immunology

ORIGINAL RESEARCH
published: 21 June 2022
doi: 10.3389/fimmu.2022.860041

The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics

Zhi-kun Ning[1†], Ce-gui Hu[2†], Jiang Liu[2†], Hua-kai Tian[2], Zhong-lin Yu[2], Hao-nan Zhou[3], Hui Li[4] and Zhen Zong[2*]*

[1] Department of Day Ward, The First Affiliated Hospital of Nanchang University, Nanchang, China, [2] Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, [3] Queen Marry College, Nanchang University, Nanchang, China, [4] Department of Rheumatology and Immunology, The First Affiliated Hospital of Nanchang University, Nanchang, China

OPEN ACCESS

Edited by:
Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Bo Chen, Wenzhou Medical University, China
Bowen Song, University of Liverpool, United Kingdom

***Correspondence:**
Zhen Zong
ndefy16133@ncu.edu.cn
Hui Li
lihui0791nc@126.com

†These authors have contributed equally to this work

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *22 January 2022*
Accepted: *11 May 2022*
Published: *21 June 2022*

Citation:
Ning Z-k, Hu C-g, Liu J, Tian H-k, Yu Z-l, Zhou H-n, Li H and Zong Z (2022) The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics. Front. Immunol. 13:860041. doi: 10.3389/fimmu.2022.860041

The interaction between hypoxia and RNA N6-methyladenosine (m6A) is an emerging focus of investigation. However, alterations in m6A modifications at distinct hypoxia levels remain uncharacterized in gastric cancer (GC). Unsupervised hierarchical clustering was performed to stratify samples into different clusters. Differentially expressed gene analysis, univariate Cox proportional hazards regression analysis, and hazard ratio calculations were used to establish an m6A score to quantify m6A regulator modification patterns. After using an algorithm integrating Least absolute shrinkage and selection operator (LASSO) and bootstrapping, we identified the best candidate predictive genes. Thence, we established an m6A-related hypoxia pathway gene prognostic signature and built a nomogram to evaluate its predictive ability. The area under the curve (AUC) value of the nomogram was 0.811, which was higher than that of the risk score (AUC=0.695) and stage (AUC=0.779), suggesting a high credibility of the nomogram. Furthermore, the clinical response of anti-PD-1/CTLA-4 immunotherapy between high- and low-risk patients showed a significant difference. Our study successfully explored a brand-new GC pathological classification based on hypoxia pathway genes and the quantification of m6A modification patterns. Comprehensive immune analysis and validation demonstrated that hypoxia clusters were reliable, and our signature could provide a new approach for clinical decision-making and immunotherapeutic strategies for GC patients.

Keywords: hypoxia, m6A, gastric cancer, immune infiltration, immune checkpoint blockade

INTRODUCTION

Gastric cancer (GC) is the fifth most malignant tumor worldwide (1). Greater than 1 million new cases have been identified, and most cases are already advanced at diagnosis, explaining why GC has the third highest number of cancer-related deaths (2). Based on the Lauren/WHO classification and the lymph node metastasis [tumor node metastasis (TNM)] staging of tumors, current treatments

exhibit a poor correlation with the molecular pathology of cancer. Despite the development of new pathological classifications, such as The Cancer Genome Atlas (TCGA) subtypes and Asian Cancer Research Group (ACRG) subtypes, the clinical predictive value of these classification systems remains insufficient (3, 4). To identify more molecular markers that are closely related to GC progression, accurately predicting developmental trends and providing individualized treatments for patients has become a troublesome point in current relevant research fields.

With greater insight into tumor research, changes in the tumor microenvironment (TME) have drawn more attention, and hypoxia plays an important role in tumorigenesis (5). Hypoxia is one of the characteristics of the microenvironment of solid tumors and one of the greatest obstacles to cancer treatment (6–8). As a master regulator of cellular adaptation to hypoxia, hypoxia-inducible factor 1 (HIF1) has been proven to extensively regulate the expression of hypoxia genes and hypoxia adaptation–related signal transduction pathways, including EPO, VEGF, iNOS, and other genes to increase oxygen transmission and PDK-1, ALDOA, bcl-2, and other genes to reduce oxygen consumption (5, 9–12). Another feature of the TME is the change in immune cells, which contributes to maintaining a complex dynamic interaction with tumor cells (13, 14). Immunotherapy, especially programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1), and immune checkpoint blockade (ICB), has made remarkable achievements in recent years (15, 16). However, sustained clinical responses are only induced in a minority of cancer patients, indicating that more studies on this topic should be performed (17, 18).

As the most common RNA modification in eukaryotic cells, N6-methyladenosine (m6A) not only plays a related role in immune regulation but also plays a vital role in the occurrence and development of cancer through various processes, such as proliferation, migration, and invasion (19, 20). m6A regulators consist of three types of proteins: "writers" with methyltransferase activity, "erasers" with demethylase activity, and "readers" with m6A binding sites (20–22). Recent studies have demonstrated that the abnormal m6A modification patterns change the TME and lead to tumor progression, and hypoxia plays a potential role (23, 24). Recently, several posttranscriptional modification databases have been established such as the m6AVar and RMBase databases (25, 26), which provided important information about m6A-related variants to explore the molecular mechanisms of m6A modification for experimental biologists. Moreover, 2 powerful m6A functional analysis tools ConsRM and m6A2Target (27, 28) were also developed. However, the specific mechanisms in GC remain elusive, so a comprehensive analysis of hypoxia and m6A is urgently needed and indispensable.

In this study, we identified three hypoxia pathway subtypes in GC. By correlating hypoxia with m6A modification patterns and defining the m6A score to quantify m6A modification patterns, we ultimately established a robust signature and prognostic nomogram. This study provides information on clinicopathological characteristics and a classification system that are more in line with reality and can be used to guide clinical decision-making. In addition, this study aims to improve GC patient survival.

MATERIALS AND METHODS

Data Collection and Preprocessing

GC patients with survival information were retrospectively collected from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/), and GC samples without clinical data were excluded. In total, 1,673 patients from ten cohorts were enrolled, including The Cancer Genome Atlas-Stomach Adenocarcinoma (TCGA-STAD), GSE13861, GSE26899, GSE26901, GSE57303, ACRG Cohort (GSE62254), Singapore Patient Cohort (GSE15459 and GSE34942), and GSE84437 (GSE84426 and GSE84433). The TCGA-STAD cohort (FPKM normalized) was transformed into the transcripts per kilobase million (TPM) format. For microarray cohorts, the normalized matrix files with expression data and clinical information were directly downloaded and log2 transformed. The remaining cohorts except TCGA-STAD were merged into one cohort, and the "sva" R package was employed to remove batch effects (29). The predictive value of the nomogram was tested using an additional cohort GSE28541. In addition, two immune checkpoint blockade treatment cohorts (IMvigor210 for PD-1 treatment and Nathanson2017 for CTLA-4 treatment) were obtained, and the corresponding normalized data were utilized to determine whether the m6A-related hypoxia signature could be used to screen immunotherapy-sensitive patients. Details are provided in **Supplementary Table S1**.

Unsupervised Hierarchical Clustering Reveals Distinct Characteristics of Different Clusters

We systematically collected a set of hypoxia-related genes (https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA) and a total of 23 m6A regulators, including 8 writers (METTL3, METTL14, WTAP, RBM15, RBM15B, ZC3H13, CBLL1, and VIRMA), 2 erasers (ALKBH5 and FTO), and 13 readers (IGF2BP1/2/3, YTHDF1/2/3, YTHDC1/2, FMR1, ELAVL1, HNRNPC, HNRNPA2B1, and LRPPRC) (22, 30). To group hypoxia clusters, we performed principal component analysis (PCA) for data reduction. According to the Kaiser–Harris criterion, principal components <1% were considered noise and removed. After calculating the Euclidean distance, the ten-combined cohort was grouped using unsupervised hierarchical clustering with the "ward. D2" linkage criterion. Target genes for increasing oxygen delivery and reducing oxygen consumption were obtained from the Hypoxia-inducible factor 1 (HIF-1) signaling pathway to explore the hypoxic status between different clusters. Similarly, the hierarchical clustering method using the "ward.D" linkage criterion divides patients into high, medium, and low clusters according to m6A regulators. Furthermore, the results were visualized in clustering

dendrograms, PCA, and t-distributed stochastic neighbor embedding (t-SNE) figures, and Kaplan Meier (KM) curves were employed to show the trends of overall survival (OS) and recurrence-free survival (RFS). Additionally, we explored the connections between the subtypes defined above and previous molecular stratifications of GC *via* a percentage stacking diagram (3, 4, 31).

Pathway Enrichment Analysis and Single-Sample Gene Set Enrichment Analysis

Using the HALLMARK gene set (downloaded from the MSigDB database v7.1) as the background pathway, gene set variation analysis (GSVA) was performed using the "GSVA" R package to show pathway differences in 3 hypoxiaClusters (32). Moreover, based on immunity-related gene sets reported in a previously published article (33), we employed GSVA enrichment analysis to investigate the distinct response patterns of hypoxiaClusters in innate and adaptive immunity.

Single-sample gene set enrichment analysis (ssGSEA) was performed for other gene sets obtained from previously published studies as follows: the biomarkers of biological processes according to Mariathasan et al. (34), hypoxia biomarkers, T-cell dysfunction, and immunotherapy resistance biomarkers and immunosuppressive cell signatures (**Supplementary Table 2**).

Immune Cell Infiltration Estimation

For each sample, the ESTIMATE algorithm was adopted to assess the tumor purity and population estimation of stromal and immune cells based on gene expression (35). Twenty-eight different immune cell infiltration patterns, including cells executing antitumor reactivity and cells delivering protumor suppression, were calculated from the gene sets reported in a previous study *via* ssGSEA (**Supplementary Table 2**). Furthermore, an additional 22 immune cells calculated by the CIBERSORT deconvolution algorithm, including neutrophils, eosinophils, mast cells, dendritic cells, macrophages, natural killer cells, regulatory T cells (Tregs), B cells, CD4+ T cells, CD8+ T cells, and plasma cells, were assessed to quantify infiltrating pattern heterogeneity (36).

Quantization of the Modification Pattern of m6A Regulators

Based on the m6A score construction method of Shen et al. (22), differentially expressed genes (DEGs) between 3 m6A clusters were extracted using the "limma" R package (37). Univariate Cox regression analysis was performed on DEGs with a p-value <0.05; then, screened genes were employed for the construction of the m6A score and normalized from -1 to 1 to reduce the effect of the gene expression value. Afterwards, we calculated the hazard ratio (HR) of all screened genes and divided them into two groups based on a cut-off score of HR=1, and the m6A score was defined as the difference value of the sums in each group. Tumor mutation burden (TMB) was calculated using "maftools" according to the somatic mutation data acquired from the TCGA database (38). Pearson correlation analysis was employed to reveal the correlation between m6A and TMB. Subsequently, the distribution differences in somatic mutations between the low and high m6A score groups were analyzed and visualized using a waterfall diagram.

Establishment of an m6A-Related Hypoxia Signature by Machine Learning

Differential expression analysis was performed to screen differentially expressed hypoxiaCluster genes between different hypoxiaClusters. The m6A-related hypoxia pathway genes (MRHPPGs) were defined based on the following criteria: correlation r >0.5 and p-value <0.001 between DEHCGs and the m6A core. Data partitioning and standardization were processed using the classification and regression training (caret) package in the R(caret) package (39). First, the entire dataset was divided into a training and testing cohort at a ratio of 6:4 using a stratified sampling method for each cohort. Then, the function "preProcess" was used to standardize the training cohort and other cohorts based on the parameters calculated in the training cohort. For feature engineering, we used 80% of the samples randomly chosen from the original sample each time. After 1,000 bootstrapping replications, genes with a p-value <0.01 that appeared greater than 900 times in univariate Cox proportional hazards regression analysis were included in further analyses. Furthermore, an algorithm integrating LASSO and bootstrapping was used to identify the best candidate predictive genes (40, 41). The optimal candidates that were repeated more than 600 times in 1,000 iterations were determined through 5 cross-validations. Then, stepwise multivariate Cox regression analysis was used to build a prognostic signature, which was determined as follows: risk score = Σ expression level of gene Xi × Cox coefficient of gene Xi. A survival decision tree was used to show the process of clinical decision-making. The predictive ability of the nomogram for 3-, 5- and 7-year OS was assessed, and external validation was performed using cohort GSE28541. A calibration curve was generated to compare the predicted survival rates with the observed survival rates (42).

Cell Culture and Quantitative Real-Time PCR

The human gastric epithelial cell line GES-1 and GC cell lines HGC-27, NCI-N87 were obtained from Shanghai Anwei Biotechnology Co., LTD, China. GES-1 and NCI-N87 were cultured in an Roswell Park Memorial Institute (RPMI) 1640 (Gibco, US) medium, and HGC-27 was cultured in a Dulbecco's modified eagle medium (DMEM) (Gibco, US) medium with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO_2 and 20% O_2 at 37°C. Total RNA was extracted using FastPure Cell/Tissue Total RNA Isolation Kit V2 (Vazyme, RC112-01) and reverse-transcribed into cDNA using HiScript III All-in-one RT SuperMix Perfect for qPCR (Vazyme, R333-01). Real-time PCR was performed using ChamQ Universal SYBR qPCR Master Mix (Vazyme, Q711-02). The primer pairs used in qRT-PCR were as follows: APOD 5′-AATCGAAGGTGAAGCCACCC-3′ (forward) and 5′-GTGCCGATGGCATAAACCAG-3′ (reverse); CCN3 5′-AGGCAGAGTTTCAGTGCTCC-3′ (forward) and 5′-TGCA GGTCCCAATGACCATC-3′ (reverse); DACT1 5′-TTGAA

CTGTTTGAGGCGAAGAG-3′ (forward) and 5′-ACTGA ACACCGAGTTAGAGGAAT-3′ (reverse); EML1 5′-CAGTT CTGCAACGATGACAGC-3′ (forward) and 5′-GCCGAA CCACATCAGCTAGAG-3′ (reverse); MMP23B 5′-TAGGC TTCTACCCGATCAACC-3′ (forward) and 5′-CGCTGTCGTCGAAGTGGAT-3′ (reverse); RBPMS2 5′-AAGACAGCCTGTTGGTTTTGT-3′ (forward) and 5′-CGAATACCGTTCAGCGCATT-3′ (reverse); TUBB6 5′-TGGTGGACTTAGAGCCAGG-3′ (forward) and 5′-CCCTTTCGCCCAGTTGTTC-3′ (reverse).

Western Blotting

The tumor cells were lysed with RIPA buffer containing a protease inhibitor cocktail. These cells were kept on ice for approximately 1 h and vortexed every 15 min at 12,000 rpm and centrifuged for 15 min. The protein concentration in the lysate supernatant was measured by Bicinchoninic acid (BCA). The whole lysates were diluted to the same concentration, 80 μl of lysates were taken and 20 μl of 5×SDS-PAGE loading buffer were added. The samples were boiled for 15 min. Approximately 10 μl for each sample were loaded when running Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE). The protein was fractionated by 12.5% SDS-PAGE. The protein was transferred to the Polyvinylidene difluoride (PVDF) membrane at 300 V for 1 h in an ice bath. The membrane was blocked with 5% Milk-TBST for 2 h at room temperature. Then, the membrane was probed with primary Abs for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:10,000), and HIF-α (1:1,000) overnight at 4°C. HRP-conjugated anti-rabbit IgG (1: 20,000) was used as a secondary Ab. After secondary Ab incubation for 2 h at room temperature, the membrane was washed for 5 times with PBST and then blotted with an Enhanced chemiluminescence (ECL) solution. The blots were imaged in the dark room with an imaging machine.

Statistical Analysis

All data processing was performed using the R 4.0.3 software. For two groups, statistical significance was estimated *via* unpaired Student's t-tests for normally distributed variables and Wilcoxon rank-sum tests for nonnormally distributed variables. For more than two groups, one-way ANOVA tests and Kruskal–Wallis tests were used (43). The cut-off values of continuous variables, such as OS, were determined using the "survminer" R package. The area under the curve (AUC) of time-dependent receiver operating characteristic (ROC) curves was visualized by the "timeROC" R package (44), and the ROC curve of the immune checkpoint blockade therapy response was assessed using the "pROC" R package (45). Differences with $p < 0.05$ were considered statistically significant (*$p < 0.05$; **$p < 0.01$: ***$p < 0.001$: ****$p < 0.0001$).

RESULTS

The Hypoxia Status in Gastric Cancer

The flow chart of this study is shown in (**Figure 1**). After unsupervised hierarchical clustering, we classified 3 clusters with distinct hypoxia statuses (**Figure 2A**). Next, we evaluated how the hypoxia status affected patient prognosis. Both overall survival (OS) and recurrence-free survival (RFS) prognostic analysis for the three major hypoxia statuses demonstrated a particularly prominent survival disadvantage in hypoxiaCluster-high patients (**Figures 2B, C**). The expression levels of target genes involved in increased oxygen delivery and reduced oxygen consumption varied among the clusters (**Figures 2D–F**), confirming that the different hypoxia clusters exhibited distinct hypoxia statuses. Patients with invasive and Epithelial-Mesenchymal Transition (EMT) subtypes were classified as hypoxiaCluster-high, whereas proliferative and TP53-negative subtypes were classified as hypoxiaCluster-low. We still observed that cancers classified as hypoxiaCluster-high exhibited poorer differentiation and were enriched in the diffuse subtype (**Supplementary Figures 1A–D**). In GC, the EMT molecular subtype and diffuse histological type were closely related to a shorter OS. Our hypoxiaCluster classification was consistent with other hypoxia characteristics (**Supplementary Figure 1E**). These results suggested that there were different hypoxia statuses with a significant prognostic value and that the GC characterized by a high hypoxia state was closely correlated with high malignancy and rapid tumor progression.

TME Landscape in GC Tumors With Distinct Hypoxia Statuses

A significant difference was found: hypoxiaCluster-high, which had the worst outcome, had the highest stromal score, immune score, and ESTIMATE score but had the lowest tumor purity (**Figure 3A**). Moreover, the log-rank test revealed that patients with high stromal scores, low immune scores, high ESTIMATE scores, or low tumor purity had a poor prognosis (**Supplementary Figures 1I, J**). These results suggested that hypoxiaCluster-high might be in a stroma activation state, which is associated with a worse outcome (46). Moreover, hypoxiaCluster-high was prominently associated with high T-cell suppression and exhaustion (**Supplementary Figure 1F**). We conducted GSVA enrichment analysis to investigate the biological behaviors among these distinct hypoxia clusters. As shown in **Supplementary Figure 1G**, hypoxiaCluster-high was dramatically enriched in stromal and metastatic activation pathways, such as EMT, angiogenesis, myogenesis, hedgehog signaling, and TNFα signaling *via* NFκB; hypoxiaCluster-low exhibited enrichment signaling pathways associated with MYC targets V2, MYC targets V1, E2F targets, and the G2 M checkpoint. To our surprise, the subsequent analysis of infiltrating immunocyte populations suggested that hypoxiaCluster-high was significantly enriched in innate immunocytes, including natural killer cells, macrophages, mast cells, MDSCs, and plasmacytoid dendritic cells (**Figure 3B**; **Supplementary Figure 1H**). A previous research reported that the immune-excluded phenotype also exhibited the presence of a great number of immunocytes, but the immunocytes remained in the matrix around the nest of tumor cells rather than penetrating the parenchyma. Stromal activation in the TME is considered to promote T-cell inhibition (15). Moreover, hypoxiaCluster-high was prominently associated with high T-cell suppression and exhaustion (**Supplementary Figure 3B**). Thus, we conjectured that stromal activation in hypoxiaCluster-high inhibited the antitumor



FIGURE 1 | Flow chart.

effect of immune cells. In addition, we found that hypoxiaCluster-high had an increased abundance of immune cell infiltration, including cells performing antitumor functions (e.g., effector memory CD4 T cells, effector memory CD8 T cells, natural killer cells, natural killer T cells, and type 1 T helper cells) and cells executing protumor suppression (e.g., immature dendritic cells, macrophages, MDSCs, neutrophils, plasmacytoid dendritic cells, regulatory T cells, and type 2 T helper cells) (**Figure 3B**). Pearson's correlation analysis suggested that the abundances of these two categories of immunocytes were significantly positively associated in the TME (**Figure 3C**). This finding indicated the existence of a feedback mechanism in which the antitumor immune response could promote the recruitment or differentiation of cells specialized for immunosuppression. Based on the above inference, we were surprised to confirm that the three hypoxia clusters had dramatically distinct TME cell infiltration features.

The m6A Methylation Modification Patterns Are Distinct Between Hypoxic Conditions

It is generally accepted that m6A methylation modification is involved in diverse biological processes, including dysregulated cell death and proliferation, the degree of tumor malignancy, and immune modifications. Therefore, we similarly classified three m6A methylation modification patterns using the same analysis of hierarchical clustering mentioned above (**Supplementary Figure 2A**) based on the mRNA expression levels of 21 regulators that presented high heterogeneity (**Supplementary Figures 2D, E**). We defined these patterns as m6Acluster high, medium, and low, respectively. The Kaplan–Meier survival analysis for the three m6Aclusters demonstrated that m6Acluster low presented a remarkable survival advantage (**Supplementary Figures 2B, C**). Patients with invasive subtypes, EMT subtypes, or hypoxiaCluster-high subtypes were also mainly enriched in m6Acluster high (**Supplementary Figures 2F, H**). To further explore the biological functions affected by m6A modification phenotypes in distinct hypoxia statuses, we performed an unsupervised clustering algorithm based on hypoxia-related genes in the three m6A methylation modification patterns. Analysis indicated that patients with m6Acluster high were mainly concentrated in the hypoxiaCluster-high group (**Figure 4A**), which confirmed again that hypoxiaCluster-high was significantly relevant to stromal activation. To further illustrate the potential biological process associated with m6A regulator modification subtypes, we established the m6A score and further tested the relation between the known signatures and the m6A score (**Figure 4B**). We observed the distribution differences of somatic mutations



FIGURE 2 | Three hypoxia types with distinct prognosis characteristic and oxygen transport status. **(A)** Identification of hypoxiaClusters by unsupervised hierarchical clustering analysis. PCA and t-SNE analysis supported to divide patients into 3 hypoxiaClusters. **(B, C)** Kaplan–Meier curves were plotted to demonstrate the difference of prognosis by OS and RFS. **(D, E)** The oxygen transport status between different hypoxiaClusters was analyzed through increasing oxygen delivery and reducing oxygen consumption target genes and correlation. The lines in the boxes represented the median value. **(F)** Between the two groups, it was revealed that cluster high had the highest increase in oxygen delivery but the lowest reduction in oxygen consumption, while the cluster low had the opposite. PCA, principal component analysis; t-SNE, t-distributed stochastic neighbor embedding; OS, overall survival; RFS, recurrence-free survival. The asterisks represented the statistical p-value (*P < 0.05; **P < 0.01; ***P < 0.001; ****p < 0.0001). The Kruskal–Wallis test was used to compare the statistical difference between three gene clusters.

between patients with high and low m6A score in the TCGA-STAD cohort. Patients with a low m6A score had more extensive TMB, and the Pearson correlation analysis confirmed that low-m6A-score tumors were significantly negatively related to tumor mutation burden (**Supplementary Figure 3A, B**). Moreover, the m6Acluster high group exhibited a significantly increased m6A score compared to the other clusters, while the m6Acluster low group showed the lowest m6A score (**Figure 4F**). In addition, patients with invasive subtypes, EMT subtypes, or IV stage had the lowest m6A score compared to other corresponding molecular/histological subtypes (**Figures 4C, D, G**), which was consistent with previous studies (46). More importantly, this is the first report that a high hypoxia status was associated with a significantly increased m6A score (**Figure 4E**). These results showed that the m6A score could also be used to evaluate certain clinical features and was closely linked to hypoxia status.

Construction and Validation of the Prognostic Signature of m6A-Related Hypoxia Pathway Genes

In total, 8 candidate predictive genes were identified (**Figures 5A, B**; **Table 1**). The formula for the risk score is as follows: risk score = 0.091592596 × APOD expression + 0.111440156 × CCN3 expression + 0.211698352 × DACT1 expression + (-0.418107247) × EML1 expression + 0.098618533 × MMP23B expression + 0.230005594 × RBPMS2 expression + 0.06395013 × TAC1 expression + 0.224582981 × TUBB6 expression. The analyses for the biological processes indicated that high-risk scores were significantly associated with increased activation of stromal pathways but presented an immunosuppressive state with decreased immune checkpoints (**Figure 5C**). KM curve analysis showed that patients with low risk scores had a better OS in the training cohort, which was consistent with the testing cohort, and the



FIGURE 3 | Landscape of the TME between distinct hypoxia status in GC. **(A)** The boxplots of the ESTIMATE method were used to explore the TME characteristics among these distinct hypoxia clusters, suggesting that hypoxia-cluster high had the highest stromal score, immune score, and ESTIMATE score but the lowest tumor purity (all P-values < 0.0001). The lines in the boxes represented median value. **(B)** The heatmap depicted the infiltrating difference of 28 immune cell types in 3 hypoxiaClusters. HypoxiaCluster-high had a higher abundance of immune cell infiltration, including cells performing an anti-tumor function (e.g., effector memory CD4 T cells, effector memory CD8 T cells, natural killer cells, natural killer T cells, and type 1 T helper cells) and cells executing pro-tumor suppression (e.g., immature dendritic cells, macrophages, MDSCs, neutrophils, plasmacytoid dendritic cells, regulatory T cells, and type 2 T helper cells). Moreover, hypoxia-cluster high was significantly rich in innate immunocyte infiltration including natural killer cells, macrophages, mast cells, MDSCs, and plasmacytoid dendritic cells. **(C)** The correlation between pro-tumor suppression and anti-tumor immunity was analyzed according to 3 hypoxiaClusters, respectively. Pearson's correlation analysis suggested that the abundances of these two categories of immunocytes have a significant positive association in TME (all P-values < 0.001). The asterisks represented the statistical p-value (****p < 0.0001). The Kruskal–Wallis test was used to compare the statistical difference between three gene clusters.

entire cohort served as the validation cohort (**Supplementary Figures 3I–K**). The prognostic accuracy of the risk score in the entire set was assessed; the areas under the ROC curve (AUCs) were 0.66 (62.94%–69.17%, 95% CI), 0.68 (65.18%–71.42%, 95% CI), and 0.67 (63.74%–70.74%, 95% CI) at 3, 5, and 7 years, respectively (**Figure 5D**). The MRHPPGs and HIF-1α expression was significantly elevated in gastric cancer. (**Figures 5E, F**) For external validation, the prognostic signature also showed a robust predictive ability (**Supplementary Figures 3C–G**). Moreover, we used the clinicopathological variables and risk score to establish a nomogram quantifying the risk assessment (**Figure 5G**). The predicted AUC values were 0.811 and 0.727 in the entire cohort and GSE28541, respectively (**Figure 5H** and **Supplementary Figure 3H**). The calibration curves presented a high credibility of the nomogram (**Figure 5I**). To better illustrate the prospect of the clinical application of the MRHPPG signature, a decision tree was used to visualize the stratification level, which displayed significant differences in survival (**Supplementary Figure 4**). Sankey diagrams clearly depicted that a high risk score was robustly related to other stratification classes with poor prognosis (**Supplementary Figure 4**). Next, we assessed the predictive value of the MRHPPG signature in the immunotherapeutic cohort. The AUC values of the IMvigor210 cohort and ICB.Nathanson2017 cohort in response to treatment were 0.648 and 0.781, respectively (**Figures 6A, B, D, E**, **Supplementary Figure 3I**). Moreover, we particularly investigated the ability of the risk score to predict the efficacy of anti-PD-L1 and anti-CTLA-4 immunotherapy, suggesting that low-risk patients showed a higher response rate to immunotherapy compared with high-risk patients (**Figures 6C, F** and **Supplementary Figure 3J**).

DISCUSSION

GC is a common malignant tumor with a high recurrence rate (1). Despite great advances in surgery, radiation, and chemotherapy over the past decade, the outcome for advanced GC remains poor (2). The TNM cancer staging system is currently the gold standard for the assessment of the prognosis of cancer, but this system does not consider gene heterogeneity (47). Moreover, since the prognosis of patients with GC varies greatly (48), the establishment of a robust classifier to stratify patients with precise prognosis prediction and risk stratification is urgently needed at present and is essential to



FIGURE 4 | Comprehensive analysis of distinct hypoxia status between 3 m6A methylation modification patterns. **(A)** The heatmap of gene set variation analysis (GSVA) was drawn on the basis of 25 immunity-related gene sets. m6Acluster high, leukocyte migration, myeloid leukocyte cytokine immune response, and mastocyte activation were mainly concentrated in the hypoxia-cluster high, which suggested hypoxia-cluster high might be in a immunosuppressed and stromal activation state. **(B)** The correlation analysis between m6Ascore and the known signatures. Orange indicates an R value > 0, blue indicates an R value < 0. **(C–F)** Calculation of the m6Ascore in different cohorts and the correlation in different subtypes, including **(C)** Singapore patient cohort (GSE15459 and GSE34942), **(D)** ACRG cohort (GSE62254), **(E)** hypoxiaCluster, **(F)** m6Acluster, **(G)** Stage. The upper and lower ends of the boxes meant the interquartile range of values. The lines in the boxes represented the median value. MSI, microsatellite instability. The Kruskal–Wallis test was used to compare the statistical difference between three gene clusters.

maximize the benefits produced by individual therapy and a timely follow-up. A large amount of convincing evidence has suggested that various malignancies are the result of complex interactions between tumor cells and nonmalignant cells in the TME, including fibroblasts, myofibroblasts, endothelial cells, and immune cells (49), which collectively contribute to the formation of a particular niche that promotes tumor growth and metastasis (3, 50, 51). In this research, using the bioinformatics analysis technology, we identified three distinct hypoxia clusters, which exhibited significantly different m6A methylation modifications and immune cell infiltration by comprehensively mining the public transcriptional data of GC. Moreover, a risk score model was constructed on the basis of 8 MRHPPGs to predict the outcome of GC patients. These findings provide a new perspective for treatment strategies to improve the prognosis and risk stratification of patients by considering the TME characteristics and transcriptomics.

As a tumor hallmark, hypoxia (reduced oxygen availability) is caused by an imbalance between increased oxygen consumption and insufficient oxygen supply, and the clinical significance of hypoxia has been widely reported in cancer therapy (52). Although the vigorous metabolism and rapid proliferation of cancer cells can stimulate the formation of a novel vasculature system that is disorderly, only a vascular system with accurate distribution in normal tissue can facilitate the delivery of



FIGURE 5 | Construction and validation of signature and nomogram. **(A)** The best candidate predictive genes were selected to construct the signature according to the frequency of genes by Lasso-bootstrapping that was defined more than 600 times in 1,000 times replications. **(B)** The coefficient value of the 8 selected genes came from the stepwise multivariate Cox regression analysis. **(C)** The difference of core biological processes was evaluated between high- and low-risk patients that were divided according to the optimal cut-off value. The lines in the boxes represented the median value. **(D)** The area under the ROC curves (AUC) of the entire data were 0.66 (62.94%–69.17%, 95%CI), 0.68 (65.18%–71.42%, 95%CI), and 0.67 (63.74%–70.74%, 95%CI) at 3, 5, and 7 years, respectively. **(E)** qRT-PCR results of MRHPPG expression level in GSE-1 and GC cell lines. (Data are presented as mean ± SD., **P < 0.01). **(F)** Western blot analyses of HIF-α protein levels in total cell lysates from paired clinical specimens of normal (N) and tumor (T) tissues from 12 patients with GC. **(G)** A survival nomogram of 3-, 5-, and 7-year OS was drawn in view of the risk score and stage. **(H)** AUC for risk score, stage, and nomogram reached at 0.659, 0.779, and 0.811, respectively, which mean a high accuracy to be a reliable method. **(I)** The calibration curve of nomogram showed a favorable result in 3, 5, and 7 years. (***P < 0.001,****p < 0.0001).

oxygenated blood (53). Here, we identified three distinct hypoxia clusters with significantly different prognoses, including cluster low with the worst prognosis and cluster high with the best prognosis, using hierarchical clustering analysis based on principal components (removing principal components less than 1%). The immune-inflamed phenotype, which is also referred to as a hot tumor, exhibited abundant immunocyte infiltration in the TME (13, 15). Although the immune-excluded phenotype also exhibited the presence of a great number of immunocytes, the immunocytes remained in the matrix around the nest of tumor cells rather than penetrating the parenchyma. The matrix was restricted to the capsule of the tumor, or it penetrated the tumor itself, illustrating that the immune cells were indeed inside the tumor (54). Consistent with the above statement, we revealed that hypoxiaCluster-high presented a significant stroma activation status and was substantially enriched in carcinogenic pathways, including EMT,

TABLE 1 | Information of 8 m6A-related hypoxia pathway genes

id	coef	HR	HR.95L	HR.95H	pvalue
APOD	0.091593	1.095918	0.953976	1.258979	0.195593
CCN3	0.11144	1.117887	0.992896	1.258612	0.065457
DACT1	0.211698	1.235775	1.074642	1.421068	0.002979
EML1	-0.41811	0.658292	0.550826	0.786723	4.27E-06
MMP23B	0.098619	1.103645	0.983001	1.239096	0.094981
RBPMS2	0.230006	1.258607	1.070618	1.479604	0.005325
TAC1	0.06395	1.066039	0.957504	1.186878	0.24309
TUBB6	0.224583	1.251801	1.066052	1.469914	0.006135

angiogenesis, the Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling pathway, myogenesis, and TGF beta signaling pathways, which are considered T-cell suppressive. Moreover, this finding further confirmed that the hypoxia cluster high was in an obvious T-cell exhaustion state. Hence, through adequately exploring the characteristics of TME cell infiltration induced by distinct hypoxia states, it was not surprising that hypoxiaCluster-high had activated innate immunity but the poorest prognosis.

m6A methylation is the most common intracellular modification and is ubiquitously present in eukaryotic mRNA (19). Accumulating evidence supports a close link between m6A regulators and hypoxic states. A recent study reported that tumor hypoxia leads to the epigenetic remodeling of m6A (55). Qing et al. (56) reported that HIF-1α-induced YTHDF1 expression was closely related to hypoxia-induced autophagy-related HCC progression. However, the biological function of m6A methylation modification in distinct hypoxia-induced immune states remains unknown. Herein, we defined three m6A subtypes with different clinical outcomes *via* the same analysis of hierarchical clustering, which further confirmed that m6A methylation dysregulation plays a critical role in the tumorigenesis and progression of various neoplasms. Specifically, m6Acluster high comprised the worst prognosis and was related to the highest hypoxic state; m6Acluster low was associated with the best prognosis and correlated with the lowest hypoxic state. By clarifying m6A gene signatures and establishing the scoring system, we could further precisely assess the effect of m6A modification patterns on GC. Patients with invasive, EMT, m6Acluster high, and IV stage subtypes were significantly associated with a higher m6A score, which demonstrated that the m6A score was a reliable and robust tool for comprehensively evaluating m6A modification patterns



FIGURE 6 | Validation of signature through two immune-checkpoint blockade treatment cohorts. **(A, D)** Kaplan–Meier curves were plotted in **(A)** IMvigor210 cohort and **(D)** Nathanson2017 cohort to confirm the credibility of the signature. **(B, E)** the AUC in IMvigor210 cohort and ICB.Nathanson2017 cohort were 0.648 and 0.781, respectively. **(C, F)** The response of immune-checkpoint blockade treatment could be connected with high- and low-risk scores, especially in anti-CTLA-4 (χ^2 test). SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response.

and an independent prognostic biomarker for predicting patient survival in GC. Detailed associations between the m6A score and clinicopathological characteristics were found in our research. Our data also suggested a substantially negative relationship between the m6A score and tumor mutation burden (TMB). Moreover, we found that the high hypoxia cluster had a higher m6A score and that the low hypoxia cluster had a lower m6A score. Based on these results, we hypothesize that the immune-excluded phenotype of GC patients was accompanied by the activation of the m6A-related hypoxia pathway and the acquisition of other biological abilities, such as EMT and angiogenesis. Previous studies reported that EMT- and TGFβ-related signaling pathway activation led to a weakened transport of T cells into tumors as well as decreased tumor cytotoxicity (34, 57).

Finally, our study focused on the MRHPPG signature that demonstrated a prognostic value. In the training group, we initially recognized 25 MRHPPGs correlated with a prognosis and established a prognostic signature comprising 8 MRHPPGs *via* multivariate Cox regression and bootstrap-based univariate analysis with LASSO. Kaplan–Meier analysis suggested that the overall survival of patients with low risk scores was better than that of patients with high risk scores. A dramatically distinct risk score existed between nonresponders and responders, suggesting that we could more accurately predict the GC patients' clinical response to anti-PD-1/CTLA-4 immunotherapy through the MRHPPG risk score. In addition, the analyses of the biological activity of the gene signature indicated that high risk scores were significantly related to lower CD8-positive effector T-cell activity, lower immune checkpoint responses, and higher EMT, further demonstrating that the activation of the m6A-related hypoxia pathway played an important role in immune states, especially in the immune-excluded phenotype. Next, we built a nomogram to calculate a score representing the OS of GC patients. The calibration plot suggested that the model has a satisfactory fitting curve and better clinical application than the traditional staging system.

Several limitations in this research should be noted. First, several independent external validations were conducted in our research, but it was still difficult to include all of the diverse features of patients from different geographic regions when cases and materials were gathered retrospectively from public databases. Second, the microenvironment features of distinct tumor spatial regions might be different; however, the samples used for analysis were all from the tumor core. Additionally, our study was not completed enough to cover related bioinformatics analysis focusing on m6A RNA modification (e.g., databases like m6AVar and RMBase and functional tools like ConsRM and m6A2Target) (25, 28, 58). Therefore, further investigations based on well-designed, prospective, multicenter studies are required.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Nanchang University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZZ, HL and Z-KN conceived and designed this study. Z-KN and H-KT collected and assembled the data. C-GH and JL drafted the manuscript. Z-LY and H-NZ revised the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

This study was supported by the National Natural Science Foundation of China (Grant Number: 81860433 and 82103645), Training Plan for Academic and Technical Young Leaders of Major Disciplines in Jiangxi Province (Grant Number: 20204BCJ23021), the Natural Science Youth Foundation of Jiangxi Province (Grant Numbers: 20192BAB215036), the Key Technology Research and Development Program of Jiangxi Province (Grant Number: 20202BBG73024), the Foundation for Fostering Young Scholar of Nanchang University (Grant Number: PY201822) and Science and Technology plan of Jiangxi Provincial Health and Family Planning Commission (Grant Number: 20195072) and Chinese Medicine Foundation of Jiangxi Provincial Health Commission Administration (Grant Number: 2018B038).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.860041/full#supplementary-material

Supplementary Figure 1 | The characteristics of 3 hypoxiaClusters. **(A–D)** The different proportion of **(A)** Singapore patient cohort subtype, **(B)** ACRG subtype, **(C)** stage and **(D)** Lauren subtype were calculated *via* 3 hypoxiaClusters, respectively. **(E)** The comparison of hypoxiaCluster and previously hypoxia clustering characteristics. **(F)** A boxplot of cell composition in different hypoxiaCluster indicated hypoxiaCluster high was associated with high T-cell suppressive and exhaustion. **(G)** The heatmap was performed to reveal the difference of gene enrichment in 3 hypoxiaClusters. **(H)** The result of CIBERSORT deconvolution algorithm was described to assess the immune cell composition in 3 hypoxiaClusters. Only red name with "*" means statistical significance. **(I–J)** Kaplan–Meier curves to display prognostic difference after dividing patients into high and low groups. The log-rank test revealed that patients with high stromal score, low immune scores, high ESTIMATE score, or low tumor purity related to poor prognosis.

Supplementary Figure 2 | Hierarchical clustering of m6A methylation modification regulators. **(A)** Unsupervised hierarchical clustering analysis for m6A regulators with "ward.D2" linkage criterion was exhibited by cluster dendrogram, PCA and t-SNE. **(B, C)** Kaplan–Meier curves were plotted to demonstrate the difference of prognosis by overall survival (OS) and recurrence-free survival (RFS). **(D)** The difference of mRNA expression level of 23 m6A regulators was plotted in a

boxplot. **(E)** the heatmap was drawn to display the relationship of 23 m6A regulators and m6A clusters. **(F–H)** The different subtypes proportion of (F) Singapore patient cohort subtype, **(G)** ACRG subtype and (H) hypoxiaCluster showed specific connection with m6A clusters.

Supplementary Figure 3 | Further analysis on m6Ascore and validation of the signature and nomogram. **(A)**.Relationship between m6Ascore and tumor microenvironment burden (TMB) was plotted after student-t test, and r_{Person} was -0.50 and $CI_{95\%}$ [-0.58, -0.42]. **(B)** The waterfall plot depicted tumor somatic mutation with low m6Ascore. The numbers and bar plot on the right showed the mutation frequency of each gene and the proportion of each variant type, respectively. **(C)** Kaplan–Meier curves of TCGA cohort to be for validation. **(D)** The AUC in TCGA-STAD cohort achieved 0.60 (53.66%-66.89%, 95%CI), 0.65 (57.03%-72.31%, 95%CI), and 0.61 (47.81%-73.75%, 95%CI) at 3, 5, and 7 years respectively. **(E)** Different proportions of TCGA cohort subtype were influenced by high- and low-risk score. **(F)** An external validation cohort of GSE28541 showed significant difference of m6A. **(G)** the AUC 95% CI were 0.66 (57.27% - 74.76%, 95%CI), 0.64 (56.35% - 72.46%, 95%CI), and 0.64 (55.95% - 71.49%, 95%CI) at 3, 5, and 7 years respectively. **(H)** AUC for riskscore, stage and nomogram attained 0.646, 0.704 and 0.727, respectively, according to the m6Ascore. **(I–K)** Kaplan–Meier curves to show the OS difference were depicted on training cohort, testing cohort, and the entire cohort ($P < 0.0001$, log-rank test).

Supplementary Figure 4 | Decision tree. **(A)** Simulating clinical decision of ACRG cohort subtypes. **(B)** Alluvial diagram was performed on hypoxiaCluster, m6Ascore, ACRG subtypes, decision cluster result, and risk clusters to analyze the mutual connection. **(C)** Kaplan–Meier curves for the decision cluster result from the ACRG decision tree. **(D)** Simulating clinical decision of Singapore patient cohort subtypes. **(E)** Alluvial diagram was performed on hypoxiaCluster, m6Ascore, Singapore patient, decision cluster result, and risk clusters to analyze the mutual connection. **(F)** Kaplan–Meier curves for decision cluster result from Singapore patient decision tree.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric Cancer: A Comprehensive Review of Current and Future Treatment Strategies. *Cancer Metastasis Rev* (2020) 39(4):1179–203. doi: 10.1007/s10555-020-09925-3
3. Adam JB, Vesteinn T, Ilya S, Sheila MR, Michael M, Brady B. Comprehensive Molecular Characterization of Gastric Adenocarcinoma. *Nature* (2014) 513 (7517):202–9. doi: 10.1038/nature13480
4. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular Analysis of Gastric Cancer Identifies Subtypes Associated With Distinct Clinical Outcomes. *Nat Med* (2015) 21(5):449–56. doi: 10.1038/nm.3850
5. Choudhry H, Harris AL. Advances in Hypoxia-Inducible Factor Biology. *Cell Metab* (2018) 27(2):281–98. doi: 10.1016/j.cmet.2017.10.005
6. Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. *Trends Cancer* (2016) 2(12):758–70. doi: 10.1016/j.trecan.2016.10.016
7. Wigerup C, Påhlman S, Bexell D. Therapeutic Targeting of Hypoxia and Hypoxia-Inducible Factors in Cancer. *Pharmacol Ther* (2016) 164:152–69. doi: 10.1016/j.pharmthera.2016.04.009
8. Yuan S, Xiang Y, Wang G, Zhou M, Meng G, Liu Q, et al. Hypoxia-Sensitive LINC01436 Is Regulated by E2F6 and Acts as an Oncogene by Targeting miR-30a-3p in non-Small Cell Lung Cancer. *Mol Oncol* (2019) 13(4):840–56. doi: 10.1002/1878-0261.12437
9. Peña-Mercado E, Garcia-Lorenzana M, Arechaga-Ocampo E, González-De la Rosa CH, Beltran NE. Evaluation of HIF-1α and iNOS in Ischemia/Reperfusion Gastric Model: Bioimpedance, Histological and Immunohistochemical Analyses. *Histol Histopathol* (2018) 33(8):815–23. doi: 10.14670/hh-11-975
10. Chang YC, Chan YC, Chang WM, Lin YF, Yang CJ, Su CY, et al. Feedback Regulation of ALDOA Activates the HIF-1α/MMP9 Axis to Promote Lung Cancer Progression. *Cancer Lett* (2017) 403:28–36. doi: 10.1016/j.canlet.2017.06.001
11. Liu T, Jin L, Chen M, Zheng Z, Lu W, Fan W, et al. Ku80 Promotes Melanoma Growth and Regulates Antitumor Effect of Melatonin by Targeting HIF1-α Dependent PDK-1 Signaling Pathway. *Redox Biol* (2019) 25:101197. doi: 10.1016/j.redox.2019.101197
12. Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, et al. Loss-Of-Function Genetic Screening Identifies ALDOA as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. *Hepatology* (2021) 74(3):1461–79. doi: 10.1002/hep.31846
13. Turley SJ, Cremasco V, Astarita JL. Immunological Hallmarks of Stromal Cells in the Tumour Microenvironment. *Nat Rev Immunol* (2015) 15 (11):669–82. doi: 10.1038/nri3902
14. Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, et al. Topography of Cancer-Associated Immune Cells in Human Solid Tumors. *Elife* (2018) 7:e36967. doi: 10.7554/eLife.36967
15. Chen DS, Mellman I. Elements of Cancer Immunity and the Cancer-Immune Set Point. *Nature* (2017) 541(7637):321–30. doi: 10.1038/nature21349
16. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations. *J Immunother Cancer* (2018) 6(1):8. doi: 10.1186/s40425-018-0316-z
17. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. *Science* (2018) 359(6371):91–7. doi: 10.1126/science.aan3706
18. Gibney GT, Weiner LM, Atkins MB. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. *Lancet Oncol* (2016) 17(12):e542–e51. doi: 10.1016/S1470-2045(16)30406-5
19. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-Methyladenosine Modulates Messenger RNA Translation Efficiency. *Cell* (2015) 161(6):1388–99. doi: 10.1016/j.cell.2015.05.014
20. Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, et al. The Interplay Between M6a RNA Methylation and Noncoding RNA in Cancer. *J Hematol Oncol* (2019) 12 (1):121. doi: 10.1186/s13045-019-0805-7
21. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-Methyladenosine and Its Role in Cancer. *Mol Cancer* (2019) 18(1):176. doi: 10.1186/s12943-019-1109-9
22. Shen X, Hu B, Xu J, Qin W, Fu Y, Wang S, et al. The M6a Methylation Landscape Stratifies Hepatocellular Carcinoma Into 3 Subtypes With Distinct Metabolic Characteristics. *Cancer Biol Med* (2020) 17(4):937–52. doi: 10.20892/j.issn.2095-3941.2020.0402
23. Wang YJ, Yang B, Lai Q, Shi JF, Peng JY, Zhang Y, et al. Reprogramming of M(6)A Epitranscriptome Is Crucial for Shaping of Transcriptome and Proteome in Response to Hypoxia. *RNA Biol* (2021) 18(1):131–43. doi: 10.1080/15476286.2020.1804697
24. Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y, et al. The Evolving Landscape of N(6)-Methyladenosine Modification in the Tumor Microenvironment. *Mol Ther* (2021) 29(5):1703–15. doi: 10.1016/j.ymthe.2021.04.009
25. Zheng Y, Nie P, Peng D, He Z, Liu M, Xie Y, et al. M6avar: A Database of Functional Variants Involved in M6a Modification. *Nucleic Acids Res* (2018) 46(D1):D139–D45. doi: 10.1093/nar/gkx895
26. Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, et al. RMBase V2.0: Deciphering the Map of RNA Modifications From Epitranscriptome Sequencing Data. *Nucleic Acids Res* (2018) 46(D1):D327–D34. doi: 10.1093/nar/gkx934
27. Song B, Chen K, Tang Y, Wei Z, Su J, de Magalhaes JP, et al. ConsRM: Collection and Large-Scale Prediction of the Evolutionarily Conserved RNA Methylation Sites, With Implications for the Functional Epitranscriptome. *Brief Bioinform* (2021) 22(6):bbab088. doi: 10.1093/bib/bbab088
28. Deng S, Zhang H, Zhu K, Li X, Ye Y, Li R, et al. M6A2Target: A Comprehensive Database for Targets of M6a Writers, Erasers and Readers. *Brief Bioinform* (2021) 22(3):bbaa055. doi: 10.1093/bib/bbaa055
29. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The Sva Package for Removing Batch Effects and Other Unwanted Variation in High-Throughput Experiments. *Bioinformatics* (2012) 28(6):882–3. doi: 10.1093/bioinformatics/bts034

30. Liu ZX, Li LM, Sun HL, Liu SM. Link Between M6a Modification and Cancers. *Front Bioeng Biotechnol* (2018) 6:89. doi: 10.3389/fbioe.2018.00089
31. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. *PloS Genet* (2009) 5(10):e1000676. doi: 10.1371/journal.pgen.1000676
32. Hänzelmann S, Castelo R, Guinney J. GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7
33. García-Mulero S, Alonso MH, Pardo J, Santos C, Sanjuan X, Salazar R, et al. Lung Metastases Share Common Immune Features Regardless of Primary Tumor Origin. *J Immunother Cancer* (2020) 8(1):e000491. doi: 10.1136/jitc-2019-000491
34. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. Tgfβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. *Nature* (2018) 554(7693):544–8. doi: 10.1038/nature25501
35. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612
36. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust Enumeration of Cell Subsets From Tissue Expression Profiles. *Nat Methods* (2015) 12(5):453–7. doi: 10.1038/nmeth.3337
37. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007
38. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer. *Genome Res* (2018) 28(11):1747–56. doi: 10.1101/gr.239244.118
39. Kerker M. Classics and Classicists of Colloid and Interface Science 8. Albert Einstein. *J Colloid Interface Sci* (1989) 129(1):291–95. doi: 10.1016/0021-9797(89)90442-6
40. Park T, Casella G. The Bayesian Lasso. *J Am Stat Assoc* (2008) 103(482):681–6. doi: 10.1198/016214508000000337
41. Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G, et al. Macrophage Correlates With Immunophenotype and Predicts Anti-PD-L1 Response of Urothelial Cancer. *Theranostics* (2020) 10(15):7002–14. doi: 10.7150/thno.46176
42. Austin PC, Steyerberg EW. Graphical Assessment of Internal and External Calibration of Logistic Regression Models by Using Loess Smoothers. *Stat Med* (2014) 33(3):517–35. doi: 10.1002/sim.5941
43. Hazra A, Gogtay N. Biostatistics Series Module 3: Comparing Groups: Numerical Variables. *Indian J Dermatol* (2016) 61(3):251–60. doi: 10.4103/0019-5154.182416
44. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and Comparing Time-Dependent Areas Under Receiver Operating Characteristic Curves for Censored Event Times With Competing Risks. *Stat Med* (2013) 32(30):5381–97. doi: 10.1002/sim.5958
45. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: An Open-Source Package for R and S+ to Analyze and Compare ROC Curves. *BMC Bioinf* (2011) 12:77. doi: 10.1186/1471-2105-12-77
46. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. M(6)A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Gastric Cancer. *Mol Cancer* (2020) 19(1):53. doi: 10.1186/s12943-020-01170-0
47. Gao JP, Xu W, Liu WT, Yan M, Zhu ZG. Tumor Heterogeneity of Gastric Cancer: From the Perspective of Tumor-Initiating Cell. *World J Gastroenterol* (2018) 24(24):2567–81. doi: 10.3748/wjg.v24.i24.2567
48. Liu Y, Wu J, Huang W, Weng S, Wang B, Chen Y, et al. Development and Validation of a Hypoxia-Immune-Based Microenvironment Gene Signature for Risk Stratification in Gastric Cancer. *J Transl Med* (2020) 18(1):201. doi: 10.1186/s12967-020-02366-0
49. Allen M, Louise Jones J. Jekyll and Hyde: The Role of the Microenvironment on the Progression of Cancer. *J Pathol* (2011) 223(2):162–76. doi: 10.1002/path.2803
50. Jiang Y, Xie J, Huang W, Chen H, Xi S, Han Z, et al. Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer. *Cancer Immunol Res* (2019) 7(12):2065–73. doi: 10.1158/2326-6066.CIR-19-0311
51. Lin R, Zhang H, Yuan Y, He Q, Zhou J, Li S, et al. Fatty Acid Oxidation Controls CD8(+) Tissue-Resident Memory T-Cell Survival in Gastric Adenocarcinoma. *Cancer Immunol Res* (2020) 8(4):479–92. doi: 10.1158/2326-6066.CIR-19-0702
52. Harris AL. Hypoxia–a Key Regulatory Factor in Tumour Growth. *Nat Rev Cancer* (2002) 2(1):38–47. doi: 10.1038/nrc704
53. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of Hypoxia in Cancer Therapy by Regulating the Tumor Microenvironment. *Mol Cancer* (2019) 18(1):157. doi: 10.1186/s12943-019-1089-9
54. Joyce JA, Fearon DT. T Cell Exclusion, Immune Privilege, and the Tumor Microenvironment. *Science* (2015) 348(6230):74–80. doi: 10.1126/science.aaa6204
55. Gu C, Wang Z, Zhou N, Li G, Kou Y, Luo Y, et al. Mettl14 Inhibits Bladder TIC Self-Renewal and Bladder Tumorigenesis Through N(6)-Methyladenosine of Notch1. *Mol Cancer* (2019) 18(1):168. doi: 10.1186/s12943-019-1084-1
56. Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, et al. HIF-1α-Induced Expression of M6a Reader YTHDF1 Drives Hypoxia-Induced Autophagy and Malignancy of Hepatocellular Carcinoma by Promoting ATG2A and ATG14 Translation. *Signal Transduct Target Ther* (2021) 6(1):76. doi: 10.1038/s41392-020-00453-8
57. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. Tgfβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis. *Nature* (2018) 554(7693):538–43. doi: 10.1038/nature25492
58. Luo X, Li H, Liang J, Zhao Q, Xie Y, Ren J, et al. RMVar: An Updated Database of Functional Variants Involved in RNA Modifications. *Nucleic Acids Res* (2021) 49(D1):D1405–D12. doi: 10.1093/nar/gkaa811

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

frontiers | Frontiers in Immunology

ORIGINAL RESEARCH
published: 06 July 2022
doi: 10.3389/fimmu.2022.813031

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma

Xiaoxuan Wang[1†], Yaxiao Lu[1†], Ziyi Liu[2†], Yidan Zhang[1], You He[2], Cong Sun[3], Lanfang Li[1], Qiongli Zhai[4], Bin Meng[4], Xiubao Ren[5], Xudong Wu[1,2], Huilai Zhang[1*] and Xianhuo Wang[1*]*

[1] Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China, [2] State Key Laboratory of Experimental Hematology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China, [3] "5+3" Integration of Clinical Medicine, Tianjin Medical University, Tianjin, China, [4] Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, [5] Department of Immunology/Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. To assign patients into different risk categories, cytogenetic abnormalities and genetic mutations have been widely applied to the prognostic stratification of DLBCL. Increasing evidence has demonstrated that deregulated epigenetic modifications and long noncoding RNAs (lncRNAs) contribute to the initiation and progression of DLBCL. However, specific lncRNAs that affect epigenetic regulation and their value in predicting prognosis and therapy response remain uncertain. Here, 2,025 epigenetic-related genes were selected, and 9 lncRNAs (PRKCQ-AS1, C22orf34, HCP5, AC007389.3, APTR, SNHG19, ELFN1-AS1, LINC00487, and LINC00877) were tested and validated to establish an lncRNA-regulating epigenetic event signature (ELncSig). ELncSig, which was established based on independent lymphoma datasets, could distinguish different survival outcomes. Functional characterization of ELncSig showed that it could be an indicator of the immune microenvironment and is correlated with distinctive mutational characteristics. Univariate and multivariate analyses showed that ELncSig was independent of traditional prognostic factors. The novel immune-related ELncSig exhibits promising clinical prognostic value for DLBCL.

Keywords: diffuse large B-cell lymphoma, signature, risk score, immune infiltration, prognosis

OPEN ACCESS

Edited by:
Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India

Reviewed by:
Arthur L. Shaffer, III, National Cancer Institute (NIH), United States
Ken Young, Duke University, United States
Hanno Maximilian Witte, Bundeswehrkrankenhaus, Germany

***Correspondence:**
Xudong Wu
wuxudong@tmu.edu.cn
Huilai Zhang
zhlwgq@126.com
Xianhuo Wang
xwang11@tmu.edu.cn

†These authors contributed equally to this work

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: *11 November 2021*
Accepted: *03 June 2022*
Published: *06 July 2022*

Citation:
Wang X, Lu Y, Liu Z, Zhang Y, He Y, Sun C, Li L, Zhai Q, Meng B, Ren X, Wu X, Zhang H and Wang X (2022) A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma. Front. Immunol. 13:813031. doi: 10.3389/fimmu.2022.813031

INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm in adults. Through cell-of-origin (COO) classification, DLBCL can be identified as activated B-cell-like (ABC), germinal center B-cell-like (GCB), and unclassified subtypes (1). The heterogeneity of DLBCL is reflected in the genetic differences among all subtypes (2). Accumulating evidence

indicates that epigenetic regulation plays an important role in DLBCL pathogenesis (3, 4). However, studies of the epigenetic typing of DLBCL are limited. Since epigenetic regulation affects cellular immunity (5), the epigenetic signature of DLBCL is particularly significant.

The tumor microenvironment is important for the growth, invasion, and spread of DLBCL (6–8). The tumor microenvironment is a local pathological environment composed of a variety of cells and biomolecules. Epigenetic regulators play critical roles in DLBCL (9). LncRNAs act in cis or trans to regulate transcription. Recent studies have shown that lncRNAs regulate the interaction between tumor cells and the microenvironment (10), thereby affecting tumor occurrence, development, and metastasis (11). However, research on the role of lncRNAs in lymphoma is not sufficient.

In this study, we developed a novel scoring signature based on lncRNAs to predict the survival outcomes of DLBCL patients. The 9-lncRNA signature provides an improved risk stratification option for patients with DLBCL and sheds new light on potential targeted therapeutic strategies, especially in immunotherapy.

MATERIALS AND METHODS

Patients

Collection and Preprocessing of Public Cohort Data

The gene expression data and clinical features of DLBCL samples were collected from the GEO database (http://www.ncbi.nlm.nih.gov/geo/) according to the following selection criteria: (1) basic clinical information on age, gender, IPI score, ECOG-PS, lactate dehydrogenase (LDH) concentration, Ann Anbor stage, extranodal sites, treatment regimen, OS, and survival status; and (2) a large sample size (>300). The GSE10846 (12) and GSE31312 (13) microarray datasets were downloaded.

TMUCIH Cohort

The TMUCIH validation cohort enrolled DLBCL patients (n = 188) at Tianjin Medical University Cancer Institute and Hospital (TMUCIH; Tianjin, China) from 2008 to 2018. All patients were diagnosed and further confirmed centrally by two experienced pathologists independently (based on the 2008 WHO classification). Patients with complete clinicopathological and follow-up data were included. The major exclusion criteria were as follows: (1) insufficient biopsy material or samples with less than 80% tumor cells, DNA content < 1 μg, and RNA < 5 ng/L; and (2) patients did not have *de novo* DLBCL. The study protocol was approved by the Institutional Review Board of TMUCIH, and all patients provided written informed consent. The reference number of the ethical approval of the current study is bc2021032.

Data Integration for the Three Cohorts

The microarray data of 305 (GSE10846) and 404 (GSE31312) samples from DLBCL datasets and TMUCIH (n = 160) were used in this study. Samples with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements were excluded. The combat function from the "sva" R package was used to remove the batch effects among different cohorts. A total of 869 patients were eligible, and the clinical information of the patients from the three datasets is shown in **Table 1**.

TABLE 1 | Demographic and baseline characteristics of patients enrolled to construct and validate the epigenetic risk score.

	GEO training cohort (GSE10846) n = 305	TMUCIH validation cohort n = 160	GEO training cohort (GSE31312) n = 404
Age (years), *n* (%)			
>60	159 (52.13)	79 (49.38)	238 (58.91)
≤60	146 (47.87)	81 (50.62)	166 (41.09)
Gender, *n* (%)			
Male	171 (56.07)	97 (60.62)	235 (58.17)
Female	134 (43.93)	63 (39.38)	169 (41.83)
ECOG-PS, *n* (%)			
<2	230 (75.41)	137 (85.63)	342 (84.65)
≥2	75 (24.59)	23 (14.38)	62 (15.35)
LDH concentration, *n* (%)			
Normal	157 (51.48)	70 (43.75)	141 (34.90)
Elevated	148 (48.52)	90 (56.25)	263 (65.10)
Ann Anbor stage, *n* (%)			
I–II	144 (47.21)	95 (59.38)	193 (47.78)
III–IV	161 (52.79)	65 (40.62)	211 (52.22)
IPI score, *n* (%)			
0–2	–	116 (72.5)	258 (63.86)
3–5	–	44 (27.5)	146 (36.14)
Extranodal sites, *n* (%)			
<2	140 (45.90)	124 (77.5)	315 (77.97)
≥2	165 (54.10)	36 (22.5)	89 (22.03)
Treatment, *n* (%)			
CHOP-like	142 (46.56)	93 (58.13)	–
R-CHOP-like	163 (53.44)	67 (41.87)	404 (100)

Elevated LDH, >245 U/L; ECOG-PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.

All of the samples from the 160 TMUCIH patients were subjected to targeted deep resequencing using 307 lymphoma-related gene panels (**Supplementary Table S1**) with a total of 26,372 probes and a total probe coverage of 1.666 Mbp. Mutations were identified in 154 of the 160 patients in the TMUCIH cohort (**Supplementary Table S2**).

Generating the lncRNA-Based Prognostic Signature

For the database samples, we obtained sequencing data from GEO, and we annotated by conversion to the corresponding probe platform ID. Then, a list of epigenetic regulatory genes was generated from GeneCards (https://www.genecards.org /), with a criterion of relevance score >0.5 (n = 2,025, **Supplementary Table S3**). To demonstrate that these 2,025 genes have epigenetically related biological functions, functional enrichment was performed by Metascape (14) (https://metascape.org/gp/index.html#/main/step1).

To assess the association between lncRNA expression and OS, we identified lncRNAs regulating epigenetic events (ELncRNAs) by correlation analysis ($|r| > 0.4$, $p < 0.01$, $n = 380$) (**Supplementary Table S4**). In the GSE10846 cohort, 305 patients were included in a training cohort to generate the prognostic signature. To construct a predictive model, we performed linear regression based on the modified LASSO algorithm using the "glmnet" R package. The ELncSig risk score associated with OS was calculated using the sum of values weighted by the coefficients from the LASSO Cox regression model. The ELncSig score was calculated as follows: (−0.28824 × PRKCQ-AS1 expression) + (0.24206 × C22orf34 expression) − (0.18161 × HCP5 expression) + (0.20887 × AC007389.3 expression) + (0.19686 × APTR expression) + (0.23126 × SNHG19 expression) + (0.33924 × ELFN1-AS1 expression) − (0.13390 × LINC00487 expression) − (0.09065 × LINC00877 expression). Patients were ranked according to the 9-lncRNA signature and dichotomized into high- and low-risk groups.

Overall Survival Probability Prediction

Receiver operating characteristic (ROC) analysis provides tools to select possibly optimal models and to discard suboptimal ones independently from (and prior to specifying) the cost context or the class distribution. In the case of a balanced diagonal, ROC analysis will tend to the point (0.5, 0.5). Points above the diagonal represent good classification results (better than random); points below the line represent bad results (worse than random). The greater the area under the curve (AUC), the better the survival probability prediction of the model. We also selected clinical characteristics that can be used as independent prognostic factors in multivariate analysis to establish the nomogram (15). The scores corresponding to clinical characteristics can be used to predict patient survival at 1, 3, and 5 years. Model calibration is evaluated by calibration plots of the predicted probability of death at 5 years versus the observed probability. The nomogram-predicted overall survival is plotted on the x-axis, with observed overall survival on the y-axis. Dashed lines along the diagonal line through the origin point represent perfect calibration models in which the predicted probabilities are identical to the observed probabilities (16).

Screening for DEGs and Pathway Enrichment

DEGs were identified between the high-risk and low-risk ELncSig groups. The "limma" R package (17) was used in the standard comparison mode. DEG cutoffs were $|\log_2\text{FoldChange}\ (\log_2\text{FC})| > 1$ and $p < 0.05$. GO functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the DEGs were performed using the "clusterProfiler" package in R ($p < 0.05$).

Determination of Immune Cell Infiltration

Immune infiltration was estimated using single-sample gene set enrichment analysis (ssGSEA) (18), and the abundance of 28 immune cell types in the tumor microenvironment was quantified in a range from 0 to 1. The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm (https://cibersort.stanford.edu/) was used to quantify the relative abundance of 22 immune cell types. After 100 permutations, the gene expression data were quantile normalized.

Significantly Mutated Genes in Important DLBCL Pathways

The accurate diagnosis of lymphoma relies on gene mutation analysis (19). Considering that each DLBCL patient had different mutation types, we chose 307 lymphoma-related genes and performed targeted gene deep sequencing to determine the genetic compositions of the two ELncSig groups. To determine the differences in important mutated genes, the "maftools" (20) R package was used. The lists of critical pathways and genes in DLBCL were obtained from Young et al. (9).

Identification of Epigenetic mRNAs Related to ELncSig

A co-expression network of ELncSig including lncRNAs and mRNAs was constructed and visualized using Cytoscape (https://cytoscape.org/). A Sankey diagram showing the associations between the prognostic ELncSig and lncRNAs, mRNAs, and risk type was constructed by the "ggalluvial" R package. The correlations of each ELncRNA with mRNAs are listed in **Supplementary Table S5**.

Immunohistochemistry Analysis and Evaluation

The use of human remnant DLBCL samples for this study from TMUCIH was approved by the TMUCIH Institutional Review Board (bc2021032). Each biopsy was reviewed by two experienced hematopathologists for diagnostic confirmation. Sections (5 μm thick) of formalin-fixed and paraffin-embedded (FFPE) lymph nodes were dewaxed, hydrated, and heated for antigen retrieval. The cells were blocked with hydrogen peroxide and normal goat serum, incubated overnight with PIM1

(Abcepta, cat# AP7932d, 1:100) and stained with 3,3′-diaminobenzidinetetra hydrochloride (DAB). The PIM1 intensity score was determined as follows: 0—no staining, 1—definite but weak staining, 2—moderate staining, and 3—strong staining. Stained tissue scores were blindly reviewed by two pathologists.

Statistical Analysis

All statistical and computational analyses were performed with R version 4.0.3 (https://www.r-project.org/). The unpaired Student's *t*-test was used to compare two clusters with normally distributed variables. Survival outcomes were estimated with the Kaplan–Meier method, and the differences between survival distributions were evaluated by log-rank analysis with the "survival" package in R software. The Wilcoxon test was used to compare two clusters with nonnormally distributed variables. Contingency table variable analysis was completed by two-sided Fisher's exact tests. We used the ELncSig risk score and clinical characteristic covariates to construct a nomogram to estimate survival. The accuracy of the nomogram was measured using the calibration curve. Univariate and multivariate analyses of prognosis were evaluated using a Cox proportional hazards regression model. The statistical significance cutoff was set at $p < 0.05$.

RESULTS

Construction of an Epigenetic-Related lncRNA Risk Signature

After removing the clinical samples meeting the exclusion criteria, a total of 869 samples were included as the subjects of this study. The study flowchart is shown in **Figure 1A**. Metascape analyses showed the diverse biological processes of 2,025 genes (**Figure 1B**).

Through Pearson correlation analysis, we identified 380 ELncRNAs ($|r| > 0.4$, $p < 0.01$), which were then subjected to univariate analysis. After modified LASSO regression analysis with tenfold cross-validation, repeated 1,000 times ($p < 0.05$) with random simulation 13 ELncRNAs were extracted (**Figures 2A, B**). After multivariate analysis, 9 lncRNAs were tested and validated to establish ELncSig (**Figure 2C**, **Supplementary Table S6**). A heatmap of the expression levels of the 9 identified lncRNAs and a scatterplot of OS with relevant risk scores are presented in **Figure 2D**. Among the 9 lncRNAs, 5 lncRNAs were identified as poor prognostic factors (**Supplementary Figure S1A**), while another 4 were identified as favorable prognostic factors (**Supplementary Figure S1B**).



FIGURE 1 | Study flowchart and epigenetic-related gene enrichment pathways. **(A)** The workflow of the study. **(B)** Different colors indicate the 2,025 epigenetic-related gene annotations and biological processes provided by Metascape.

Evaluation of ELncSig as an Independent Prognostic Factor for DLBCL

To identify the efficacy of ELncSig for DLBCL survival prediction, the training cohort samples were divided into a low-risk group (n = 152) and a high-risk group (n = 153) using the median risk score as a cutoff point. Low-risk patients had significantly better OS than high-risk patients (**Figure 3A**). Kaplan–Meier analysis in the internal validation cohort also indicated that ELncSig could be a good prognostic factor (**Figure 3B**). This association remained markedly significant in the multivariate Cox model in the training and validation cohorts (**Table 2**). Data from another external validation cohort from GSE98588 are shown in **Supplementary Figure S2**. One external validation cohort (GSE31312) only contained patients treated with an R-CHOP-like regimen, and their survival could be acceptably stratified by the ELncSig risk score (**Figure 3C**). Because the risk score model was developed based on all patients, to verify its reliability, we tested the model in patients who were only treated with an R-CHOP-like regimen in the training cohort (GSE10846) and the external validation cohort (GSE98588). The ELncSig model was effective in these patient populations treated with R-CHOP (**Supplementary Figure S3**).

Next, we calculated the AUCs for each ROC curve to assess the predictive accuracy of the model. The AUC value is often used as the evaluation criterion for a model (21). In time-dependent ROC analysis at 1, 3, and 5 years, the AUC values were 0.765, 0.780, and 0.760, respectively (**Figure 3D**). For the validation cohorts, higher AUC values were obtained for 5-year survival (**Figures 3E, F**).

The tumor-related clinicopathological features of the two ELncSig groups were evaluated in the training cohort. We found that the patient age (p = 0.003), plasma lactate dehydrogenase (LDH) levels (p =0.007), Eastern Cooperative Oncology Group performance status (ECOG-PS, p = 0.002), COO classification (p = 0.018), and extranodal sites (p = 0.038) were significantly correlated with ELncSig (**Figure 3G**, **Supplementary Table S7**). The tumor-related clinicopathological features in these datasets were inferior to ELncSig (**Figure 3H**) in the training cohort. A nomogram for 1-, 3-, and 5-year mortality was constructed (**Figure 3I**), and the calibration for 5 years indicated that the mortality estimated by the nomogram was close to the actual mortality (**Figure 3J**). Hence, ELncSig predicts 5-year survival better. The validation cohort results are shown in **Supplementary Figure S4**.

Identification of DEGs Between the ELncSig Groups

To uncover the biological distinction between the two ELncSig groups, we performed DEG analysis in the GSE10846 and TMUCIH cohorts combined. The heatmap of the DEGs between the high-risk and low-risk ELncSig groups is shown in **Figure 4A** (|fold change| >1.5, adjusted p < 0.01). After comparing the high-risk group with the low-risk group, 172 upregulated and 154 downregulated genes were identified (**Supplementary Table S8**). We found that the primary central nervous system DLBCL-related protein HPDL, the tumor necrosis factor receptor superfamily member TNFRSF13B, and the serine/threonine protein kinase family members PIM1 and

TABLE 2 | Univariate and multivariate Cox regression analysis of predictors of survival outcomes in the training and validation cohorts.

	Univariate Analysis		Multivariate Analysis	
Variable	***p***	**HR (95% CI)**	***p***	**HR (95% CI)**
GSE10846 training cohort				
Age (>60 vs. ≤60)	<0.001	0.48 (0.330–0.697)	0.003	0.56 (0.38–0.82)
Gender (Female vs. Male)	0.659	0.92 (0.646–1.318)	0.908	1.02 (0.71–1.47)
COO class (GCB vs. nonGCB)	<0.001	2.57 (1.724–3.839)	0.018	1.65 (1.09–2.50)
LDH concentration (Elevated vs. Normal)	<0.001	0.41 (0.280–0.591)	0.007	0.57 (0.38–0.86)
ECOG-PS (≤1 vs. ≥2)	<0.001	2.77 (1.916–4.004)	0.002	1.86 (1.24–2.78)
Rituximab (No vs. Yes)	0.001	0.54 (0.366–0.787)	0.956	1.01 (0.62–1.65)
Extranodal sites (<2 vs. ≥2)	0.053	1.86 (0.993–3.471)	0.038	2.13 (1.04–4.35)
ELncSig (high risk vs. low risk)	<0.001	0.24 (0.155–0.364)	<0.001	0.26 (0.16–0.43)
TMUCIH validation cohort				
Age (>60 vs. ≤60)	0.028	0.56 (0.329–0.937)	0.036	0.53 (0.29–0.96)
Gender (Female vs. Male)	0.445	1.23 (0.722–2.099)	0.748	0.91 (0.51–1.62
ECOG-PS (≤1 vs. ≥2)	0.407	1.33 (0.675–2.634)	0.267	1.53 (0.72–3.26)
LDH concentration (Elevated vs. Normal)	0.002	0.43 (0.257–0.726)	0.274	0.68 (0.34–1.36)
COO class (GCB vs. nonGCB)	0.073	1.61 (0.956–2.727)	0.002	2.44 (1.21–4.21)
IPI score (0–2 vs. 3–5)	<0.001	2.91 (1.741–4.868)	0.795	0.88 (0.35–2.25)
Rituximab (No vs. Yes)	0.176	0.69 (0.402–1.181)	0.093	0.62 (0.35–1.08)
Ann Anbor stage (I–II vs. III–IV)	0.012	1.93 (1.156–3.215)	0.540	1.24 (0.62–2.49)
Extranodal sites (<2 vs. ≥2)	<0.001	2.88 (1.691–4.912)	0.011	2.26 (1.21–4.21)
ELncSig (high risk vs. low risk)	<0.001	0.28 (0.153–0.495)	<0.001	0.28 (0.14–0.54)

HR, hazard ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; RCHOP, rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisone; LDH, lactate dehydrogenase; COO, cell of origin; GCB, germinal center B-cell like.



FIGURE 2 | Construction of the epigenetic-related lncRNA signature (ELncSig). **(A)** Thirteen epigenetic-related lncRNAs were selected by LASSO Cox regression analysis. **(B)** Cross-validation for tuning parameter selection in the proportional hazards model. **(C)** A forest map showing 9 lncRNAs identified by the stepwise method. **(D)** Risk score distribution, survival status, and lncRNA expression of DLBCL patients in high- and low-risk groups classified by the 9-ELncRNA signature in the training cohort.

PIM2 were upregulated in the high-risk group, while the histone gene HIST1H1B and protective lncRNAs in ELncSig, such as LINC00487 and LINC00877, were downregulated in the high-risk group (**Figure 4B**).

Subsequently, KEGG enrichment analysis of the DEGs indicated enrichment of primary immunodeficiency, the T-cell receptor signaling pathway, cytokine–cytokine receptor interaction, the PI3K-Akt signaling pathway, and Th17-cell differentiation (**Figure 4C**, **Supplementary Table S9**). GO enrichment analysis indicated enrichment of genes involved in positive regulation of leukocyte cell–cell adhesion, regulation of T-cell activation, and T-cell co-stimulation (**Figure 4D**, **Supplementary Table S10**). After GSEA of the high-risk and low-risk groups, similar results were found, as shown in **Supplementary Figure S5**.

Estimation of the Tumor-Infiltrating Immune Cells of the Two ELncSig Groups

The pathway enrichment results indicated that the different prognoses of ELncSig are closely associated with immune infiltration. We assessed the composition of tumor-infiltrating immune cells in DLBCL samples by the CIBERSORT algorithm (22). The histogram showed that memory B cells, M0 macrophages, and T cells were obviously highly abundant in DLBCL samples (**Figure 5A**), and they might play essential roles in the initiation and development of DLBCL (23, 24). Using ssGSEA to show the different immune components between the two ELncSig groups, we found that compared with the high-risk group, $CD8^+$ T cells, T helper cells, macrophages, Th1 and Th2 cells, CCR, and T-cell co-stimulatory cells were enriched in the low-risk ELncSig group ($p < 0.05$, **Figure 5B**). We further compared the ESTIMATE score, stromal score, immune score, and tumor purity (25). As shown in **Figure 5C**, the low-risk ELncSig group had significantly higher ESTIMATE scores, stromal scores, and immune scores and a lower tumor purity ($p < 0.001$).

Potential of ELncSig as an Indicator of Immunotherapy Response in DLBCL Patients

Immunogenic cell death (ICD) and immune checkpoints (ICPs) play important roles in the tumor immune microenvironment (26–28). As shown in **Figure 6A**, the expression levels of various ICD genes, such as CXCL10, IFNAR2, P2RX7, TLR4, EIF2A, HMGB1, and TLR3, were significantly upregulated in the low-risk ELncSig group. Similar to ICD genes, ICPs can also reflect the immune status of the tumor microenvironment. The PD-1 and PD-L1 checkpoints were highly expressed in the high-risk ELncSig group (**Figure 6B**). The survival distribution of the two patient groups stratified by ELncSig and high/low ICP gene



FIGURE 3 | Prognostic value of the risk model including 9 epigenetic-related lncRNAs. **(A–F)** Kaplan–Meier survival curves of the high- and low-risk groups and time-dependent receiver operating characteristic (ROC) curves at 1-, 3-, and 5-year overall survival (OS) in the training (GSE10846) and validation (TMUCIH and GSE31312) cohorts. **(G)** Heatmap showing the comparison of the clinicopathological characteristics of DLBCL patients in the high- and low-risk GSE10846 groups. **(H)** Time-dependent ROC curve analyses for predicting OS at 5 years with clinicopathological characteristics. **(I)** The nomogram was constructed using high and low ELncSig scores, age, LDH, GCB vs. non-GCB, ECOG, and extranodal sites to predict 1-, 3-, and 5-year survival. **(J)** Calibration plots for the probability of 5-year survival in the training cohort.

expression was compared. As shown in **Figures 6C, D**, patients with low ELncSig and high PD-1/PD-L1 had significantly better survival than those with high ELncSig and high PD-1/PD-L1 (log-rank $p < 0.0001$), and patients with low ELncSig and low PD-1 also had prolonged survival relative to those with high ELncSig and low PD-1 (log-rank $p < 0.0001$). Similar results for two other important checkpoints, TNFRSF4 and IDO1, are shown in **Supplementary Figure S6**.

Differences In Important Gene Mutations Between the Two ELncSig Groups

The use of cytogenetic abnormalities and genetic mutations for the prognostic stratification of DLBCL and assignment of patients into different risk categories has been widely studied (2, 29). We investigated whether critical differences in pathways related to somatic mutation frequencies exist between the two groups. Because the online databases lack sufficient mutation information, we further analyzed significantly mutated genes in the TMUCIH validation cohort by performing targeted deep resequencing of 307 lymphoma-related gene panels. Based on the results of previous studies, we established a mutational landscape of the important genes in DLBCL (**Figure 7A**, **Supplementary Table S11**).

Abundant genetic alterations in various critical pathways, such as the epigenetic regulator pathway (KMT2D, $p = 0.034$), the BCR and TLR signaling pathway (MYD88, $p = 0.003$), B-cell development and differentiation (BCL11A, $p = 0.02308$), and the cell cycle pathway (BTG1, $p = 0.009$), were significantly enriched in the high-risk



FIGURE 4 | Gene expression differences and relevant biological pathways between the high- and low-risk ELncSig groups. **(A)** Heatmap of differentially expressed genes between the high- and low-risk ELncSig groups and their clinicopathological characteristics. **(B)** The volcano plot showing upregulated and downregulated genes between the two groups ($|\log_2 FC| > 1$, adjusted $p < 0.05$). **(C)** Heatmap showing the KEGG pathways enriched in the high- and low-risk ELncSig groups. **(D)** Circle map showing the immune-related pathways regulated by DEGs between the two groups and the genes included in the pathways.



FIGURE 5 | Differences in immune infiltration between the high- and low-risk ELncSig groups. **(A)** The composition of immune cells assessed by the Cell Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm in the training cohort. **(B)** Heatmap showing the relative abundances of 28 infiltrating immune cell subpopulations between the high- and low-risk ELncSig groups according to single-sample gene set enrichment analysis (ssGSEA). **(C)** The ESTIMATE score, stromal score, immune score, and tumor purity of EC1 and EC2 according to the CIBERSORT algorithm.



FIGURE 6 | Impact of immunogenic cell death (ICD) modulators and immune checkpoint gene expression on clinical outcome. **(A)** Differential expression of ICD modulators between the high- and low-risk ELncSig groups. **(B)** Immune checkpoint expression of PD-1 and PD-L1. **(C, D)** Kaplan–Meier survival curves of overall survival among the four patient groups stratified by ELncSig and PD-1 and PD-L1. *p < 0.05, **p < 0.01, ***p < 0.001.

ELncSig group. Interestingly, SPEN (p = 0.027) in the NOTCH pathway was mutated more frequently in the low-risk ELncSig group.

KMT2D (lysine methyltransferase 2D, MLL2), a chromatin epigenetic modifier, plays a vital role in modulating ICP blockade (30). MYD88 mutation is one of the most remarkable drivers in the development of DLBCL (31), and the L265P mutation is now thought to be common to virtually all NHLs and occurs in between 4% and 90% of cases, depending on the entity (32). PIM1, as a DEG and a high-frequency gene in DLBCL, also affects the prognosis of patients (33) and has a trend of mutational differences between the two groups. Hence, we selected these three genes to analyze their specific mutation sites. It was obvious that in the high-risk group, PIM1 had more vital mutation sites in S97T, E135Q, and K183-L184del, and it has already been reported that mutated PIM1 may lead to a poor prognosis (34) (**Figures 7B–D**).



FIGURE 7 | Differences in somatic mutations between the high- and low-risk ELncSig groups in the TMUCIH validation cohort. **(A)** Oncoplot analysis of critical mutated genes and pathways in DLBCL between the high- and low-risk ELncSig groups (two-sided Fisher's exact test). **(B–D)** Specific mutated site analysis of KMT2D, MYD88, and PIM1.



FIGURE 8 | Co-expression network and validation of prognostic ELncSig lncRNAs and the associated genes. **(A)** A co-expression network of ELncSig lncRNAs and mRNAs was constructed and visualized using Cytoscape. The red hexagons indicate prognostic lncRNAs, and the green rectangles indicate ELncSig mRNAs. **(B)** Sankey diagram showing the associations between prognostic ELncSig lncRNAs, mRNAs, and risk type. **(C, D)** Immunohistochemical images and differential analysis of PIM1 in high- and low-risk ELncSig (***p < 0.001, by Student's t-test).

Verification of ELncSig-Influenced mRNAs

We built a ceRNA network on the basis of the expression profiles of miRNAs and ELncSig-included lncRNAs and mRNAs in patients with DLBCL. In total, 3 lncRNA nodes, 15 miRNA nodes, and 31 mRNA nodes were identified as differentially expressed profiles (|fold change| >1.5, $p < 0.05$, **Figure 8A**). In the present study, a ceRNA network containing 2,025 genes affecting epigenetic regulation was constructed (**Supplementary Figure S7A**). Once again, the 2,025 epigenetic regulatory genes affected by these lncRNAs and their corresponding risk groups were identified. We observed that TET2, E2F1, KDM1A, HDAC7, and KMT2A were regulated by ELncSig lncRNAs (**Figure 8B**, **Supplementary Figure S7B**). PIM1, PIM2, and PIK3R1 were also affected, which means that ELncSig could not only regulate epigenetic-related genes but also affect genes related to other pathways.

PIM1 is a gene regulated by ELncSig and has significantly different mRNA levels between the high- and low-risk groups. Strikingly, high PIM1 expression was significantly correlated with the high-risk ELncSig group (**Figures 8C, D**).

DISCUSSION

Most studies have focused on establishing a new signature of protein-coding genes in DLBCL (35). Based on the 7 subtypes constructed by Wright et al., a probabilistic classification tool for DLBCL genotypes (LymphGen algorithm) was proposed, and 63.1% of tumors can be identified by their genotypes (29). Establishing these signatures mostly relies on quantifying gene transcript levels. We were inspired to show that epigenetic genes play an important role in lymphoma and affect immunity through immune-related gene pairing and attempted to construct a reasonable prognostic model using 9 lncRNAs that are closely correlated with epigenetic-related gene combinations (10, 11). We did not use their expression values at the beginning of signature construction.

In general, high-abundance lncRNAs possess significant biological functions (36). Our findings suggest that ELncSig can be used to identify epigenetic-related genes and predict patient prognosis. In addition, lncRNAs can efficiently pair with protein-coding genes. Our model can distinguish between

high- and low-clinical risk patients with the advantage of clinical practicability. Because lncRNAs are associated with immune infiltration, it is reasonable for them to affect the immune microenvironment and the activation of immune cells and to be predictable of the response to immune therapy. In fact, studies have already found that PRKCQ-AS1 and HCP5, which are included in our ELncSig, play important roles in the process of lymphoma (37, 38), while other lncRNAs were revealed in DLBCL for the first time. Blandino et al. reported that C22orf34 expression gradually decreased from gallstones to gallbladder cancer (39). Guan et al. showed that APTR contributes to osteosarcoma progression through repression of miR-132-3p and upregulation of YAP1 (40), and Zhou et al. reported that APTR promotes uterine leiomyoma cell proliferation by targeting ERa to activate the Wnt/β-Catenin pathway (41). SNHG19 and ELFN1-AS1 have been used to predict the survival of triple-negative breast cancer and non-small cell lung cancer, respectively (42, 43). LINC00487 was shown to be a protective factor in hepatocellular carcinoma (44), and LINC00877 was found to have lower expression in bone marrow samples (45). Some of the roles of these 9 ELncRNAs in solid tumors are similar to those in DLBCL, while others are different. In summary, these lncRNAs are associated with the occurrence and development of tumors; hence, the proposed model can identify novel biomarkers for further research in DLBCL.

We referred to the modified LASSO model used by Sveen et al. (46) to construct the initial signature system. In the process of inclusion in the Cox regression model, the factors were ranked according to their frequency, which suggests the impact of the factor on the model. We assessed the ELncSig risk model using a QQ test and found a normal distribution. Thus, we used the median value to separate patients into high- and low-risk groups. Subsequently, we performed univariate and multivariate analyses of clinicopathological characteristics, calculated AUC values, constructed a nomogram, and assessed its calibration to evaluate the robustness of this model. After analyzing survival outcomes, clinical features, tumor immune infiltration, biomarkers related to checkpoint inhibitors, immune therapy predictions, mutations, the constructed ceRNA network, and immunohistochemical confirmation, the results implied that this ELncSig model worked well in the training and validation cohorts.

Mutations in the gene encoding the KMT2D (or MLL2) methyltransferase are highly recurrent and occur early during tumorigenesis in DLBCL. DLBCL-associated KMT2D mutations impair KMT2D enzymatic activity, leading to diminished global H3K4 methylation in GCB cells and DLBCL cells (47), and KMT2D could be a modulator of ICP blockade (30). For MYD88, L265P is a gain-of-function driver mutation. The L265P mutant promotes cell survival by spontaneously assembling a protein complex containing IRAK1 and IRAK4 (48). PIM1 belongs to the PIM kinase family and has been proven to exhibit ABC-associated mutations (49). We also explored the specific mutation sites of these important molecules in DLBCL and further clarified the reason why the high-risk group had a poor prognosis.

In recent years, immunotherapies based on checkpoint inhibitors have shown promising results in the treatment of aggressive malignancies, including Hodgkin's lymphoma (27). PD-L1 overexpression has also been observed in the aggressive ABC/non-GCB subtype of DLBCL (50). To explore the relationship between ELncSig and tumor-infiltrating immune cells, we used three common methods to estimate immune-infiltrating cells: ESTIMATE, CIBERSORT, and ssGSEA. We found that the low-risk ELncSig group was more positively related to tumor-infiltrating immune cells, such as $CD8^+$ T cells, macrophages, Th2 cells, and major histocompatibility complex (MHC) class I. Subsequent immune-related scores also showed that the low-risk ELncSig group had a better immune microenvironment. When tumor ICD is induced, the ratio of cytotoxic T lymphocytes (CTLs) to Tregs in the tumor increases, indicating good patient prognosis. In contrast, a decrease in this ratio may suggest a poor prognosis (51). Similar to ICDs, ICPs can also reflect the immune status of tumor microenvironments. In the present study, significantly prolonged survival was observed for patients with low ELncSig and low ICP gene expression, implying that these patients with low ELncSig may have a better response to ICP therapy.

CONCLUSION

We constructed an lncRNA signature based on epigenetic-related genes to predict the prognosis of DLBCL. We also proved that this new signature could affect other coding proteins in addition to epigenetic genes. Importantly, ELncSig might be associated with immune infiltration levels and even the efficacy of tumor immunotherapy.

DATA AVAILABILITY STATEMENT

Training and external validation samples were obtained from the GEO online datasets GSE10846, GSE31312 and GSE98588. All data generated or analyzed during this study are included in this published article and its supplementary information files. Additional related-data are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Tianjin Medical University Cancer Institute and Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XXW, XDW, XHW, and HLZ contributed to the study conception and design. XXW, YDZ, YXL, and ZYL collected

and analyzed the data. LFL, YH, and CS performed data acquisition. QLZ and BM reviewed the pathology results. XBR provided technical help. XXW and XHW drafted the manuscript. XDW, XHW, and HLZ reviewed and revised the manuscript. XHW and HLZ contributed to study supervision. All authors read and approved the final manuscript.

FUNDING

This study was supported by grants from the Natural Science Foundation of Tianjin (19JCYBJC26500), the National Natural Science Foundation of China (81770213), and the Clinical Oncology Research Fund of CSCO (Y-XD2019-162).

ACKNOWLEDGMENTS

The authors thank Yang He for providing technical assistance and insightful suggestions for this study and the Marvel Medical Laboratory of Tianjin Marvelbio Technology Co., Ltd. for providing assistance with next-generation sequencing and bioinformatics analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.813031/full#supplementary-material

Supplementary Figure 1 | Kaplan–Meier analysis of 9 prognosis-related lncRNAs.

Supplementary Figure 2 | Validation of ELncSig in the GSE98588 cohort. **(A)** A forest plot showing the 9 lncRNAs identified by the stepwise method in the external validation cohort. **(B)** Risk score distribution, survival status and lncRNA expression of DLBCL patients in the high- and low-risk groups classified by the 9-ELncRNA signature in the external validation cohort. **(C)** Kaplan-Meier analysis of the different risk groups. **(D)** Time-dependent receiver operating characteristic (ROC) curves for 1-, 3-, and 5-year overall survival (OS) in the external validation cohorts.

Supplementary Figure 3 | Validation of ELncSig performance in two external cohorts treated with R-CHOP-like regimens. **(A)** ELncSig performance for samples from patients treated with R-CHOP-like regimens in the GSE10846 dataset. **(B)** ELncSig performance for samples from patients treated with R-CHOP-like regimens in the GSE98588 dataset.

Supplementary Figure 4 | Validation of ELncSig in the TMUCIH cohort. **(A)** Risk score distribution, survival status and lncRNA expression of DLBCL patients in the high- and low-risk groups classified by the 9-ELncRNA signature in the TMUCIH validation cohort. **(B)** A nomogram was constructed using high and low ELncSig scores, age, LDH, GCB vs. non-GCB, ECOG and extranodal sites to predict 1-, 3- and 5-year survival. **(C)** Calibration plots for the probability of five-year survival in the training cohort. **(D)** Time-dependent ROC curve analyses for predicting OS at 5 years with clinicopathological characteristics.

Supplementary Figure 5 | GSEA of the DEGs in the training cohort.

Supplementary Figure 6 | Immune checkpoint genes related to clinical outcome. **(A, B)** Kaplan–Meier survival curves of overall survival among four patient groups stratified by ELncSig and TNFRSF4 and IDO1.

Supplementary Figure 7 | Coexpression network and validation of prognostic ELncSig lncRNAs and the associated epigenetic-related genes. **(A)** A coexpression network of ELncSig lncRNAs and mRNAs (only epigenetic-related genes) was constructed and visualized using Cytoscape. Red hexagons indicate prognostic lncRNAs, and green rectangles indicate ELncSig mRNAs. **(B)** Sankey diagram showing the associations among prognostic ELncSig lncRNAs, mRNAs (only epigenetic-related genes), and risk type.

Supplementary Table 1 | The 307 gene panel design.

Supplementary Table 2 | Targeted gene deep sequencing of the TMUCIH validation cohort.

Supplementary Table 3 | Epigenetic related genes from GeneCards with relevance scores >0.5.

Supplementary Table 4 | The 380 epigenetic related lncRNAs list.

Supplementary Table 5 | The correlation between epigenetic genes and lncRNAs.

Supplementary Table 6 | The 9 epigenetic-related genes used for multivariate Cox regression in the training and validation cohorts.

Supplementary Table 7 | Multivariate Cox regression of tumor-related clinicopathological features.

Supplementary Table 8 | Differentially expressed gene results.

Supplementary Table 9 | KEGG enrichment of DEGs for two merged cohorts.

Supplementary Table 10 | GO enrichment of DEGs for two merged cohorts.

Supplementary Table 11 | Gene alterations in the TMUCIH validation cohort.

REFERENCES

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. *Nature* (2000) 403(6769):503–11. doi: 10.1038/35000501
2. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2018) 378(15):1396–407. doi: 10.1056/NEJMoa1801445
3. Isshiki Y, Melnick A. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). *Curr Cancer Drug Targets* (2021) 21 (4):274–82. doi: 10.2174/1568009620666210106122750
4. Bakhshi TJ, Georgel PT. Genetic and Epigenetic Determinants of Diffuse Large B-Cell Lymphoma. *Blood Cancer J* (2020) 10(12):123. doi: 10.1038/s41408-020-00389-w
5. Meyer SN, Scuoppo C, Vlasevska S, Bal E, Holmes AB, Holloman M, et al. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. *Immunity* (2019) 51(3):535–47.e9. doi: 10.1016/j.immuni.2019.08.006
6. Kline J, Godfrey J, Ansell SM. The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. *Blood* (2020) 135 (8):523–33. doi: 10.1182/blood.2019000847
7. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma Microenvironment: Culprit or Innocent? *Leukemia* (2008) 22(1):49–58. doi: 10.1038/sj.leu.2404970
8. Hopken UE, Rehm A. Targeting the Tumor Microenvironment of Leukemia and Lymphoma. *Trends Cancer* (2019) 5(6):351–64. doi: 10.1016/j.trecan.2019.05.001

9. Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic Alterations and Their Clinical Implications in DLBCL. *Nat Rev Clin Oncol* (2019) 16(10):634–52. doi: 10.1038/s41571-019-0225-1
10. Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N, et al. Identification of Tumor Immune Infiltration-Associated lncRNAs for Improving Prognosis and Immunotherapy Response of Patients With non-Small Cell Lung Cancer. *J Immunother Cancer* (2020) 8(1):e000110. doi: 10.1136/jitc-2019-000110
11. Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, et al. Computational Recognition of lncRNA Signature of Tumor-Infiltrating B Lymphocytes With Potential Implications in Prognosis and Immunotherapy of Bladder Cancer. *Brief Bioinform* (2021) 22(3):bbaa047. doi: 10.1093/bib/bbaa047
12. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal Gene Signatures in Large-B-Cell Lymphomas. *N Engl J Med* (2008) 359(22):2313–23. doi: 10.1056/NEJMoa0802885
13. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive Gene Expression Profiling and Immunohistochemical Studies Support Application of Immunophenotypic Algorithm for Molecular Subtype Classification in Diffuse Large B-Cell Lymphoma: A Report From the International DLBCL Rituximab-CHOP Consortium Program Study. *Leukemia* (2012) 26(9):2103–13. doi: 10.1038/leu.2012.83
14. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. *Nat Commun* (2019) 10(1):1523. doi: 10.1038/s41467-019-09234-6
15. Moller-Petersen J. Nomogram for Predictive Values and Efficiencies of Tests. *Lancet* (1985) 1(8424):348. doi: 10.1016/s0140-6736(85)91128-6
16. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to Predict Outcomes After (177)Lu-PSMA Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: An International, Multicentre, Retrospective Study. *Lancet Oncol* (2021) 22(8):1115–25. doi: 10.1016/S1470-2045(21)00274-6
17. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007
18. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA Interference Reveals That Oncogenic KRAS-Driven Cancers Require TBK1. *Nature* (2009) 462(7269):10–12. doi: 10.1038/nature08460
19. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2021) 384 (9):842–58. doi: 10.1056/NEJMra2027612
20. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer. *Genome Res* (2018) 28(11):1747–56. doi: 10.1101/gr.239244.118
21. Fawcett T. An Introduction to ROC Analysis. *Pattern Recogn Lett* (2006) 27 (8):861–74. doi: 10.1016/j.patrec.2005.10.010
22. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust Enumeration of Cell Subsets From Tissue Expression Profiles. *Nat Methods* (2015) 12(5):453–7. doi: 10.1038/nmeth.3337
23. Ling HY, Yang Z, Wang PJ, Sun Y, Ju SG, Li J, et al. Diffuse Large B-Cell Lymphoma-Derived Exosomes Push Macrophage Polarization Toward M2 Phenotype *via* GP130/STAT3 Signaling Pathway. *Chem Biol Interact* (2022) 352:109779. doi: 10.1016/j.cbi.2021.109779
24. Zhang TT, Liu HQ, Jiao L, Zhang ZZ, He J, Li LF, et al. Genetic Characteristics Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL. *J Immunother Cancer* (2022) 10(4):e004114. doi: 10.1136/jitc-2021-004114
25. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612
26. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic Cell Death and DAMPs in Cancer Therapy. *Nat Rev Cancer* (2012) 12(12):860–75. doi: 10.1038/nrc3380
27. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer. *N Engl J Med* (2012) 366(26):2455–65. doi: 10.1056/NEJMoa1200694
28. Wang L, Mo S, Li X, He YZ, Yang J. Single-Cell RNA-Seq Reveals the Immune Escape and Drug Resistance Mechanisms of Mantle Cell Lymphoma. *Cancer Biol Med* (2020) 17(3):726–39. doi: 10.20892/j.issn.2095-3941.2020.0073
29. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma With Therapeutic Implications. *Cancer Cell* (2020) 37 (4):551–68.e14. doi: 10.1016/j.ccell.2020.03.015
30. Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, et al. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. *Cancer Discovery* (2020) 10(12):1912–33. doi: 10.1158/2159-8290.CD-19-1448
31. Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, et al. MYD88 Mutations Identify a Molecular Subgroup of Diffuse Large B-Cell Lymphoma With an Unfavorable Prognosis. *Haematologica* (2020) 105 (2):424–34. doi: 10.3324/haematol.2018.214122
32. Weber ANR, Cardona Gloria Y, Cinar O, Reinhardt HC, Pezzutto A, Wolz OO. Oncogenic MYD88 Mutations in Lymphoma: Novel Insights and Therapeutic Possibilities. *Cancer Immunol Immunother* (2018) 67(11):1797–807. doi: 10.1007/s00262-018-2242-9
33. Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, et al. PIM1 Kinase Regulates Cell Death, Tumor Growth and Chemotherapy Response in Triple-Negative Breast Cancer. *Nat Med* (2016) 22(11):1303–13. doi: 10.1038/nm.4198
34. Shen R, Xu PP, Wang N, Yi HM, Dong L, Fu D, et al. Influence of Oncogenic Mutations and Tumor Microenvironment Alterations on Extranodal Invasion in Diffuse Large B-Cell Lymphoma. *Clin Transl Med* (2020) 10(7):e221. doi: 10.1002/ctm2.221
35. Wright GW, Wilson WH, Staudt LM. Genetics of Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2018) 379(5):493–4. doi: 10.1056/NEJMc1806191
36. Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, et al. The Novel lncRNA BlackMamba Controls the Neoplastic Phenotype of ALK (-) Anaplastic Large Cell Lymphoma by Regulating the DNA Helicase HELLS. *Leukemia* (2020) 34(11):2964–80. doi: 10.1038/s41375-020-0754-8
37. Hu L, Zhao J, Liu Y, Liu X, Lu Q, Zeng Z, et al. Geniposide Inhibits Proliferation and Induces Apoptosis of Diffuse Large B-Cell Lymphoma Cells by Inactivating the HCP5/miR-27b-3p/MET Axis. *Int J Med Sci* (2020) 17(17):2735–43. doi: 10.7150/ijms.51329
38. Liang Y, Zhu H, Chen J, Lin W, Li B, Guo Y. Construction of Relapse-Related lncRNA-Mediated ceRNA Networks in Hodgkin Lymphoma. *Arch Med Sci* (2020) 16(6):1411–8. doi: 10.5114/aoms.2020.98839
39. Blandino A, Scherer D, Rounge TB, Umu SU, Boekstegers F, Barahona Ponce C, et al. Identification of Circulating lncRNAs Associated With Gallbladder Cancer Risk by Tissue-Based Preselection, Cis-eQTL Validation, and Analysis of Association With Genotype-Based Expression. *Cancers (Basel)* (2022) 14 (3):634. doi: 10.3390/cancers14030634
40. Guan H, Shang G, Cui Y, Liu J, Sun X, Cao W, et al. Long Noncoding RNA APTR Contributes to Osteosarcoma Progression Through Repression of miR-132-3p and Upregulation of Yes-Associated Protein 1. *J Cell Physiol* (2019) 234(6):8998–9007. doi: 10.1002/jcp.27572
41. Zhou W, Wang G, Li B, Qu J, Zhang Y. LncRNA APTR Promotes Uterine Leiomyoma Cell Proliferation by Targeting ERalpha to Activate the Wnt/beta-Catenin Pathway. *Front Oncol* (2021) 11:536346. doi: 10.3389/fonc.2021.536346
42. Li XX, Wang LJ, Hou J, Liu HY, Wang R, Wang C, et al. Identification of Long Noncoding RNAs as Predictors of Survival in Triple-Negative Breast Cancer Based on Network Analysis. *BioMed Res Int* (2020) 2020:8970340. doi: 10.1155/2020/8970340
43. Yang B, Miao S. lncRNA ELFN1-AS1 Predicts Poor Prognosis and Promotes Tumor Progression of Non-Small Cell Lung Cancer by Sponging miR-497. *Cancer Biomark* (2022). doi: 10.3233/CBM-210393
44. Ye JX, Wu SY, Pan S, Huang JQ, Ge LY. Risk Scoring Based on Expression of Long Non-Coding RNAs can Effectively Predict Survival in Hepatocellular Carcinoma Patients With or Without Fibrosis. *Oncol Rep* (2020) 43(5):1451–66. doi: 10.3892/or.2020.7528
45. Zimta AA, Tomuleasa C, Sahnoune I, Calin GA, Berindan-Neagoe I. Long Non-Coding RNAs in Myeloid Malignancies. *Front Oncol* (2019) 9:1048. doi: 10.3389/fonc.2019.01048
46. Sveen A, Agesen TH, Nesbakken A, Meling GI, Rognum TO, Liestol K, et al. ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. *Clin Cancer Res* (2012) 18(21):6001–10. doi: 10.1158/1078-0432.CCR-11-3302

47. Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, et al. Disruption of KMT2D Perturbs Germinal Center B Cell Development and Promotes Lymphomagenesis. *Nat Med* (2015) 21(10):1190–8. doi: 10.1038/nm.3940
48. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically Active MYD88 Mutations in Human Lymphoma. *Nature* (2011) 470(7332):115–9. doi: 10.1038/nature09671
49. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, et al. Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture the Molecular and Biological Heterogeneity of the Disease. *Blood* (2016) 127 (18):2203–13. doi: 10.1182/blood-2015-09-672352
50. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N Engl J Med* (2015) 372(4):311–9. doi: 10.1056/NEJMoa1411087
51. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. *Cancer Res* (2011) 71(17):5670–7. doi: 10.1158/0008-5472.CAN-11-0268

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

frontiers | Frontiers in Immunology

TYPE Original Research
PUBLISHED 09 August 2022
DOI 10.3389/fimmu.2022.903758

OPEN ACCESS

EDITED BY
Dipyaman Ganguly,
Indian Institute of Chemical Biology (CSIR), India

REVIEWED BY
Tong Lu,
The Second Affiliated Hospital of Harbin Medical University, China
Jinhui Liu,
Nanjing Medical University, China

*CORRESPONDENCE
Xiaolong Yan
yanxiaolong@fmmu.edu.cn
Jing Han
hanjing.cn.@163.com
Xiaofei Li
lxfchest@fmmu.edu.cn

SPECIALTY SECTION
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

RECEIVED 24 March 2022
ACCEPTED 21 July 2022
PUBLISHED 09 August 2022

CITATION
Wang Y, Lu G, Xue X, Xie M, Wang Z, Ma Z, Feng Y, Shao C, Duan H, Pan M, Ding P, Li X, Han J and Yan X (2022) Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
Front. Immunol. 13:903758.
doi: 10.3389/fimmu.2022.903758

Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment

Yuanyong Wang[1], Guofang Lu[2,3], Xinying Xue[4,5,6], Mei Xie[6], Zhaoyang Wang[1], Zhiqiang Ma[7], Yingtong Feng[1], Changjian Shao[1], Hongtao Duan[1], Minghong Pan[1], Peng Ding[1], Xiaofei Li[8]*, Jing Han[9]* and Xiaolong Yan[1]*

[1]Department of Thoracic Surgery, Tangdu Hospital of Air Force Military Medical University, Xi'an, China, [2]Department of Physiology and Pathophysiology, National Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, China, [3]State Key Laboratory of Cancer Biology and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China, [4]Department of Respiratory Disease, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, China, [5]Department of Respiratory Disease, School of Clinical Medicine, Weifang Medical University, Weifang, China, [6]Department of Respiratory and Critical Care, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China, [7]Department of Oncology, Chinese People's Liberation Army General Hospital, Beijing, China, [8]Department of Thoracic Surgery, Xi'an International Medical Center Hospital, Xi'an, China, [9]Department of Ophthalmology, Tangdu Hospital of Air Force Military Medical University, Xi'an, China

Ferroptosis is a more relatively recently identified type of programmed cell death, which is associated with tumor progression. However, the mechanism underlying the effect of ferroptosis-related long non-coding RNAs (lncRNAs) in lung adenocarcinoma (LUAD) remains elusive. Therefore, the current study aimed to investigate the role of ferroptosis-related lncRNAs in LUAD and to develop a prognostic model. The clinicopathological characteristics of patients and the gene sequencing data were obtained from The Cancer Genome Atlas, while the ferroptosis-associated mRNAs were downloaded from the FerrDb database. A ferroptosis-related lncRNA signature was established with Least Absolute Shrinkage and Selection Operator Cox regression analysis. Furthermore, the risk scores of ferroptosis-related lncRNAs were calculated and LUAD patients were then assigned to high- and low-risk groups based on the median risk score. The prognostic model was established by K-M plotters and nomograms. Gene set enrichment analysis (GSEA) was performed to evaluate the association between immune responses and ferroptosis-related lncRNAs. A total of 10 ferroptosis-related lncRNAs were identified as independent predictors of LUAD outcome, namely RP11-386M24.3, LINC00592, FENDRR, AC104699.1, AC091132.1, LANCL1-AS1, LINC-PINT, IFNG-AS1, LINC00968 and AC006129.2. The area under the curve verified that the established signatures could determine LUAD prognosis. The nomogram model was used to assess the predictive accuracy of the

established signatures. Additionally, GSEA revealed that the 10 ferroptosis-related lncRNAs could be involved in immune responses in LUAD. Overall, the results of the current study may provide novel insights into the development of novel therapies or diagnostic strategies for LUAD.

KEYWORDS

ferroptosis, lncRNA, lung adenocarcinoma, prognosis, tumor microenvironment

Introduction

Lung cancer is a type of cancer with high morbidity and mortality rates worldwide. It is estimated that approximately 25% of patients with lung cancer die from the disease, while the total overall 5-year survival rate is <20% (1). Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all types of lung cancer, with adenocarcinoma, squamous carcinoma, adenosquamous carcinoma, large cell carcinoma and sarcomatoid carcinoma being the major pathological subtypes of NSCLC (2). Lung adenocarcinoma (LUAD) is the most common type of NSCLC (3). In addition, as a highly heterogeneous type of cancer with complex molecular mechanisms, lung cancer is resistant to several targeted therapies or the therapies are ineffective in certain patients, thus posing a substantial challenge in the treatment of lung cancer (4). Therefore, identifying specific carcinogenesis-related factors and novel biomarkers for the accurate diagnosis, individualized therapy and prognosis of LUAD is of significant importance.

Recently, ferroptosis has been identified as a unique type of iron-dependent programmed cell death, characterized by the accumulation of intracellular reactive oxygen species and lipoperoxide (5). It has been also reported that iron-dependent cell death serves a crucial regulatory role in tumor growth and is involved in the effectiveness of tumor radiotherapy and immunotherapy (6). Therefore, combining drugs targeting iron-dependent cell death-related signaling pathways can improve the anti-tumor efficacy of the above therapies. Chen et al. (7) demonstrated that the natural product erianin, isolated from Dendrobium gold, could induce iron-dependent cell death and exert anti-tumor effects in lung cancer cells *via* the Ca^{2+}/CaM signaling pathway. Accumulating evidence has suggested that ferroptosis is associated with several biological processes in LUAD (8–10). However, the mechanisms underlying the regulation of ferroptosis remain elusive and are far from being exploited in cancer therapy. Therefore, identifying the crucial regulators of ferroptosis is a critical step for the therapeutic application of this process in cancer treatment.

Long non-coding RNAs (lncRNAs), non-coding (nc) RNAs >200 nucleotides in length, are not associated with protein translation, but they serve a vital role in gene regulation (11). More specifically, it has been suggested that the enhanced function or expression of lncRNAs can be involved in several diseases, including cancer. Emerging evidence has indicated that ferroptosis can be modulated by several lncRNAs. For example, Wang et al. (12) showed that LINC00618 could accelerate ferroptosis in an apoptosis-dependent manner in leukemia. Another study revealed that lncRNA PVT1 could regulate ferroptosis *via* the microRNA (miR)-214/transferrin receptor 1/p53 axis in acute ischemic stroke (13). Additionally, lncRNA MT1DP could enhance NSCLC sensitivity to promote ferroptosis *via* the miR-365a-3p/nuclear factor erythroid 2-related factor 2 axis (14). The above findings supported the critical role of lncRNAs in treating several types of cancer.

LncRNAs are involved in gene regulation *via* their direct binding with their target RNAs to regulate their translation or stability. It has been demonstrated that the above interactions are dependent on the binding of lncRNAs to their target RNAs, thus providing the appropriate substrates for protein functions or prohibitory protein effectors (15). Therefore, herein, the limma package, one of the analytical methods in the R language software, was used to perform a comprehensive analysis of gene expression profiles in LUAD (16). To identify ferroptosis-related lncRNAs associated with LUAD prognosis, co-expression and Cox and Least Absolute Shrinkage and Selection Operator (LASSO) regression analyses were performed. Furthermore, nomograms were established to evaluate the prognostic value of these lncRNAs and their capacity in predicting immune responses in LUAD. The results of the current study could assist in improving the diagnosis of LUAD at an early stage of the disease and in providing individualized treatment approaches for patients with LUAD.

Materials and methods

Datasets and patients

The clinical data and gene expression profiles from three LUAD datasets were downloaded from The Cancer Genome Atlas (TCGA) database. A total of 535 LUAD samples were included in the present study. Data exclusion criteria were as

follows (1): h istologically confirmed LUAD and (2) available information on survival and gene expression. Finally, 513 patients with corresponding clinicopathological information were included for further study. A total of 513 LUAD patients were randomized 7:3 into a training cohort (359 patients) and a test cohort (154 patients).

Identification of ferroptosis-related lncRNAs

Based on previous studies, ferroptosis-related mRNAs are listed in Supplementary Table 1 (17–19). Firstly, the expression profile of lncRNAs and mRNAs were obtained from TCGA. Subsequently, the expression profile of ferroptosis-related lncRNAs were extracted from ferroptosis-related mRNAs using co-expression analysis (20). R was used to evaluate the association between the expression levels of lncRNAs and ferroptosis-related mRNAs in LUAD specimens. The association was determined using Pearson's correlation coefficient analysis ($P<0.05$; $r>0.40$).

Validation of risk score

The limma package, a commonly used R package, was utilized to analyze the differential expression of ferroptosis-related lncRNAs with a threshold of $P<0.05$ and absolute log2 (fold change) >1 (21). The overall survival (OS) rate was set as the clinical endpoint of the present study. Univariate Cox regression analysis was performed to establish the ferroptosis-related lncRNA model. Hazard ratio (HR) >1 was considered to indicate a significant association.

Furthermore, the association of the selected differentially expressed lncRNAs (DElncs) with prognosis were then investigated. The prognostic value of the selected DElncs was determined using LASSO Cox regression analysis provided by the glmnet R package (22). The risk scores of the key lncRNAs were obtained *via* measuring their expression levels and LASSO regression coefficients (23). Finally, the LUAD samples were used as training cohorts and divided for subsequent analyses into low- and high-risk groups, using the median risk score as the cut-off point.

The SurvivalROC and "survival" R packages were used to assess the power of the prognostic model (21). Additionally, the survival between the low- and high-risk groups was evaluated using the "survival" package and Kaplan-Meier log-rank test (24).

Independent prognostic analysis and construction of nomogram

To evaluate whether the ferroptosis-related lncRNA model was independent from clinical factors, such as sex, age, smoking and clinical stage, and whether the model exhibited a significant value in predicting OS, univariate and multivariate Cox regression analysis was carried out in the LUAD datasets downloaded from TCGA. The independent prognostic factors were assessed by multivariate Cox regression analysis and a prognostic nomogram plot was constructed in R (25).

Functional enrichment analysis

Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were performed to determine the biological function of the selected lncRNAs (26). A heatmap was constructed to visualize the abundance of the selected DElncs in both groups of TCGA database.

Immunogenomic landscape analyses

ESTIMATE (27) and TIMER (28), two bioinformatics analysis software, were used to estimate the immunogenomic functions, cell infiltration and expression of immune checkpoint molecules. The differences were compared with Wilcoxon test.

Prediction of immunotherapy response and sensitivity to chemotherapy

The pRRophetic R package was utilized to predict chemosensitivity between the two risk groups in the LUAD cohorts. Several common anticancer drugs were identified, including AICAR, AKT inhibitor VIII, bicalutamide, bleomycin, cyclopamine, doxorubicin, epothilone B, etoposide, lapatinib, obatoclax, mesylate, parthenolide, PD.173074, pyrimethamine, salubrinal, shikonin and vinorelbine. The half-maximal inhibitory concentration (IC_{50}) of the above drugs was determined (29, 30).

Reverse transcription-quantitative PCR (RT-qPCR)

A total of 45 pairs of LUAD tissues were obtained from the Tangdu Hospital of Air Force Medical University. The present study was approved by the Ethics Committee of the Tangdu Hospital of Air Force Medical University. GAPDH served as the internal control for qPCR. The relative expression levels of 10 signature lncRNAs were calculated using the $2^{-\Delta\Delta Cq}$ method (31).

Results

Acquisition of ferroptosis-related lncRNAs and mRNAs

A total of 259 ferroptosis-related genes were obtained from FerrDb (Supplementary Table 1). GO and KEGG analysis of the ferroptosis-related mRNAs revealed that the majority of mRNAs were enriched in apoptosis-related processes such as autophagy, oxidative stress and ferroptosis (Figure 1). Additionally, the clinical characteristics and gene expression profiles in the LUAD cohort were downregulated in the datasets obtained from TCGA. To obtain significant lncRNAs, samples with low expression levels were excluded using a cut-off value of mean expression >0.5 across all samples. Subsequently, the association between the expression levels of ferroptosis-related mRNAs and lncRNAs in LUAD samples was assessed using the limma package in R language. The threshold for correlation was set as correlation coefficient >0.4 and P<0.05. Finally, a total of 2,420 ferroptosis-related lncRNAs were identified.



FIGURE 1
Ferroptosis-associated mRNAs in The Cancer Genome Atlas cohort. **(A)** Bar and **(B)** cluster plots of significantly enriched Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways, respectively, are shown.

Construction and validation of a prognostic ferroptosis-related lncRNA model in TCGA cohort

According to the LASSO Cox regression model, the top 10 significantly differentially expressed mRNAs are shown in Figure 2 total of 10 ferroptosis-related lncRNAs associated with OS were obtained through distinctive formulas and the risk score for each individual was calculated. Based on the median risk score, the 359 LUAD patients were divided into the high- (n=179) and low-risk (n=180) groups.

As shown in Figure 3A, LUAD patients with low-risk scores exhibited a significantly poorer mortality rate. As the risk score was increased, the risk of mortality was also elevated, while the survival rate was reduced (Figures 3B, C). The same results are shown in the validation cohort (Figures 3D–F). The risk heatmap illustrates the expression profile of lncRNAs between the high- and low-risk groups (Figure 3G). Additionally, the expression levels of 10 ferroptosis-related lncRNAs were notably associated with several clinical features, including clinical stage, T stage and N stage. The aforementioned results indicated that the expression levels of RP11-386M24.3, LINC00592, FENDRR, AC104699.1, AC091132.1, LANCL1-AS1, LINC-PINT, IFNG-AS1, LINC00968 and AC006129.2 were significantly different in the current prognostic model.

Independent prognostic analysis of OS and construction of a predictive nomogram in LUAD

Subsequently, the present study evaluated whether clinical features, such as age, sex, clinical stage, smoking history and risk scores were independent prognostic factors using multivariate Cox regression and decision curve analyses. The results demonstrated that clinical stage and risk score were independent predictive factors for OS (Figures 4A, B). Furthermore, the diagnostic efficacy of other baseline factors and that of risk scores in LUAD patients were compared *via* calculating the area under the curve (AUC). AUC values of 0.778 and 0.721 were obtained in the model for risk scores and clinical stage, respectively (Figure 4C). The above values were higher compared with other parameters, thus verifying that the ferroptosis-associated lncRNA signature exhibited enhanced diagnostic value compared with other prognostic factors in LUAD patients. In Figure 4D, the survival rate for the first three years is presented. Additionally, a nomogram was constructed to predict OS in patients with LUAD based on independent predictors derived from a multivariate Cox risk regression analysis model (Figure 4E).

Analysis of immunity based on N6-methyladenine (m^6A) methylation and immune checkpoint inhibitors

Subsequently, the current study determined the infiltration rate of immune cells and immune-related functions in both risk groups using the XCELL, TIMER, MCP counter, CIBERSORTx, QUANTISEQ and EPIC tools, and single sample gene set enrichment analysis (ssGSEA) algorithms to evaluate the association between immune function and LUAD prognosis. As shown in Figure 5, a significant difference was obtained between the two risk groups. Additionally, significant differences were observed between the high- and low-risk groups in terms of immune function, including antigen-presenting cell co-stimulation, inflammation, cytolytic activity, parainflammation, T cell co-stimulation and type I IFN



FIGURE 2
Top 5 differentially upregulated and downregulated ferroptosis-related long non-coding RNAs between lung adenocarcinoma and normal samples. HR, hazard ratio.



FIGURE 3
Development and validation of the prognostic ferroptosis-associated long non-coding RNA signature. **(A, D)** Kaplan-Meier curve, **(B, E)** risk score, **(C, F)** survival status and **(G)** heatmap are shown. ***means p<0.001.

responses (P<0.05; Figure 5A). In addition, the expression levels of HNRNPC, METTL3, RBM15, YTHDC1, YTHDC2 and ZC3H13, key factors of m^6A methylation, were notably decreased (Figure 5B). Immunophenoscore analysis and the expression levels of immune modulators were used to predict the response of patients with LUAD to immune checkpoint inhibitors (ICIs). Therefore, the expression levels of the immune modulators CD160, CD200, CD244, CD27, CD276, CD28, PDCD1 and TIGIT were markedly reduced in the high-risk group compared with the low-risk group (P<0.05; Figure 5C). The aforementioned findings suggested that the ferroptosis-related prognostic signature could predict the possible efficacy of ICIs in patients with LUAD and could be considered as a classifier for treatment selection.

Analysis of immune cell infiltration

A heatmap of immune responses based on TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCPcounter, XCELL and EPIC tools is shown in Figure 6. The results suggested that the risk score was negatively associated with immune cell infiltration in LUAD samples, with an immunoreactive status in the low-risk group.



FIGURE 4
Independent prognostic factors for OS in LUAD. **(A)** Multivariate Cox regression analysis is shown. **(B)** Decision curve analysis is presented. **(C)** ROC curves of risk scores and other clinical characteristics based on OS are shown. **(D)** ROC curves predicting the OS of patients with LUAD at 1, 3 and 5 years are shown. **(E)** Nomogram validating the OS of patients with LUAD. OS, overall survival; ROC, receiver operating characteristic; LUAD, lung adenocarcinoma. *means p<0.05, **means p<0.01, ***means p<0.001.

GSEA

A total of 10 ferroptosis-related lncRNAs were also associated with immune responses. This finding was further investigated *via* comparing the immune-related functions in GSEA between the two groups. The results demonstrated that immune system processes and immune response were markedly enriched in the low-risk group compared with the high-risk group (Figure 7).



FIGURE 5
Immune function analysis of ferroptosis-related genes in The Cancer Genome Atlas in the lung adenocarcinoma cohort. **(A)** Single sample gene set enrichment analysis algorithms are shown. **(B)** Methylation levels are shown. **(C)** Check points are shown. *P<0.05, **P<0.01 and ***P<0.001. Ns means no significance.

Ferroptosis-associated lncRNAs can predict the response to chemotherapy

Furthermore, the current study aimed to evaluate the potential of the lncRNA signature in advising on systemic therapies. The pRRophetic algorithm was used to evaluate the IC_{50} values of the drugs and to predict the effect of ferroptosis-related lncRNAs on chemotherapy response between the high- and low-risk groups. The analysis revealed that LUAD patients could be sensitive to 11 types of traditional anti-cancer drugs (Figure 8).

Compare ROC and survival status with published signature in tumor microenvironment

To highlight the superiority of our model, we compared the published literature on ferroptosis-related lncRNAs, among which Gao et al. (32), Guo et al. (33), Fei et al. (34), Lu et al. (35). and our TME signature, the 5-year ROCs were 0.646, 0.568, 0.609, 0.669 and 0.947, respectively (Figures 9A–E). Figures 9F–J shown that the survival state of the above model. These results show that our signature has higher sensitivity and specificity than other models.

Analysis of the expression of ferroptosis-related lncRNAs in LUAD

The expression levels of 10 candidate ferroptosis-related lncRNAs were determined by RT-qPCR in LUAD and paired normal samples. The results demonstrated that LINC00592, AC104699.1 and IFNG-AS1 were significantly upregulated in LUAD tissues, while RP11-386M24.3, FENDRR, AC091132.1, LANCL1-AS1, LINC-PINT, LINC00968 and AC006129.2 were notably downregulated (Figure 10). These above results were consistent with the results of the database analysis.



FIGURE 6
Comparison of immune analysis between both risk groups. The ESTIMATE, TIMER, MCP counter and CIBERSORTx algorithms were used to compare the cellular components or cell immune responses between the high- and low-risk groups. ns, not significant.



FIGURE 7
Gene set enrichment analysis is presented. P<0.05; False discovery rate <0.05.



FIGURE 8
Prediction of response to common chemotherapeutic drugs between the low- and high-risk groups. **(A–P)** Patients in the high-risk group (n=267) exhibited higher estimated half-maximal inhibitory concentration compared with patients in the low-risk group (n=244).

Discussion

LUAD is the most common type of NSCLC. In recent years, despite the advances in screening, diagnosis and treatment, the pathogenesis of LUAD remains elusive due to its complex underlying genetic and molecular mechanisms (36). As emerging non-coding gene biomarkers, lncRNAs are gaining increasing attention and can play an essential role in the occurrence and progression of several types of cancer, including LUAD (37, 38). Ferroptosis is a recently identified type of programmed cell death, characterized by the excessive accumulation of iron-dependent reactive oxygen species and lipid peroxides, and is closely associated with pathophysiological processes in several diseases, including LUAD (39). However, ferroptosis-related lncRNAs capable of predicting the prognosis of patients with LUAD are still unknown. Therefore, the present study aimed to construct a prognostic model *via* identifying ferroptosis-related lncRNAs to predict LUAD and improve the OS of patients.

Correlation analysis was used to screen 2,420 ferroptosis-associated lncRNAs. Among them, 259 ferroptosis-related mRNAs were obtained. Univariate Cox regression analysis revealed 29 ferroptosis-associated lncRNAs with potential prognostic value in LUAD. Lasso regression analysis was used for dimensionality reduction to avoid overfitting, while multivariate Cox regression analysis was applied to construct a signature of 10 ferroptosis-related lncRNAs with the lowest Akaike Information Criterion (AIC) values. Furthermore, all patients were assigned to high- and low-risk groups based on the median risk score. Based on univariate and multivariate Cox regression analysis, risk score was identified as an independent risk factor for prognosis of patients with LUAD. The AUC values were then calculated to verify the distinguishing ability and accuracy of the lncRNA signature. Additionally, based on multivariate analysis a model was established, which could directly reflect the extent to which risk scores could exert an effect on predicting OS.



FIGURE 9
Compare the models among other's signature. **(A–E)** AUC at 1, 3, 5 years for different models. **(F–J)** Significance of Survival State in Different Models.

Previous studies demonstrated that LINC00592 could be a prognostic biomarker for disease free survival in gastric and cervical cancer (40, 41). In addition, another study revealed that IFNG-AS1 could enhance the secretion of IFN-γ in human natural killer cells (42). A previous study also showed that the down-regulated expression of lncRNA LINC00968 in LUAD was associated with the proliferation, migration and invasion (43). Emerging evidence has suggested that LANCL1-AS1 plays a key role in regulating NSCLC (44, 45). LANCL1-AS1 could be also considered as a novel target for treating patients with NSCLC (44). Al-Raawi et al. demonstrated that JARID2-AS1 could be involved in an auto-regulatory loop, m odulating the expression of JARID2, which in turn could be involved in differentiation processes *via* interacting and probably recruiting PRC2. However, the effects of CTD-2017D11.1, AC002117.1 and AC007036.4 lncRNAs remain unknown. Therefore, future studies focusing on the above lncRNAs are urgently needed to develop novel strategies for the diagnosis and treatment of LUAD.

Tumor-associated immune responses play an important role in cell infiltration and metastasis in the tumor microenvironment. In turn, lncRNAs and ferroptosis serve key regulatory roles in tumor-associated immune responses (46–48). Herein, immune-related GSEA revealed that immune system processes and metabolic pathways were markedly enriched in the low-risk group compared with the high-risk one, thus



FIGURE 10
Expression of ferroptosis-related long non-coding RNAs in lung adenocarcinoma tissues by reverse transcription-quantitative PCR is shown. *P<0.05.

suggesting that low-risk patients could present ferroptosis-associated anti-tumor immune responses, eventually enhancing the survival rate of LUAD patients.

Recently, with the discovery of lncRNA functions, growing advancements have been achieved regarding the effects of ferroptosis on cancer therapy. However, the association between lncRNAs and ferroptosis remains to be fully investigated, especially in LUAD. In the present study, 10 lncRNAs associated with iron degeneration were identified using data obtained from TCGA. In addition, the implication of the above lncRNAs in immune responses and metabolic pathways were also explored.

However, the current study has some limitations. Firstly, only data obtained from TCGA was used to establish a ferroptosis-related lncRNA prognostic model and to evaluate its validity. In addition, the number of experiments on detecting the expression levels of the identified ferroptosis-associated lncRNAs in clinical samples and cell lines were limited. Therefore, further *in vitro* experiments are needed to fully elucidate the mechanisms underlying the effects of ferroptosis-related lncRNAs on LUAD.

Conclusion

In the present study, signatures of 10 ferroptosis-associated lncRNAs with potential independent prognostic value that were associated with immune responses were identified in LUAD and validated. The results suggested that the above lncRNAs could serve as potential prognostic indicators and be considered as novel therapeutic strategies focusing on ferroptosis, thus improving the prognosis of patients with LUAD.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of the Tangdu Hospital of Air Force Medical University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

XY, XL, and JH contributed to the conception and design of the study. YW, GL, XX, MX, ZW, ZM, YF, CS, and HD analyzed the data and wrote the manuscript. MP and PD collected and analyzed the data. All authors contributed to the article and approved the submitted version.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 82173252, 81871866 and 81700007), the Shaanxi Social Development Science and Technology Key Project (grant no. 2016SF-308) and the Project of Tangdu Hospital, The Fourth Military Medical University (2018 Key Talents).

Acknowledgments

We appreciate the free use of The Cancer Genome Atlas and FerrDb databases.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.903758/full#supplementary-material

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin* (2021) 71(1):7–33. doi: 10.3322/caac.21654

2. Wang Y, Lu T, Wang Q, Liu J, Jiao W. Circular RNAs: Crucial regulators in the human body (Review). *Oncol Rep* (2018) 40(6):3119–35. doi: 10.3892/or.2018.6733

3. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers–a review. *Eur J Cancer* (2012) 48(9):1299–311. doi: 10.1016/j.ejca.2012.03.007

4. Calvayrac O, Pradines A, Pons E, Mazieres J, Guibert N. Molecular biomarkers for lung adenocarcinoma. *Eur Respir J* (2017) 49(4):1601734. doi: 10.1183/13993003.01734-2016

5. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* (2012) 149(5):1060–72. doi: 10.1016/j.cell.2012.03.042

6. Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. *Nat Rev Clin Oncol* (2021) 18(5):280–96. doi: 10.1038/s41571-020-00462-0

7. Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration *via* calcium/calmodulin-dependent ferroptosis. *Signal Transduct Target Ther* (2020) 5(1):51. doi: 10.1038/s41392-020-0149-3

8. Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga A, Martin A, et al. Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. *Cell Rep* (2020) 33(9):108444. doi: 10.1016/j.celrep.2020.108444

9. Li G, Yang J, Zhao G, Shen Z, Yang K, Tian L, et al. Dysregulation of ferroptosis may involve in the development of non-small-cell lung cancer in xuanwei area. *J Cell Mol Med* (2021) 25(6):2872–84. doi: 10.1111/jcmm.16318

10. Lou JS, Zhao LP, Huang ZH, Chen XY, Xu JT, Tai WC, et al. Ginkgetin derived from ginkgo biloba leaves enhances the therapeutic effect of cisplatin *via* ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. *Phytomedicine* (2021) 80:153370. doi: 10.1016/j.phymed.2020.153370

11. Liu B, Xiang W, Liu J, Tang J, Wang J, Liu B, et al. The regulatory role of antisense lncRNAs in cancer. *Cancer Cell Int* (2021) 21(1):459. doi: 10.1186/s12935-021-02168-4

12. Wang Z, Chen X, Liu N, Shi Y, Liu Y, Ouyang L, et al. A nuclear long non-coding RNA LINC00618 accelerates ferroptosis in a manner dependent upon apoptosis. *Mol Ther* (2021) 29(1):263–74. doi: 10.1016/j.ymthe.2020.09.024

13. Lu J, Xu F, Lu H. LncRNA PVT1 regulates ferroptosis through miR-214-mediated TFR1 and p53. *Life Sci* (2020) 260:118305. doi: 10.1016/j.lfs.2020.118305

14. Meng F, Zhou Y, Dong B, Dong A, Zhang J. Long non-coding RNA LINC01194 promotes the proliferation, migration and invasion of lung adenocarcinoma cells by targeting miR-641/SETD7 axis. *Cancer Cell Int* (2020) 20(1):588. doi: 10.1186/s12935-020-01680-3

15. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer* (2018) 18(1):5–18. doi: 10.1038/nrc.2017.99

16. Wang Y, Lu T, Wo Y, Sun X, Li S, Miao S, et al. Identification of a putative competitive endogenous RNA network for lung adenocarcinoma using TCGA datasets. *PeerJ* (2019) 7:e6809. doi: 10.7717/peerj.6809

17. Nie J, Shan D, Li S, Zhang S, Zi X, Xing F, et al. A novel ferroptosis related gene signature for prognosis prediction in patients with colon cancer. *Front Oncol* (2021) 11:654076. doi: 10.3389/fonc.2021.654076

18. Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. *Int J Biol Sci* (2020) 16(13):2430–41. doi: 10.7150/ijbs.45050

19. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. *Cell* (2017) 171(2):273–85. doi: 10.1016/j.cell.2017.09.021

20. Yuan M, Wang Y, Sun Q, Liu S, Xian S, Dai F, et al. Identification of a nine immune-related lncRNA signature as a novel diagnostic biomarker for hepatocellular carcinoma. *BioMed Res Int* (2021) 2021:9798231. doi: 10.1155/2021/9798231

21. Li M, Liang M, Lan T, Wu X, Xie W, Wang T, et al. Four immune-related long non-coding RNAs for prognosis prediction in patients with hepatocellular carcinoma. *Front Mol Biosci* (2020) 7:566491. doi: 10.3389/fmolb.2020.566491

22. Gupta S, Lee REC, Faeder JR. Parallel tempering with lasso for model reduction in systems biology. *PloS Comput Biol* (2020) 16(3):e1007669. doi: 10.1371/journal.pcbi.1007669

23. Lian P, Wang Q, Zhao Y, Chen C, Sun X, Li H, et al. An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer. *Aging (Albany NY)* (2019) 11(17):6930–40. doi: 10.18632/aging.102225

24. Wei C, Liang Q, Li X, Li H, Liu Y, Huang X, et al. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. *J Cell Biochem* (2019) 120(9):14916–27. doi: 10.1002/jcb.28754

25. Liu J, Cui G, Ye J, Wang Y, Wang C, Bai J. Comprehensive analysis of the prognostic signature of mutation-derived genome instability-related lncRNAs for patients with endometrial cancer. *Front Cell Dev Biol* (2022) 10:753957. doi: 10.3389/fcell.2022.753957

26. Yuan H, Liu J, Zhao L, Wu P, Chen G, Chen Q, et al. Prognostic risk model and tumor immune environment modulation of m5C-related LncRNAs in pancreatic ductal adenocarcinoma. *Front Immunol* (2021) 12:800268. doi: 10.3389/fimmu.2021.800268

27. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612

28. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res* (2020) 48(W1):W509–14. doi: 10.1093/nar/gkaa407

29. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and *in vitro* drug sensitivity in cell lines. *Genome Biol* (2014) 15(3):R47. doi: 10.1186/gb-2014-15-3-r47

30. Liu J, Mei J, Wang Y, Chen X, Pan J, Tong L, et al. Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma. *Int J Biol Sci* (2021) 17(2):448–59. doi: 10.7150/ijbs.51207

31. Wang Y, Wang Z, Shao C, Lu G, Xie M, Wang J, et al. Melatonin may suppress lung adenocarcinoma progression *via* regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. *J Pineal Res* (2022): e12813. doi: 10.1111/jpi.12813

32. Gao C, Kong N, Zhang F, Tang T, Li J, Ding H, et al. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification. *BMC Med Genomics* (2022) 15(1):15. doi: 10.1186/s12920-022-01164-5

33. Guo Y, Qu Z, Li D, Bai F, Xing J, Ding Q, et al. Identification of a prognostic ferroptosis-related lncRNA signature in the tumor microenvironment of lung adenocarcinoma. *Cell Death Discovery* (2021) 7(1):190. doi: 10.1038/s41420-021-00576-z

34. Fei X, Hu C, Wang X, Lu C, Chen H, Sun B, et al. Construction of a ferroptosis-related long non-coding RNA prognostic signature and competing endogenous RNA network in lung adenocarcinoma. *Front Cell Dev Biol* (2021) 9:751490. doi: 10.3389/fcell.2021.751490

35. Lu L, Liu LP, Zhao QQ, Gui R, Zhao QY. Identification of a ferroptosis-related LncRNA signature as a novel prognosis model for lung adenocarcinoma. *Front Oncol* (2021) 11:675545. doi: 10.3389/fonc.2021.675545

36. Keshava HB, Tan KS, Dycoco J, Huang J, Berkowitz A, Sumner D, et al. Long-term assessment of efficacy with a novel thoracic survivorship program for patients with lung cancer. *J Thorac Cardiovasc Surg* (2021) (5):1645-53.e4. doi: 10.1016/j.jtcvs.2021.11.026

37. Peng J, Liu F, Zheng H, Wu Q, Liu S. lncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2. *Cell Cycle* (2021) 20(1):126–41. doi: 10.1080/15384101.2020.1864128

38. Zhang L, Zhang K, Liu S, Zhang R, Yang Y, Wang Q, et al. Identification of a ceRNA network in lung adenocarcinoma based on integration analysis of tumor-associated macrophage signature genes. *Front Cell Dev Biol* (2021) 9:629941. doi: 10.3389/fcell.2021.629941

39. Lu T, Xu R, Li Q, Zhao JY, Peng B, Zhang H, et al. Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma. *Mol Ther Oncolytics* (2021) 21:134–43. doi: 10.1016/j.omto.2021.02.011

40. Cheng C, Wang Q, Zhu M, Liu K, Zhang Z. Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients. *Cancer Cell Int* (2019) 19:123. doi: 10.1186/s12935-019-0846-6

41. Yuan LY, Qin X, Li L, Zhou J, Zhou M, Li X, et al. The transcriptome profiles and methylation status revealed the potential cancer-related lncRNAs in patients with cervical cancer. *J Cell Physiol* (2019) 234(6):9756–63. doi: 10.1002/jcp.27661

42. Stein N, Berhani O, Schmiedel D, Duev-Cohen A, Seidel E, Kol I, et al. IFNG-AS1 enhances interferon gamma production in human natural killer cells. *iScience* (2019) 11:466–73. doi: 10.1016/j.isci.2018.12.034

43. Wu C, Bian X, Zhang L, Hu Y, Wu Y, Pei T, et al. Long noncoding RNA LINC00968 inhibits proliferation, migration and invasion of lung adenocarcinoma through targeting miR-22-5p/CDC14A axis. *3 Biotech* (2021) 11(10):433. doi: 10.1007/s13205-021-02981-8

44. Acha-Sagredo A, Uko B, Pantazi P, Bediaga NG, Moschandrea C, Rainbow L, et al. Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. *Br J Cancer* (2020) 122(7):1050–8. doi: 10.1038/s41416-020-0742-9

45. Wang Y, Fu J, Wang Z, Lv Z, Fan Z, Lei T. Screening key lncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis. *Cancer biomark* (2019) 25(4):313–24. doi: 10.3233/CBM-190225

46. Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. *Nat Immunol* (2021) 22(5):560–70. doi: 10.1038/s41590-021-00899-0

47. Zhu T, Ma Z, Wang H, Wei D, Wang B, Zhang C, et al. Immune-related long non-coding RNA signature and clinical nomogram to evaluate survival of patients suffering esophageal squamous cell carcinoma. *Front Cell Dev Biol* (2021) 9:641960. doi: 10.3389/fcell.2021.641960

48. Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. CD8 (+) T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature* (2019) 569(7755):270–4. doi: 10.1038/s41586-019-1170-y

Frontiers in Immunology

Explores novel approaches and diagnoses to treat immune disorders.

The official journal of the International Union of Immunological Societies (IUIS) and the most cited in its field, leading the way for research across basic, translational and clinical immunology.

Discover the latest Research Topics

See more →

Frontiers

Avenue du Tribunal-Fédéral 34
1005 Lausanne, Switzerland
frontiersin.org

Contact us

+41 (0)21 510 17 00
frontiersin.org/about/contact